P00001606T0076|0 10|Comparison
P00008171T0000|14 21|aspects
P00008997A0472|5 8|CSF
P00010943A0733|0 10|Flurazepam
P00012653T0045|0 4|Beta
P00013683A0210|20 31|CO2 removal
P00015731A0090|12 26|administration
P00022143T0000|14 19|study
P00023348A0601|11 17|polyps
P00024600A0522|13 31|HMG dosage regimen
P00025557A0100|9 20|CO2 content
P00027739T0000|0 31|Serum gamma glutamyltransferase
P00027967A0207|3 11|contrast
P00029555A0861|9 18|exception
P00029953T0045|0 15|Characteristics
P00030183T0000|0 8|Takayasu
P00030937A0119|0 4|SGPT
P00033873T0001|0 29|Gamma glutamyl transpeptidase
P00034935A0545|0 8|Patients
P00038408T0000|10 21|stimulation
P00039271T0000|13 19|action
P00041512T0067|0 9|Abstracts
P00048373A0377|0 7|Removal
P00050628A0202|3 6|IgG
P00052597T0000|0 7|Studies
P00054900A0226|11 26|reaction stains
P00055040A0000|4 16|out-patients
P00056837A0000|7 24|mediastinoscopies
P00056901A0308|2 9|mixture
P00060529A0695|15 28|control group
P00061478T0000|5 18|complications
P00063680T0000|9 18|diagnosis
P00064414A1098|0 5|Sings
P00066874T0000|24 54|fluid alpha fetoprotein levels
P00072928T0000|0 14|Serum-ferritin
P00073344A0367|5 13|subjects
P00074758T0000|0 8|Patients
P00083846T0000|0 7|Albumin
P00084275T0063|0 7|Preface
P00086313A0000|12 19|strains
P00088391A0181|13 24|hand factor
P00089778A0000|4 17|concentration
P00092689A0352|7 8|%
P00094639A0313|0 8|Prazosin
P00096241A0087|0 2|T4
P00097989A0106|15 23|analysis
P00100540T0000|0 19|Aspirin intolerance
P00100791A0425|6 13|results
P00101300A0257|3 8|cases
P00105401A0635|4 10|effect
P00105903A0288|12 20|research
P00111174A0351|30 40|properties
P00112627A0542|0 13|Pentobarbital
P00113657A0628|0 7|Pb foil
P00114144A0189|32 37|study
P00115974A0576|4 10|groups
P00117748T0000|0 12|Erythromycin
P00118044A0000|16 29|displacements
P00118810T0001|10 17|disease
P00119339A0400|8 14|animal
P00122718A0500|4 12|majority
P00129659T0000|0 11|Variability
P00130573T0054|0 3|VII
P00131739T0001|20 27|indices
P00133214T0064|4 12|concepts
P00136175A1137|4 15|maintenance
P00137671A0896|6 18|observations
P00139624A0318|6 11|hours
P00139827A0000|0 17|Radioimmunoassays
P00142718A0156|12 20|patients
P00146327A0147|4 12|majority
P00149899T0001|0 10|Prediction
P00150066A0100|13 23|fibrinogen
P00150066A0554|18 30|haemorrhages
P00154430A0906|4 22|Southern technique
P00155973A0387|29 35|limits
P00159600A0871|0 2|SV
P00163384A0000|4 11|carcass
P00167544A0067|10 14|ears
P00168176A0000|0 7|Patulin
P00168431T0000|0 20|Steroid glucuronides
P00172199A0270|4 10|matrix
P00173860A0475|0 10|Riboflavin
P00176742T0000|0 11|Polyglactin
P00183063A0300|4 13|incidence
P00188387A0975|0 7|Studies
P00193088A0196|21 29|subjects
P00193587T0000|0 15|EEG theta waves
P00196255A0000|0 17|REM dream content
P00198510T0000|0 11|Innervation
P00199012T0000|8 21|ACTH syndrome
P00201881A0487|11 18|finding
P00205074A0000|8 24|hypophosphatemia
P00209664A0836|13 24|correlation
P00210220X0000|10 24|neurochemistry
P00211881A0602|0 7|Efforts
P00216939T0001|0 6|Effect
P00219533T0001|0 12|Distribution
P00219565A0172|4 13|incidence
P00219674A0000|0 14|Technetium-99m
P00221136A0984|10 20|phenomenon
P00221725A0523|4 11|decline
P00222102A0227|0 9|Treatment
P00222827A0000|0 7|Workers
P00224013A0661|6 9|VO2
P00225352T0000|22 33|alterations
P00227393T0000|0 10|Modulation
P00227610A1593|14 22|respects
P00231555T0001|0 6|Effect
P00232354A0286|0 10|Serum ACTH
P00232456T0000|0 7|Anatomy
P00234206T0000|0 8|Bertioga
P00234264A0164|0 38|Gamma glutamyl transpeptidase activity
P00234626T0036|0 3|XXI
P00239014A0000|29 35|method
P00239169T0000|0 26|Dopamine receptor blockade
P00240016T0033|0 2|V.
P00240518A0000|21 30|procedure
P00242427T0001|5 10|field
P00254537T0000|7 16|graduates
P00261981A0434|20 39|serum somatomedin A
P00264240A1843|4 13|sequences
P00265964A0562|5 14|mechanism
P00267764A0651|5 11|report
P00294502T0001|0 9|Diagnosis
P00300314A0132|19 29|infections
P00303189A0247|18 21|way
P00304240A0369|22 27|tests
P00304310A0000|4 13|end-stage
P00304806A0760|7 12|basis
P00313766A0666|3 11|patients
P00316723A0558|0 7|Changes
P00321261A0104|12 20|response
P00330364A0132|2 7|total
P00331128A0000|5 11|levels
P00331936T0000|0 9|Detection
P00336354A0543|4 12|response
P00336547A0000|4 18|mortality rate
P00337102T0058|0 8|Williams
P00339289T0049|0 3|Use
P00340692T0033|1 9|Emeritus
P00342623A0228|10 18|vaccines
P00350465T0000|10 19|diagnosis
P00352569A0000|8 21|oxygen supply
P00354315T0000|8 19|dysfunction
P00358945A0225|12 18|period
P00361059T0000|2 7|study
P00361340A0529|12 21|phenomena
P00369397A0280|6 9|FSH
P00369683T0000|0 10|Adriamycin
P00377466A0188|10 18|controls
P00378492A0475|0 13|Renin studies
P00378735A0000|22 27|trial
P00381783T0000|0 32|Bone marrow transplantation-1979
P00383169A0000|8 15|article
P00384744T0000|26 38|hypofunction
P00385457A0187|10 20|inhibition
P00386251A0899|4 23|IDF standard method
P00390932T0001|9 17|antigens
P00393598A0198|4 10|course
P00397806T0039|6 20|Algerian cases
P00401521A0138|12 19|percent
P00401676A0414|20 27|staging
P00406585T0001|9 19|hematology
P00409927A0570|0 8|Neomycin
P00411465A0142|34 41|section
P00413854A0958|0 7|Changes
P00414575T0000|11 21|evaluation
P00415543A0320|0 11|Recognition
P00416758T0001|0 9|Isolation
P00417166T0000|16 23|profile
P00417301T0001|12 22|mechanisms
P00418341T0000|11 21|adaptation
P00420460A0291|3 11|patients
P00423649A0259|6 16|techniques
P00425547A0000|3 11|patients
P00427715A0000|2 7|total
P00429151T0000|0 4|Year
P00429893A0000|24 29|array
P00429949A0000|21 46|World Health Organization
P00430889T0001|16 24|fistulas
P00431832T0001|0 18|Plasma ion changes
P00432615A0541|12 23|differences
P00435187T0000|17 30|flowers bloom
P00437749A0242|8 28|treatment modalities
P00439618T0001|0 17|Lethal Tachmalcor
P00439716T0001|21 31|evaluation
P00445259T0000|0 28|Serum ferritin concentration
P00445720A0263|13 30|pressure gradient
P00450367T0000|14 19|trail
P00450559A0269|7 12|basis
P00450760T0001|0 16|Cryoglobulinemia
P00451192A0248|0 4|Data
P00453780A0430|17 35|serum IgA response
P00454780A0340|0 19|Ultimate strengthes
P00456424A0000|4 11|effects
P00463973A0000|0 15|Platelet number
P00464387A1185|7 19|measurements
P00465223A0373|9 17|patients
P00465681A0000|2 6|rise
P00465829T0000|0 6|Nernst
P00473229T0000|0 7|Effects
P00473249T0000|0 6|Effect
P00474064A0205|8 17|situation
P00476020T0000|4 16|biochemistry
P00476572A0139|26 32|lesion
P00477794T0000|0 7|Effects
P00478714T0000|0 8|Efficacy
P00479222A0682|0 10|Resistance
P00479246T0000|31 44|osteomyelitis
P00481612A1121|28 37|receptors
P00483716A0366|3 7|case
P00484177A0242|5 15|expression
P00485615A0935|6 10|data
P00488534A0308|3 11|addition
P00490336A0181|6 25|conduction velocity
P00493818A0422|4 12|failures
P00494659A0391|18 29|metabolites
P00495097A0663|6 21|characteristics
P00497494A0112|4 15|ventilation
P00499588T0000|0 23|Carbohydrate metabolism
P00503336A0285|21 25|CAEC
P00506559A0000|14 33|inhalation toxicity
P00506649T0000|0 7|Changes
P00509703A0581|6 17|differences
P00510341T0036|2 7|study
P00512215A0000|12 17|study
P00513284A0000|15 26|preparation
P00513284A1255|18 22|days
P00516545T0001|11 26|characteristics
P00517890A0468|12 17|route
P00519173A0126|7 15|patients
P00521732T0000|8 17|excretion
P00524451A0136|25 43|locomotor activity
P00528144T0000|7 11|role
P00534613A0000|0 11|Irradiation
P00535520A0239|13 23|exceptions
P00540707A0255|27 34|results
P00541752A1032|9 23|determinations
P00550399A0615|18 24|causes
P00553858A0000|9 14|Grice
P00555492A1034|7 14|changes
P00555495T0000|0 5|Study
P00555583T0000|0 16|Pharmacokinetics
P00557559A0170|7 16|compounds
P00564032A0724|0 7|Changes
P00564943A0444|0 6|Calves
P00565136T0000|8 17|mortality
P00565314A0293|0 11|Guinea pigs
P00569989A0239|6 26|halothane anesthesia
P00574222T0000|8 16|kindling
P00574956A0304|21 31|stereotypy
P00575231A0422|0 4|None
P00577440A0298|7 15|duodenum
P00578648T0048|11 18|effects
P00580106T0000|0 9|Treatment
P00580151A0706|74 86|testosterone
P00583004A0445|12 36|1,8-dihydroxy-9-anthrone
P00583522T0001|33 41|problems
P00587791T0054|0 7|Nursing
P00589073A0000|18 49|plasma prolactin concentrations
P00590594T0000|8 27|allotransplantation
P00592887T0000|9 17|reaction
P00593119T0001|0 9|Screening
P00594466T0001|4 13|induction
P00594617A0192|21 32|correlation
P00597715A0256|0 9|One-third
P00598012A0174|3 25|girls prolactin levels
P00599601A0260|45 55|procedures
P00600943T0001|2 7|cases
P00601401A0181|8 27|hemoglobin solution
P00602622A0362|11 24|ulcer therapy
P00602702A0309|7 14|patient
P00603783A0647|0 12|Serum levels
P00606849T0000|22 35|heart disease
P00614915T0001|0 10|Vitrectomy
P00616575A0000|13 24|sensitivity
P00617815A0215|14 29|L-R differences
P00618078A0367|2 10|decrease
P00619305A0759|22 28|groups
P00619782A0058|5 9|tans
P00619948A0000|6 13|effects
P00621626T0000|0 14|Stress effects
P00622556A0111|20 28|collagen
P00623361A0221|0 7|Smoking
P00626014T0001|4 13|malignity
P00627039T0000|0 11|Elimination
P00627129A0944|6 15|responses
P00627202T0000|0 9|Diuretics
P00628990A0000|6 14|patients
P00630713T0000|0 10|Evaluation
P00633909A0000|20 28|patients
P00635143T0001|0 6|Action
P00635194A0093|0 15|Kodak XV-2 film
P00636526T0033|0 9|Diagnosis
P00637637T0000|13 20|factors
P00639410T0000|0 9|Cortisone
P00640584A0250|20 29|principle
P00641395A0441|5 18|blood samples
P00644314T0000|8 24|hypersensitivity
P00644539A0783|23 33|inhalation
P00646023T0058|13 20|studies
P00646193T0000|0 7|Potency
P00656008T0000|0 10|Prevention
P00657551T0000|0 11|Measurement
P00659962T0000|18 38|riboflavin excretion
P00663166A0000|13 24|angiography
P00664320T0000|8 17|detectors
P00665053A0276|39 43|type
P00665214A0374|4 10|method
P00665336A0908|12 16|time
P00668122A0414|0 8|Analysis
P00669800A0579|7 11|mice
P00676416A0320|27 32|years
P00676790T0000|0 18|Angiotensin effect
P00681550A0000|0 7|Procion
P00681571T0028|11 19|findings
P00682762T0001|0 19|Silicosis mortality
P00685922A0451|31 41|strictures
P00686836A0000|0 7|Pentane
P00693987T0001|0 14|Thromboplastic
P00696680A0000|4 11|authors
P00696858A0000|4 10|effect
P00701144T0000|10 18|analysis
P00701462A0722|0 16|Urine antibodies
P00702773A0327|0 11|Althoug RBF
P00703350A0418|0 13|99mTc phytate
P00703932A0000|4 12|patients
P00704675A0199|4 8|mass
P00710217T0001|9 14|cysts
P00710372A0302|25 36|dysfunction
P00712117A0521|8 16|outbreak
P00713525A0268|8 17|decreases
P00715180T0074|0 6|Effect
P00715753A0241|3 26|biopsies CK-MB fraction
P00716366T0001|0 5|Value
P00722298A0619|10 18|analysis
P00722652A0118|13 37|2nd-generation schizonts
P00725257A0452|15 25|pD2 values
P00725336T0000|0 36|Newcastle disease virus surveillance
P00725534A0888|34 43|challenge
P00725752T0001|0 9|Treatment
P00726581T0122|0 6|Orthop
P00728718T0000|0 15|Thyroid disease
P00729003A1182|0 8|Residues
P00733067A0188|12 18|reflux
P00736376A0371|8 13|stage
P00737422A0832|0 9|Pathogens
P00740409A0000|4 18|histochemistry
P00741476A0000|14 19|woman
P00743335T0001|0 14|Reaction times
P00745775A0170|16 24|patients
P00747722A0486|4 8|data
P00748978T0000|0 20|Serum relaxin levels
P00753237A0000|25 35|phenomenon
P00755245A0000|0 6|Effect
P00755671A0485|17 24|heparin
P00755869A0216|0 23|Contingency contracting
P00756511T0036|0 9|Dietetics
P00757244A0000|4 11|results
P00759049A0185|4 15|micromethod
P00759400T0000|0 18|Platelet serotonin
P00762763A0253|12 21|incidence
P00764737X0000|4 18|vigilance task
P00767155T0001|4 12|December
P00767161A0837|12 21|increases
P00768220X0000|4 14|motor unit
P00771729X0000|19 25|system
P00775582T0000|11 21|properties
P00779272T0001|12 19|studies
P00780639X0000|17 24|antigen
P00792847A0000|25 48|antilymphocyte globulin
P00799988A0554|7 12|basis
P00803867A0315|0 8|Patients
P00806295A0193|0 10|Absorption
P00807356T0001|33 41|activity
P00808266T0000|0 8|Advances
P00808898A0000|25 29|data
P00811852T0001|9 21|satisfaction
P00812183T0000|11 26|transfer factor
P00818380A0239|11 17|factor
P00819176T0001|4 10|effect
P00821833A0000|5 11|report
P00822611A0467|14 20|number
P00823087A0608|0 8|Deflunia
P00825571T0031|0 3|III
P00827364A0000|6 16|instrument
P00830568A0000|23 32|secretion
P00832096T0000|9 27|calcium metabolism
P00833472A0907|20 27|patient
P00836637A0000|13 23|experiment
P00837262A0000|4 18|responsiveness
P00837811A0675|2 11|diagnosis
P00838152A0863|17 38|mean temperature rise
P00839378A0649|13 19|Viso V
P00842406A0771|18 23|tests
P00842522T0000|20 30|intubation
P00843232A0100|4 14|background
P00843670T0000|4 9|sense
P00846559A0000|7 14|strains
P00847967T0000|19 23|uses
P00851041A0000|12 17|study
P00851286A0375|0 6|Deaths
P00857024A0888|0 10|Recurrence
P00863184T0043|0 10|Adaptation
P00863773T0000|0 7|Dangers
P00866577A0579|0 9|Treatment
P00868301A0043|3 25|diethyl ether solution
P00868903A0000|0 8|Amikacin
P00870859A0121|4 8|data
P00871237A0601|7 15|activity
P00872442T0000|0 10|Estimation
P00872922A0204|4 9|acids
P00874942T0000|13 23|amnionitis
P00875778T0000|0 10|Evaluation
P00876722T0000|10 20|meningitis
P00877857A0763|0 13|Serum amylase
P00879329A0176|7 26|control preparation
P00879829A0564|0 7|Infants
P00881630A0000|18 25|effects
P00885562A0281|6 10|GAGs
P00890028A0507|4 17|length scales
P00891370A0000|16 28|arteriograms
P00892353A0686|3 14|hypotension
P00898500A0246|4 8|sera
P00903772A0359|0 8|Wherever
P00909114A0000|0 18|Diallylnitrosamine
P00910823A0196|5 9|term
P00911590T0000|13 22|responses
P00913623A0242|4 13|mechanism
P00915090A0536|12 16|days
P00916099A0000|0 17|Self-emasculation
P00917572T0001|0 11|Possibility
P00917721A0484|5 13|analysis
P00918556A0000|4 14|prevalence
P00918965A0728|22 30|patients
P00920381T0000|18 26|glycogen
P00921032T0000|11 21|evaluation
P00921911A0159|0 6|Levels
P00926272A0000|16 21|cause
P00926604A0504|0 11|Propranolol
P00926751A0000|7 14|studies
P00927633T0001|9 17|electron
P00928529T0001|0 16|Feeding behavior
P00929418T0001|0 4|Role
P00930947A0629|15 32|drug interactions
P00931089T0001|12 18|arrest
P00932738A0116|14 28|blood pressure
P00932817A0499|0 10|Iodine-123
P00933251T0000|8 18|meningioma
P00935526A0000|4 16|difficulties
P00938594A0149|3 12|cessation
P00941050T0000|4 10|effect
P00947327A0000|15 21|survey
P00947834X0000|0 7|RESULTS
P00951909X0001|14 27|loop syndrome
P00952734T0000|0 6|Letter
P00954819A1041|6 10|data
P00956364A0138|0 14|Batch cultures
P00956554A0414|6 13|samples
P00958550T0001|0 6|Crisis
P00959656A0250|9 14|women
P00961711T0000|0 18|Hematology problem
P00962222A0633|27 37|variations
P00962277T0000|0 13|Haemodilution
P00964758T0001|15 27|plasmacytoma
P00967223T0059|0 2|I.
P00968181A0264|14 20|calves
P00970320A0000|4 15|performance
P00970488A0105|24 32|increase
P00970839A0118|0 13|Rainbow trout
P00974901A0080|0 11|Stimulation
P00975314T0001|8 19|amenorrhoea
P00975540T0000|16 23|methods
P00980255T0000|0 11|Application
P00984209A0614|0 20|Serum gastrin levels
P00985110T0001|9 20|projections
P00985276A0000|0 9|Preflight
P00985279A0493|0 4|Mean
P00986800A0325|4 13|Cu values
P00986925A0002|4 10|effect
P00987649T0001|0 5|State
P00988572A0000|0 14|Oxygen tension
P00989973A0000|4 12|response
P00992316A0178|23 38|pressure curves
P00993176A0066|6 15|myoglobin
P00996272A0397|18 25|sources
P00996364X0000|0 1|E
P00999494A0000|4 12|patients
P01000378T0000|0 6|Effect
P01003819A0498|9 13|help
P01004298A0744|5 15|up-grading
P01009451A0728|12 20|controls
P01009739T0001|0 6|Effect
P01009841T0001|5 16|innervation
P01010638A0161|4 8|feed
P01012640T0001|8 23|characteristics
P01012904A0333|15 34|interference effect
P01019207A0232|37 47|conditions
P01021091T0000|4 13|influence
P01027644T0001|11 15|test
P01030985T0090|0 2|I.
P01035457A0623|7 13|tumour
P01036714A0072|0 7|Studies
P01044338A0240|9 21|measurements
P01047417T0000|10 37|National Health Dis-service
P01047895T0001|3 12|criticism
P01048020T0000|0 8|Critique
P01048968A0152|6 13|studies
P01050144A0297|20 28|decrease
P01050400T0000|0 11|Improvement
P01057137A0192|3 13|difference
P01064124A0560|9 10|d
P01067493A0119|18 25|pattern
P01071715A0903|17 26|technique
P01075075T0038|0 2|I.
P01078982A0227|62 78|cyclophosphamide
P01080374A0709|0 8|Evidence
P01081904A0198|26 34|catheter
P01082726A0248|4 13|influence
P01082833A0000|38 43|agent
P01083321X0000|3 9|stands
P01083375T0000|0 19|Alpha-1 antitrypsin
P01083784T0000|0 25|Lymphocyte subpopulations
P01084413A0271|2 7|range
P01087288T0000|2 12|comparison
P01088654T0001|0 9|Technique
P01090210A0417|0 4|Mean
P01092248T0000|8 14|status
P01093055T0000|0 7|Calcium
P01093845A0208|0 14|Modern studies
P01093847A0000|15 21|action
P01096741X0000|11 17|growth
P01097100A0217|4 12|patients
P01098179A0167|0 7|Results
P01098592A0567|0 10|IgG levels
P01099693T0000|0 6|Letter
P01101272T0000|0 10|Assessment
P01103390A0149|15 24|behaviour
P01107226A0808|9 23|amphotericin B
P01113908A0475|19 27|increase
P01116254A0000|22 36|administration
P01116466A0185|0 19|Thromboplastin time
P01118293A0150|4 8|data
P01119586A0337|0 20|Glycogen utilization
P01119658A0000|4 11|records
P01122015A0467|9 12|vol
P01123658A0000|4 11|authors
P01124944A0830|18 26|attitude
P01125117A0183|3 7|none
P01128985A0000|31 37|method
P01130186A0568|24 31|patient
P01130531A0224|0 17|Nerve stimulation
P01131946T0001|0 6|Effect
P01138215T0001|0 4|Risk
P01138330A0204|7 14|pouches
P01140184A0342|0 16|Liver microsomes
P01141114A0188|16 20|work
P01145884T0028|39 44|study
P01147436T0000|13 38|Burkitt Lymphoma Registry
P01147502T0000|0 10|Vitrectomy
P01148868A0284|14 28|clearance rate
P01150658A0683|5 13|sequence
P01156631A0658|4 36|mean plasma sodium concentration
P01156814T0000|0 9|Editorial
P01157191A0536|17 28|dose levels
P01157614T0000|0 7|Effects
P01158512T0000|20 33|dehydrogenase
P01158838A0438|57 66|flow rate
P01159822A0353|14 23|epithelia
P01168607A0672|12 26|administration
P01168908A0000|0 16|Prostaglandins F
P01168956A0552|12 16|date
P01170143A0247|0 6|Groups
P01171020A0711|4 11|effects
P01171935A0313|4 14|appearance
P01172734T0035|0 11|Association
P01172917T0000|0 6|Letter
P01174873T0000|0 14|Retinoblastoma
P01176905A0094|12 21|melatonin
P01178153A0056|0 2|D.
P01178637T0001|0 15|Atherosclerosis
P01185956A0722|4 11|authors
P01186344A0303|4 14|attainment
P01190120A0832|17 30|% lengthening
P01190251A0335|0 7|Caution
P01191955A0077|19 23|test
P01191964A0000|6 12|groups
P01193458T0001|8 27|isotope cystography
P01193770T0000|0 14|Air ion action
P01194673A0652|3 11|evidence
P01201977T0000|4 18|interpretation
P01202616A0466|10 23|retransfusion
P01206772T0000|2 7|study
P01206896T0001|0 15|Characteristics
P01208811T0001|0 5|Study
P01209618A0409|0 10|Tobramycin
P01211754A0192|26 31|cases
P01215067A0000|24 34|resistance
P01217450A0295|4 22|Chemical occlusion
P01224116A0576|23 31|patients
P01225339A0590|21 31|occlusions
P01228258A0000|14 25|preparation
P01228882A0437|13 24|correlation
P01233561T0001|9 18|lactation
P01235347T0001|13 27|cardiotoxicity
P01236224T0001|9 18|pathology
P01237206A0199|0 13|Demonstration
P01241437A0152|4 12|patients
P01241588A1470|4 15|alterations
P01241866A0682|7 15|increase
P01242636A0678|4 11|results
P01243628A0286|8 13|cases
P01244236A1122|4 11|results
P01245162A0262|0 9|Reduction
P01246210A0648|4 17|calcium ratio
P01247475A0000|7 16|diagnosis
P01248124A0281|6 17|cholesterol
P01249198A1097|4 27|serum FT3 concentration
P01252223A0347|4 11|authors
P01253191T0000|2 6|note
P01256410T0001|2 12|activities
P01259027A0416|4 11|concept
P01261005A0711|34 43|variation
P01262596T0000|13 23|compromise
P01264640T0028|2 6|case
P01265443A0159|11 18|glucose
P01265887T0001|9 30|factor VIII inhibitor
P01267446A0210|0 16|Biohydrogenation
P01272816A0000|4 9|study
P01275335A0158|11 17|agents
P01275541A0405|25 37|CPK activity
P01276105A0313|3 11|contrast
P01278251A0000|4 11|authors
P01279197T0000|11 19|analysis
P01279352A0297|4 8|site
P01279352A0473|8 16|extracts
P01279352A1197|20 22|NF
P01279374A0396|38 43|genes
P01279696A0862|9 16|studies
P01280413T0001|0 9|Treatment
P01280807A0575|13 15|Kd
P01281322A0604|21 33|relationship
P01281472T0000|0 6|Rabbit
P01281771T0000|0 16|Characterization
P01282014A0275|0 7|Animals
P01282638A0934|4 20|prophylactic use
P01284032A0213|0 2|AP
P01284595A0102|4 13|isolation
P01284828T0001|0 28|Tissue plasminogen activator
P01285009A0000|0 15|Gene constructs
P01285358A0396|0 13|Serum gastrin
P01285554T0000|0 9|Prospects
P01285807A0365|4 8|mean
P01286732A0572|7 19|hepatomegaly
P01287197A0761|14 19|group
P01292230A0283|8 13|drugs
P01294345A0591|28 39|improvement
P01295373A0651|4 13|magnitude
P01295500A0366|12 20|patients
P01296815A0059|26 30|gene
P01297332A0983|5 13|analysis
P01297332T0000|11 19|analysis
P01298173A0153|12 19|history
P01298398A0461|4 10|method
P01299489A0788|26 31|study
P01300914A1066|7 14|absence
P01301171A0979|10 15|cases
P01302765A0999|6 16|components
P01304515A0178|13 20|results
P01304809T0001|4 9|years
P01309244A0798|4 10|target
P01309587A0715|12 27|transactivation
P01309593A0095|4 21|UCR core sequence
P01309593A1092|6 13|studies
P01309815A0972|14 29|scr1-1 mutation
P01309860A0559|13 22|sequences
P01309894A0807|5 10|Rep78
P01309910A0428|0 28|Nucleotide sequence analysis
P01310154A0879|6 13|results
P01310178A0876|4 32|JS78 mutation changes Gln243
P01310879A0000|2 19|patient suffering
P01310899A0339|14 32|receptor structure
P01310935T0000|11 16|UbcD1
P01312005A0600|0 8|Analysis
P01313715A0461|4 8|goal
P01313846A0850|0 10|Comparison
P01313894A1179|17 24|pattern
P01313909A0526|4 14|phenotypes
P01314457T0000|0 8|Analysis
P01314841A0724|0 9|Treatment
P01314953A1266|3 11|contrast
P01315706A0000|9 24|differentiation
P01316125A0176|4 14|experiment
P01316125A0382|4 10|points
P01316459A0311|0 4|Acad
P01316461A1083|26 36|S2 protein
P01316476A0842|15 29|TATA sequences
P01316476A1428|4 7|ORF
P01316680A0643|19 26|IR5 ORF
P01316900A0000|4 16|DNA sequence
P01316903A0296|21 25|form
P01316903A1040|0 18|RNA polymerase IIA
P01317376A0981|0 21|Fructokinase activity
P01318310A0000|0 16|Plasma membranes
P01318739A0410|19 39|patients vincristine
P01320255A0795|6 13|results
P01320640A0336|0 11|Tumor cells
P01321277A0342|24 27|end
P01321277A0664|0 3|ROS
P01321280A0494|14 20|number
P01321332A0970|10 29|transfection assays
P01321336A0000|4 19|enhancer region
P01321336A0731|4 19|splice variants
P01321337A0318|18 27|component
P01321337A1161|31 45|MATa cna1 cna2
P01324172A0880|0 10|Antibodies
P01324385A0329|0 7|METHODS
P01324404A0813|23 40|activation domain
P01324404A1208|0 10|HNF-3 beta
P01324406A1250|9 14|roles
P01324639T0000|0 16|Susceptibilities
P01325221A0870|11 17|arrest
P01325386A0766|4 19|hit1-1 mutation
P01326329A0703|8 24|base pair region
P01326557T0000|0 7|Cloning
P01327280A0000|3 7|rats
P01327758A0000|0 11|Replication
P01327967A0668|12 24|inactivation
P01328197A0985|6 14|findings
P01328219A1397|0 6|NSCL-1
P01328681A0149|19 27|proteins
P01328681A0348|0 7|Ruddell
P01328854T0000|9 19|MEF-2 site
P01328884T0000|0 19|Truncation variants
P01329039A0239|13 28|E-box consensus
P01329039A0951|0 19|Intermediate levels
P01330077A0000|0 20|T-cell receptor beta
P01330309A1134|4 17|CANNTG motifs
P01330975T0000|11 25|polyneuropathy
P01331057A0000|29 34|COX12
P01331060A0768|4 13|structure
P01331086T0000|10 27|promoter elements
P01331292A1425|27 36|instances
P01331501A0397|34 42|peptides
P01331516A0103|6 13|mutants
P01332589A0666|4 8|MICs
P01332964A0247|12 20|promoter
P01333035T0000|0 7|Mapping
P01333047A0404|28 41|growth factor
P01333053A0110|8 17|mechanism
P01333125A0000|2 13|combination
P01333317A1008|12 18|region
P01334428A1102|0 2|Km
P01334493A0289|13 17|form
P01334518T0000|0 10|Strategies
P01337142A2043|16 51|glycoprotein alpha-subunit promoter
P01338867A0503|0 10|Comparison
P01339125A0153|0 18|Laboratory studies
P01339373T0000|0 9|Structure
P01339391A0000|41 47|region
P01339468A0272|4 16|ORF1 protein
P01339773A0000|2 7|total
P01339773A0778|4 17|relationships
P01339815A1545|15 27|correlations
P01340470A0000|15 27|protein gene
P01341119A0450|5 21|research studies
P01346262A0377|14 19|study
P01346534T0000|0 16|Characterization
P01347476T0000|0 7|Mapping
P01347664A1026|5 13|mutation
P01347908T0000|4 13|rationale
P01347944A0964|11 18|studies
P01348504A0757|10 35|pol alpha-primase complex
P01348508A0313|19 28|positions
P01348590A0000|19 27|analysis
P01349705T0000|0 7|Effects
P01349837T0000|0 11|cDNA clones
P01350780A0184|0 30|Amino acid sequence comparison
P01350932A1123|11 15|site
P01352113A0002|20 26|events
P01352113A0231|14 21|effects
P01353478T0000|0 11|Interaction
P01354506T0000|26 34|diseases
P01357190A0726|9 18|exception
P01357528A0084|4 19|subunit protein
P01358190A0654|0 12|Substitution
P01358592A0752|25 32|pathway
P01358758A0000|11 18|portion
P01358880A0251|12 31|amino acid sequence
P01359588A0375|5 16|computation
P01360180A0513|9 16|efforts
P01360180A1568|32 50|P68 amino terminus
P01360294A0000|5 11|August
P01363080A0710|7 13|acuity
P01363166T0001|0 16|Currents aspects
P01364100A0377|3 11|addition
P01370281A0461|0 10|Sequencing
P01370446A0818|6 11|sites
P01371181A0688|16 24|plasmids
P01371272A1167|0 12|Perturbation
P01371275T0000|13 23|expression
P01371413A0742|3 11|addition
P01371863A0000|62 73|gene family
P01372365A1202|8 13|sites
P01372456A0426|0 8|Necrosis
P01372802A1481|3 10|summary
P01372900A0448|6 11|exons
P01372900A1017|44 56|organization
P01373374A0735|0 10|Homodimers
P01374331A0636|8 12|gene
P01374392A0341|4 23|hydrophobicity plot
P01374398A0951|12 31|translation protein
P01374688A0471|5 10|group
P01375224A0152|24 32|evidence
P01375913A0484|37 57|DNA oligonucleotides
P01376319T0000|0 4|Gene
P01377696A0000|4 9|chick
P01377764A0309|4 13|carcinoma
P01377818A0468|3 11|addition
P01377962A1012|3 11|contrast
P01378052A0594|8 12|acoR
P01378127A0841|13 20|effects
P01378431A0202|0 2|C.
P01378506A0884|18 38|full-deletion mutant
P01378526A0535|34 53|FK506 plasma levels
P01379032A0495|7 14|percent
P01379150A0996|6 17|cibenzoline
P01380062A0097|0 9|T antigen
P01380076A0165|4 10|method
P01380454A0451|29 44|protein product
P01380716A0174|11 18|tissues
P01380825A0622|0 22|Northern blot analyses
P01383690A1023|4 18|ARG SH2 domain
P01383695A0100|15 31|EBV B-cell clone
P01384040A1043|20 30|activation
P01384165A0000|3 7|rats
P01384229A0175|31 35|role
P01385462A0151|65 69|runs
P01386210A0293|25 28|use
P01386897A0000|0 5|Entry
P01387105A0933|8 30|Southern blot analyses
P01388160A1102|6 21|residue Glu-381
P01389362T0000|0 9|Porcelain
P01389573A1071|0 4|TBPf
P01389585A0825|22 32|Scotchbond
P01391001A0583|30 44|yeasts species
P01392012A0228|21 32|vasopressin
P01392277A0000|0 8|Comments
P01392358A0389|6 11|reply
P01394200A0592|4 19|treatment group
P01394655A0615b|0 15|Urease activity
P01395755A1023|26 37|differences
P01396432A0388|16 21|range
P01396444A0934|4 15|experiments
P01396572A0320|23 36|plasmid pUC19
P01396583A0204|2 14|cDNA library
P01396592A1113|4 15|experiments
P01396601A0986|3 11|contrast
P01398068A0948|0 9|Complexes
P01398071A0526|6 17|temperature
P01398073A0986|6 13|results
P01398074A0697|4 17|gene sequence
P01398074A1081|4 22|RNase MRP RNA gene
P01398098A0770|0 20|Clone pSRc200 hybrid
P01398104A0834|11 18|results
P01398106A0754|0 8|Cleavage
P01398140A0488|18 33|Xenopus U7 gene
P01399206A0375|4 11|results
P01400217T0000|11 19|analysis
P01400396A1265|4 12|promoter
P01400401A0065|3 9|humans
P01400401A0854|0 21|Western blot analyses
P01400775A0435|6 13|results
P01402647A0114|0 13|DR1 molecules
P01403222A0391|5 12|article
P01403391T0000|8 19|hepatitis B
P01404401A0740|11 25|ATPase cluster
P01404612A0303|29 32|Ads
P01406630A0545|0 9|Alignment
P01406630A0965|15 18|p50
P01406656A1075|18 23|clone
P01406677A0000|26 42|control elements
P01406688A0898|0 19|Sequencing analysis
P01406703A1435|15 35|Y1 cell cDNA library
P01407286A0427|0 7|Autopsy
P01408090A0572|4 13|technique
P01408137A0974|4 12|sequence
P01408219A0670|13 21|patients
P01408474A0531|0 14|PaO2 threshold
P01409581A0206|23 26|E26
P01409643A0618|9 31|lambda gt11 expression
P01410071T0000|0 12|Blood levels
P01413984A0737|23 29|effect
P01414219A0319|13 23|volunteers
P01418272A1072|8 13|ng/mL
P01418494T0000|9 15|spikes
P01418542A0000|4 10|effect
P01418834A0987|14 33|hematocrit decrease
P01418860A0797|4 11|effects
P01419945A1386|0 12|Localization
P01420177A1065|0 12|Substitution
P01420223T0000|0 12|Significance
P01420363A0818|4 8|TIMP
P01420363T0000|0 11|Involvement
P01420579A0292|7 25|serum neutralizing
P01421145A1190|0 13|Fractionation
P01421390T0000|13 18|trial
P01421609A1067|6 10|data
P01422265A0263|4 24|IgG subclass profile
P01423454A0309|0 11|Examination
P01423738A0639|13 17|hand
P01424674A0000|12 22|pemphigoid
P01425653T0000|4 11|effects
P01425921A1286|19 27|features
P01426635A0496|12 19|profile
P01427034A0440|11 18|introns
P01427457A0000|38 43|trial
P01428490A0671|12 22|prevalence
P01428513A0440|53 60|persons
P01429596A1669|7 12|basis
P01429624A0328|4 9|shift
P01429714A0730|0 4|Clin
P01429724A0664|4 8|data
P01429740A1065|45 56|presequence
P01429768T0000|6 25|neutrophil response
P01429836A0457|0 10|Disruption
P01429836A1205|9 13|form
P01431380A0244|17 31|field research
P01431602A0229|11 17|method
P01431809T0000|0 19|Nucleotide sequence
P01432453T0000|0 10|Validation
P01433391A0594|5 16|consequence
P01433502A1163|6 13|results
P01433524A0788|9 15|domain
P01435698A0000|3 8|order
P01436261A0145|0 27|Subcutaneous administration
P01437562A0462|9 19|antibodies
P01438224A0749|57 59|J.
P01438287T0000|15 30|vaccinia vector
P01441120T0000|0 3|Use
P01441818T0001|0 15|Interferon type
P01443047A0773|9 16|changes
P01443745T0000|12 23|interaction
P01443748A1190|4 12|pressure
P01446132A0328|4 16|air embolism
P01446828A1088|7 13|region
P01447139A0208|0 2|V.
P01447189A1546|6 10|data
P01447189T0000|0 12|Purification
P01448107A0361|29 43|GCN2 mutations
P01448806A0135|0 14|Administration
P01448917A0775|0 11|Comparisons
P01448932T0000|0 47|Rice dwarf phytoreovirus segment S12 transcript
P01449183A0795|3 11|addition
P01449301A0710|0 17|Cold cardioplegia
P01450815A0337|4 12|addition
P01451771A0619|15 23|analyses
P01452037A0000|15 20|genes
P01452584T0000|23 33|exotoxin A
P01452703A0782|0 18|Laboratory studies
P01454518A0336|13 25|significance
P01454819A0000|0 21|Mono-ADP-ribosylation
P01456888A0074|9 15|reason
P01457380A0000|4 13|tramtrack
P01457695T0000a|0 7|Removal
P01457695T0000b|0 7|Removal
P01458170A0155|0 10|Adapromine
P01459447A0484|6 15|sequences
P01459451A0478|19 33|antirepression
P01459885A0705|9 13|days
P01459921A0000|41 58|Hampshire wethers
P01460054A0478|10 15|ICSBP
P01460054A0968|11 16|ICSBP
P01460772T0001|2 6|case
P01462786T0000|0 23|Dynamic decision making
P01464329T0000|22 29|protein
P01464606A0344|11 18|amounts
P01467088T0075|0 9|Abstracts
P01467828A0542|6 13|results
P01468625A0282|10 17|library
P01468625A1080|13 17|ACT1
P01469042A0355|6 17|CENP-B gene
P01469047A1606|17 24|portion
P01470243A0871|16 24|subgroup
P01470741T0062|0 12|Distribution
P01471602A0362|16 19|use
P01473196A1016|24 36|reabsorption
P01473207A0582|23 31|findings
P01473234A1001|0 12|Green pepper
P01474990A0000|10 15|clone
P01475381T0001|0 11|Brucellosis
P01476376T0000|0 5|Assay
P01477021A0394|0 7|RESULTS
P01478672A0795|4 15|phage clone
P01480183A0000|16 22|region
P01480183A1689|25 35|mechanisms
P01480470A0323|0 6|BiP670
P01482912A0617|4 7|CEM
P01483755A0000|9 31|resonance spectroscopy
P01483771A1335|25 27|NA
P01485648A0000|31 36|value
P01486836A0774|0 8|Patients
P01487144A0505|18 30|gene segment
P01490493A0416|5 9|part
P01492463T0001|0 5|Alena
P01493864A0619|0 16|Dopamine neurons
P01495069A0392|0 4|DIBA
P01496348A0000|0 6|Caries
P01496784A0939|4 11|results
P01497582A0593|15 20|group
P01498607A0000|11 31|nucleotide sequences
P01499213A0185|4 8|case
P01499616A0136|9 19|blood flow
P01502157A0000|0 5|ME1a1
P01504178T0000|16 21|years
P01504853A0299|10 14|LHRH
P01505488A0231|26 34|patients
P01505516A0928|23 27|acid
P01506705A0282|7 17|V-A bypass
P01506746A0476|0 21|Greater rupture force
P01509798A0520|3 11|rest AFF
P01511231A0085|20 34|smoking habits
P01511950T0000|0 8|Exposure
P01512259A0867|23 33|phenomenon
P01512654A0503|13 17|hand
P01512941A0000|50 62|levofloxacin
P01513114A1133|9 32|serum creatinine levels
P01513213A0231|0 17|Model predictions
P01516427T0000|25 35|tomography
P01516829A0113|27 31|SNF2
P01516829A0460|13 22|LexA-GAL4
P01518396T0000|0 9|George T.
P01518833A0397|2 26|lambda gt10 cDNA library
P01518849A0165|0 2|NE
P01518926T0000|9 15|topics
P01522699A0092|0 7|Methods
P01523111A0769|0 7|Factors
P01524549A0241|5 18|GH deficiency
P01525153A0359|3 11|contrast
P01525966T0000|28 34|stones
P01526658A0454|0 3|IFI
P01526690T0000|19 25|action
P01527020A0511|12 21|junctions
P01529530T0000|25 40|gene expression
P01531086A0127|4 8|cDNA
P01531214A0885|10 14|LD50
P01531632A0000|14 22|proteins
P01532229A1264|11 16|study
P01532796A0107|0 9|Mutations
P01532914A0067|0 7|Expense
P01533760T0000|0 28|Estrogen replacement therapy
P01535242A0557|10 16|FDC-P1
P01536153A0574|34 44|difference
P01536575A1213|14 21|finding
P01537334A0507|4 8|gene
P01537845A0571|24 36|c-myb clones
P01538401A1244|5 30|base-pair oligonucleotide
P01538403A1058|14 28|reconstitution
P01539996A0588|2 12|comparison
P01541556A1040|14 23|palmitate
P01541577A0000|3 12|volunteer
P01542565A0220|7 26|tobacco L12 protein
P01542565T0000|38 49|protein L12
P01542667A0125|4 8|gene
P01542686A0000|10 17|cloning
P01542730A1982|44 50|pacing
P01543909A0787|34 44|K562 cells
P01544854A0699|7 12|drugs
P01544918A1240|0 16|Characterization
P01544928A1252|0 10|Comparison
P01545523A0000|19 34|quantifications
P01545787A0345|17 25|enhancer
P01545792A0000|12 32|myosin light chain-2
P01545792A0492|0 20|Deletion mutagenesis
P01545797A0587|0 20|Disruption mutations
P01545806T0000|22 30|analysis
P01545818A0696|4 8|p130
P01546522A0000|0 8|Probable
P01547775A1024|6 10|data
P01547787A0548|0 21|Proprotein processing
P01547942A0120|14 17|LAP
P01547957A1083|19 43|oligodeoxyribonucleotide
P01548756A1102|10 23|hybridization
P01548891A0635|4 9|level
P01549118A0000|4 45|Caenorhabditis elegans vitellogenin genes
P01549123A0480|4 13|MET4 gene
P01549125A0140|4 13|functions
P01549129A0356|26 33|domains
P01549346A0000|4 23|c-Ets-1 oncoprotein
P01549465A0122|9 36|transactivation experiments
P01551176A0000|0 8|GR63178A
P01551568A1476|0 22|Marker rescue analysis
P01551898A1084|5 11|vector
P01551910A0313|0 20|Competition analysis
P01551910A0978|5 14|DNA motif
P01552052A0139|0 9|OBJECTIVE
P01552457T0000|0 24|Intrapocket chemotherapy
P01552662A0398|16 26|blood flow
P01552853A1377|6 17|temperature
P01553407T0000|0 8|Problems
P01554334A0000|23 39|gamma-interferon
P01555556A0565|0 15|Control Tmuscle
P01556068A0000|4 34|Klebsiella aerogenes gene maoA
P01556111A0241|15 22|regions
P01557217A0272|39 46|lesions
P01557411A1282|16 24|D1A gene
P01558942A1369|8 20|observations
P01559209T0000|0 13|Preceptorship
P01560021A0379|25 30|basis
P01560774A0885|8 10|kb
P01562659A0676|0 11|Institution
P01563343A0548|0 13|Lac operators
P01563635T0000|0 14|Overproduction
P01564653A0307|8 17|companies
P01565093A0179|5 10|March
P01565882A0737|17 24|changes
P01566576A0605|0 4|Keck
P01567649A0139|17 18|%
P01568960A1129|11 20|mechanism
P01569015A0120|16 21|FRAME
P01569102A0708|0 6|Domain
P01569344A0404|8 14|cities
P01569581A0482|17 25|evidence
P01569584A0672|0 18|Hybridization data
P01569945A0529|4 13|SEN1 gene
P01572549A0000|0 24|Protein tyrosine kinases
P01573270A0000|4 11|IA4 mAb
P01577056A0178|40 45|study
P01577740A1111|0 16|Primer extension
P01577819A0709|12 33|PRP-precursor alleles
P01579472A1018|19 35|enhancer element
P01579537A0000|15 20|years
P01580738T0001|0 9|Allagille
P01581409A0398|0 11|Sensitivity
P01581577A1186|0 5|PSI-G
P01581965A0388|7 17|C-terminus
P01582413A0192|14 25|mutagenesis
P01582413A0759|0 12|Dimerization
P01582500A0178|14 25|rhythmicity
P01583819A0377|0 3|SEA
P01584812T0000|16 26|expression
P01585014A0000|3 13|experiment
P01586901A0000|10 22|interactions
P01587267A1144|4 17|sequence data
P01587763A0402|6 22|body irradiation
P01588270A1029|2 11|reduction
P01588315A0356|0 6|AgMNPV
P01588913A0000|2 6|gene
P01588961A0000|0 4|STP1
P01588963A1153|12 22|antibodies
P01588965A0000|0 18|GCR1 gene function
P01589576A0170|4 16|decay curves
P01592545A0726|24 38|blood pressure
P01594554A0845|6 13|results
P01596007A0908|12 18|events
P01597170A0000|6 13|rabbits
P01597272A0077|3 8|women
P01597462A0457|0 10|Disruption
P01600531A0483|9 13|flow
P01601181A0842|4 19|60A transcripts
P01601869A1389|9 16|segment
P01603088A1121|6 13|results
P01605038T0001|0 9|Influence
P01607223A0000|7 21|investigations
P01608239T0001|16 24|barriers
P01611699A0000|6 28|pyridoxine derivatives
P01612085A0624|4 24|serum erythropoietin
P01613640A0158|4 21|coating materials
P01615049A0000|4 10|eating
P01615182A0206|12 17|study
P01615493A0408|4 6|HC
P01615493A0975|0 10|Argatroban
P01616475A0756|6 13|results
P01617242T0000|0 15|FDA regulations
P01617776A0343|31 37|system
P01617801A0088|0 6|DESIGN
P01618027A1108|16 27|transcripts
P01618243T0000|12 31|amine pressor tests
P01618256A0521|4 8|mean
P01619114A0383|14 19|study
P01619642A0131|5 12|parents
P01620118A0470|13 21|proteins
P01620129A0417|22 33|interaction
P01620610A1070|3 13|conclusion
P01620781A0611|19 27|subjects
P01621584A0183|0 6|UF-021
P01623900A0670|6 20|blood pressure
P01624425A0907|10 17|protein
P01625131A0452|18 24|biopsy
P01625527A0000|6 28|blood serotonin levels
P01626372T0000|0 7|Tissues
P01626430A1112|4 14|homologies
P01626440A0449|8 29|application solutions
P01626631A0557|7 20|Rett syndrome
P01627106A0320|13 23|experiment
P01627828A0475|3 12|agreement
P01627830A0000|4 9|cDNAs
P01628201A0824|0 14|Incidence rate
P01628806A1347|13 31|sequence variation
P01628904A0386|10 19|screening
P01629768A0131|0 7|Lesions
P01630454A0635|8 12|poly
P01630455A0448|16 23|protein
P01630569A0605|9 23|amphotericin B
P01631229T0000|0 13|Cutis aplasia
P01633435A0743|4 9|DRF-2
P01633816A0667|15 20|clone
P01634308A0191|0 27|Cardiovascular risk factors
P01634400A1101|0 16|Production costs
P01634464A0163|12 19|patient
P01634861A1336|11 19|contrast
P01636339A0200|0 7|Account
P01636714A0845|4 11|results
P01637758A0532|3 11|addition
P01639092A0776|0 5|Lewis
P01639724A0452|2 15|control group
P01640778A0485|24 30|method
P01641628A0869|4 14|modalities
P01642060A0471|13 24|application
P01643943A0300|14 33|lung cancer tissues
P01644751A0590|10 23|reading frame
P01644796A0374|8 13|study
P01644814A0068|4 9|virus
P01644821A1259|9 17|butyrate
P01644831A0824|3 14|examination
P01645902A1462|17 24|results
P01645905A0341|0 13|Nucleoprotein
P01646157A0414|33 59|alpha-GalNAc cDNA sequence
P01646487A0874|0 8|Patients
P01646753A0336|4 10|reason
P01647070A0232|11 25|JCV T antigens
P01647656A0000|4 12|relation
P01647813A0512|11 21|transcript
P01648142A1170|3 11|patients
P01648530A0000|17 25|M region
P01649173A0160|3 11|addition
P01649318A0734|0 6|EBNA-2
P01649318A1222|6 17|experiments
P01649539T0000|0 16|Plasma vitamin E
P01649835A0822|31 43|PBR/IBP cDNA
P01650524A0837|12 17|phase
P01650557T0000|11 18|results
P01651232A0152|5 9|mRNA
P01651918A0000|47 61|cDNA fragments
P01652372A0153|19 23|SWI5
P01652515A0379|3 11|contrast
P01652755A1492|21 45|transfection experiments
P01653173A0619|5 15|repression
P01653236A0895|18 21|p50
P01653238A1062|13 50|12-O-tetradecanoyl-phorbol-13-acetate
P01653238A1715|0 3|TPA
P01653918A0286|38 46|pressure
P01654349A0327|0 11|Feed intake
P01655126T0000|0 20|Extraction procedure
P01655713A0294|8 13|study
P01656220T0000|0 3|axl
P01656221A1319|0 9|Alignment
P01656235A0946|26 33|element
P01656675A0236|0 18|Capnography curves
P01657246A0325|4 33|transcription initiation site
P01657249A1019|22 24|CA
P01657415A0837|0 16|Intron K1 cox1.2
P01657594A0472|28 35|mutants
P01657969A1420|9 20|alterations
P01658356A1369|4 11|results
P01658356T0000|0 13|Recombination
P01658375A0854|4 24|nucleotide sequences
P01658468A0123|15 21|months
P01658741A1047|4 12|strategy
P01659685T0000|16 25|promoters
P01660486A1756|4 11|results
P01660925T0000|0 18|Transfer RNA genes
P01661369A0825|15 19|strD
P01662609A0398|8 13|genes
P01662794A0640|0 10|Expression
P01662807A1182|4 10|factor
P01662884A1029|0 12|Temafloxacin
P01664192A1577|18 25|effects
P01669611A0142|4 11|patient
P01671675A0483|14 25|clone pKB11
P01671675A0905|5 15|conclusion
P01673220A0578|14 23|isolation
P01674177T0001|0 20|Histamine-2 blockade
P01674242A0358|4 13|clearance
P01674369A0417|21 28|element
P01674662A0000|38 52|heroin addicts
P01674817A0862|3 11|homology
P01674817T0000|0 9|Mutations
P01675154T0000|11 21|infarction
P01675424A0991|18 28|difference
P01675637T0033|9 30|amino acid difference
P01675763A1389|8 16|benefits
P01678287A1308|18 44|Antp TATAA binding protein
P01678392A0648|6 25|% confidence values
P01679068A0000|10 17|infants
P01679124A1368|12 19|studies
P01679749A1171|4 16|localization
P01681075A0429|8 11|min
P01682484A0680|16 24|stenosis
P01682509A0539|16 24|evidence
P01682542A0690|5 12|country
P01684791A0000|15 22|element
P01686909A0299|13 21|increase
P01687050T0000|11 16|value
P01688841A0430|0 10|Expression
P01688972A0803|10 12|VT
P01690703A0285|0 10|Venkatesan
P01690728A1166|4 12|presence
P01690812A0000|16 17|%
P01691184A0995|0 6|Gap b3
P01692135A0783|13 42|rtFc gamma R alpha cDNA clone
P01692837A0390|5 10|genes
P01692962A0980|7 17|expression
P01694009A0112|5 9|exon
P01694014A0716|0 9|Treatment
P01694280A0000|27 42|ventriculoscope
P01694525A0000|0 25|Isopenicillin N isomerase
P01695098A1116|0 9|Serum IgG
P01695116A0078|4 11|patient
P01695314A0762|11 16|mg/dl
P01695314T0000|0 20|Platelet aggregation
P01695322A0000|0 5|Wnt-1
P01695378A1406|0 9|Induction
P01695905A0480|0 10|GLUT5 mRNA
P01697611A0738|24 30|tumors
P01697683T0000|0 14|Identification
P01697928A1214|26 43|sequence homology
P01698761A1059|17 35|DNA rearrangements
P01698772A0238|7 9|J.
P01699944A1538|6 13|results
P01700272A0838|0 15|Polyadenylation
P01701088A1335|0 12|Co-existence
P01702361A0621|10 17|studies
P01702426A0196|22 28|region
P01702426A1006|6 9|set
P01702432A1296|0 26|Northern blotting analysis
P01702972A0613|8 26|cDNA hybridization
P01703335T0000|20 29|disorders
P01703632T0000|15 25|suppressor
P01707659A0458|64 68|gene
P01707800A0354|13 39|N13-N20 interpeak interval
P01708098A0922|20 46|complex DNA binding assays
P01708771A1215|0 22|Sequence determination
P01708774A0203|4 16|DNA sequence
P01709486A0000|11 19|mutation
P01709933T0000|0 9|Isolation
P01710766A0349|4 12|proteins
P01710768A1172|4 11|results
P01710979T0000|4 7|SH2
P01710985A0315|0 4|Chem
P01711041A0348|6 12|clones
P01711041A0962|4 18|C5 alpha-chain
P01711048T0000|13 21|mutation
P01712296A0157|4 24|nucleotide sequences
P01713213A0000|4 11|protein
P01713213A0488|20 30|pim-1 cDNA
P01714322A0969|5 11|report
P01714358A0990|7 22|kDa polypeptide
P01714452A0559|0 8|Homology
P01714902A0221|3 11|addition
P01715593A0838|5 16|desipramine
P01715975A0885|9 16|effects
P01716292A0000|12 20|analysis
P01716629A0000|17 28|cDNA clones
P01717718A1255|14 29|point mutations
P01717833A1223|4 26|alpha inhibin promoter
P01717833T0000|0 10|Regulation
P01717925A0477|0 10|Comparison
P01717994T0000|0 7|Cloning
P01718043A0384|3 11|patients
P01718983A1640|0 2|E.
P01719684A0494|10 17|results
P01720555A1087|28 41|B2 transcript
P01720843A1506|6 13|results
P01721261T0000|0 16|Pharmacokinetics
P01721884A0962|31 36|match
P01722319A0849|0 8|Analysis
P01722479A0302|16 30|concentrations
P01723619A0766|12 16|rate
P01723962A0165|4 12|activity
P01724982A0237|50 61|HCV EIA kit
P01725547A0354|0 9|Diltiazem
P01725622A0292|10 21|transfusion
P01726211A0502|6 18|risk factors
P01726631T0001|0 12|Epidemiology
P01727488A1146|18 23|cDNAs
P01727494A0000|0 14|Vaccinia virus
P01730412T0000|0 3|Max
P01730747A0205|18 20|G1
P01731107A0928|0 13|Substitutions
P01731933T0000a|0 2|Zn
P01731933T0000b|0 2|Zn
P01731979A1408|4 22|tissue specificity
P01732033A0000|4 19|pathophysiology
P01732736A1076|0 11|Transcripts
P01732752A0156|14 21|B cells
P01733105A0127|4 10|genome
P01733358A0240|6 12|tumors
P01734020A1318|0 14|Immunostaining
P01734283A0817|32 45|RAP74 protein
P01734570T0000|0 7|Effects
P01735347A0482|23 29|insult
P01735447A0271|4 8|size
P01735447A0833|10 30|active-site mutation
P01735721A0185|14 33|amino acid sequence
P01736093A0731|15 27|CAT activity
P01736651A0104|9 14|Women
P01736844T0000|0 12|Testosterone
P01737741A0000|0 10|BACKGROUND
P01737789A0800|25 35|breakpoint
P01738470A0441|0 8|Patients
P01738653T0014|0 4|Bone
P01738936A0292|4 12|patients
P01739439A0257|0 7|Complex
P01739956A0638|0 10|Management
P01740121A0136|17 24|problem
P01740330A0329|0 2|J.
P01740437A0851|17 29|core protein
P01740448A1735|17 38|transmembrane regions
P01740682A0703|0 8|Toxicity
P01741249A0177|0 4|W.G.
P01742341A0499|5 10|study
P01742606A0000|2 27|mouse brain beta-spectrin
P01742879A0471|0 7|RESULTS
P01744039A0511|4 13|fragments
P01744042A1355|4 15|csbA fusion
P01744119A0757|4 15|constraints
P01747972T0000|13 20|therapy
P01748067A0000|14 19|trial
P01748194A0767|10 17|lesions
P01748287T0000|18 26|proteins
P01748292A0000|17 22|cDNAs
P01748630A0125|0 25|Growth factor stimulation
P01751163A0000|4 11|authors
P01751255A0529|8 14|output
P01751970A0209|0 19|Amino acid residues
P01752441A0000|16 26|activation
P01752792A0000|25 33|evidence
P01753317A0879|6 13|results
P01754381A0000|14 18|step
P01756195A1117|3 11|addition
P01756539A0354|10 22|hypertension
P01757341A0591|4 19|volume fraction
P01758750A0000|0 15|Airway pressure
P01759052A0786|0 4|Appl
P01759282A0000|0 6|Issues
P01760166A0963|0 10|CONCLUSION
P01761736A0158|0 9|Diltiazem
P01762053A0557|4 12|granules
P01762914A1218|11 23|uPA promoter
P01762917A0615|15 18|Ser
P01763065A0913|0 2|P.
P01763106A0070|20 28|behavior
P01764899A0399|4 9|model
P01765095A0680|0 36|12-O-Tetradecanoylphorbol 13-acetate
P01765266A0000|3 17|Xenopus laevis
P01765269A0308|6 13|introns
P01765375A0290|4 8|mRNA
P01765386A0305|8 14|report
P01765407A0866|7 15|exposure
P01766666A0788|0 10|Antibodies
P01766876A0000|2 8|method
P01766999A0000|11 19|activity
P01767060A0000|5 10|study
P01767592A0682|25 34|sequences
P01767899A0136|7 23|thrombocytopenia
P01768648A0853|15 25|properties
P01769189A0000|0 12|Plasma lipid
P01769919A0393|9 25|threshold shifts
P01770651T0001|25 35|evaluation
P01771593A1152|17 19|TA
P01771593A1232|17 23|adults
P01771959A0442|6 10|PTCA
P01772201T0001|14 21|patient
P01772341A0852|6 10|data
P01774062A0257|9 12|YAC
P01774063A0161|14 32|backcross analysis
P01774093T0000|15 22|outcome
P01774822A0289|26 34|computer
P01776306A0572|12 19|patient
P01776715A0489|3 8|delay
P01777841A0744|13 23|mechanisms
P01779299A0000|23 34|alterations
P01779433A0694|11 18|finding
P01779769A0000|4 12|sequence
P01780235A0094|4 14|EPO levels
P01781923A0744|18 29|sensitivity
P01782424A0278|4 13|existence
P01782669A0496|36 48|temperatures
P01782982A0155|0 10|Felodipine
P01783088A1136|14 22|patients
P01783375A1066|4 11|mapping
P01784589A0000|41 45|role
P01785749A0695|6 13|changes
P01786094T0001|8 16|contents
P01787085A0331|13 24|experiments
P01788002T0001|0 14|Magnetotherapy
P01791363A0208|6 13|results
P01791754T0000|11 19|analysis
P01792580A0198|6 18|blood donors
P01792914T0000|15 22|relapse
P01797459A0103|0 10|Mycoplasma
P01797467A0000|0 5|RU486
P01798407A1011|4 12|presence
P01804671A1001|3 7|line
P01806314A0322|5 10|cells
P01808049A0262|0 16|CT abnormalities
P01808136T0000|4 11|effects
P01808186A0984|0 4|Pigs
P01808602A0000|11 19|patients
P01808829A0510|0 4|TPTA
P01809854A0106|0 8|Examples
P01810108A0000|6 21|phase slug flow
P01810154A0491|10 18|children
P01811243A0000|0 8|Regional
P01811948A0289|15 20|study
P01812102A0101|12 25|study reports
P01812690A0475|3 7|case
P01814182A0000|10 15|doses
P01816655T0000|0 6|Review
P01817497A0715|0 10|Resolution
P01822581A0533|7 16|instances
P01822995T0000|0 28|Maize rbcS promoter activity
P01823520A0183|0 12|Measurements
P01823524A0238|22 28|number
P01824713A0964|4 19|12S E1A product
P01824944A0988|6 15|treatment
P01825027T0000|0 4|PAS1
P01826003A0694|4 8|gene
P01826043A0431|4 35|pp90rsk-protein kinase activity
P01827068T0000|6 12|GATA-3
P01827203A0136|21 42|transcription factors
P01828248A0189|17 29|UvrA protein
P01829060A0649|4 15|ED30 values
P01829460A0329|0 26|Southwestern blot analysis
P01830114A1587|19 25|effect
P01830928A0361|23 41|microtubule motors
P01832019A0265|77 84|animals
P01832152A0000|4 39|incompatibility group W plasmid pSa
P01832152A0902|24 37|start signals
P01832197T0001|0 7|Imaging
P01833185A0547|4 22|Thr161Val mutation
P01833637A0531|4 13|abundance
P01833716A0990|0 12|Deregulation
P01837787T0000|11 22|Mov-34 gene
P01837842A1410|0 4|CREB
P01839414T0000|4 12|spectrum
P01840513A1019|33 43|SL-2 cells
P01840607A0294|29 33|UTRs
P01840608A0823|4 14|N-terminus
P01840711A0000|4 14|RNA genome
P01840902A1089|31 37|system
P01842498A0000|8 18|cDNA clone
P01842867A0696|3 13|conclusion
P01844017A0410|24 36|relationship
P01844878A0000|2 8|vector
P01844982A0324|0 6|Chagas
P01845829A0158|9 17|analysis
P01845885A1003|27 31|unit
P01845899A0000|21 26|virus
P01846206A0665|9 15|region
P01846489A1119|40 55|protease domain
P01846491A0459|22 31|positions
P01846803A0688|5 11|result
P01847464A0856|14 29|cotransfections
P01847665A1079|4 12|findings
P01848300A0910|11 19|evidence
P01848871A0392|5 10|study
P01849509T0000|0 14|Identification
P01849675A0167|17 29|relationship
P01849734A1063|10 30|PR55 beta transcript
P01850096A0662|0 12|Heterodimers
P01850105A1093|4 11|effects
P01850127A0000|7 18|association
P01850893A0286|19 29|antibodies
P01851386T0092|12 34|Lung Cancer Task Force
P01851527T0000|4 21|promoter activity
P01851756A0743|0 4|Biol
P01851862A0273|0 20|Nucleotide sequences
P01851876A0129|5 12|element
P01852438A0928|4 13|MVV-value
P01852603A0000|4 8|rad9
P01853796T0000|0 6|Review
P01854339A0221|7 13|region
P01855255T0000|10 20|initiation
P01856021A0577|4 10|method
P01857143A0351|4 11|patient
P01857326A0160|0 10|Oculus-500
P01860846A0663|10 14|cDNA
P01861034A0798|6 15|resection
P01861188A0000|0 12|Plate luting
P01862027A0212|6 14|features
P01862455T0000|0 16|Thyroid lymphoma
P01863768A0649|4 11|protein
P01863887A0174|0 17|Space limitations
P01864510A0946|0 10|Dd PK1 RNA
P01864821A0000|12 17|forms
P01864837A1029|12 21|structure
P01865010A0000|0 8|Patterns
P01867069A0000|6 15|CD-1 mice
P01869565A1254|0 3|USF
P01869907A2146|4 24|across-fiber pattern
P01869968A0000|9 30|radioactivity content
P01869968A0673|7 26|regression analysis
P01870194A0302|6 33|immunodeficiency virus type
P01870428A0677|0 11|Thigh girth
P01870500A0276|0 13|Contributions
P01871033A0434|0 5|Tests
P01871135A0295|4 8|cDNA
P01871971A0836|0 8|Analysis
P01872856A0277|0 8|Recovery
P01873999A0000|56 68|model system
P01874195A0139|28 39|GH receptor
P01874752A0948|47 66|conditions cdc2/p58
P01875922A0770|0 17|Mutation analysis
P01876836T0000|0 14|Identification
P01878489A0959|14 22|response
P01878755A0496|7 12|ileum
P01881595A0476|0 8|Formalin
P01881671T0001|0 6|Uptake
P01882240A0526|21 30|attention
P01882386A0000|4 17|effectiveness
P01883992A0922|6 13|results
P01884435A0088|5 10|study
P01884998A1135|4 11|members
P01885006A0995|4 11|domains
P01885613A1298|0 11|Information
P01885752A0198|0 21|Chlamydia trachomatis
P01885915A0000|15 25|infections
P01886043A0380|4 7|SMX
P01886368A0000|0 16|PO2 measurements
P01886774A0000|27 34|domains
P01888896A0505|2 17|deletion series
P01889753A0441|4 14|nucleotide
P01890362A0305|10 18|patients
P01890989A1392|36 44|elements
P01892680A0907|0 8|Toxicity
P01893195A0000|24 31|monkeys
P01893927A0704|25 33|pressure
P01894696A0301|0 2|J.
P01895358A0000|0 6|Limits
P01895370A0199|14 24|reductions
P01895384A0746|4 20|IE0 gene product
P01895393A0745|10 19|promoters
P01895555T0001|0 10|Evaluation
P01896777T0000|0 17|Ivermectin uptake
P01897515A0348|0 25|Bone marrow abnormalities
P01898113A0265|12 23|uptake rate
P01898164A0839|37 43|repair
P01898928A0260|0 26|DNA hybridization analysis
P01899209A0883|0 9|Increases
P01899287A0726|0 10|Expression
P01899409T0000a|0 12|Determinants
P01899846A0862|15 30|rbcL-rbcS locus
P01900194T0000|0 12|Relationship
P01901405A0694|0 8|Analysis
P01901443A0297|14 22|patients
P01901664T0064|2 7|cases
P01901859A0000|0 7|UDP-Gal
P01901946A0243|12 27|oligonucleotide
P01901950T0000|0 21|Sequence requirements
P01903404A0688|17 34|ejection fraction
P01903841A0125|11 26|lysine residues
P01903841A1449|4 29|plasmid shuffle technique
P01904154A0164|15 19|case
P01904437A0000|0 13|Transcription
P01904546A0671|0 10|Disruption
P01905199A0210|4 10|effect
P01905517A1076|4 7|ORF
P01906111A1295|5 10|study
P01906166A0119|0 11|Mitomycin-C
P01906509A0072|8 13|study
P01906692A0321|0 13|INTERVENTIONS
P01907265A0670|28 34|result
P01907941A0275|14 28|I kappa B beta
P01909027A0922|0 17|Sequence analysis
P01909621A0119|21 33|hemodialyses
P01909960A0134|14 23|injection
P01910505A0000|7 25|wuzi yanzong pills
P01911767T0000|0 9|Mutations
P01913955A0177|15 22|changes
P01915580A0889|6 13|results
P01916168A0969|3 8|study
P01916405A0242|10 26|mucosa tattooing
P01916632A0431|9 19|production
P01917943A0621a|0 17|Sequence analysis
P01917943A0621b|0 17|Sequence analysis
P01917962A0152|4 16|cDNA segment
P01918010A0000|0 18|Lipoprotein lipase
P01918010A1730|0 8|Deletion
P01918070A0281|16 23|binding
P01918073A0150|0 10|Comparison
P01919831T0000|12 31|management casebook
P01921463T0000|3 20|ASSEMBLER routine
P01922082A0149|0 10|Expression
P01922734T0000|0 11|Habituation
P01922739A0336|22 26|ROSP
P01923167A0000|0 29|Blood flow velocity waveforms
P01923628T0001|13 21|analysis
P01923766A0485|0 17|Sequence analysis
P01923803A0609|0 8|Position
P01923985A0111|0 8|Symptoms
P01924315A0158|7 12|yeast
P01924920A0115|13 20|samples
P01925092A0000|9 22|investigators
P01925092A0304|12 17|hours
P01927421A0181|17 29|examinations
P01927845A0107|10 20|morphology
P01928923A0000|0 13|Equine amnion
P01930470A0337|26 35|incidence
P01930660T0000|13 26|growth factor
P01931966A0490|0 6|Fusion
P01932650A0435|3 8|group
P01932695A1155|4 15|suppression
P01933614A0406|4 10|effect
P01934378A1219|9 40|muscle metaboreceptor responses
P01934378T0000|9 49|muscle metaboreceptor exercise responses
P01936213T0000|0 10|Evaluation
P01936348A0155|4 16|examinations
P01936997A0795|0 19|RNA gel retardation
P01937790A0292|4 11|vaccine
P01937989A0383|5 11|groups
P01938178T0000|0 12|Applications
P01939131A0871|4 13|construct
P01939199A0588|18 23|TFIID
P01939827A0150|13 25|pretreatment
P01939878A0765|17 31|solidification
P01939899A2043|8 13|model
P01939906A0233|5 19|generalization
P01942033T0000|0 13|Determination
P01943184A1050|12 17|cells
P01945430A0660|13 22|technique
P01947449A0191|4 10|effect
P01947449A1082|4 24|Diffusion limitation
P01948783A0000|21 27|effect
P01952827A0215|7 11|time
P01954355A0997|0 19|Monitoring patients
P01954835A0000|0 23|Echinococcus granulosus
P01956285A0000|4 12|sequence
P01956491A0095|8 17|treatment
P01958368A0556|0 9|Evolution
P01958821T0000|9 32|fluorescence microscopy
P01960974A0000|0 7|Toluene
P01961213A0150|27 37|HCB-levels
P01961747A0000|2 33|herpesvirus proteinase activity
P01961996A0522|0 7|Adult H
P01963419A0501|9 30|silver liquid chamber
P01963438T0000|14 31|electron transfer
P01963858T0001|10 20|activation
P01964989A0145|0 15|Urine specimens
P01967130A0645|14 28|pair EFIA cDNA
P01968043A0908|23 34|cDNA clones
P01968061A0371|0 3|Sci
P01968156T0000|0 20|Dose standardisation
P01968224A0119|4 19|coding sequence
P01970560A1024|14 21|fusions
P01970801A0925|29 34|genes
P01970926A0000|7 17|exercise K
P01970984A0668|10 19|treatment
P01971191A1271|37 44|agonist
P01972379T0042|0 12|DNA sequence
P01973384A0206|34 47|binding sites
P01974550A0362|16 19|CBF
P01974876A1051|17 57|restriction fragment length polymorphism
P01975157A0836|12 26|transformation
P01975428A0151|0 9|Telomeres
P01976638A1135|47 53|region
P01977585A0222|11 17|enzyme
P01977856A1036|5 10|study
P01978834A0076|9 42|abomasum lambda gt11 cDNA library
P01978857A0504|10 13|use
P01982061A0615|12 20|TATA box
P01982061T0000|0 16|Characterization
P01982190T0001|6 15|cirrhosis
P01982997A1104|0 11|Examination
P01983026A0483|9 19|heart rate
P01984665T0000|0 10|Processing
P01985301T0000|9 16|therapy
P01985920A0156|8 17|screening
P01985920T0000|0 7|Cloning
P01985924A0554|4 12|addition
P01986225A0250|19 33|identification
P01986241A0117|0 9|Induction
P01986254A0452|0 25|Gel mobility shift assays
P01986360A0000|6 12|clones
P01988041A0281|4 12|sequence
P01989561A0100|4 15|application
P01989999A0000|17 27|synthetase
P01990254A0791|0 17|Immunophenotyping
P01990266A0678|12 36|UV cross-linking studies
P01991521A0481|4 11|results
P01992459A0000|13 24|interaction
P01992742A0000|16 23|records
P01992953A0247|8 14|levels
P01992953T0000|0 24|Alanine aminotransferase
P01993181T0000|0 28|Nucleotide sequence analysis
P01993656A1860|8 17|ARF cDNAs
P01995951A0000|18 24|repeat
P01996312A0454|0 3|DNA
P01997465A0276|18 25|changes
P01999035A0383|10 19|follow-up
P01999459A0795|0 2|A.
P01999999T0001|10 18|luxation
P02000093A0794|0 9|Landsberg
P02001033A1907|3 10|summary
P02002051A0276|19 28|isolation
P02002051T0000|0 14|Isoform C beta
P02002511A0637|8 20|applications
P02004521A0266|0 8|Patients
P02004705A0686|4 17|cdr1 sequence
P02005547A0121|19 32|understanding
P02006558A0000|0 23|Displacement thresholds
P02007045A0092|4 11|authors
P02008982A0463|0 5|ELISA
P02010912A0366|8 13|paper
P02011924A0729|18 24|number
P02012097T0000|11 23|fluctuations
P02012789A0051|12 26|family history
P02014928T0000|13 19|asthma
P02015921A0523|10 21|subdivision
P02016053A0752|0 31|Amino acid sequence comparisons
P02016769A0720|27 36|strengths
P02017159A0646|0 6|Grasso
P02017271A0502|8 14|months
P02017414A0307|0 3|Age
P02019572A0000|16 29|DNA sequences
P02020082A0356|4 15|disturbance
P02020314A1290|2 6|dose
P02021630A1104|6 17|differences
P02022188A0112|12 20|analysis
P02022188A1463|21 34|gene products
P02022920A0334|4 19|C4BP alpha gene
P02023097A0000|10 37|immunodeficiency virus type
P02023421A0343|9 22|proliferation
P02023904A0120|4 13|CDC7 gene
P02024252A0000|11 16|years
P02024488A0506|0 4|HeLa
P02024625A0202|0 11|Differences
P02024791A0582|0 12|MEASUREMENTS
P02024816A0521|9 14|ELISA
P02025515A0979|3 7|view
P02026144A0741|9 16|control
P02026147A0000|14 17|Ca2
P02026461A0760|8 13|cases
P02026491A0399|4 12|patients
P02027839A0250|4 11|muscles
P02028125A0101|4 14|prevalence
P02029468A0296|0 24|Serum TNF concentrations
P02030910A0000|8 14|clones
P02030910A1070|0 34|Polymerase chain reaction analysis
P02033038A0309|28 43|E3 polypeptides
P02033062A1169|8 25|promotor function
P02034655A1224|4 9|alpha
P02034655T0000|0 16|Characterization
P02034669A0293|16 26|transcript
P02034676A0267|4 14|homologues
P02035805T0000|0 28|Angina haemorrhagica bullosa
P02036066A0000|16 23|effects
P02038293A0919|0 10|Conclusion
P02038326A0538|4 21|gcd2-503 mutation
P02038784A0317|6 14|patients
P02041088A1053|15 32|enhancer activity
P02044785A0000|9 13|case
P02044950A0258|10 35|polymerase chain reaction
P02044975A0380|10 16|volume
P02045366A1149|0 23|Hydrophobicity analysis
P02045524A0000|18 30|availability
P02045809A0331|3 11|contrast
P02046202A0625|4 13|remainder
P02047597A0149|26 34|vulvitis
P02052544A0641|17 31|DNA polymerase
P02052592A0000|33 37|cell
P02053289A0701|20 34|nt differences
P02054754A0919|13 23|principles
P02055484A0538|12 24|PCR products
P02056553T0000|12 17|shock
P02060052A0954|6 10|data
P02061282A0447|4 12|sequence
P02061333A0784|3 11|evidence
P02061333A1359|6 18|observations
P02062116A0688|0 9|Pargyline
P02062933A0738|15 21|choice
P02064119A1172|20 29|responses
P02065022A0747|11 20|deletions
P02066246A0258|18 22|list
P02068085A1273|16 24|evidence
P02069738A0000|2 8|method
P02069873X0000|0 9|Mechanism
P02070227T0000|12 24|cell seeding
P02072238T0000|0 17|Menetrier disease
P02072798A0330|18 31|stabilization
P02073222A0269|13 21|patients
P02075876A0408|4 22|stimulus threshold
P02075876T0001|0 8|Analysis
P02076620A0548|13 37|plasma fibrinogen levels
P02076620T0000|0 11|Gemfibrozil
P02076816T0000|20 27|pathway
P02077560T0000|4 8|role
P02078080T0040|4 15|application
P02078570A0287|7 12|cases
P02079811A0407|4 11|authors
P02080902A0183|3 12|adulthood
P02081463A0110|19 29|regulation
P02083199A1175|0 22|Phosphopeptide mapping
P02083230A0938|12 20|sequence
P02083253A1512|4 28|TCF-1 alpha binding site
P02083546A0000|21 27|method
P02088781A0653|4 11|results
P02089054A0121|0 3|IdB
P02091890A0614|8 13|model
P02092131T0000|6 12|method
P02093033T0001|0 6|Effect
P02093741A0211|0 15|Data collection
P02093888A0293|0 5|ARPIA
P02094221A0247|0 8|Diuresis
P02094257T0000|11 16|value
P02095150T0000|8 25|strain adaptation
P02099622A1046|0 20|Immuno-cytochemistry
P02102823A0492|0 19|Promoter activities
P02102831A1282|7 14|regions
P02103140A1088|10 11|%
P02103403A0149|3 10|patient
P02105497A1092|16 26|comparison
P02106287A0478|0 13|Spore inocula
P02107073A0584|9 23|overexpression
P02107548A0727|8 25|transcription-PCR
P02109544A0000|16 20|cost
P02110145T0000|0 10|Sequencing
P02110148A0423|11 27|HindIII fragment
P02111015A0574|19 30|amino acids
P02113015A0295|9 17|seizures
P02113174A0064|13 20|protein
P02113174A0957|0 7|Krox-24
P02113455A0207|20 31|variability
P02113699A0372|4 12|patients
P02113901A0000|9 12|CO2
P02115111T0000|0 10|Expression
P02115115A1053|38 48|suggestion
P02115116A1137|4 11|results
P02115118A0565|5 7|Mr
P02115121A0000|0 13|Yeast mutants
P02115122A0562|9 17|residues
P02115572A1323|21 40|V lambda pseudogene
P02115889A0436|8 13|paper
P02116071A0000|17 22|study
P02116537A1237|7 16|influence
P02117799T0000a|0 4|Uses
P02117799T0000b|0 4|Uses
P02118519A0516|37 53|consensus motifs
P02118525A0737|3 11|addition
P02118612A0629|7 14|minutes
P02119530T0000|0 9|Influence
P02119626A0471|11 16|scars
P02119946T0000|9 18|dysphagia
P02120707A0594|19 25|assays
P02120833A0000|3 10|Denmark
P02121371T0000|4 13|NF1 locus
P02122454A1042|11 22|replacement
P02123029A0478|9 16|isotype
P02123293A0227|0 5|Petko
P02123295A0645|0 10|Disruption
P02123300T0000|45 51|factor
P02123466A0272|11 18|members
P02123467A0811|13 23|expression
P02123820A0000|0 7|Effects
P02123875A0223|23 31|features
P02123877A1452|23 28|c-fos
P02124433A0235|7 15|patients
P02124710A0193|12 20|proteins
P02124710A1624|5 10|model
P02125016A0145|0 4|PBSX
P02125153A0410|18 25|relapse
P02126417A0408|7 15|controls
P02126504A0602|12 25|Rh-antibodies
P02129338A0568|12 31|amino acid sequence
P02131652A0883|15 42|serum gastrin concentration
P02131666A0483|17 22|group
P02131902A0000|5 10|study
P02132636A0188|0 8|Subjects
P02133731A1572|5 7|S3
P02135343A0131|8 15|article
P02135536A0621|8 12|case
P02137704A0000|19 24|group
P02138707A0198|46 76|lambda gt11 expression library
P02138915A1060|4 12|p36 gene
P02138992A0911|19 28|treatment
P02139473A1603|61 65|site
P02139891A0532|10 18|promoter
P02141425A0175|18 36|fingertip-to-floor
P02142240A0506|15 26|differences
P02142486A0367|0 11|Teicoplanin
P02142921T0000|12 52|hormone-releasing hormone analog therapy
P02142955A0248|3 14|Experiments
P02142993A0176|13 20|picture
P02143023A0729|22 38|octamer elements
P02143186A0867|3 13|comparison
P02143186A1306|0 22|Northern blot analysis
P02143768T0000|0 9|Impaction
P02143961A0400|5 20|antidepressants
P02144290A1444|0 3|Sci
P02144558A1022|2 18|needs assessment
P02144610A1306|0 9|TCR alpha
P02145195A0253|7 16|stem-loop
P02145268A0746|12 31|nucleotide sequence
P02145268A1454|6 12|losses
P02146266A0000|15 37|BamHI-HindIII fragment
P02146495A0706|10 18|peptides
P02147223A1047|3 11|contrast
P02147422A0000|35 39|gene
P02148219A0508|22 32|hypothesis
P02148291A0173|28 48|HSE oligonucleotides
P02148508A0374|0 5|Fluid
P02148508A1478|4 11|results
P02148799A0000|4 12|nmr gene
P02149487A0348|6 41|days dexamethasone suppression test
P02149566A0478|4 9|ratio
P02149570T0000|10 18|necrosis
P02150473T0067|9 14|study
P02151229A0000|0 8|Regional
P02151229A0921|0 18|Mean ROI-A/B ratio
P02153243A0965|6 10|data
P02153683A1579|5 11|result
P02153977A0364|6 11|genes
P02154467A0709|4 15|PC2 protein
P02154474A1504|25 34|sequences
P02154599A0382|8 13|study
P02154599T0000|4 22|zta transactivator
P02154602A0092|16 23|homolog
P02154686A0185|0 9|Fragments
P02154885A0153|4 9|sites
P02155017A1106|13 21|benefits
P02156828A0164|12 31|amino acid sequence
P02157067A0610|0 7|Summers
P02157141A0923|19 28|T antigen
P02157764A1115|2 18|rabbit antiserum
P02157882T0000|0 12|Conservation
P02158099A0487|13 34|cotransfection assays
P02158927A0000|23 33|nucleotide
P02159470A1432|9 16|binding
P02159559A0779|26 38|interference
P02160502A0471|3 33|recombination signal sequences
P02160622A0000|20 30|properties
P02160955A0899|0 10|Constructs
P02162049A0291|16 21|issue
P02162103A0000|28 33|cDNAs
P02162467A0311|13 28|cytR expression
P02162754A0339|18 23|sites
P02162754A0801|0 3|PAO
P02162835A0989|22 43|sequence similarities
P02163347A0472|4 17|cDNA sequence
P02163382A0169|20 33|O7-LPS region
P02163394T0000|4 13|sacT gene
P02164585A0416|4 16|TraD protein
P02164585A0814|4 19|protein product
P02164588A0266|15 23|HN genes
P02164604A0399|4 11|studies
P02164604A1574|13 21|analysis
P02164637A0515|0 10|Disruption
P02165181A0299|5 11|cohort
P02165589A0000|2 6|gene
P02165589A0888|2 9|portion
P02166040A0385|21 29|vanadate
P02166416A0419|4 13|diagnosis
P02166825A0198|3 8|order
P02167321T0000|2 11|DNA motif
P02167467T0000|4 20|26S rRNA binding
P02167784A0109|18 26|subjects
P02168640A0268|12 24|correlations
P02169887A0360|4 15|transcripts
P02170687A0000|4 18|E6/E7 promoter
P02172672T0001|2 6|case
P02173399A0333|27 35|controls
P02173405A0270|15 26|abnormality
P02174105A1232|20 28|analysis
P02174427A1574|5 12|strains
P02174861A0736|0 10|Regulation
P02174974A0000|0 13|Transcription
P02175433A0575|36 54|beta A-globin gene
P02175908A0805|12 21|mutations
P02176021T0000|0 13|Determination
P02176152A0896|18 20|RA
P02176209A0954|23 26|EFI
P02176232T0001|0 12|Risk factors
P02176822A0000|16 30|protein kinase
P02179052A1044|18 19|Y
P02179188A1223|25 41|motile responses
P02179815A0582|7 15|p59v-rel
P02180935A0535|8 19|experiments
P02181760A0311|0 10|Blood flow
P02182240A0355|2 7|total
P02182323A0121|17 28|transcripts
P02182618A0168|4 21|promoter activity
P02183467A0668|19 23|ORFs
P02185140A0000|29 38|14DM gene
P02185250A0726|0 11|Truncations
P02187091A0721|19 29|resistance
P02187871T0000|4 14|ANB1 locus
P02188096A0955|4 16|contribution
P02188168A0000|0 10|Serum beta
P02190122A0633|5 17|emancipation
P02190134A0572|3 10|therapy
P02193033A0195|0 2|R.
P02194273A0913|9 30|hyperimmune globulins
P02194972T0000|12 19|effects
P02195025T0000|0 10|Regulation
P02195715A0143|11 22|individuals
P02195715T0000|9 15|stroke
P02196176A0749|0 5|TREB7
P02196311A1034|6 13|results
P02196450A0870|0 8|Analysis
P02196565A0606|25 33|factor I
P02196565T0000|0 19|Yeast Gal11 protein
P02198259A0685|0 8|Deletion
P02198289A0436|15 23|peptides
P02199311A0620|9 31|transcription extracts
P02200150A1381|8 16|patients
P02200315A0278|0 3|IgG
P02200736A1003|6 13|factors
P02201770A0188|12 23|flea larvae
P02201901A0229|28 36|antibody
P02201905A1004|13 20|results
P02202496T0000|9 18|nutrition
P02203672A1542|24 38|cytocentrifuge
P02204029A0184|0 23|RNase protection assays
P02204621T0000|0 9|Isolation
P02204623A0000|4 24|juxtamembrane region
P02204625A1130|5 9|gene
P02204810A1080|7 13|region
P02206430A0197|0 4|Pups
P02206789A0002|4 12|efficacy
P02206858A0000|11 20|protein C
P02208762A0228|4 15|grandfather
P02209237A0239|24 32|shunting
P02209243A0237|12 19|protein
P02209540A1362|16 20|Ets1
P02209605A0510|12 20|sequence
P02209811T0000|12 22|peroxidase
P02212540A0473|21 35|wall specimens
P02213566A0000|4 11|effects
P02217307T0000|0 8|Evidence
P02217741T0001|4 17|interrelation
P02218094A0395|19 25|tissue
P02219751A0517|10 18|saccades
P02220102A0271|0 9|Incidence
P02220304A0501|4 9|study
P02223652A0939|6 29|antithrombin unit basis
P02223773A0000|0 39|Chick brain actin depolymerizing factor
P02223928T0069|8 18|experience
P02225687A0546|0 18|Comprehensive care
P02227438A0492|0 25|Primer extension analysis
P02228615A0974|4 8|85Sr
P02229068A0156|0 15|Gene constructs
P02229072A1012|5 18|growth arrest
P02229282A0454|0 8|Patients
P02229541T0000|0 5|Giant
P02231162T0000|8 15|studies
P02231479A0585|5 11|parent
P02233626T0000|34 42|symptoms
P02233680A1115|6 13|results
P02233715A0914|4 13|induction
P02233729A1065|5 14|mutations
P02234345A0215|10 19|cyst wall
P02234731A0503|17 22|class
P02236002A0958|6 13|mammals
P02236022A0000|4 23|protooncogene c-myb
P02236060A1671|0 12|Modification
P02236064A1178|0 20|S6 kinase activation
P02236276T0000|0 4|Rats
P02237431A0000|0 10|Expression
P02237431A0833|4 22|Ets-1 binding site
P02241742A0766|9 13|flow
P02241892A0681|0 11|Utilization
P02242222T0000|13 20|address
P02243093A0000|6 32|T-cell leukemia virus type
P02243386A0113|33 39|serial
P02246362T0000|4 27|Jenkins Activity Survey
P02246447A0460|10 18|evidence
P02246803A0692|4 10|result
P02247069A0261|4 13|TUP1 gene
P02247072A0794|4 29|SUP44 suppressor mutation
P02247081A0223|15 25|disruption
P02247924A0078|14 18|case
P02248732A1113|24 28|data
P02249872A1051|5 16|interaction
P02250919A0404|0 11|Perceptions
P02251119A0319|0 7|Results
P02252891T0000|14 21|protein
P02252953A0300|22 27|girls
P02253274A0000|4 16|Mauriceville
P02253663A0687|14 20|rhythm
P02254282T0000|0 8|Sequence
P02254418A0641|5 12|strains
P02254749A0133|10 15|cDNAs
P02256678A1224|25 46|footprinting analysis
P02257251T0000|0 15|Pathophysiology
P02257899T0000|16 27|interaction
P02258918A0242|12 16|lung
P02259334A0205|13 21|promoter
P02259795A0570|12 23|consumption
P02261254A0168|0 11|Experiments
P02262439A0508|0 12|MCh infusion
P02264601A0000|0 22|Taste reactivity tests
P02265055A0417|0 21|Plasma concentrations
P02266679A0740|0 9|Plasma Al
P02268461A0224|4 12|survival
P02269281A1276|4 14|occurrence
P02269426A0428|0 3|IST
P02270096T0000|10 18|activity
P02270587A0000|15 29|treatment need
P02270834A0123|9 15|method
P02272095A0832|6 13|results
P02273690T0001|0 7|Effects
P02274343A0064|7 23|foot pathologies
P02274509A0623|0 17|Liver dysfunction
P02276891T0000|0 12|Coenzyme Q10
P02277005A0227|4 22|CT characteristics
P02277319A0211|21 34|preservatives
P02277452A0116|6 14|patients
P02278217A0372|8 14|groups
P02278474A0000|0 33|Serum Fibrin Degradation Products
P02280777T0000|4 24|uteroglobin promoter
P02281118A1191|0 34|Prostaglandin synthesis inhibitors
P02281330A0556|16 36|oxygen concentration
P02281948A0245|4 8|corn
P02282815T0000|0 12|Significance
P02283148T0000|0 12|Significance
P02283378A0385|11 20|procedure
P02283378T0000|7 13|method
P02283873A0308|10 15|group
P02284393A0751|8 16|research
P02284573A0943|17 21|MoAB
P02287860T0001|33 38|study
P02289102A0114|9 27|audiotape cassette
P02289639A0989|9 15|change
P02290216T0001|0 6|Effect
P02291144A0493|10 18|accuracy
P02291628A0264|11 15|part
P02292272T0000|0 22|Interlimb coordination
P02293019A0000|0 19|Antileukoproteinase
P02293664A0946|17 23|series
P02294048A0881|24 58|% amino acid sequence similarities
P02295521A0922|10 19|relations
P02296509A0997|21 38|household members
P02298741A0809|0 8|Analysis
P02299543A0317|54 61|outlook
P02300541A0000|17 24|effects
P02300577A0852|4 14|beta chain
P02300759A0000|16 25|protocole
P02303158T0000|20 30|expression
P02303470A0242|4 11|introns
P02303874A1643|17 33|titration period
P02305014A0226|13 19|series
P02306539T0000|0 3|Use
P02307067A1348|4 15|persistence
P02307371A0263|14 23|mechanism
P02307613A0783|0 40|Erythrocyte protoporphyrin concentration
P02307848A0347|11 20|sequences
P02307848T0042|32 42|complexity
P02307850A0000|8 34|RNK-16 lambda-gt11 library
P02307850A1197|4 13|induction
P02308496A0000|4 9|paper
P02310261A0115|4 11|abscess
P02310300A0298|5 19|% lymphography
P02310350A0221|12 17|study
P02310496X0000|8 26|memory impairments
P02311544A0086|0 7|Studies
P02312470A0774|4 17|BAL-to-plasma
P02312689A0360|4 21|kappa coefficient
P02315151T0020|7 14|systems
P02315472A0583|20 32|imaging time
P02317413A0364|0 8|Patients
P02317554T0000|0 13|Determination
P02318208A0817|15 22|element
P02319610A1527|13 22|relevance
P02320008A0651|0 6|TMBr-1
P02320999A0606|4 13|procedure
P02322535A0658|0 6|Intron
P02323517A0557|8 9|h
P02324102A1157|0 10|Comparison
P02324104A0151|16 17|%
P02324104A0516|5 11|levels
P02324104A0929|16 25|C subunit
P02324104A1195|16 20|exon
P02325208A0209|0 6|French
P02325895T0000b|16 20|type
P02326716A0139|0 7|Methods
P02326946T0000|0 43|Plasma lecithin/cholesterol acyltransferase
P02327159T0001|0 4|Lars
P02328328A0419|15 21|status
P02329840A0383|4 15|application
P02330041A0335|0 10|Expression
P02330110A1085|19 37|laboratory studies
P02330333A0325|0 13|Accumulations
P02331361A0268|20 28|increase
P02332018A0538|12 19|absence
P02332798A0725|4 13|afferents
P02333239T0000|11 14|age
P02333545A0313|4 16|distribution
P02333749A0411|23 42|regression analysis
P02334972A0145|4 15|examination
P02335034A0584|39 50|heat stress
P02335521T0000|15 45|vitellogenin activator element
P02335713A0905|7 18|correlation
P02335815A0530|7 24|carboxyl terminus
P02336338A0931|4 11|effects
P02339005T0000|0 6|Effect
P02339447A0162|21 28|7,7-2H2
P02340595A0124|0 17|Sequence analysis
P02341669A0000|0 11|Experiments
P02342477A1292|10 14|UfAP
P02343033A0000|8 13|light
P02344529T0000|15 22|anaemia
P02347102A0000|4 27|pseudolymphoma syndrome
P02347407A0217|25 30|field
P02347655A0193|18 22|lung
P02348225A0192|0 4|Mean
P02348408A0126|0 9|Attitudes
P02348728A1153|17 27|DNA ploidy
P02349827A0193|24 30|system
P02349942A0287|14 21|factors
P02349998A0297|0 21|Dopamine SERS spectra
P02351239A0693|6 14|findings
P02351297A0000|23 40|toxicity research
P02353453A1249|4 9|order
P02353875A0800|4 11|results
P02354381A0207|13 23|treatments
P02355293A0749|21 32|differences
P02355765A0220|4 11|patient
P02355920A0681|2 24|consensus binding site
P02356823A0063|14 20|method
P02357537A0451|4 11|effects
P02358975A0709|70 78|symptoms
P02360336A0574|0 4|Drug
P02361008T0000|0 7|Changes
P02361575T0000|7 15|toxicity
P02361812A1110|4 14|kg FFM SMR
P02362161T0000|0 6|MK-927
P02362803A0608|12 21|fragments
P02368931A0587|3 36|addition serum IgE concentrations
P02370571A0663|4 12|findings
P02371273A0144|20 24|unit
P02371517A0747|11 19|patients
P02372496A0782|0 17|Co-administration
P02372712A0002|4 11|effects
P02373686T0000|10 20|expression
P02373810A1118|3 11|contrast
P02374886A0305|4 30|Community Adjustment Scale
P02376023A0307|15 21|months
P02378615A0807|4 20|protein sequence
P02378945A0487|5 15|adaptation
P02383693A0301|20 26|column
P02383771A0544|14 25|examination
P02384265A0947|6 13|results
P02384389A0854|9 14|trend
P02386485A0554|4 23|nucleotide sequence
P02386895A0496|0 10|Toxicities
P02388685A0577|4 11|results
P02390538A0000|11 18|infants
P02390633T0000|6 18|encephalitis
P02390989A0745|16 27|counterpart
P02391344T0000|10 17|cloning
P02392032A0657|4 11|results
P02392511T0000|0 32|Serotonin 5-HT2 receptor binding
P02393001A0324|9 12|%BF
P02393895A0918|4 13|RF values
P02394707A0789|0 17|Promoter elements
P02394718A0130|11 16|genes
P02395868A0322|4 11|pattern
P02396415T0001|0 7|Results
P02398897A0000|11 32|transcription factors
P02399053A0153|23 27|rats
P02399053A1032|4 6|Lm
P02400070T0000|0 10|Comparison
P02400457A0469|3 13|Experiment
P02402678A0463|23 35|formulations
P02403035A0621|11 24|reading frame
P02403634A0788|0 17|Sequence analysis
P02403926A0000|4 19|trk-2h oncogene
P02403926A0307|0 10|Antibodies
P02404451A1532|18 44|scanning-deletion analysis
P02405393T0000|25 41|characterization
P02405589A0000|0 11|Information
P02405818A0550|0 16|Branch occlusion
P02406570A0466|17 22|sites
P02406570A0898|3 14|examination
P02406992A0192|38 47|disorders
P02408248A0414|41 47|action
P02409297A0984|11 20|antiserum
P02411513A0667|6 21|characteristics
P02417023T0001|0 4|Role
P02417669A0218|3 27|maximum photosensitivity
P02418701A0000|17 27|likelihood
P02419327A0998|4 20|priming activity
P02419588A0284|0 2|A.
P02420432A1060|14 25|conjunction
P02423533A1314|4 10|levels
P02423533A1790|4 9|cDNAs
P02423773T0001|13 19|method
P02423850A0292|0 17|Deletion analysis
P02424743A0280|4 6|N1
P02427024X0000|0 9|Tolerance
P02427797A0199|6 10|dogs
P02427812A0865|6 13|results
P02427869A0939|13 17|beta
P02431314A0834|17 23|Hansel
P02436005A0707|6 13|results
P02437625A0197|4 9|study
P02437792T0000|0 10|Comparison
P02437895A0000|2 7|probe
P02438637T0000|0 18|Mucolipidosis type
P02442837A0060|17 23|groups
P02443028A0695|3 9|reflow
P02443924A0083|8 16|patients
P02444507A0240|0 17|Lysozyme activity
P02445751A0925|19 31|measurements
P02446871A1021|12 21|structure
P02449431A1121|0 22|ATP gamma S inhibition
P02451872A0391|4 12|recovery
P02452313A0114|0 8|ASL-8123
P02454390T0000|0 8|Enhancer
P02454976A0944|15 22|results
P02455821A0099|4 8|gene
P02456827A0899|4 8|4-AP
P02457922A0991|0 13|Hybridization
P02458080T0000|0 9|Prognosis
P02458234T0000|6 12|method
P02458699A0650|0 8|Svensson
P02459309T0000|11 18|release
P02461368A0162|8 14|report
P02462047A0208|7 17|flap areas
P02462305A1071|4 20|size discrepancy
P02462523A0394|9 27|KpnI-SalI fragment
P02463050A0514|4 49|corticosterone synthesis inhibitor metyrapone
P02464097T0000|4 11|effects
P02466414A0000|24 28|dogs
P02466665A0202|22 29|protein
P02468795A1086|0 5|Serum
P02469451A0239|4 17|investigation
P02470955A0101|6 13|studies
P02473156A0000|2 6|cDNA
P02473198A0613|0 8|Dopamine
P02473619A0202|12 25|sensitization
P02473693A0174|5 13|approach
P02473718A0000|4 17|investigation
P02473907A1338|8 13|C mAb
P02473942A1207|18 23|plots
P02474093T0000|0 11|Angiotensin
P02474110A1039|3 11|addition
P02474204A0105|10 15|cells
P02474356A0559|4 9|ratio
P02475506A0878|4 8|mRNA
P02475717A0565|0 15|Tissue necrosis
P02476030A0000|21 28|surface
P02476664A0563|28 36|sequence
P02477373A0930|12 20|TATA box
P02479635A0659|0 14|Cotransfection
P02479823A0727|0 17|Sequence analysis
P02480419A0735|15 24|cirrhosis
P02480959A0470|5 18|P-450scc mRNA
P02481230A1258|29 51|bovine alpha transgene
P02481429T0000|8 26|staining technique
P02481779A0213|0 7|NIK-244
P02482293A1518|17 44|T24 bladder carcinoma cells
P02482511A0860|6 34|phosphodiesterase inhibitors
P02483210A0000|15 20|value
P02483438A0498|7 12|basis
P02484714T0000|11 23|organization
P02484994T0001|12 27|gamma globulins
P02485188A0415|10 27|chondroitinase AC
P02486634A0632|11 20|perfusion
P02487898A0315|5 23|NGF administration
P02488148A1156|11 18|program
P02489032A0000|0 14|Immunoglobulin
P02489753A0581|4 11|results
P02489895T0001|0 13|Muscle action
P02492111A0670|5 6|%
P02492111A0868|42 49|effects
P02493644A0588|11 20|3T3 cells
P02495745T0000|17 24|effects
P02496090A0252|7 10|CO2
P02496100T0000|28 33|assay
P02496109A0754|9 20|experiments
P02497340A0989|22 36|antibody genes
P02498322A0226|25 34|complexes
P02498652A0460|6 18|transfection
P02500432A1416|37 51|CAT expression
P02502096A0462|22 32|blood flow
P02502602A0323|0 9|Tonometry
P02502960A0762|11 13|p.
P02504603T0000|0 9|Isolation
P02505087A1037|19 43|dimerization specificity
P02506390T0001|0 6|Growth
P02506740A0742|34 39|hours
P02507523A0791|4 16|ORF1 product
P02507815A0000|0 8|Kindling
P02508306A0528|9 21|infiltration
P02508726A0498|6 18|case reports
P02509123A0371|7 15|sessions
P02510242A0313|10 15|cases
P02511069A0532|17 26|mutations
P02511150T0025|8 14|status
P02511207A0282|0 2|K.
P02511430A0000|17 19|bp
P02511898A0000|5 10|paper
P02512010A0801|4 22|PETCO2 measurement
P02514498A0000|8 16|CO2/HCO3
P02515953A0459|10 15|study
P02517008A0481|10 18|patients
P02518645T0001|9 23|Chagas disease
P02518691A0251|14 44|IL2R alpha promoter constructs
P02519327T0001|12 22|rheumatism
P02519679T0000|0 10|Inefficacy
P02520622A0200|6 14|patients
P02521217A1035|27 34|protein
P02521674T0000|0 7|Mapping
P02522297A0000|4 10|effect
P02523800A1178|27 35|sequence
P02525044A1026|4 18|recovery index
P02526165X0000|4 8|sign
P02527365T0000|0 15|Xenopus homolog
P02527745A0865|0 22|Southern blot analyses
P02528329A0000|6 22|missense mutants
P02528730A1073|10 18|exons 2a
P02529378A0536|0 20|S1 nuclease analysis
P02530413A0195|3 18|supine position
P02530470A0604|12 22|prevalence
P02531203A0241|13 24|predictions
P02532032A0385|0 21|Plasma concentrations
P02532210A0000|4 23|adenovirus E1A gene
P02534067A0316|0 14|Administration
P02535460A1443|0 15|RNA transcripts
P02536096A0327|3 13|HeLa cells
P02536160A0518|26 35|condition
P02537441A0231|0 4|None
P02537485A0841|7 20|formalin test
P02538450A0000|17 28|cDNA clones
P02538656A0172|32 42|E1 mutants
P02538720A0582|0 4|UbiA
P02541251A1327|12 19|T2 gene
P02541882A0251|0 17|Radiation therapy
P02542194A1496|6 13|results
P02542270A0000|4 15|methylation
P02542612A0530|0 20|S1 nuclease analysis
P02543226A1559|25 35|likelihood
P02543621A0788|0 8|Analysis
P02543679A1291|16 24|evidence
P02543734A0414|10 26|oligonucleotides
P02544059A0377|0 7|Effects
P02545357A0000|4 34|mustard chloroplast gene rps16
P02545903A0639|0 10|Antibodies
P02546234A1382|28 39|tachycaydia
P02547079A0910|13 28|calcium balance
P02547611A0318|0 8|Clone 4c
P02547706A0928|4 15|application
P02547706T0001|0 8|Validity
P02547778A0786|11 17|nature
P02548683T0001|8 15|account
P02549036A0000|4 31|Bacillus subtilis phage phi
P02549343A1008|3 14|consequence
P02549417A0000|13 19|stages
P02550118A0610|37 50|infiltrations
P02550682A0411|13 22|incidence
P02551886A0332|0 16|Restriction maps
P02552143A0748|0 3|VP5
P02552316A0526|30 40|caretakers
P02554310A0419|3 11|contrast
P02555177A0488|9 14|pet54
P02555418A0973|0 7|Insert2
P02555519A0798|19 29|variations
P02555703T0000|0 25|Tyrosine kinase oncogenes
P02556264A0278|5 19|TC-II enhanson
P02556269A0187|4 13|DNA helix
P02556603A0606|23 34|improvement
P02557217A0000|0 14|Beta-endorphin
P02557217A0398|4 8|data
P02557350A0632|4 17|DNA sequences
P02559630A0270|17 23|values
P02560415T0012|16 21|tumor
P02562787A0637|23 30|protein
P02562825A0413|0 14|Responsiveness
P02565405T0000|0 8|Drug use
P02565683A0841|11 21|heart rate
P02565807A1198|3 11|contrast
P02566613A0831|10 18|sequence
P02566613T0000|0 28|Somatostatin gene expression
P02566680A0820|3 11|contrast
P02567030A0482|35 49|discrimination
P02568930T0000|0 9|Isolation
P02569411A0151|6 17|termination
P02571924A0000|8 13|cells
P02572777T0000|0 22|Tumour necrosis factor
P02572928T0000|0 10|Monitoring
P02573303A0000|4 12|decrease
P02573336A0000|3 13|experiment
P02573829T0000|13 25|conservation
P02573836A0244|25 35|importance
P02574016A0428|25 28|TOF
P02574052A0910|15 26|differences
P02574193A0663|0 9|Selection
P02574551T0000|0 14|Antihistamines
P02575174A0229|32 40|efficacy
P02575490A1021|0 22|Northern blot analysis
P02575567T0001|0 25|Materials science studies
P02575959A0643|4 16|latency time
P02576405A0223|3 11|patients
P02577458A0412|4 14|discussion
P02577867T0000|19 26|homolog
P02580830A1131|9 17|sequence
P02582240A1009|5 19|ATP/GTP ratios
P02582918A0000|6 38|hepatitis B vaccine immunization
P02584969A0119|17 23|design
P02585492A1005|14 35|complementation tests
P02586485A0511|0 5|GN101
P02586513A0622|0 8|Analysis
P02590097A0093|8 19|involvement
P02590391A0442|0 4|None
P02590540A0741|7 12|women
P02590615A0636|27 32|state
P02590869A0743|16 22|calves
P02591078A0000|7 21|investigations
P02591969A0961|4 12|elements
P02592543A0106|12 19|studies
P02592640A0466|5 11|values
P02592961A0327|0 6|COGLAB
P02595451A1136|6 10|data
P02595451T0000|17 29|deletion map
P02597484A0624|5 12|respect
P02597549A0964|20 28|patients
P02598034A0000|0 23|Middle-latency auditory
P02598745A0251|30 45|Sylvius fissure
P02599995A1031|14 30|activity studies
P02600306A0140|55 64|detection
P02601707A0986|0 22|Gel retardation assays
P02602150A0993|16 22|plants
P02603374A0383|8 17|rhinotomy
P02603923A0220|20 34|skin incisions
P02604420A0234|7 16|challenge
P02605160A0000|4 10|effect
P02605182A0936|12 28|protein sequence
P02605679A0306|0 8|Analysis
P02607766A0000|2 10|protocol
P02609112A0000|0 14|Reagent strips
P02614668A0971|22 35|concentration
P02615078A0283|14 24|antibodies
P02617623A0740|0 6|LON-72
P02620085A0656|0 6|Animal
P02621983T0001|0 12|Significance
P02623038A0632|3 10|changes
P02627159A0899|21 34|IgG4 antibody
P02629109A0000|13 30|fertility decline
P02630543A0210|19 36|staining affinity
P02631505A0382|0 10|Ampicillin
P02631566A0151|0 14|Alkoxymetgyl-3
P02631743A0275|20 29|incidence
P02631887A0000|7 15|patients
P02632904A0619|4 12|relation
P02634490A0186|17 26|diagnosis
P02634872A0000|0 10|Retrograde
P02636920T0001|14 19|study
P02637597A0362|12 19|studies
P02638964A0372|4 18|maximum stress
P02641762T0001|9 22|heart disease
P02642466T0000|0 17|Sequence analysis
P02642976A1474|10 29|consensus sequences
P02644735A0427|3 12|FP mutant
P02645276T0088|0 12|Construction
P02645431A1562|6 10|data
P02646007T0000|32 40|leukemia
P02647403A0000|13 27|hallucinations
P02647918A0423|13 18|group
P02647918A0588|0 11|Application
P02647937A0191|14 22|sequence
P02648396A0565|3 15|Rat-1a cells
P02648396A1033|13 22|formation
P02648646A0216|0 26|Platelet activating factor
P02648646A0932|25 36|correlation
P02649445A0412|5 7|BG
P02649811T0000|11 24|contraception
P02650663A0178|6 12|rating
P02651448A0000|25 29|drug
P02651487A0000|31 55|calcium channel blockers
P02655381A0000|5 12|studies
P02656257A0000|18 42|DNA inversion system Cin
P02657388A1011|4 21|terminator region
P02657883A0000|0 10|US-Doppler
P02657883T0001|0 7|Doppler
P02664229A0138|9 17|cosmesis
P02666034A1520|14 22|patients
P02666404A0220|4 25|galactose transporter
P02666568A0000|28 36|patients
P02667259A0331|25 29|cent
P02668691A0570|5 9|mRNA
P02669199A0000|0 21|Tumor necrosis factor
P02670457T0000|4 23|calcium requirement
P02674141A1202|12 28|cysteine residue
P02674327A0493|4 7|p34
P02674671A0601|23 40|DNA transformants
P02674674A1308|4 11|results
P02674679A1237|7 12|basis
P02675492A0806|15 23|patients
P02677002A0205|35 42|enzymes
P02677429A0366|0 14|Survival rates
P02677666A0356|0 7|Mapping
P02679804A2000|4 12|products
P02680843A0724|10 21|application
P02684159A0870|0 22|Hybridization analysis
P02684585T0001|0 25|Agranulocytosis treatment
P02685331A0523|4 29|R. meliloti nifH promoter
P02685461A0380|15 23|symptoms
P02685565A0165|35 39|form
P02686588A0592|17 25|analysis
P02686749A0000|14 33|health significance
P02686980A0000|3 8|order
P02686985A0811|2 38|transcription factor exclusion assay
P02688772T0000|0 10|Psychiatry
P02689136A1851|14 21|effects
P02689439A0000|14 40|glutathione S-transferases
P02689439A0402|33 40|regions
P02689544A0456|0 5|Model
P02691557A0273|4 13|incidence
P02691811A0355|19 22|min
P02691998A0672|12 16|data
P02692881A0354|3 13|comparison
P02693208A0166|21 25|role
P02693593A0866|12 19|protein
P02694731A0241|13 17|hand
P02695914T0000|4 21|stereoselectivity
P02700977A0444|0 10|Scotchbond
P02702566A0000|2 13|combination
P02702849A0418|0 31|Metformin plasma concentrations
P02703121T0000|0 9|Diagnosis
P02703925A0359|39 51|subgroupings
P02704579A1078|14 26|relationship
P02705072A0464|0 10|End points
P02705296A0231|24 30|weight
P02705556A1049|5 7|RV
P02707909A0209|3 21|alternative method
P02708288A0139|0 21|Liquid chromatography
P02708288A0621|4 19|dichloromethane
P02708353A1080|0 28|Primer extension experiments
P02708353A1452|19 44|polymerase chain reaction
P02709081T0000|0 10|Validation
P02709819A0495|9 12|ADR
P02711145T0000|0 18|HIV infectiousness
P02711167A0818|5 8|day
P02711601A0601|18 28|inhibition
P02712246T0042|33 48|characteristics
P02712450A0989|13 18|PACO2
P02713310T0000|0 14|Fundus changes
P02713520T0000|8 20|dose effects
P02713994A0482|4 9|titer
P02714525A0529|0 13|Kidney weight
P02714852T0000|8 17|variation
P02717133T0001|2 8|method
P02717349A0311|0 3|Men
P02718683A0142|0 20|Handgrip dynamometry
P02720966A0455|17 22|fluid
P02721169A0171|0 9|NERVTRACK
P02723503T0000|0 9|Swim-over
P02724227T0000|0 17|Perfusion washout
P02725495A0929|15 23|sequence
P02725513A0617|31 50|CHO spacer promoter
P02727909A0383|9 18|amplitude
P02729666A0267|12 34|intergroup differences
P02731611A0134|4 10|author
P02731671A0000|13 21|toxicity
P02732341A0000|52 59|studies
P02733116T0000|9 28|National Institutes
P02733690T0000|10 17|cloning
P02735364A1330|13 18|model
P02736482A0550|3 11|contrast
P02739739T0000|0 25|COUP transcription factor
P02740196A0704|3 13|Experiment
P02740347A0644|0 13|Cosmid clones
P02740627A0137|4 17|oxygen uptake
P02740874A0957|11 17|damage
P02740955A0333|13 21|patients
P02743842A0000|12 17|study
P02743981A0347|0 11|Transcripts
P02744123A0237|19 26|results
P02744490A0894|0 8|Evidence
P02745280A0276|8 13|level
P02745444A0391|4 33|transcription initiation site
P02745666A0000|12 20|biopsies
P02746099A0000|4 12|mobility
P02747653A0910|22 29|protein
P02748188A0091|30 35|group
P02748595A0492|20 38|baboon liver class
P02749215A0000|9 20|proteinuria
P02751080A0176|16 20|shot
P02752303A0000|0 14|Lithium delays
P02752629A0163|0 7|Dynamic
P02752651A0480|3 12|admission
P02756731T0001|0 14|Prostaglandins
P02756878A0075|4 10|nature
P02757033A0905|24 30|effect
P02757862T0000|8 18|experience
P02758382A0478|0 7|Obesity
P02760922A0000|22 39|ribonucleoprotein
P02761008X0000|0 29|Brain cholinesterase activity
P02761150A0000|4 10|effect
P02761492A0124|4 12|findings
P02761537A0168|0 13|Heating cells
P02761540A0873|0 17|Deletion analysis
P02762006A0071|0 4|Cord
P02762198T0001|0 4|Reye
P02763467A0903|21 39|polyacrylamide gel
P02764797A0182|0 5|PULSE
P02765001A0105|9 13|JPsA
P02765214A0486|14 19|Kurti
P02766330A0779|4 10|author
P02766508A0421|2 25|correlation coefficient
P02766745T0000|17 22|study
P02767166A0368|20 38|lipid peroxidation
P02767733A0690|17 24|grading
P02772495A0641|0 6|Asthma
P02773507A0750|2 7|value
P02773930T0000|13 19|kidney
P02774271A0000|0 9|Halothane
P02774808A0194|4 10|values
P02775136A1151|6 13|results
P02775333A1137|0 10|Buflomedil
P02776471A0235|32 39|animals
P02776742A0000|0 10|Heart rate
P02776823A0000|13 22|tolerance
P02777797A0720|0 22|DNA blot hybridization
P02778237A0585|11 15|term
P02778873A0761|8 15|segment
P02779752A0000|3 13|1-Naphthyl
P02779752A0776|3 17|m-Chlorophenyl
P02780157A0576|19 26|feature
P02781495T0001|0 7|Changes
P02781567A0544|2 6|soap
P02783181A0000|33 43|activities
P02784507A0000|10 37|immunodeficiency virus type
P02787430A0124|12 24|panniculitis
P02789062A0000|27 30|4F2
P02789062A1420|2 6|cDNA
P02789180A0407|39 50|hypertrophy
P02789217A1323|8 24|IL6 mRNA species
P02790009A0375|0 19|Sequencing analysis
P02790009A1052|11 18|protein
P02792270A1220|14 29|EPSP components
P02792430A0000|0 11|Experiments
P02793216A0876|13 17|hand
P02793620A0214|24 28|cows
P02793753A0354|12 16|lobe
P02794828A0214|4 10|system
P02795923A0000|3 8|order
P02796216A0063|4 11|disease
P02796988A0735|4 28|transcription factor Sp1
P02797877A0475|4 19|combination PIP
P02798953A0307|7 13|sample
P02799892A0154|16 19|use
P02800417A0332|7 12|group
P02800435A0000|6 17|experiments
P02802280A0495|15 26|differences
P02805945A0000|4 15|percentages
P02806916A0000|10 19|DNA clone
P02807780A0143|4 7|use
P02808232A0681|6 12|limits
P02809116A0237|29 36|effects
P02809651A0492|8 12|turn
P02809722A0926|19 26|patient
P02809831A0799|3 11|contrast
P02810911A0372|4 14|accuracies
P02811378A0250|15 20|forms
P02811378A0379|20 27|studies
P02813369A0390|28 33|males
P02813404T0000|14 26|antigen gene
P02814182A1211|3 7|rats
P02814820A0967|11 20|Roux limb
P02815229A0139|4 14|treatments
P02816251A0397|28 39|capillaries
P02817724A0075|4 15|examination
P02818122A0000|8 12|deal
P02818260T0000|10 16|glioma
P02820128A1333|3 8|terms
P02820128A1670|4 16|significance
P02821340A0434|19 27|exercise
P02824334A0972|6 10|data
P02825139A0661|19 22|DNA
P02825750A0260|16 24|patients
P02826127A0709|37 48|interaction
P02826717A0179|0 6|Anoxia
P02826729A0790|0 6|Growth
P02828926A1870|24 31|factors
P02829183A0117|0 21|DNA sequence analysis
P02830214A0000|4 10|effect
P02830265A0341|0 6|RPA190
P02830282A0155|16 26|A1 protein
P02831398A0346|0 7|Irmiere
P02831556A0173|6 15|offspring
P02831796A0000|7 29|immunodeficiency virus
P02832149A1009|4 8|lack
P02832293T0000|4 7|use
P02832744A0403|12 27|mos transcripts
P02833012A0428|14 20|L mRNA
P02833021A1185|4 11|results
P02833049A0630|0 10|Variations
P02833049A1041|3 11|analysis
P02833101T0000|9 15|crisis
P02833517A0467|29 38|sequences
P02834478A0000|14 29|weight heparins
P02834843A0000|17 25|activity
P02836623A1094|0 2|Mo
P02837575A0979|0 14|Sodium dodecyl
P02837763A0259|0 19|Amino acid sequence
P02838246A0225|0 22|Herpes virus infection
P02838319A0527|0 4|RVEF
P02838710A0299|4 10|levels
P02839488A1314|13 19|assays
P02839716A0673|9 14|cells
P02839716A1907|4 13|mechanism
P02840034A1266|9 19|evaluation
P02840376A0461|1 9|anti-IIa
P02843495A0544|0 12|Introduction
P02843694T0001|8 27|E-B virus infection
P02844767A0191|12 21|structure
P02844767A0596|4 22|Nostoc petBD genes
P02844767A1022|0 23|RNA blot hybridizations
P02844797A1225|12 26|muscle isoform
P02845654A0510|0 12|Substitution
P02846640A0643|28 36|bacteria
P02846852A1459|4 10|number
P02848842A0643|2 8|family
P02849100A0441|21 29|sequence
P02849759A0865|4 17|SV40 enhancer
P02850472A0112|18 29|origin core
P02850967T0000|0 9|Induction
P02850971A0180|9 29|oligodeoxynucleotide
P02852805A0216|15 21|solids
P02852894T0000|0 6|Causes
P02853799T0001|4 15|progression
P02853922A0596|9 12|IOP
P02856622T0001|0 3|Use
P02859434T0000|0 13|Poor response
P02861067A0000|4 7|aim
P02861144A0242|8 16|analysis
P02861238T0000|8 13|virus
P02862656T0000|0 7|Changes
P02863492A0544|15 26|differences
P02863747T0000|0 11|Replacement
P02865502T0000|24 29|trial
P02868446A0184|15 22|domains
P02868848A0167|9 19|vancomycin
P02869125A0120|0 8|Fentanyl
P02870249T0000|13 25|chemotherapy
P02870720A0188|0 10|Bisoprolol
P02870851A0349|0 6|Output
P02872786A0147|21 29|equation
P02873593A0581|13 17|rats
P02874078A0252|15 38|luteal phase deficiency
P02874635T0000|9 17|exposure
P02875224A1059|0 11|Reperfusion
P02875967A0377|4 15|sensitivity
P02876820A0841|13 21|acidosis
P02876899A0568|3 7|Days
P02877124A0000|15 20|B6AF1
P02878100A0674|8 15|results
P02879906A0000|0 7|Studies
P02879951T0000|0 7|Effects
P02880841A0313|10 19|stability
P02882893A0301|0 16|Body temperature
P02883327A0413|4 25|polyadenylation sites
P02883871A1075|2 6|drug
P02883963A0000|4 12|patients
P02884860A0329|0 9|Terazosin
P02885517T0000|8 20|blood donors
P02889352A0000|5 13|patients
P02889495A0000|29 34|study
P02890200T0001|44 49|tumor
P02892762A0296|20 35|repeat elements
P02894689A0000|34 47|DNA fragments
P02894741A0000|26 31|doses
P02894789A0954|13 29|recovery indexes
P02895472A0178|22 30|colonies
P02895566A0187|0 3|DPA
P02895754A0000|10 31|percent isoproterenol
P02897651A0000|0 15|Hyperthyroidism
P02898752A0683|9 20|correlation
P02899177A0605|20 29|technique
P02899792T0000|0 9|Oestrogen
P02900760A0073|6 23|sequence elements
P02901498A0354|4 16|biosynthesis
P02901763A0977|0 11|Codon usage
P02902615A0000|25 34|treatment
P02902656A0481|13 19|testes
P02902844A1219|14 18|gene
P02902927A0145|22 31|isolation
P02903500A0278|26 36|properties
P02904322A0002|25 33|antelope
P02906027A0553|3 22|sequence comparison
P02906027A1156|14 22|features
P02906249A1195|13 18|group
P02906673T0000|0 8|Efficacy
P02907308T0001|2 7|cases
P02907533A0362|5 9|loss
P02907533T0000|0 7|Effects
P02909528A1081|9 26|promoter activity
P02910496A0583|2 18|decamer sequence
P02910989T0000|0 7|Effects
P02911540A0478|2 9|patient
P02913368A1037|0 20|Pharmacology studies
P02914422A0409|0 17|Computer analysis
P02914492A0183|3 12|admission
P02916764A0253|4 16|risk factors
P02918474A0817|8 17|verapamil
P02919483A0091|14 18|boys
P02919530A0000|31 42|reperfusion
P02919832A0144|8 15|disease
P02920591A0251|12 22|assessment
P02923687A0218|21 33|relationship
P02925013A1112|30 36|levels
P02925568A0460|10 17|effects
P02926499A0340|35 47|analog model
P02927391A0238|26 36|proviruses
P02928112T0000|10 17|cloning
P02928376A0312|16 20|work
P02929056T0000|11 14|use
P02930623A0404|7 23|flexion whiplash
P02934778A0702|4 8|data
P02934889A0558|0 11|Oxfendazole
P02934891A0845|14 20|method
P02935638A0000|41 50|structure
P02936163T0000|0 17|Platelet function
P02936284A0357|12 23|degradation
P02938185A0223|12 22|cell lines
P02939260A1553|19 47|amino acid sequence analysis
P02940334A0141|0 7|Group A
P02941237A0160|14 22|instance
P02943562T0000|0 24|Penicillinase production
P02947866A1416|19 27|analysis
P02949170A0184|5 10|study
P02950216A0084|11 15|flow
P02957125A0601|8 16|patients
P02958204A0175|19 26|effects
P02958233A0123|13 20|picture
P02958660A1094|4 8|data
P02959089T0000|11 17|effect
P02960012A0838|4 13|frequency
P02962859A0276|13 23|antibodies
P02963517A0453|13 21|analysis
P02964329A0000|4 16|pathogenesis
P02965149A0727|14 19|study
P02966671A0151|17 27|end points
P02966671A0551|0 8|Schedule
P02967496A0182|18 28|transcript
P02967915A0000|17 49|hormone 1,25-dihydroxyvitamin D3
P02967915A0968|3 11|addition
P02968055A0984|4 7|HOI
P02969316A0002|14 21|ability
P02969819A0814|0 22|Ig D-JH recombinations
P02970061A0271|4 14|RAD18 gene
P02970640A0341|7 35|absorption spectrophotometry
P02971603A0883|5 13|patients
P02971710A0734|0 5|Plots
P02971957A0287|27 31|mesh
P02973304A0000|15 21|course
P02975680A0000|10 29|accommodation night
P02975753A1333|0 27|Oligonucleotide mutagenesis
P02976332A1277|4 17|concentration
P02979426T0000|0 21|Organ transplantation
P02979834T0000|0 7|Effects
P02981457A0368|0 2|D.
P02981840A0907|11 24|pair sequence
P02982332T0001|0 5|Phase
P02983316A0310|16 24|segments
P02983331T0000|0 8|Evidence
P02985812A0984|11 18|feature
P02985820A1287|10 27|sequence elements
P02986279A0000|3 15|milk samples
P02987220A0472|0 10|Subcloning
P02987777A0000|6 11|cases
P02988457A0650|4 8|data
P02989637A0671|6 10|data
P02989786A0328|7 14|absence
P02991060A0465|6 20|IgG antibodies
P02993630A1190|5 13|analysis
P02994253A0482|6 13|dosages
P02994336A0864|0 2|FK
P02995967T0000|17 30|protooncogene
P02995999A0000|4 21|sequence analysis
P02997622A0916|11 19|sequence
P02997777A0609|18 29|experiments
P02998016A0527|4 12|homology
P02998043A1199|0 11|Examination
P02999267A0606|10 13|FAP
P02999267A0885|4 13|intensity
P03000457A1554|8 21|kDa precursor
P03000489A0822|9 20|lymphocytes
P03001054A0703|30 35|nicks
P03001084A0406|4 12|sequence
P03001086A0587|14 33|amino acid sequence
P03001110A0546|5 20|phosphorylation
P03001353A0146|3 15|temperatures
P03001645A0785|4 9|pet56
P03001705T0000|10 24|transformation
P03001952A0958|24 32|patients
P03002501A1327|0 10|Comparison
P03002786A0143|4 9|group
P03003695A0395|0 10|Comparison
P03004364A0775|42 52|activities
P03004739A0753|16 17|C
P03004982A0199|4 23|nucleotide sequence
P03004982A1094|15 23|sequence
P03005231A0649|27 36|sequences
P03006066A0653|7 22|P135gag-myb-ets
P03007281A0905|4 16|Dox-A2 locus
P03008094A0697|15 18|end
P03008405A0532|8 17|outbreaks
P03009366A0438|41 48|studies
P03009826A0201|14 20|clones
P03010281A0220|4 10|copies
P03011793A0582|9 23|reading frames
P03013477A0000|3 8|order
P03013841A0207|0 8|Cattaneo
P03014515T0000|6 27|alpha-galactosidase A
P03014593A0681|0 8|Diazepam
P03015611A0331|4 23|amino acid sequence
P03015628A1078|0 11|Osteocalcin
P03015953T0000|0 8|Analysis
P03016301A0605|10 22|v-myc codons
P03016506A0611|14 20|vector
P03016883A0000|3 6|men
P03017225A0706|11 20|carcinoma
P03017996A0731|11 23|biosynthesis
P03018491A0840|4 18|hexanucleotide
P03019505A0390|5 13|patients
P03020001A0781|20 36|mini-Mu elements
P03020513T0000|15 22|subunit
P03021050A0501|26 31|peaks
P03021088A0135|11 18|periods
P03022129A0842|16 22|arrays
P03023067A0779|0 11|Translation
P03023679A0624|14 20|weight
P03023682A0271|0 9|Insertion
P03023859A0000|7 11|DNAs
P03023887A0470|0 21|Nuclease footprinting
P03023970A0922|10 16|insert
P03024343A0372|4 10|tumors
P03024703A1036|11 17|region
P03025606T0000|16 31|control signals
P03025655T0000|15 21|domain
P03025661A0260|0 7|Gluzman
P03025862A0860|9 13|exon
P03026915A1024|21 30|sequences
P03027661A0000|4 14|activities
P03027779A0000|0 17|SPECT examination
P03027905A0632|0 21|Plasma renin activity
P03029111A0155|4 11|mutants
P03031602A1001|11 16|group
P03032143A0218|2 12|centromere
P03032964T0000|13 21|function
P03033283A0837|25 29|loci
P03033283A1415|30 34|sets
P03034570A0943|12 17|genes
P03034956A0666|3 11|contrast
P03035056T0000|7 13|lambda
P03035218T0000|0 14|Identification
P03035658A0355|21 31|anesthesia
P03036415T0000|0 9|Influence
P03036817A0213|25 36|mutagenesis
P03036933A0774|0 12|ACTH release
P03037334A0932|39 55|promoter element
P03038643A1374|6 10|data
P03038891A0935|0 17|Northern analyses
P03039177A0503|4 9|group
P03039387A0920|33 49|cyclophosphamide
P03040023A0113|0 8|Morphine
P03040403A0155|4 12|PSS gene
P03041046A0127|8 14|A-MuLV
P03041802A0975|4 12|presence
P03042778A0643|4 8|gene
P03045117A0936|16 22|values
P03045725A0872|21 32|suppression
P03046655A0000|12 28|prevalence study
P03046931A0247|17 23|eIF-4A
P03048024A0418|14 21|culture
P03049570A1242|6 18|similarities
P03050147A0896|6 15|infection
P03050147A1520|5 16|observation
P03052327A1474|3 7|view
P03052641A0204|17 26|compounds
P03053713A0752|0 14|DNA sequencing
P03057259A0514|4 16|relationship
P03059171A1232|0 14|Administration
P03060846T0000|11 19|analysis
P03060953A0481|0 7|Animals
P03061301A0624|0 22|Prostacyclin formation
P03061301A1409|9 18|excretion
P03061383A0000|13 21|activity
P03062370A0000|0 4|GCN4
P03062370A0384|6 13|results
P03064524A0160|4 12|efficacy
P03064811A0485|4 23|amino acid sequence
P03065140A0273|6 15|mutations
P03065141A0448|4 11|results
P03065610A0375|4 12|rci gene
P03065621T0000|0 9|Structure
P03066131A0000|8 14|survey
P03066208A0310|13 24|examination
P03066625A0756|29 36|studies
P03067505A0688|6 18|prostacyclin
P03069046A0126|4 10|method
P03069980T0000|0 7|Factors
P03072021A0696|4 24|amino acid sequences
P03072580A0455|0 12|Van der Ende
P03073091A0338|7 23|insulin infusion
P03073091A0449|0 7|Amounts
P03073192T0000|0 53|Mycobacterium avium-intracellulare complex infections
P03075154T0000|0 10|Recurrence
P03076124A0496|4 26|bile acid sequestrants
P03078268A0529|32 39|aspects
P03079276T0029|0 8|Analysis
P03080793T0000|0 9|Statement
P03083441T0000|0 13|Modifications
P03088643A0000|16 20|rats
P03090237A0202|12 21|schedules
P03090372A0607|12 35|glucose tolerance tests
P03091849A0000|4 11|effects
P03097509A0654|10 14|rise
P03097643A1357|10 21|BALB/c gene
P03098018A0139|9 17|findings
P03102289A0786|4 8|data
P03104245A0402|6 14|patients
P03104248A0322|7 15|Stage IA
P03104914T0000|0 9|Mechanism
P03104982A0690|6 9|age
P03108171A0088|0 10|Ritanserin
P03109147A0000|0 15|Ethylene glycol
P03109147T0127|0 8|Research
P03109954A0945|4 11|results
P03110119A0267|7 9|BH
P03110678A0702|0 10|Comparison
P03110692A0156|14 18|mg/l
P03110746A0146|9 19|percentage
P03110794A0991|3 12|overdoses
P03110801A0532|25 50|plasma prolactin response
P03111946A0309|3 9|effect
P03112028A0404|18 26|patients
P03112412A0985|3 11|addition
P03114188A0907|30 38|problems
P03114829T0000|24 34|correlates
P03114995T0000|0 7|Effects
P03115087A0515|9 15|weight
P03115787A0633|5 13|patients
P03117046T0000|0 9|Isolation
P03117147A1059|16 21|study
P03118631A0140|3 14|differences
P03119227A0079|4 16|DNA sequence
P03119485A0476|4 15|requirement
P03120334A0893|5 6|%
P03123310A0000|28 37|Gart gene
P03123983T0000|4 8|role
P03125420A0421|0 4|Biol
P03125422A0202|4 11|results
P03126531T0000|0 8|Reversal
P03127034A0591|4 14|heart rate
P03127463A1017|6 11|rIL-3
P03132498A0730|6 14|patients
P03133250A0000|26 31|study
P03133360A1215|4 12|findings
P03134872T0029|0 7|Apropos
P03137105A0146|2 24|prostaglandin analogue
P03137346A0319|4 18|nucleolin gene
P03137601A0212|9 38|L-threo-dihydroxyphenylserine
P03138190A0347|12 19|amounts
P03138449A0759|20 25|delta
P03139750A0000|12 17|basis
P03142875A0366|28 52|6-kilobase cDNA sequence
P03143048A1091|0 15|HDL-cholesterol
P03143485A0366|4 11|Euglena
P03144705A0859|4 16|distribution
P03146017A0983|4 23|nucleotide sequence
P03146150T0000|0 12|Potentiation
P03146784A0158|6 15|receptors
P03147912A0422|12 28|hyperventilators
P03149774A0173|7 14|IA task
P03150015T0001|9 17|research
P03150296A0594|25 28|use
P03154072A0862|4 20|protein mixtures
P03159903A0352|7 10|end
P03166458A1356|2 19|protein footprint
P03167060A0000|13 26|growth factor
P03168709A0000|19 25|fields
P03171221A0531|4 15|variability
P03171279A0158|16 26|conclusion
P03172863T0000|0 6|Effect
P03175942A0706|5 11|effect
P03178097A0000|4 22|CHARGE association
P03178161A0000|11 16|brush
P03178626A0137|0 8|Aviators
P03179496T0000|0 10|Evaluation
P03180595A1040|8 33|gallbladder visualization
P03181276A0422|3 17|micrograms PAF
P03182802A0278|0 3|Sci
P03182872A1122|0 4|Chem
P03183103A0000|11 26|MR examinations
P03183127A0068|0 10|Comparison
P03184267A0000|4 8|feed
P03185322A1305|7 18|correlation
P03185540T0000|0 7|Factors
P03186091T0000|0 6|Change
P03186270T0001|13 22|diagnosis
P03190481A0292|4 8|test
P03190914A0149|14 37|migration differentials
P03192537A0370|23 33|amino acid
P03192724A0000|14 31|style differences
P03192799T0000|0 9|Statement
P03192950A0566|0 4|Sera
P03194410A0771|3 14|UOxase mRNA
P03195167A0104|4 26|platelet adhesion rate
P03198436T0000|13 22|treatment
P03198525A0164|11 24|feedlot trial
P03199043A0248|0 9|Existence
P03199436A1060|11 24|gene clusters
P03200488A0439|4 11|results
P03200844A1211|12 20|sequence
P03207975A0709|12 17|hours
P03208493A0849|15 30|filtration rate
P03209019A0662|17 35|promotion bioassay
P03212551T0001|4 16|pathogenesis
P03212929A0000|3 18|ELISA procedure
P03214709A0559|6 9|min
P03216131A0559|9 16|isolate
P03218714A0000|16 20|girl
P03219107A0212|4 13|incidence
P03220077A0274|11 19|survival
P03223123T0001|9 19|evaluation
P03227288A0542|10 17|infants
P03227568T0001|0 7|Variety
P03228518A0339|44 51|samples
P03228785A1047|0 8|Recovery
P03229917A0099|30 39|resection
P03232410A1467|40 45|cases
P03233862T0000|0 20|Neuromyelitis optica
P03234790T0001|0 6|Effect
P03235487A0404|0 13|Incorporation
P03237446A0377|0 4|None
P03239106A0856|15 33|phosphorus content
P03243027T0000|21 31|regulation
P03243920A0591|24 65|plasma concentration-effect relationships
P03246999A0483|4 12|increase
P03249792A0241|9 16|factors
P03249840A0411|0 21|Baseline measurements
P03251210A0981|5 13|children
P03253219T0000|7 14|voltage
P03256150A1866|4 11|results
P03257146A1037|6 13|results
P03258069A0000|4 12|purposes
P03259437A0140|16 50|neonates serum alpha-amylase value
P03261005A0216|0 7|Records
P03261223A0644|9 17|patients
P03261331A0563|0 5|SPECT
P03263357A0112|35 47|relationship
P03263465T0000|11 20|MHC class
P03264073A0224|11 22|derivatives
P03264299A0679|13 17|mice
P03264886A0000|8 18|population
P03267732A0788|18 37|Ga-fbg scintigraphy
P03268555T0000|9 19|assessment
P03270085A0382|0 14|Hypomagnesemia
P03274204A0642|0 12|Dentalplaque
P03275867A0187|0 4|GRFI
P03275873A0379|4 11|effects
P03276246A0037|14 17|use
P03276924A0090|16 22|tumors
P03278829A0082|4 15|indications
P03280021A1615|13 15|dT
P03280807A0000|0 9|Mutations
P03280807A1447|4 12|behavior
P03280912T0000|0 23|Antituberculosis agents
P03280946A0375|13 29|immunity protein
P03282232A0743|0 10|Antibodies
P03282813A0794|24 29|range
P03283881A0216|7 15|patients
P03285764A0675|0 19|Hyperprolactinaemia
P03286611A1198|0 4|Yang
P03287597T0000|10 18|function
P03292076A0820|8 19|endotoxemia
P03292082A0486|3 11|contrast
P03293844T0000|0 4|Diet
P03296019T0000|0 18|Time delay effects
P03296212A0603|4 10|future
P03296254A0556|6 17|differences
P03297181A0127|17 25|subjects
P03298134A0000|5 11|report
P03300118A0392|0 15|Oxygen delivery
P03304015T0000|9 18|chemistry
P03304866T0001|0 17|Revascularization
P03305875T0000|7 15|orthoses
P03306340A0537|20 26|spread
P03308909A0485|10 17|enzymes
P03309892A0637|16 27|observation
P03311954A0000|14 19|study
P03312033A0501|0 11|Monotherapy
P03312514A0756|4 11|N3 wave
P03315359A0732|0 11|Proctoscopy
P03317796A0853|7 20|control group
P03319621A0707|3 11|contrast
P03319646T0000|0 21|Plasma renin activity
P03319912A0000|0 10|Cephradine
P03320875A2090|29 37|Supramid
P03322829A0952|4 8|size
P03325081A0524|8 19|keratopathy
P03326381A0423|20 28|findings
P03329716A0187|4 12|activity
P03330711T0000|22 30|activity
P03331525T0001|11 16|study
P03331933T0048|3 17|Felix Lagrange
P03332022A1094|11 37|cysteine clustering region
P03332848A0000|27 41|Doppler probes
P03334950A0000|4 18|German Society
P03335127A0176|4 11|program
P03335398A0568|11 17|levels
P03335444A0000|2 7|study
P03335651A0000|12 18|method
P03335923A0257|11 19|patients
P03337024A0000|12 19|studies
P03338154T0000|5 19|concentrations
P03340548A1018|7 20|chicken liver
P03340726A1103|5 14|histology
P03340774A0328|11 20|estimates
P03343730A0486|14 25|association
P03344586T0000|0 16|New technologies
P03344812A0924|17 21|data
P03345706A0561|4 15|correlation
P03346157A0000|18 23|times
P03346210A0000|14 27|growth factor
P03348382A0785|15 22|ouabain
P03351478A0371|10 17|regions
P03352254A0203|18 27|structure
P03352439T0000|6 35|cord abduction rehabilitation
P03352727T0000|0 2|UK
P03352947T0001|2 6|case
P03354295A0157|8 14|spread
P03354341A0177|15 30|filtration rate
P03355122A0238|10 14|meal
P03359860A0000|4 13|relations
P03360667A0000|16 22|effect
P03360948A0477|12 15|CAP
P03361653A0459|21 27|system
P03366720A1335|7 13|change
P03366864A0099|4 13|skin site
P03368701A0113|21 32|reliability
P03370815T0000|6 15|detection
P03371139A0829|11 16|group
P03371806A0000|11 26|data processing
P03371894A0355|0 19|Vimentin positivity
P03372422A0558|4 23|maximum deflections
P03373755T0001|7 19|developments
P03375184A0000|4 26|spermicide nonoxynol-9
P03377864A0000|16 22|fields
P03377891A0652|14 25|disturbance
P03378994T0000|8 22|administration
P03379058A0188|0 21|Nucleotide sequencing
P03380547A0169|0 3|SPA
P03381039A0364|3 11|contrast
P03382310A0903|9 22|technetium Tc
P03382772A0319|0 18|Practical interest
P03382855A0368|4 15|artery cuff
P03383897A0189|18 24|action
P03384033A0155|10 15|units
P03384272A0145|17 25|location
P03387665A0000|4 15|development
P03390074A0000|0 19|Electroglottography
P03395009A1750|12 20|analysis
P03395164A0000|20 27|effects
P03395249A1044|18 29|examination
P03396437A0321|10 18|problems
P03396628A0207|11 29|observation period
P03398433T0001|4 9|state
P03398714A0594|15 17|RH
P03398823A0459|4 11|effects
P03400694A0245|0 8|PATIENTS
P03401060A0000|5 14|melanomas
P03402183A0171|4 13|TA muscle
P03403313A0298|20 33|control rates
P03403412A0000|4 11|effects
P03403480A0299|10 20|suspension
P03403826T0000|86 98|measurements
P03404334T0000|0 13|Water content
P03404495A0172|0 22|Thyroid function tests
P03406054A0351|0 4|Data
P03407676A0585|8 17|infection
P03407843T0000|0 6|Papers
P03413681A0659|9 22|heart disease
P03413890T0001|0 9|Prognosis
P03417104A0536|20 27|results
P03417588T0000|0 6|Liquid
P03417668A1233|6 14|findings
P03418727A0992|25 36|penetration
P03420266A0000|4 15|interaction
P03420324A0178|9 13|rats
P03420466A0000|4 13|incidence
P03421425A0878|6 14|patients
P03423732A0341|0 8|Addition
P03427474A0853|17 29|control rats
P03427613A0659|35 41|system
P03428084A0430|6 21|degrees stimuli
P03428274A0000|8 14|factor
P03429306T0000|2 13|Golgi study
P03429371A1051|17 38|cephalothin clearance
P03430221A1236|4 12|findings
P03434347A0358|0 9|Mean rCBF
P03436119A0000|22 32|tomography
P03436529A1066|4 13|structure
P03436877A0950|0 2|Kf
P03439248A0000|18 25|methods
P03440780A0779|11 18|results
P03441587A0000|0 8|Research
P03443144A0409|6 31|aspirin esterase activity
P03443566A0675|8 19|experiments
P03443573A0329|8 21|least-squares
P03443609A0000|4 8|role
P03446332A0831|0 13|Nitrofurazone
P03448035T0000|8 14|tumors
P03449358T0001|16 21|study
P03450438A0446|0 7|X2 test
P03451761A0215|8 22|baseline study
P03452920T0001|0 3|Man
P03457330A0271|4 12|patients
P03459385T0000|0 7|Allergy
P03459736A0184|4 13|criterion
P03463537T0001|9 15|method
P03463543A1613|0 8|Enoxacin
P03465957A1008|0 21|Mean fluorosis scores
P03466730A0210|10 22|dysfunctions
P03473253A0000|31 53|cohort mortality study
P03473379A0183|4 13|diagnosis
P03476002A0148|0 4|Hair
P03478354A0436|11 16|herds
P03479897A0961|13 17|hand
P03484075T0001|0 19|Emergency treatment
P03484894A0782|6 11|cases
P03485064A0135|2 7|total
P03486405A0341|23 30|portion
P03487348A0000|13 20|version
P03488532A0235|22 28|report
P03491190A0233|4 17|detectability
P03493240T0000|14 24|properties
P03494649A0472|23 32|challenge
P03499608A1054|6 10|data
P03499657A0000|0 11|Osteocalcin
P03499822A0182|22 41|regression analysis
P03504971A0000|0 6|Hexsyn
P03507689A0000|9 41|phage-plasmid expression vectors
P03508698A0535|3 8|order
P03510185A0187|0 5|Natl.
P03513989A0580|8 15|ethanol
P03513989A1149|25 33|disorder
P03515840A0000|30 35|cases
P03516189A0406|4 12|patients
P03517388A0763|26 37|CK-MB level
P03520729A0381|12 19|changes
P03522105A1011|5 36|trough serum TOB concentrations
P03526279T0000|15 22|schools
P03528748A0414|5 20|maxicell system
P03531317A0930|20 24|loss
P03534581A0976|4 13|incidence
P03536682A0572|0 9|Ovulation
P03536864A0000|12 16|work
P03537686A0099|10 14|size
P03537711A0181|0 2|W.
P03537721A0491|7 15|analysis
P03537721A0876|13 25|observations
P03537727A0243|4 8|poly
P03540591A0330|9 20|translation
P03540853A0652|15 34|amino acid sequence
P03541263A0368|12 22|techniques
P03542945T0000|0 13|Ciprofloxacin
P03543485A0069|22 32|mechanisms
P03543936A0000|4 13|rho genes
P03544858A0374|6 15|component
P03545955A0751|4 17|glucose areas
P03545955A1378|4 26|serum insulin response
P03549045A0878|0 3|SCL
P03550444T0000|0 11|Development
P03552363A0568|12 32|serum insulin levels
P03553149A0299|33 44|mutagenesis
P03553439A0404|4 10|latter
P03555318T0000|4 16|pharmacology
P03556834T0000|6 25|inhalation toxicity
P03559193A0000|12 25|investigation
P03559232T0000|14 19|study
P03559287T0000|0 10|Legionella
P03561036T0000|0 10|Lymphatics
P03561622A0659|10 16|resort
P03563399A0534|4 20|signal durations
P03563604A1075|4 15|spleen rate
P03567017A0000|9 15|dosing
P03568311A0273|6 14|patients
P03568311A1361|13 22|tamponade
P03570455A0433|0 7|Rabbits
P03571135T0000|7 12|value
P03572706A0329|21 36|interpretations
P03575656A0120|30 43|chemical form
P03577670A0102|4 9|study
P03577670A0236|4 13|diagnosis
P03578948A0448|11 22|ventilation
P03581160A0583|20 41|heart rate reactivity
P03582149T0001|19 25|survey
P03582184A0448|0 5|Drugs
P03582982A0000|2 7|study
P03583001A0111|22 31|procedure
P03584426A0706|17 28|enterotoxin
P03586925T0001|0 11|Development
P03590911T0001|24 34|dermatosis
P03591464A0840a|17 21|test
P03591464A0840b|17 21|test
P03592297A0138|0 17|Dorsal foot TcpO2
P03592297A0679|3 11|subjects
P03595418A0688|4 24|nucleotide sequences
P03597218A0901|13 27|concentrations
P03597269A0409|10 15|model
P03600633A1069|0 4|Cell
P03600705T0000|0 6|Timing
P03601275A0601|6 23|dopamine infusion
P03601533T0001|11 21|importance
P03602261A0238|36 45|condition
P03605895A0888|6 14|patients
P03607109A0370|10 19|processes
P03607961T0001|13 19|action
P03608916A0790|3 8|cases
P03608989A0668|5 11|region
P03610663A0201|5 13|approach
P03610674T0000|4 10|effect
P03612316A0102|7 11|rats
P03612648A0085|27 46|lupus anticoagulant
P03615550A0000|4 11|effects
P03615550A1094|20 27|effects
P03615763A0170|0 4|Data
P03616174A1069|14 20|change
P03616237T0001|11 29|status epilepticus
P03618039A0126|4 12|presence
P03619249A0428|14 21|markers
P03622423A0000|0 6|Groups
P03622571A0208|0 18|Radionuclide study
P03625688A0372|0 14|Immobilization
P03625762A0308|0 10|Comparison
P03626129T0001|0 7|Effects
P03627720A0196|30 38|features
P03628532A0000|4 8|role
P03628596A0000|0 7|Samples
P03628713A0961|9 20|experiments
P03628794A0648|4 12|patients
P03629973A0240|0 2|W.
P03629974A1468|0 10|Comparison
P03632739T0000|0 22|Cyclosporine treatment
P03635597A0377|3 11|addition
P03637037T0000|15 31|teaching booklet
P03645733T0001|0 15|Hyperthyroidism
P03649340A1119|35 45|precursors
P03651330T0000|24 31|lesions
P03651840A0266|8 27|MAO inhibition data
P03652083A0720|13 19|region
P03653226A0833|25 50|tissue-distribution study
P03658866A0081|9 28|lupus erythematosus
P03659603A0797|7 14|evening
P03659805A0404|16 28|significance
P03659994A0150|6 13|changes
P03663789A0568|6 13|results
P03664038A0000|4 11|purpose
P03666957A0219|0 9|Organisms
P03668003T0000|24 34|microscopy
P03668396A0171|6 27|equilibrium solutions
P03668736A0177|12 22|deviations
P03672532A1111|26 33|effects
P03673640A0533|4 16|MAO subjects
P03673881A0000|25 33|accuracy
P03676054A0865|3 8|group
P03676174A0730|3 9|calves
P03678269A0633|0 5|Today
P03678372A0170|4 10|number
P03679407A0556|6 13|results
P03679756A0830|11 30|nerve fiber defects
P03680791A0230|15 20|grade
P03682805A0375|0 12|Serum levels
P03684378A0653|14 18|milk
P03684517A0462|10 18|training
P03685073A0200|18 22|dose
P03687078T0001|0 10|References
P03687148T0187|0 8|Salzburg
P03687313A0000|8 30|glucosidase inhibitors
P03688202A0377|4 10|models
P03688301A0129|17 22|cases
P03688676A0487|9 20|conversions
P03690262A0428|4 21|maximum amplitude
P03691316A0560|21 36|contact allergy
P03692331A0000|4 10|effect
P03693543A0405|39 58|Rhodococcus species
P03694102A0000|4 15|development
P03696899T0001|0 32|Blood serum erythropoietin level
P03697587T0000|4 28|XXXXY chromosome anomaly
P03697798T0001|0 11|Contraction
P03697971A0311|4 18|selenium level
P03698251T0000|0 15|Oxygen delivery
P03700952A0273|0 7|Infants
P03701640A1178|6 13|results
P03703493A0654|4 10|number
P03704087A0394|7 15|subjects
P03709191A0125|37 43|cortex
P03709627A0247|4 12|subjects
P03710973A0817|0 4|Mean
P03712050T0000|0 28|Indium-111 leukocyte imaging
P03712106A0000|4 10|effect
P03712153T0000|17 54|Haemophilus influenzae type b disease
P03713187A0691|9 16|lesions
P03714348A0833|0 7|Factors
P03714473A0496|0 9|Induction
P03717475A0208|0 3|New
P03717936A0252|0 8|Amikacin
P03720615A0434|20 24|part
P03720966A1043|18 35|acid N absorption
P03721594A0000|0 8|Adhesion
P03721666A0000|0 6|Nickel
P03722016A0797|4 14|FFA levels
P03728230A0104|15 23|hospital
P03732252A0556|17 25|analyses
P03733563A0716|14 39|herd X period interaction
P03733563A0820|0 8|Liver TG
P03734641A0203|4 11|results
P03736081A0465|18 32|sinus pressure
P03738919A0000|0 14|Calcifications
P03743683A0000|5 11|series
P03743702A0158|16 17|%
P03744168T0001|16 22|action
P03745833A0258|3 13|transition
P03746053A0670|0 8|Findings
P03746107A0192|29 33|cent
P03746508A0390|0 8|Failures
P03746601A0299|21 29|problems
P03746896A0890|27 34|results
P03746906A0000|4 11|studies
P03747493A0000|15 23|patients
P03749226A0506|5 18|phencyclidine
P03750700T0001|0 13|Possibilities
P03751308T0001|0 5|Study
P03753022A0000|10 18|lymphoma
P03755623A1233|8 22|investigations
P03755673A0054|15 20|cases
P03757294A0414|7 12|cases
P03758250A0000|29 38|movements
P03759330A0713|4 15|combination
P03759731A0992|6 15|clearance
P03761122T0000|4 13|relations
P03761523A0000|4 8|rats
P03763241A0446|20 28|weakness
P03763836T0001|0 7|Results
P03765552A0582|4 13|mechanism
P03765731A0918|0 10|Incidences
P03766370A0546|12 20|r values
P03768208A0879|6 13|results
P03769224A0000|12 16|data
P03770143A1209|4 15|possibility
P03771670T0058|0 10|Prevention
P03771703A0000|14 38|trimethylsilylcarbamates
P03771749A0465|0 4|MICs
P03772471A1054|14 22|patients
P03774111T0000|0 8|Evidence
P03776080A0400|16 39|post-mortem examination
P03776438A0000|0 14|Glucocorticoid
P03776779A0238|26 35|treatment
P03777398A0156|0 8|Examples
P03779182A0370|12 24|drug problem
P03779205A0459|11 19|patients
P03780248A0274|9 20|differences
P03780371A0792|11 20|sequences
P03780704A0573|8 16|increase
P03781000A0101|5 9|lack
P03781948T0000|12 22|adaptation
P03783160A0285|0 8|Compound
P03785212A0091|18 47|hamster S14 protein sequences
P03785212A1128|0 13|RPS14 introns
P03788231A0802|25 32|aspects
P03789052A0527|15 30|tissue response
P03791645A1124|6 14|findings
P03795488A0487|21 28|lesions
P03799323A0501|15 25|hematocrit
P03799790A0146|10 18|examiner
P03802195A0481|6 21|fusion proteins
P03805090A0645|16 24|analyses
P03806696A0000|11 19|toxicity
P03810361A0576|33 59|plasma cortisol estimation
P03810867A0305|12 20|patients
P03811852A0109|4 8|risk
P03814493T0000|0 12|Chlorambucil
P03818467A0180|0 8|Selenium
P03818866A0116|0 15|Framingham Type
P03820222A0203|27 34|potency
P03824908A0116|4 19|M reading frame
P03826871A0000|3 6|ion
P03827071T0040|0 2|II
P03828209T0000|15 22|changes
P03828500T0001|0 15|Intensification
P03829848T0001|0 19|Autotransplantation
P03830147A0000|4 17|relationships
P03830255A0074|64 76|distribution
P03835413A0616|4 15|observation
P03836777T0001|0 13|Practical use
P03836853A0204|18 37|year survival rates
P03836854T0000|0 10|Inhibition
P03837609T0000|22 27|study
P03838797A0903|0 17|Northern blotting
P03840480T0000|16 24|families
P03841627T0001|0 12|Chemotherapy
P03843496A0919|10 15|years
P03843676A0381|7 20|extrapolation
P03848527T0020|0 13|Hisako Minowa
P03857577A0413|0 24|Deletion mapping studies
P03860162A0000|0 13|Incorporation
P03861687A0000|29 34|males
P03862898A0563|0 9|Serum IgM
P03863231A0530|4 15|M-3 subtype
P03863561A0405|11 16|Strep
P03865743A0859|6 13|results
P03866085A0795|32 55|suppository formulation
P03869442A0223|3 11|addition
P03871298A0217|7 22|photon emission
P03871445T0000|0 8|Computer
P03873141A0304|6 23|patients vagotomy
P03874921A0862|0 13|Documentation
P03875231A0627|0 3|MRI
P03877298A0718|4 11|results
P03878585A0507|4 28|percentage RFR reduction
P03880838T0000|0 9|Diagnosis
P03881260A0000|2 20|yeast DNA fragment
P03882029A0000|16 21|study
P03883052T0001|3 9|memory
P03883541A0200|4 27|H2 receptor antagonists
P03885983A0254|6 13|results
P03887085A0000|7 15|efficacy
P03887769A0093|4 8|Mean
P03887769A0584|7 13|region
P03888621A0185|15 19|gene
P03890486A0000|20 42|lymph node enlargement
P03891766A1473|0 12|Interference
P03894482A0549|4 12|patients
P03896991T0000|0 14|New techniques
P03898382A0000|18 37|subtraction imaging
P03904004A1577|31 37|energy
P03904952T0000|0 17|Nursing education
P03908196T0000|0 19|Shear bond strength
P03908493A0246|14 23|advantage
P03910310A0666|7 14|concept
P03911052A0909|17 23|DIL-CP
P03911702A0530|40 45|model
P03911965A0513|24 36|significance
P03912247A0282|4 10|volume
P03913522A0000|5 10|aging
P03914875T0001|5 16|candidiasis
P03915540A0863|3 11|addition
P03920700A0491|53 67|responsiveness
P03921727A0523|4 18|concentrations
P03922116A0197|4 16|distribution
P03923828A1031|4 16|availability
P03923976T0001|0 16|Thrombophlebitis
P03925712A0229|0 8|Biopsies
P03928357A0340|0 20|Laboratory pyrolyses
P03928442A0463|14 20|degree
P03928678T0000|38 49|contraction
P03929486A0309|22 27|trial
P03929610A0268|13 23|discomfort
P03930549A0209|4 10|sample
P03930894T0000|0 7|Changes
P03931293A0437|7 14|absence
P03931797A0134|12 22|prevalence
P03933232T0000|6 16|classicism
P03933784A0420|13 19|origin
P03934667A0124|18 32|crsA mutations
P03935117T0000|10 16|effect
P03935375A0414|5 12|article
P03935797A0183|4 8|data
P03936828T0000|8 19|thyroiditis
P03937294A0404|0 22|Plasma secretin levels
P03937481T0001|19 32|microanalysis
P03939317A0352|2 12|comparison
P03940426A0618|0 7|Results
P03940733A0755|11 17|method
P03940818T0000|10 21|hepatitis A
P03944212A0166|0 15|Tissue pressure
P03944239A0780|12 16|time
P03946125T0000|0 4|Drug
P03952387A0336|8 19|compartment
P03953361A0000|16 23|effects
P03956647A1063|0 11|Dissolution
P03956695A0617|0 18|Cortisol excretion
P03959045A0000|4 11|studies
P03963860A0137|2 7|total
P03964489A1195|8 18|% decrease
P03964855A0254|0 11|Angiography
P03965012A0163|4 11|results
P03966687A0000|14 20|impact
P03967144T0001|0 13|Hypersplenism
P03970191A0275|11 19|activity
P03972038A0000|4 14|topography
P03972185A0137|13 18|state
P03974790A0053|12 23|CT findings
P03976323A0821|14 25|correlation
P03977577T0000|0 24|Shoulder forearm support
P03977603A0326|0 9|Piroxicam
P03978045A0857|6 14|findings
P03978132A0108|3 17|MCCP functions
P03979084A1019|9 16|kidneys
P03980386A0000|14 21|effects
P03981421A0246|2 11|flow rate
P03981640A0168|27 31|ends
P03981952T0000|4 12|efficacy
P03982288T0000|0 15|Doctor Berglund
P03984683A0000|6 16|appearance
P03985849A0221|16 30|rhinosinusitis
P03987818A0440|6 10|data
P03987857A0733|12 19|muscles
P03988001A0227|26 53|rat blood chloroform levels
P03989827T0000|4 13|frequency
P03992022A0330|0 10|Activities
P03995513T0000|0 11|Doxorubicin
P03997467A0000|4 10|effect
P03998071T0000|0 25|Electrochemical detection
P03998813A0406|15 26|experiments
P03999219A0463|0 14|Ultrastructure
P04000347A0442|22 30|criteria
P04001413A0093|9 16|purpose
P04001490T0001|4 18|POEMS syndrome
P04002131A0506|9 26|disease remission
P04002667A0181|19 27|patients
P04004168A0000|4 12|siblings
P04005190A1288|4 11|extract
P04011338A0620|10 18|patients
P04011466T0000|7 16|diameters
P04013576A0981|12 25|investigation
P04013604A0412|15 24|frequency
P04014833A0400|0 14|Hydrocortisone
P04014861A0000|12 23|feasibility
P04015988T0000|0 20|Marrow cell necrosis
P04017295A0139|4 14|comparison
P04018444A0000|17 21|acid
P04019066A0000|15 31|field potentials
P04021281T0001|0 14|Ultrastructure
P04021305A0530|16 32|desympathization
P04021431A0000|0 4|OODG
P04021437A0000|6 16|infections
P04024685A0650|9 10|%
P04025178A0126|14 22|analyses
P04025179A0955|3 8|group
P04026903A0512|0 11|Polysorbate
P04026972T0000|11 36|alcohol reaction profiles
P04027182T0000|0 8|Vitiligo
P04028871A0133|4 20|pharmacokinetics
P04031488A1091|7 13|degree
P04032268A0358|9 20|UV detector
P04032349A0000|3 11|patients
P04032716A0299|4 24|mean transfer ratios
P04033402A1112|28 36|hormones
P04034220A0205|20 28|spectrum
P04034666T0000|6 30|extremity weight bearing
P04036838A0918|6 12|factor
P04037809A0964|28 42|dose schedules
P04038454A0984|25 45|plasma retinol level
P04038702A0768|4 11|results
P04039109A0139|5 10|laser
P04039307A0613|3 4|d
P04039439A0000|14 19|quail
P04039439A0842|5 10|study
P04039525A0475|0 6|Plasma
P04039667T0000|14 27|visualisation
P04039744A0141|6 13|results
P04040083A0000|0 11|Rabbit eyes
P04040307A0145|7 12|birth
P04040339T0001|0 18|Monitoring changes
P04040858A0000|6 15|September
P04041307A0614|4 11|results
P04041346T0000|17 28|arrhythmias
P04043489A0648|0 7|Visidex
P04048245A0331|0 9|Treatment
P04050771A0474|4 7|Cox
P04050821A0531|19 29|mechanisms
P04051521T0001|0 8|Duration
P04052919A0205|6 10|data
P04055593A0523|27 37|processing
P04056218A0463|5 10|slope
P04056256A0416|0 20|Histamine reactivity
P04058985A0000|14 19|doses
P04061342A0512|36 45|elevation
P04062128T0028|0 19|National Institutes
P04063732A0509|3 11|controls
P04066194A0163|0 19|Greater attenuation
P04066274A0265|12 20|patients
P04067540A0413|4 15|comparisons
P04068663A0452|10 17|rabbits
P04068774A1292|9 22|relationships
P04068969A0300|0 5|L3-L4
P04069756T0025|0 9|Diagnosis
P04070725A0442|0 14|Component P100
P04071063A0863|12 23|differences
P04073848T0000|0 7|Failure
P04074214A0000|0 7|Factors
P04075021T0000|1 4|14C
P04075061A0355|4 11|runners
P04079738A0677|4 9|rates
P04081425T0016|9 16|aspects
P04082267A0720|16 20|days
P04082592T0000|0 17|Blood eosinophils
P04084607A0663|4 16|imino proton
P04084896A0569|4 18|recommendation
P04085589A0264a|13 24|correlation
P04085589A0264b|13 24|correlation
P04086403A1016|0 5|Gains
P04086657T0000|21 32|development
P04086993T0000|0 5|Daily
P04088233A0309|4 16|transit time
P04088396A0145|10 31|patients grades 1-2-3
P04088733T0001|0 8|Activity
P04088936T0001|12 19|studies
P04093211A0560|37 44|ability
P04101003T0001|0 9|Relations
P04102280T0000|0 9|Treatment
P04103248T0000|0 11|Improvement
P04113011T0000|4 19|desensitization
P04114211T0000|6 15|excretion
P04115870T0000|0 11|Experiences
P04123217T0000|0 9|Formation
P04123662T0000|0 10|Evaluation
P04138224T0095|4 10|effect
P04139081T0001|5 15|antibodies
P04139943T0001|0 13|Demonstration
P04140567T0001|0 20|Histamine metabolism
P04143528A0394|31 43|nomenclature
P04145244T0000|0 10|Relaxation
P04152725T0001|0 7|Studies
P04160980T0000|13 20|control
P04164595T0020|0 8|Evidence
P04164669T0000|26 41|kinin formation
P04172166T0000|0 13|Poliomyelitis
P04175007T0001|7 14|problem
P04176249T0001|0 10|Assessment
P04176268T0000|0 15|Aluminium resin
P04176625T0000|0 5|Value
P04179445T0036|0 2|D.
P04189158T0000|0 10|Prevention
P04194466T0000|0 16|Serotonin levels
P04196986T0000|14 31|fluid transferrin
P04213917T0001|5 12|dosages
P04214345T0000|8 16|relation
P04226360T0001|0 9|Disorders
P04239041T0045|4 10|effect
P04246054T0028|0 6|Effect
P04247472T0001|7 12|cycle
P04247966T0000|0 9|Lactation
P04262268T0001|0 7|Studies
P04263748T0042|23 29|review
P04281856T0001|0 3|Age
P04282315T0001|0 13|Sensitization
P04284435T0000|0 10|Vitamin D3
P04289156T0000|4 13|incidence
P04291759T0048|0 18|Laboratory aspects
P04295031T0062|6 12|effect
P04305850T0000|0 9|Androgens
P04308979T0000|0 6|Effect
P04311951T0001|12 18|action
P04315233T0128|22 32|experiment
P04316696T0001|0 6|Enzyme
P04321861T0001|9 41|glutathione reductase deficiency
P04323641T0000|0 7|Studies
P04325736T0001|0 13|Serodiagnosis
P04328746T0073|0 17|Ultrasound effect
P04335965T0000|0 10|Metastasis
P04350410T0000|0 7|Genesis
P04364369T0000|0 22|Pre-beta-1 lipoprotein
P04369884T0000|0 10|Conditions
P04371279T0000|0 7|Absence
P04377003A0000|13 19|method
P04377328T0027|0 2|I.
P04385060T0000|0 10|Disulfiram
P04387103T0000|0 9|Particles
P04392584T0000|20 28|malarias
P04394290T0000|2 7|study
P04407649T0000|13 27|arachnoid cyst
P04418687T0000|0 7|Effects
P04423347T0001|0 6|Copper
P04428800T0001|0 6|Effect
P04428981T0000|0 8|Kinetics
P04429269T0000|7 16|transport
P04437406T0000|15 26|description
P04445874T0001|0 9|Pathology
P04446923T0001|9 24|characteristics
P04460692T0000|9 15|topics
P04468264T0053|0 8|Problems
P04482661T0001|9 15|course
P04487835T0001|3 10|parents
P04487920T0001|9 39|Icelandic Red Cross activities
P04488232T0001|0 7|Effects
P04488271T0001|0 9|Treatment
P04495034T0000|13 26|methylbenzene
P04506738T0000|0 9|Junctions
P04510102T0000|0 18|Electrocardiograms
P04511139T0001|0 10|Composites
P04512496T0000|0 7|Hodgkin
P04515631T0000|0 5|Value
P04518624T0000|0 22|Glutathione peroxidase
P04524081T0000|16 24|response
P04533208T0083|0 7|Changes
P04536964T0000|14 16|pH
P04539552T0001|14 21|studies
P04543036T0001|0 10|Directives
P04544430T0001|0 11|Proceedings
P04544704T0001|0 6|Method
P04546974T0000|0 10|Variations
P04547933T0000|14 30|fibril formation
P04548483T0001|0 15|Blood platelets
P04551650T0001|0 14|Cell viability
P04552263T0000|15 22|schools
P04562038T0001|8 21|investigation
P04563045T0000|0 7|1,3-bis
P04578686T0000|0 12|Pneumothorax
P04579436T0000|26 40|colour changes
P04580044T0047|9 22|relationships
P04583791T0000|8 15|history
P04598670T0000|6 23|graft irradiation
P04600603T0001|0 6|Letter
P04613073T0001|0 4|Role
P04615525T0001|4 10|effect
P04615828T0001|5 13|birthday
P04621188T0000|0 10|Morphology
P04622430T0000|9 18|afferents
P04624863T0001|0 9|Mechanism
P04627477T0001|0 18|Resistance pattern
P04632967T0000|19 27|pressure
P04638365T0001|0 6|Effect
P04640155T0045|0 9|Sex ratio
P04645078T0001|13 22|processes
P04646045T0001|18 24|tumors
P04653144T0000|0 16|General formulae
P04654249T0000|0 11|Measurement
P04656185T0000|0 26|Glucose disappearance rate
P04661961T0001|7 13|values
P04676734T0000|4 16|relationship
P04679438T0001|11 17|effect
P04679807T0000|9 27|acid concentration
P04704137T0001|0 4|Role
P04704186T0000|0 14|Range behavior
P04712626T0000|0 21|Chemical constituents
P04718233T0000|0 27|Methyl mercury intoxication
P04727344T0000|0 18|Microdetermination
P04729063T0000|13 20|justice
P04730467T0000|0 7|Effects
P04733391T0000|0 28|Metal coordination compounds
P04746559T0053|0 10|Estimation
P04752455T0000|0 20|Disability insurance
P04753073T0000|0 6|Choice
P04753286T0000|0 11|Suppression
P04757217T0000|0 7|Studies
P04758799T0000|0 12|Pneumothorax
P04759722T0000|0 17|Polycythemia-1973
P04760826T0000|9 16|anxiety
P04764049T0001|18 34|nephronophthisis
P04766888T0000|6 21|heparin therapy
P04778129T0000|0 18|9,11-Seco steroids
P04782788T0001|14 26|examinations
P04784432T0001|0 13|Possibilities
P04787472T0001|0 6|Change
P04787716T0000|0 12|Observations
P04788701T0001|0 11|Combination
P04789916T0001|0 8|Analysis
P04791420T0000|0 11|Proceedings
P04794218T0001|12 20|K agents
P04796997T0000|7 19|reproduction
P04801663T0049|30 40|properties
P04803629T0001|14 20|system
P04810131T0000|0 6|Letter
P04813394T0000|0 10|Evaluation
P04820791T0001|21 25|acid
P04824747T0000|0 17|Nonteratogenicity
P04826272T0074|0 3|VII
P04828587T0000|0 9|Isolation
P04837183T0000|0 12|Observations
P04839176T0001|0 6|Effect
P04843031T0000|4 10|levels
P04852635T0000|0 4|Lack
P04863895T0000|0 12|Relationship
P04871589T0001|8 16|solution
P04878680T0000|0 7|Effects
P04884060T0000|4 25|Twentieth Anniversary
P04890336T0001|21 28|pattern
P04909355T0000|17 32|Actinomycetales
P04911925T0001|0 34|Electrocardiographic QRS complexes
P04919613T0001|0 5|Study
P04921762T0000|8 20|preservation
P04925617T0000|7 10|bar
P04941419T0000|0 28|Yusuf Dawood Docrat L.R.C.P.
P04941951T0000|0 3|Dr.
P04942414T0000|4 14|metabolism
P04947347T0000|0 13|Spleen weight
P04948325T0000|0 9|Isolation
P04959816T0000|15 20|fluid
P04967824T0000|0 7|Effects
P04970131T0001|5 23|reflexions apropos
P04970918T0069|0 10|LA-3848-MS
P04973523T0000|15 22|studies
P04975676T0000|29 40|alterations
P04976988T0000|0 13|Heterogeneity
P04989251T0000|0 8|Analysis
P04990556T0000|0 12|Reactivities
P04992478T0000|0 18|Plasma histaminase
P04999086T0001|14 19|study
P05000171T0000|4 10|effect
P05005311T0000|0 14|Immunogenicity
P05012220T0000|9 19|experience
P05015678T0000|18 29|tautomerism
P05020660T0000|0 7|Factors
P05021912T0000|18 29|sensitivity
P05025918T0000|0 11|Angiography
P05027295T0034|0 14|Cholinesterase
P05027799T0000|0 18|Sodium restriction
P05028628T0001|26 38|examinations
P05031074T0001|0 19|Serum lipid changes
P05031659T0000|11 20|treatment
P05034373T0000|11 15|role
P05045351T0000|9 18|breathing
P05049711T0000|8 22|session report
P05060388T0000|18 25|studies
P05065548T0075|7 19|constituents
P05066316T0001|0 8|Relation
P05068271T0000|0 9|Influence
P05075857T0000|0 31|Oscilloscope triggering circuit
P05081814T0000|0 11|Derivatives
P05083872T0000|4 10|status
P05087496T0000|9 17|arteries
P05091970T0000|10 16|agents
P05093030T0001|0 10|Separation
P05095988T0001|13 22|treatment
P05101762T0000|0 14|Spasmus nutans
P05110049T0001|4 8|data
P05114515T0000|17 31|enzyme release
P05119546T0001|0 9|Treatment
P05120197T0000|13 25|pancreatitis
P05123884T0000|10 20|metabolism
P05124707T0001|0 8|Dynamics
P05124972T0042|0 2|I.
P05128149T0001|0 18|Surgical treatment
P05132558T0000|4 15|interaction
P05133723T0000|0 6|Effect
P05135168T0000|0 13|New alkaloids
P05138738T0001|2 6|case
P05145925T0000|15 21|nature
P05152314T0001|11 23|oscillations
P05154132T0000|4 9|value
P05162342T0001|10 16|tumors
P05170106T0034|0 7|Results
P05172320T0001|0 7|Studies
P05172970T0001|4 11|problem
P05174753T0001|14 24|dysostosis
P05177935T0001|0 9|Proposals
P05203499T0001|21 34|scintillation
P05210791T0001|0 9|Pneumonia
P05253274T0001|0 12|Osteosarcoma
P05274128T0001|4 11|content
P05274526T0000|0 7|Relapse
P05276380T0000|0 9|Influence
P05284310T0000|16 24|fluoride
P05285978T0076|7 13|report
P05299993T0000|0 12|Modification
P05303700T0066|0 12|SAM-TR-68-54
P05305671T0000|8 18|discussion
P05308271T0000|0 3|BIM
P05309471T0000|0 8|Problems
P05316745T0000|0 13|Aedes aegypti
P05322558T0000|0 18|Homograft response
P05322747T0034|12 17|study
P05340801T0000|0 10|Mycotoxins
P05344097T0000|0 7|Factors
P05353667T0000|7 26|cord representation
P05356107T0001|11 17|action
P05357390T0001|0 4|Auto
P05359464T0000|0 8|Pitfalls
P05362866T0000|0 15|Renin secretion
P05363816T0001|4 8|need
P05364951T0001|0 14|Histopathology
P05368978T0000|0 11|CNS effects
P05372511T0105|0 18|Diethylene benzene
P05379901T0000|0 13|Midge control
P05388567T0000|4 11|effects
P05389125T0000|16 25|behaviour
P05394352T0000|0 12|Genitography
P05394461T0001|0 14|Tolerance test
P05410590T0000|4 8|role
P05410641T0000|8 15|percent
P05412122T0000|3 9|Methyl
P05412687T0000|11 19|invasion
P05413428T0000|4 16|distribution
P05414186T0001|10 29|Hong Kong influenza
P05417431T0001|6 16|disagnosis
P05421537T0001|0 12|Difficulties
P05424220T0001|0 19|Lipid concentration
P05425195T0001|0 8|Behavior
P05437405T0000|11 18|forearm
P05441564T0001|0 7|Studies
P05445187T0000|16 29|heat exchange
P05451324T0000|0 11|Calibration
P05456002T0000|0 8|Mae West
P05460466T0001|0 11|Elimination
P05463837T0023|13 26|configuration
P05466177T0001|12 19|effects
P05471866T0000|4 39|plasma growth hormone concentration
P05472485T0000|8 32|cochlear response curves
P05474466T0001|6 27|hemagglutination test
P05488121T0000|0 16|CO2 assimilation
P05492285T0000|4 11|biology
P05496619T0000|8 16|profiles
P05497793T0000|0 7|Effects
P05500957T0001|4 15|association
P05501347T0001|4 10|effect
P05502054T0000|0 8|Leukemia
P05525652T0064|12 18|report
P05529283T0000|0 12|Quantitation
P05532854T0001|17 31|manifestations
P05533214T0001|0 17|Iodine metabolism
P05536803T0001|6 16|body water
P05544291T0031|0 2|V.
P05552149T0000|0 3|18F
P05552642T0000|0 11|Propagation
P05553261T0000|0 6|Health
P05555149T0001|23 29|method
P05556977T0001|0 13|Morphogenesis
P05560428T0001|30 40|expression
P05567721T0000|0 13|Sensitivities
P05572662T0000|0 7|Central
P05574818T0000|4 7|Lab
P05593469T0001|16 24|injuries
P05594277T0051|4 16|modification
P05595036T0001|0 8|Students
P05621339T0001|24 29|doses
P05627251T0000|9 15|shifts
P05642051T0000|19 40|department management
P05671267T0000|3 22|Dimethylaminopropyl
P05672903T0001|0 23|Osteogenesis imperfecta
P05683363T0001|0 13|Investigation
P05683809T0000|0 6|Effect
P05684081T0001|0 12|Measurements
P05689427T0052|3 37|N-Alkyl-N-2-chloroethylaminomethyl
P05692759T0001|0 11|Nephrectomy
P05693602T0001|0 10|Evaluation
P05693605T0001|0 13|Determination
P05715613T0000|0 7|Sterols
P05718386T0001|8 12|cyst
P05718500T0001|13 25|observations
P05718994T0000|12 27|fibro-elastosis
P05719031T0000|0 7|Studies
P05719746T0001|0 8|Children
P05722341T0000|0 14|Identification
P05725509T0000|0 8|Steroids
P05727222T0000|4 11|effects
P05732641T0001|0 6|Trials
P05733952T0001|4 16|significance
P05733953T0001|4 10|effect
P05734847T0000|0 7|Studies
P05740389T0001|0 9|Relations
P05742879T0000|0 15|Transformations
P05749438T0001|13 24|anesthetics
P05750950T0001|0 6|Estrus
P05751819T0000|4 11|bearing
P05758469T0001|0 20|Hemodynamics changes
P05760665T0000|0 17|Caries prevention
P05763287T0063|0 2|I.
P05763347T0000|9 21|applications
P05769307T0000|0 18|Automatic view box
P05774062T0000|0 11|Measurement
P05779953T0000|0 6|Effect
P05781385T0000|4 16|significance
P05782943T0001|0 12|Relationship
P05787318T0000|10 17|effects
P05789870T0001|0 42|Phosphate glucose dehydrogenase deficiency
P05792868T0000|0 37|Evidence forthe electroosmosis theory
P05792911T0000|0 7|Effects
P05794247T0000|0 6|Effect
P05796272T0000|13 37|chlorpromazine cataracts
P05797287T0069|0 2|I.
P05798063T0000|0 10|Specialist
P05799686T0001|4 15|possibility
P05805644T0001|0 9|Variation
P05806615T0001|10 21|degradation
P05806936T0000|0 10|Absorption
P05807222T0052|0 13|Ion injection
P05810259T0001|0 17|Polyvinyl alcohol
P05819249T0000|0 6|Mining
P05822499T0034|4 13|structure
P05823624T0031|4 8|need
P05826818T0098|0 2|I.
P05833022T0001|7 16|character
P05836483T0000|17 25|teratoma
P05837169T0001|0 14|Methoxyflurane
P05839844T0000|0 14|Histochemistry
P05847772T0001|11 20|disorders
P05850652T0001|0 5|Study
P05857301T0000|0 8|Chemical
P05858571T0000|9 15|trials
P05859016T0000|0 26|Hydroxypropyl methacrylate
P05879595T0094|0 10|Statistics
P05881833T0001|7 16|diagnosis
P05884183T0001|0 10|Experience
P05890093T0000|0 5|Study
P05890351T0001|6 23|antitetanus serum
P05893495T0001|0 7|Studies
P05896996T0001|3 13|catabolism
P05901778T0000|4 10|effect
P05902458T0001|0 11|Naphthalene
P05909034T0000|0 7|Studies
P05917315T0026|2 13|case report
P05919308T0001|0 12|Interactions
P05930797T0000|8 15|studies
P05933228T0000|11 18|rhythms
P05938720T0000|0 5|Story
P05939748T0000|18 27|Pap smear
P05942953T0049|0 2|I.
P05947377T0001|11 22|test iodine
P05949971T0000|0 11|Persistence
P05959588T0000|0 7|Studies
P05960999T0001|0 5|Value
P05967610T0000|11 25|nerve function
P05969185T0001|0 10|Concussion
P05982700T0000|0 5|Study
P05985275T0000|14 23|substance
P05992157T0001|4 17|pathogenicity
P05994421T0045|0 13|Consanguinity
P05995140T0001|7 13|amount
P05999607T0001|0 7|Studies
P06012827T0000|16 23|studies
P06027841T0000|8 12|spin
P06035001T0000|8 20|observations
P06048505T0000|0 11|Derivatives
P06051644T0000|8 12|Slot
P06054411T0000|0 18|Retention behavior
P06065507T0000|19 30|hypertrophy
P06070204T0025|0 3|XXI
P06072512T0000|9 19|evaluation
P06073427T0001|16 32|characteriaztion
P06074093T0001|0 4|Iron
P06074640T0001|0 9|Symposium
P06084279A0218|21 29|patients
P06084810A0169|20 24|mRNA
P06084864T0001|18 36|alpha fetoproteins
P06085839A0721|22 33|possibility
P06088722A0171|0 7|Courses
P06089575A0464|0 11|Stimulation
P06090369A0000|24 32|patients
P06090458A0407|4 27|PEPCK promoter fragment
P06091914A0000|13 19|tumors
P06092048A1111|9 14|cases
P06092588T0000|0 17|Hepatitis B virus
P06093354A0000|18 28|DNA clones
P06093363A0612|0 3|USA
P06094591A0000|4 26|envelope glycoproteins
P06095372A0435|4 8|drug
P06095774T0001|13 20|aspects
P06096246T0000|0 6|Effect
P06096380A0662|7 11|mRNA
P06096863T0000|9 25|activation sites
P06097027A0000|17 25|provirus
P06097285A1077|21 32|haloperidol
P06098719A0369|13 19|effect
P06098828A0352|4 11|results
P06099656T0000|0 12|Construction
P06101359T0000|0 9|Diagnosis
P06108610A0518|0 8|Theories
P06109017A0000|4 11|effects
P06110026T0000|0 10|Endorphins
P06111283T0032|0 15|Trial treatment
P06113084T0000|8 22|taurine levels
P06113443T0000|0 10|Separation
P06119262T0000|4 18|roll-over test
P06120429T0000|4 23|thyroglobulin assay
P06121577A0280|14 24|reductions
P06130348T0000|0 9|Isolation
P06131038A0000|0 6|Plasma
P06131378A0818|10 14|mRNA
P06136374A0151|8 26|water temperatures
P06137028A0624|0 11|Propranolol
P06138015T0114|6 12|report
P06138313A0948|4 22|distribution phase
P06141764A0339|0 28|Hybrid-selection experiments
P06142279T0000|0 4|Risk
P06143734T0000|9 19|metabolism
P06147504A0086|4 12|patients
P06150069A0422|4 12|patients
P06151518A0000|9 13|acid
P06151942A0235|0 5|Serum
P06152670T0000|0 15|Plasma secretin
P06152844T0000|0 6|Effect
P06153936A0784|11 16|cases
P06155967A1132|4 16|radiologists
P06158844A0000|0 11|Thalamotomy
P06161823A0129|11 19|capsules
P06162419A0118|45 52|maximum
P06163433T0000|0 6|Effect
P06165068A0547|22 27|juice
P06165132A0000|3 13|experiment
P06165551A0793|8 25|inappropriateness
P06167806A0000|4 11|ability
P06173032T0000|4 10|effect
P06173860A0000|8 13|cases
P06175691T0000|0 31|Bacillus cereus cross-infection
P06181216A0070|38 46|patients
P06182979A0807|14 22|category
P06184276T0001|8 14|course
P06184487A1485|5 9|mRNA
P06185014A0642|21 42|complement factor C3c
P06185493A0468|2 19|polypeptide chain
P06189698A0246|4 18|P165 component
P06191243T0000|13 25|drawing size
P06193351A1010|18 32|administration
P06198241A0209|6 13|fusions
P06198532A0982|44 52|tendency
P06199132A0179|0 8|Toxicity
P06200300A0409|9 19|electrodes
P06203843A0757|0 8|Products
P06204120T0001|0 3|Use
P06208024A0168|5 13|fraction
P06208477A0000|4 16|construction
P06209403A0562|10 17|repeats
P06209499A0682|11 18|effects
P06212776A0000|3 9|Cabras
P06214605A0123|4 10|number
P06216125A0470|3 11|addition
P06217859T0000|0 10|Experience
P06218005A0948|12 20|patients
P06223586A0000|0 18|Immunochemotherapy
P06223586A0460|28 39|mitomycin C
P06224974A0833|0 4|Data
P06225279A0498|14 21|surface
P06227570A0523|3 11|contrast
P06229542T0045|11 27|characterization
P06230499A0128|42 53|irradiation
P06233924T0000|0 11|Fibrin gels
P06234369T0000|12 23|vaccination
P06234786A0606|0 20|Radiogallium imaging
P06237518A0117|14 30|coupling reagent
P06238540A0798|12 28|volume stiffness
P06238704T0001|0 9|Synthesis
P06239545A0649|0 11|Weight loss
P06240448A0652|4 10|effect
P06241900A0000|5 10|study
P06241980A0855|0 15|Oxygen profiles
P06242113T0001|0 20|Cultivation technics
P06244732T0000|0 16|Radioimmunoassay
P06245672T0000|10 31|macrophage inhibition
P06246254A0676|0 18|Restriction enzyme
P06251469A0830|20 36|library isolates
P06252520T0000|0 14|Catecholamines
P06252883A0100|29 35|strain
P06254403A0000|4 18|antibody titer
P06254973A1757|0 4|Poly
P06258699T0000|15 20|trial
P06258806A0963|21 30|insertion
P06259220A0000|5 16|experiments
P06259220A0464|0 10|Experiment
P06259389A0000|11 17|period
P06270347A0740|2 17|22K polypeptide
P06272844A0000|19 24|virus
P06277159T0033|2 12|hypothesis
P06278424A0145|25 37|requirements
P06278544T0027|0 10|Physiology
P06279309A0000|4 10|genome
P06281759A1086|8 13|RNase
P06281786A1222|13 18|clone
P06281891A0399|25 33|pathways
P06286191T0000|0 11|Restoration
P06286443A0498|14 31|serum ACTH levels
P06286549A0000|0 7|WR-2721
P06287212A1352|3 7|fact
P06287231A0914|3 11|addition
P06287737A0477|4 13|frequency
P06290859A0426|7 27|hepatitis B patients
P06290899T0000|0 6|Survey
P06291369A0000|6 14|patients
P06295429A0412|4 15|combination
P06296833A0000|4 13|mutations
P06298014A0647|4 13|ensembles
P06298720A0893|11 23|conservation
P06300662T0000|2 21|cDNA cloning vector
P06300836A0285|0 13|Hybridization
P06304771A1284|8 16|sequence
P06306342A1156|3 13|conclusion
P06307099A1005|0 12|Lung density
P06308536T0001|4 30|hepatitis A virus antibody
P06308607A0375|4 13|junctions
P06309020A0473|0 8|Naloxone
P06309855T0000|0 21|Gel route preparation
P06309969T0055|0 2|I.
P06310159A0000|6 9|RNA
P06310457A0000|14 24|recordings
P06310553T0000|10 19|structure
P06310608A0749|4 11|mutants
P06314276T0000|0 8|Plasmids
P06314312A0359|16 31|soybean protein
P06316347A0852|4 13|dnaQ-lacZ
P06316623A0188|8 19|prevalences
P06318078T0000|0 10|Expression
P06318091A0395|4 24|splice acceptor site
P06318322A0350|26 31|model
P06319040A1627|41 56|system activity
P06319071A0173|7 15|subjects
P06319072A0711|22 33|morning dip
P06319421A0937|4 10|effect
P06319740A1331|21 25|gp54
P06320380T0001|0 18|Surgical treatment
P06321505A0401|2 19|promoter sequence
P06321634A0123|22 27|mRNAs
P06321770A1353|4 14|expression
P06322183A1070|0 16|NPT II synthesis
P06323556A0126|11 22|tomographic
P06324089A0453|12 21|structure
P06324121A0256|11 13|MW
P06325415A0757|13 23|difference
P06327039A0743|15 26|correlation
P06327292A0846|16 40|Shine-Dalgarno sequences
P06327638A0155|4 15|gene cat-86
P06328002A0000|23 36|sarcoma virus
P06328012A0549|15 27|EBNA protein
P06328485A0277|28 47|nucleotide sequence
P06328504A0161|0 3|USA
P06330082A0329|0 2|A.
P06330478A0304|4 12|patients
P06331684A0607|15 19|test
P06333433A0000|7 15|isolates
P06333878T0000|12 25|acid overdose
P06336045A0261a|0 9|Frog type
P06336045A0261b|0 9|Frog type
P06340643A0598|0 4|DMCM
P06340703A0324|0 9|Grimelius
P06341139A0213|0 13|Blood glucose
P06341661T0001|9 12|use
P06342141A0226|41 54|understanding
P06345840A0348|3 11|patients
P06346427A0000|25 39|insulin levels
P06349364A1051|6 13|results
P06350092A0916|20 25|phase
P06354594A0114|6 13|oranges
P06355483A0134|4 9|genes
P06360426A0501|12 22|hydrolysis
P06361318A0440|13 27|efficacy rates
P06361318A1127|0 11|Side effect
P06362143A0565|0 21|Plasma renin activity
P06362239T0001|0 13|Martin Luther
P06362602T0001|0 11|Enhancement
P06364265T0062|8 30|gamma-ray spectroscopy
P06367414A0000|0 8|Bepridil
P06369355A0834|0 8|Analysis
P06369954T0000|0 7|Effects
P06370553A0444|8 29|plasma norepinephrine
P06372563T0000|6 14|response
P06373409A1163|0 9|Lauciello
P06373855A0000|7 23|biopsy specimens
P06374369A1112|6 10|data
P06374418A0877|4 12|aspirate
P06376227A0217|0 3|EGV
P06379363A0415|13 18|tests
P06381438A1280|0 28|Lung prostacyclin production
P06382374A0206|17 20|min
P06384983T0000|0 10|Management
P06385474T0001|9 18|treatment
P06388189T0001|0 15|Transplantation
P06388818A0000|4 12|patients
P06391496T0000|0 6|Effect
P06394228T0073|0 7|Results
P06394347A1024|0 12|Hydrallazine
P06395804A0382|0 15|Urease activity
P06397009A0204|6 17|description
P06401749T0000|4 10|effect
P06402480A0373|4 18|susceptibility
P06402859A0000|0 16|Antithrombin III
P06404842A0127|9 17|patients
P06406060A0000|15 24|cisplatin
P06407348A0516|0 3|New
P06411659A0264|3 13|facilities
P06411659A0793|24 37|energy intake
P06412385A0356|10 18|patients
P06413492A0990|0 6|Commun
P06414990A0057|16 24|analysis
P06415299A0233|17 22|doses
P06419251T0000|0 20|Movement programming
P06426493A0331|13 16|min
P06428116T0000|37 51|hypothyroidism
P06429992T0000|0 19|Gonadotropin levels
P06433442T0000|0 8|Freezing
P06434572A0157|6 14|children
P06434587A0551|5 12|patient
P06435565A0648|6 13|changes
P06437579A0727|0 10|Cimetidine
P06439114A0677|0 11|Ceftazidime
P06439135A0250|0 12|Regional CBF
P06441624A0263|4 11|results
P06443550T0000|4 14|management
P06443639T0001|0 5|Study
P06443714T0001|11 33|Rhodnius prolixus Stal
P06444119A0340|15 23|organism
P06446048A0356|37 44|by-pass
P06451557A0777|0 11|Deformities
P06452461A0930|22 33|correlation
P06452827T0001|18 27|recording
P06453290A0000|4 15|development
P06454625A0000|24 41|animal experiment
P06459831T0001|0 14|Cardiovascular
P06460889A0111|12 22|injections
P06460889A0512|3 8|doses
P06463429A0414|8 10|VE
P06466804A0686|0 8|Exposure
P06467241A0000|0 21|Modern cancer therapy
P06467797A0233|18 29|correlation
P06468565A0000|4 23|response properties
P06468632A0135|0 11|Endothelium
P06468673A0358|25 42|E2 concentrations
P06468694A0441|0 11|Stimulation
P06473219T0000|0 5|Value
P06473252A1073|5 15|experiment
P06479362A0680|0 14|Hydrocortisone
P06479976A0386|21 32|differences
P06480542A0000|18 23|study
P06482179A0497|0 15|Catch-up growth
P06482318A0117|0 20|Thrombocyte function
P06482665A0735|4 12|findings
P06483863A0000|7 18|experiments
P06486932A0000|15 21|deaths
P06487290A0000|9 18|estradiol
P06492188A0615|11 12|d
P06493655A0415|9 26|FHR decelerations
P06494215A0248|4 18|response chain
P06494297A0939|4 11|results
P06494766A0241|21 31|dispersion
P06495195A0536|29 34|tests
P06497671T0001|0 7|Changes
P06501086A0165|12 23|alterations
P06503132A0784|0 3|SFP
P06503329A0588|12 22|birth mass
P06503885A0342|5 18|machine drift
P06505014A1192|6 19|uncertainties
P06506074A0456|0 13|E2 treatments
P06507629A0717|3 11|contrast
P06508393T0000|0 13|Serodiagnosis
P06513456T0001|0 23|Adenyl cyclase activity
P06516369T0001|0 11|Proteinuria
P06516847A0393|37 48|pneumococci
P06516977T0000|0 8|Reaction
P06517816A0388|0 2|HA
P06520418A0325|4 11|results
P06521802A0251|0 22|Scientific cooperation
P06521999A0677|27 34|results
P06524202A0167|6 13|variant
P06524727A0601|0 11|Lymphocytes
P06524761A0596|21 31|difference
P06527379T0044|12 36|proline/alanine sequence
P06527872T0000|27 38|projections
P06531286A0382|0 7|Removal
P06535384A1115|18 25|subtest
P06539738T0000|18 28|evaluation
P06541019A0555|4 12|patients
P06541932A0000|0 7|Methods
P06542372A0159|12 17|paper
P06542918A1131|30 44|discrimination
P06545651A0346|0 21|Ammonia concentration
P06546392A0542|8 17|respect C
P06548953T0001|6 24|thyroid stimulator
P06555107A1227|17 31|administration
P06568939A0000|0 9|Brainstem
P06571587T0000|0 7|Effects
P06579147A0060|21 29|features
P06579152A1061|36 39|NPF
P06582285A0222|28 34|safety
P06584416A0157|6 18|radiologists
P06585277A0000|5 8|man
P06588306A0076|21 43|prophylactic treatment
P06588501T0059|26 31|study
P06591992A0569|3 15|anisotropism
P06593862T0001|0 19|Hepatitis B vaccine
P06594105A0560|15 21|values
P06597709A0596|42 52|asbestosis
P06599282T0001|13 20|pattern
P06600533T0000|0 11|Azygos vein
P06602580A0664|13 20|history
P06602600A0582|4 13|Sarns 51F
P06606043A0598|10 17|changes
P06607427A0000|6 17|experiments
P06607714T0000|0 15|Limb allografts
P06609166A0209|4 10|method
P06610347A0581|11 18|periods
P06612373A0000|5 10|paper
P06615053A0202|8 16|patients
P06615403A0718|16 29|LAD occlusion
P06625058A0666|4 14|population
P06627123A0000|7 18|Wistar rats
P06627569T0001|0 2|HL
P06629370A0252|5 13|patients
P06630319A0244|0 8|Brain pH
P06634712A0557|4 11|results
P06643612A0000|27 34|methods
P06648156T0034|13 20|remarks
P06652293A0353|23 28|point
P06653755A0192|6 29|clofelin administration
P06654047A0694|5 15|phenomenon
P06654686T0001|0 11|Combination
P06655634A0195|11 17|series
P06656249T0000|0 23|Nursing home discharges
P06657559A0489|0 5|Trial
P06658029A0086|4 23|carcinogen bioassay
P06658445A0140|8 15|effects
P06658586T0001|0 23|Angionephroscintigraphy
P06659982A0231|4 12|analysis
P06662623A0124|1 5|82Br
P06667015A0832|12 20|findings
P06667868T0001|17 23|status
P06668316A0178|21 42|reversed-phase column
P06669864T0001|4 9|liver
P06670732A0000|16 21|study
P06671047A1124|6 13|results
P06671065A0000|0 12|Serum lipids
P06671385A0856|4 6|NA
P06671925T0000|0 23|Amikacin concentrations
P06672094A0390|4 12|subgroup
P06674374T0000|0 32|Hepatitis B vaccination strategy
P06674516A0350|15 28|drip infusion
P06674977A1181|13 21|families
P06675047A0000|4 11|authors
P06683807A0160|13 21|patients
P06683876A0244|6 11|cells
P06684624A0298|20 31|mortalities
P06684624A0736|8 40|N-acetylglucosaminidase activity
P06685004A0000|4 16|associations
P06685177T0000|0 12|Dipetalonema
P06685536A0502|10 15|years
P06685643A0179|4 18|concentrations
P06686454A0585|19 27|activity
P06687953T0000|12 28|defence capacity
P06689413A0174|4 13|apparatus
P06689513T0001|16 23|studies
P06691304A0284|4 9|range
P06692517T0000|4 11|effects
P06692631A0129|9 18|interface
P06694380A1483|0 9|Plasma NE
P06694778A0000|13 34|hemodialysis patients
P06698047A0445|4 20|Prolactin levels
P06700231A0259|14 29|tumor resection
P06700469T0000|8 30|hospital accreditation
P06702257T0001|0 16|Antithrombin III
P06702643A0000|12 25|infant hearts
P06704467A0539|16 27|sensitivity
P06705456A0346|0 10|Absorption
P06707357A0180|14 26|observations
P06709310A0000|2 6|case
P06709700A0230|11 22|compartment
P06711642A0093|12 30|immunoglobulinuria
P06712314A0148|8 14|number
P06713200A0630|0 21|Epileptiform activity
P06713204A0867|4 17|AD components
P06714298X0000|52 59|preload
P06714354A0194|0 7|Monkeys
P06715792A0295|0 17|HBB concentration
P06716977A0136|4 11|samples
P06718064T0001|0 18|Plasma lactoferrin
P06719057A0181|4 14|importance
P06720371T0000|0 11|Pilot study
P06721188A0200|16 24|analysis
P06723849A0197|14 19|tract
P06726257A1179|13 22|reduction
P06726257T0000|0 7|Effects
P06728580A0291|12 19|measles
P06731302A0930|3 10|patient
P06732946A0281|4 15|measurement
P06734713T0000|0 10|Diclofenac
P06735247A0803|13 48|plasma enteroglucagon concentration
P06738410T0000|0 14|Blood pressure
P06740373A0891|8 13|study
P06740697A0318|4 11|results
P06740919A0162|6 23|Amblyomma lepidum
P06743061A0239|11 18|percent
P06744024A0000|0 8|Morphine
P06748227A0423|4 8|maps
P06749072A0116|8 23|urate excretion
P06750608A1442|0 9|Mutations
P06751455A0117|30 40|gallstones
P06753902A0437|7 15|patients
P06754662T0001|8 33|angiolymphoid hyperplasia
P06755468A0180|0 7|Regions
P06755986A0382|15 22|strains
P06760394T0001|7 24|tooth replacement
P06762025A0171|4 37|13,14-dihydro-15-keto-metabolites
P06762321T0000|0 19|Nucleotide sequence
P06763897A0216|4 16|hypertension
P06764669T0001|13 26|determination
P06767648A0734|0 12|Measurements
P06772370A0342|0 6|Volume
P06772612A0000|0 7|Effects
P06775834A0000|0 5|HLA-A
P06776918T0000|0 17|Trypanosoma cruzi
P06777229A0243|4 12|subjects
P06781339A0501|5 10|study
P06781728A0690|4 15|alterations
P06782612A0142|13 20|measure
P06782869A0263|0 16|Nitrogen balance
P06784123A0286|0 10|Production
P06784123A0771|11 19|C mu RNA
P06784123T0000|0 11|Transcripts
P06785113A0337|44 52|activity
P06786756T0000|4 8|role
P06788388A0000|13 22|mechanism
P06790572A0330|7 15|isolates
P06791500A0622|4 14|evaluation
P06793764T0001|0 11|Host lipids
P06794480A0785|29 39|difference
P06794666A0208|16 39|neuroeffector influence
P06795119T0000|0 21|Lens aldose reductase
P06795654A0434|0 12|Fenfluramine
P06795832A0148|7 13|course
P06795900A0000|4 10|effect
P06795971A0000|4 15|rat incisor
P06796300A0759|21 37|prolactin levels
P06797063A0000|0 6|Factor
P06798609A0000|31 35|rats
P06801778T0001|0 12|Significance
P06802500T0001|0 18|Thyreoliberin VUFB
P06803634A0810|3 12|silicosis
P06805504A0629|23 31|N values
P06805537T0001|0 8|Advances
P06807149A0222|5 10|study
P06807149T0000|0 10|Comparison
P06807192A0312|0 4|LCBF
P06807659T0001|0 12|Phagocytosis
P06808287T0001|0 9|Detection
P06808529A0167|4 13|stability
P06809474A1156|0 14|Bile bilirubin
P06809586T0000|0 28|Autoimmune manipulation aids
P06810070A0502|6 16|properties
P06810694A0328|4 12|decrease
P06810694A1000|0 13|Apo A-I level
P06812389A0658|0 5|TEMTU
P06815368A0203|21 29|mannitol
P06816053A0849|7 15|patients
P06816123A0526|0 8|Selenium
P06816442T0001|11 16|value
P06816609A0639|5 31|% blood pressure reduction
P06817410A0982|18 24|months
P06818113A0384|10 18|patients
P06821147A0468|0 19|Sulphur amino acids
P06822645T0039|0 4|Time
P06823837A0562|38 48|wavefronts
P06825641A0076|14 33|landfill operations
P06826813A0264|0 8|Vesicles
P06828396A0095|4 9|level
P06829082A0187|24 35|hypothermia
P06830033A0661|8 20|observations
P06830351A0397|13 20|Sugiura
P06833047A0000|5 10|study
P06833422T0000|0 13|Determination
P06835516A0000|2 6|case
P06835914A0192|0 17|Copper treatments
P06837312A0000|14 21|intimal
P06838388A0896|19 30|development
P06840803A0397|13 18|signs
P06842629A0446|12 27|GMBF reductions
P06848729A0000|7 15|children
P06849842T0000|0 33|Penicillin-G degradation products
P06851280A0144|0 17|Plasma fibrinogen
P06851327A0000|5 13|patients
P06853042A0282|15 28|acidification
P06854957T0066|0 9|Detection
P06856306T0000|4 21|Tullio phenomenon
P06856669A1004|6 13|results
P06858449A0335|0 12|Disturbances
P06858640A0262|7 12|basis
P06858805A0314|5 11|groups
P06858967A0167|0 27|Serum lactate dehydrogenase
P06863087A0664|9 10|D
P06864837T0000|0 8|Efficacy
P06864955T0000|15 19|MMWR
P06868345A0000|4 12|presence
P06869215A0347|5 11|levels
P06869986A0000|12 21|platelets
P06872800T0000|6 10|type
P06873504T0000|13 26|relationships
P06875478A0542|2 22|microU/l thyrotropin
P06876006A0930|0 15|Echosismography
P06876317T0033|0 13|Relationships
P06880563A0516|4 14|prevalence
P06880604A0167|2 14|reassessment
P06880650A0316|4 11|results
P06882578A0464|7 27|ultramarathon runner
P06883385A0509|3 11|patients
P06884450A0234|11 18|tumours
P06886031A0898|6 16|PGE levels
P06886948A0750|7 12|rates
P06890622A0067|40 48|platelet
P06890935T0001|0 6|Behcet
P06891051A0587|0 8|Survival
P06891270A0000|4 10|effect
P06895559A0000|0 11|Terbutaline
P06895663A0810|8 15|therapy
P06897114A0240|15 20|motif
P06902722T0000|15 20|phase
P06911559T0000|0 10|Statistics
P06916588A0304|4 18|infection rate
P06919347T0001|8 12|year
P06928974T0000|4 21|electrocardiogram
P06931124A0109|14 19|place
P06935514A0000|4 11|Authors
P06938948T0001|10 13|IgA
P06946314T0000|0 16|Serum IgE levels
P06946693T0000|0 3|Use
P06948398A0523|25 35|management
P06948493T0026|0 5|Range
P06948868A0082|4 10|scores
P06950004T0047|0 5|Study
P06953957A0503|8 32|creatine kinase activity
P06957125T0000|16 26|blood flow
P06957633T0001|0 11|Development
P06959130A0996|4 25|arginyl peptide bonds
P06962492A0612|9 15|growth
P06962634A0190|13 20|methods
P06963337T0000|44 55|hyperplasia
P06966678A0523|20 24|rate
P06969638A0180|5 17|examinations
P06972179A0556|9 19|IgE levels
P06972443A0375|17 27|evaluation
P06972501A0615|0 11|Correlation
P06973664A0000|2 6|case
P06975206A0279|10 24|administration
P06977605T0000|0 10|Endorphins
P06978566A0197|3 11|necropsy
P06981991A0756|0 14|Aneurysmectomy
P06984225A0367|0 5|REV I
P06986168A0304|9 18|sequences
P06992600A0405|4 27|extraction measurements
P06993660A0000|12 21|responses
P06994035T0001|3 19|line calculation
P06994049T0001|0 9|Detection
P06997203A0325|3 19|rubella patients
P07004236A0741|4 11|results
P07007181T0000|4 10|effect
P07007591A0324|4 21|residue functions
P07015018A0395|12 20|extracts
P07015262A0396|4 8|days
P07016141A0238|13 23|blood flow
P07018810A0002|0 26|Plasma renin concentration
P07021505A0510|6 17|acclimation
P07026328A0369|7 16|diabetics
P07034479A1050|12 15|RMI
P07037479T0000|5 18|cracked-tooth
P07038189A2301|14 21|results
P07038684A1050|9 33|peptide map similarities
P07040659A0212|4 12|patients
P07044389T0000|0 5|Facts
P07044562T0000|5 8|Pap
P07044842A2062|4 16|relationship
P07045156A0204|36 41|assay
P07049690T0000|11 18|lesions
P07053251A0666|33 40|effects
P07061263A0293|14 22|pressure
P07061350A0042|8 15|Science
P07062036A0072|0 4|Rats
P07062269A0798|39 47|receptor
P07063606T0000|0 9|Microwave
P07064662A0222|26 33|lesions
P07064923T0000|0 9|Diagnosis
P07065206A0398|6 19|control sheep
P07068493A0414|16 20|rate
P07068493A0636|21 29|increase
P07068496A0000|16 22|volume
P07068887A0000|17 28|reliability
P07072635A0000|9 15|method
P07073520A0153|20 34|hemofiltration
P07075024A0540|18 23|cases
P07075438T0000|12 34|serial xeroradiography
P07076222A0543|0 15|Recommendations
P07078263T0000|0 3|Use
P07079595A0848|24 35|correlation
P07080496A0097|17 30|investigation
P07081327A0546|23 28|fluid
P07084198T0000|0 15|Selenium status
P07084617A0204|15 24|follow-up
P07084814T0000|0 11|Preparation
P07088195T0019|2 6|note
P07090151A0165|7 14|turnout
P07094856A0115|18 23|study
P07094905A0644|33 43|injections
P07096587A0267|20 28|patients
P07097182A0480|4 12|duration
P07105635A0412|0 7|Samples
P07106323A0560|6 13|results
P07106534A0160|8 11|way
P07107287A1083|12 17|doses
P07107462A0202|4 13|steepness
P07107773A0000|41 45|acid
P07109788A0333|3 10|concept
P07110999A0160|30 39|disorders
P07112320A0086|0 32|CSF adenosine deaminase activity
P07112471A0639|0 20|Histamine reactivity
P07112654A0388|47 57|difference
P07113365A0737|0 5|Ficat
P07113897A0285|26 37|differences
P07114083A0153|6 18|MOPP therapy
P07116298A1079|21 25|type
P07116962A0299|4 21|COP-PAWP gradient
P07119890T0000|0 2|Re
P07124743A1223|10 15|study
P07125064T0000|33 41|findings
P07125238T0000|4 13|pia mater
P07126067T0000|13 25|reproduction
P07126413A0000|12 27|delivery system
P07130335A1081|0 14|Administration
P07132408A0387|11 15|time
P07134924A0640|16 21|types
P07135112T0000|0 6|Repair
P07136524A0180|17 27|literature
P07136569A0000|3 8|Malmo
P07137927A0000|7 11|past
P07140060T0000|16 27|dislocation
P07140493A1045|5 10|study
P07141130A0615|13 23|evaluation
P07143347T0000|0 6|Cramps
P07147622T0000|16 31|storage disease
P07149047A0260|12 23|dog vessels
P07149303T0000|16 22|action
P07154928T0001|0 12|Modification
P07155579T0001|13 28|bacteriospermia
P07158726T0001|0 7|Triumph
P07160491A0547|15 21|effect
P07162146A0000|4 15|application
P07165767T0000|0 12|Mastocytosis
P07168531T0001|6 24|Onchocerca species
P07169630A0983|26 33|absence
P07172690A0547|11 17|factor
P07173729A0000|9 26|penetration tests
P07174046T0000|0 16|Vibrio fluvialis
P07174122A0000|0 21|Serum creatine kinase
P07174437A0181|0 9|Organisms
P07175474A0102|4 9|cause
P07179412A1131|19 23|cost
P07180901A0539|30 40|blood flow
P07181985A0107|10 28|mg mitomycin/20 ml
P07182523A0462|5 11|groups
P07183576A0157|19 32|concentration
P07184375T0001|14 19|study
P07184598T0001|9 18|secretion
P07184774T0000|0 14|Re-examination
P07184795A0517|13 27|determinations
P07190627T0000|10 15|study
P07190869A0316|0 4|CDDP
P07191183A0505|0 9|Treatment
P07191804A0000|13 21|response
P07191972A0391|14 25|temperature
P07192369T0000|2 8|method
P07192722A0682|26 43|parathyroidectomy
P07194905A0332|0 3|TCZ
P07195615A0087|4 10|number
P07195880A0621|5 9|test
P07202224A0452|4 15|preferences
P07202525A0200|5 10|trial
P07202919A0142|0 5|Ulcer
P07203410T0000|0 13|Family visits
P07205120T0000|14 21|overlay
P07205967T0000|8 16|reaction
P07208984A0000|0 5|Brain
P07214230T0000|0 10|Inhibition
P07214665A0000|14 25|combination
P07217329A0000|2 8|method
P07217523A0364|0 7|Results
P07218008T0000|7 26|response properties
P07219297T0000|10 18|approach
P07219821T0028|24 38|considerations
P07221179A0156|17 21|fall
P07221354T0000|0 6|Theory
P07225300A0968|6 13|results
P07225540A0193|16 19|gas
P07226440T0000|4 16|hemodynamics
P07228955A0000|8 15|authors
P07234308A0121|6 19|drug regimens
P07234755A0838|4 13|monocytes
P07234974T0000|14 22|features
P07235317T0000|9 17|accuracy
P07235355A0462|13 21|subjects
P07236351A0812|19 27|recovery
P07237123T0000|28 42|unit responses
P07237560A1038|10 19|deletions
P07237817T0000|0 16|Cross reactivity
P07240343A0000|0 12|Strontium-90
P07242929T0001|0 9|Recording
P07243380A0327|6 8|hr
P07247059A0775|0 16|Catheter transit
P07249497A0688|6 11|women
P07249544A0343|9 20|temperature
P07249660T0000|0 13|Determination
P07249895A0177|15 19|role
P07251564A0569|13 14|%
P07252346A0223|11 20|technique
P07253335T0000|0 7|Effects
P07256543A0814|8 13|study
P07259325A0394|0 8|Survival
P07260389A0221|0 12|Methisergide
P07260987A0336|4 20|plasma half-life
P07262239T0000|0 7|Effects
P07262625A0000|0 22|Corticosteroid therapy
P07263374T0000|7 20|lung function
P07263421A0351|5 9|Sair
P07263745T0000|10 31|Charnley arthroplasty
P07264787A0351|11 19|patients
P07266969A0246|4 16|relationship
P07267675A0000|28 41|cephalosporin
P07268828A0000|2 19|fluoroimmunoassay
P07270163A0684|27 38|projections
P07270991A0149|5 20|pollen allergen
P07274042A0249|0 3|DMI
P07274428A0000|21 32|experiments
P07274482A0000|13 20|neurons
P07274505A0660|3 11|controls
P07276210T0000|0 5|Assay
P07277222A1391|8 13|waves
P07278104T0001|0 25|Leukocyte enzyme activity
P07278578T0001|8 14|status
P07280654A0000|3 13|literature
P07282444A0075|11 16|cases
P07282552A0990|3 10|Group V
P07282943A0097|30 39|decreases
P07283110A0000|10 12|B1
P07286057A0159|9 30|AUC infinity analyses
P07293100T0001|0 17|Gastrin secretion
P07293327T0001|0 24|Fibrinogen determination
P07295033A0513|7 13|period
P07295417A0092|34 41|regions
P07296303A0418|0 9|Responses
P07296997A0125|9 17|patients
P07297576A0454|22 47|drinking water ad libitum
P07297978A0570|11 15|data
P07298209A0291|4 17|determination
P07298259T0000|0 13|Determination
P07298523T0000|0 6|Effect
P07299857A0294|0 11|LD50 values
P07304905A0336|0 15|Autotransfusion
P07306839T0001|0 8|Electron
P07308849A0817|14 25|differences
P07309562T0000|40 53|determination
P07310206A0154|4 16|architecture
P07311881T0000|0 12|MSMS Council
P07312707T0000|0 8|Chordoma
P07320153T0000|0 5|Micro
P07323063A0000|63 67|rats
P07323573A0644|9 13|zone
P07326596A0061|4 18|IgA deficiency
P07327097A0647|3 10|PB mice
P07328000T0000|0 21|Nutritional cataracts
P07330073T0000|0 10|Prevention
P07337609A0531|14 18|mean
P07340196T0001|17 30|determination
P07341346A0174|19 32|shunt vessels
P07345217A0000|11 24|complications
P07347728T0000|0 14|Arachnoid cyst
P07349416A0337|21 32|summer coat
P07354367A0162|0 11|Hypotension
P07355527A0467|14 23|procedure
P07356273T0022|27 42|cell carcinomas
P07365183A0000|7 15|patients
P07369183T0000|8 17|artifacts
P07369458A0606|44 53|technique
P07372433A0000|26 39|relationships
P07372928A0105|0 5|Tests
P07375836T0000|13 20|work-up
P07375864A0431|4 11|authors
P07376165T0001|0 7|Ecthyma
P07377378A0143|0 20|Estrogen replacement
P07377954A0117|14 21|aspects
P07379334A0503|0 7|Changes
P07380615A0478|39 50|possibility
P07385543T0001|0 10|Importance
P07385920A0189|4 11|results
P07385933A0085|10 22|iv injection
P07386500A0174|9 31|clotting factor assays
P07386864T0000|21 29|dialysis
P07387242A0236|0 15|Blood variables
P07392519T0001|8 15|changes
P07393856A0314|5 11|result
P07393976A0000|4 11|ability
P07394364A0738|30 53|gas exchange parenchyma
P07395750A0294|0 16|Underestimations
P07396545A0217|0 12|Chemotherapy
P07397066T0000|0 15|Drug inhibition
P07401318A0823|18 29|temperature
P07405701T0000|23 32|responses
P07406527A0212|7 10|end
P07408970A0706|4 9|hours
P07410037A0752|9 22|stone-formers
P07413144T0018|0 8|Analysis
P07413242A0000|20 25|study
P07413441T0070|17 29|localisation
P07413781A0169|12 23|stimulation
P07413806T0000|17 25|amygdala
P07414817T0001|0 19|Cataract extraction
P07415340A0280|0 6|Number
P07416204A0437|14 20|animal
P07418498A0217|3 8|spite
P07418829A0191|0 12|Implications
P07419485A0158|8 13|study
P07423803T0001|0 9|Treatment
P07425838A0182|12 16|case
P07426101A0124|8 14|plasma
P07426604A0397|4 9|C18:1
P07426745A0177|14 20|growth
P07428037A0989|26 37|nucleotides
P07429009T0121|12 19|anatomy
P07431059A0000|7 21|cadaver brains
P07432288A0218|0 20|Serum antibody titre
P07434431A0203|16 25|refeeding
P07434456A0286|19 24|units
P07435185A0074|4 12|symptoms
P07436187A0147|4 9|study
P07436459A0245|67 77|acid ratio
P07436702A0156|4 19|control persons
P07436794A0148|5 18|control group
P07438346A0381|3 5|pH
P07438482A0145|13 18|right
P07440085T0061|0 18|Arm function tests
P07440430A1074|4 9|lambs
P07445971A0241|9 17|response
P07449221A0086|4 13|operation
P07449253A0411|17 22|group
P07450031A0691|7 24|sedative activity
P07450388A0406|3 11|patients
P07453919A0000|6 14|patients
P07455042A0457|26 33|imaging
P07455521A0414|4 8|ESEG
P07456774A0448|29 34|drugs
P07457931A0655|8 14|series
P07458171A0086|19 26|species
P07461226A0958|3 11|symptoms
P07461848A0230|4 15|mean values
P07462481A0422|12 35|backscatter coefficient
P07463294A1216|5 7|wk
P07463465A0297|6 15|infection
P07466831A0714|0 17|Pentachlorophenol
P07467975A0316|0 15|Family planning
P07469692A0000|4 26|term osteomesopycnosis
P07471210A0384|4 15|87K protein
P07472582A0993|4 18|identification
P07472736A0278|13 22|component
P07473169A0133|0 5|EUK-8
P07473742A0187|4 17|protein ELT-1
P07474078A0838|12 20|contrast
P07474085A0932|14 23|R protein
P07474124A1360|6 13|results
P07474140A1036|17 28|mutagenesis
P07474451A0000|9 26|resonance imaging
P07474617A1035|0 8|Patients
P07474772A0274|4 33|Laser Scanning Ophthalmoscope
P07475733T0000|0 7|Malaria
P07475793T0000|0 3|BSE
P07476164A1602|3 11|addition
P07476701A0654|18 24|levels
P07476963A0000|0 10|Peroxisome
P07476971A0381|40 56|SKUT-1B-20 cells
P07476975A0492|4 10|number
P07477245A0625|5 12|strains
P07478514A0237|31 34|rat
P07478523A0551|3 11|addition
P07478525A1177|5 12|classes
P07479004A0421|19 40|mobility shift assays
P07482069A0606|23 26|MTX
P07483276A0139|0 8|Analysis
P07483285A0322|6 23|HPV16 E6/E7 cDNAs
P07483857A0350|0 24|Correlation coefficients
P07487067A0592|4 24|translation products
P07487363A0447|4 16|serum levels
P07487811A0000|4 15|experiments
P07487908A0230|5 13|sequence
P07488247T0000|11 19|analysis
P07488291A0934|16 28|observations
P07488959T0000|3 11|approach
P07489502A0000|4 31|influenza virus NS1 protein
P07490079A0825|14 21|regions
P07490079T0000|10 17|cloning
P07490083A0000|9 20|anhydrase V
P07490156A0647|0 10|Vitamin D3
P07490278A0799|11 17|domain
P07490742A0636|5 12|finding
P07490766T0000|27 35|parallel
P07490770A0267|0 10|Comparison
P07491111A0221|15 17|GR
P07491305A0102|5 10|study
P07491791A0263|4 21|promoter mutation
P07493327A0507|49 58|integrity
P07493627A0882|0 9|Treatment
P07494244A0335|7 14|absence
P07494274A1015|11 22|experiments
P07494293A0585|6 13|results
P07494303A0000|6 33|immunodeficiency virus type
P07494306A0240|20 29|potential
P07494314A1287|22 32|regulation
P07495059T0078|0 7|Results
P07495120A0260|25 30|Phase
P07495726A1189|6 12|motifs
P07496184T0001|7 14|history
P07496400A0525|3 11|contrast
P07498727A0724|13 24|requirement
P07498791A0680|11 19|mutation
P07499242A0898|9 16|tissues
P07499252A0150|3 19|hGM-CSF receptor
P07499394A0187|0 2|J.
P07499401A0444|4 12|identity
P07499409A0367|0 4|TPBF
P07499421A0237|15 20|study
P07499848A0409|13 24|stimulation
P07500386A0870|15 38|GapIII protein activity
P07500597A0212|7 11|time
P07500950A0000|2 19|tobacco homologue
P07500953A0305|5 21|ADR1 gene dosage
P07501016T0000|15 25|giga-maser
P07501458A0578|19 42|C/EBP family inhibitors
P07501700A0000|4 11|effects
P07501992A0125|6 14|incisors
P07504171A0715|19 41|growth factor receptor
P07504171A1214|20 35|Src SH2 mutants
P07504712A0843|6 18|observations
P07505349A0702|10 19|lethality
P07505798A0000|26 31|sites
P07506253A0742|5 13|enhancer
P07507187T0000|0 9|Mechanism
P07507207A0991|19 35|IRF binding site
P07507458A0250|43 51|patients
P07508082A0821|12 20|decrease
P07508140A0448|0 27|Hepatitis B surface antigen
P07508250A0537|36 47|correlation
P07508441A0487|0 10|Antibodies
P07508954A0000|18 36|complex peroxidase
P07509053A0139|4 8|role
P07509449A0000|17 21|gene
P07509450A0705|14 33|methylation pattern
P07509472A1320|0 10|CONCLUSION
P07509624T0000|11 18|mapping
P07509811A1357|0 4|GTRE
P07510461A0731|4 11|patient
P07510635A0479|4 12|antibody
P07510724A1208|4 15|lymph nodes
P07511444A0728|0 13|HCV infection
P07511444T0000|0 27|Hepatitis C virus infection
P07511496A1511|5 26|plasma concentrations
P07511818A0485|33 49|cell populations
P07512159A0992|0 11|Improvement
P07512258A0441|0 21|Liver transplantation
P07512552A0270|0 4|Joys
P07513703T0000|0 10|Activation
P07514295A0000|0 24|Tyrosine phosphorylation
P07514301A0000|37 51|protein kinase
P07516337A1119|10 13|Lck
P07516466A1054|3 11|contrast
P07516469A1025|8 11|Src
P07516597A1017|21 27|effect
P07516866A0000|14 26|PRL receptor
P07517544A0515|8 12|days
P07517869A0411|17 34|dephosphorylation
P07518257A0351|4 13|promoters
P07518426A0000|0 13|Interleukin-8
P07518460A0771|13 17|hand
P07518561A0496|27 57|p72syk protein tyrosine kinase
P07518578A0000|17 24|protein
P07519447T0000|0 12|Organization
P07519463A0000|42 57|work efficiency
P07519481A1275|10 12|Sl
P07519606A1269|0 13|Anti-NPROSP-C
P07520098A0211|18 20|Db
P07521009A0377|6 13|mutants
P07521285A1109|4 12|findings
P07521601A0000|14 28|growth factors
P07521916T0000|0 7|Effects
P07522163T0000|0 12|Presentation
P07523363A0440|24 29|HpaII
P07523710T0000|0 9|Diagnosis
P07524265T0000|29 47|stimulating factor
P07525548A1380|4 11|results
P07525596A0584|71 75|Fpr3
P07525843A0859|0 9|Dilutions
P07526609A0736|9 19|expression
P07527168A0524|0 12|Microvessels
P07528028A1192|26 36|cell lines
P07528325A0165|7 14|studies
P07528531A0904|9 19|infections
P07528667A0834|6 22|initiation sites
P07528746A1049|0 26|Phosphoamino acid analysis
P07528772A0616|33 45|requirements
P07528772A1539|16 24|tyrosine
P07529124A0119|22 31|structure
P07529504A0000|36 51|characteristics
P07529516A0474|15 23|patients
P07530128A0578|41 50|serum PSA
P07530502A0974|0 8|Addition
P07530502T0000|15 27|Steel factor
P07530549A0956|0 8|Analysis
P07531321A0369|0 8|Patients
P07532278A0833|0 7|Horvath
P07533527A0128|0 10|Cell lines
P07533758A1038|4 24|amino acid sequences
P07533858A1503|18 39|alanine substitutions
P07533880T0000|4 16|FinO protein
P07534285A0155|8 13|paper
P07534286A0842|2 23|chicken paxillin cDNA
P07534297A0141|25 50|pair HindIII DNA fragment
P07534306A0444|30 46|GrsA derivatives
P07535593A0714|0 3|CD7
P07535768A1076|0 9|HVH2 mRNA
P07537267A2094|6 10|data
P07537362A1112|8 19|association
P07537736A0453|4 11|results
P07537851A0000|0 13|Transcription
P07537851A0891|0 11|Experiments
P07538068A1094|15 22|results
P07538122A0800|8 14|report
P07538173A0307|0 9|MBP-Rep68
P07538818A0197|21 28|regions
P07539119A0291|42 51|mutations
P07539119A0985|5 14|mutations
P07539314T0000|0 7|Changes
P07540607A0709|0 11|Retreatment
P07540773A0576|4 10|levels
P07540866A1069|17 31|insulin effect
P07541589A0652|12 21|variables
P07541912A0485|0 17|Sequence analysis
P07542577A0438|4 19|fusion proteins
P07542616A0313|0 5|GCD10
P07542616A0486|0 5|GCD10
P07542698A0137|0 7|Sources
P07543592A0624|27 33|mutant
P07543684A1027|17 21|cAMP
P07543868A0414|12 29|restriction sites
P07544357A0808|5 10|PPC-1
P07545510A0735|4 16|gene product
P07545920A1336|9 14|genes
P07546256A0000|32 37|study
P07546293A0968|4 11|results
P07546294A0000|4 18|RAD6/UBC2 gene
P07546794A0100|0 16|Echocardiography
P07547220A0229|12 32|screening programmes
P07547500A0066|28 42|fusion protein
P07547510A0261|49 54|sites
P07548425A0000|16 20|cats
P07548858A0000|4 13|flow rate
P07549005A0530|9 30|parallax measurements
P07550216A0195|23 29|limits
P07551787A0917|4 11|outcome
P07552974A0217|9 21|requirements
P07553942A0810|4 20|pea rps10 intron
P07554541A0587|12 16|care
P07555373A0000|0 15|Serum magnesium
P07557091A0314|0 7|METHODS
P07557276A0526|0 24|Alanine aminotransferase
P07557387A0241|8 13|study
P07557424A0124|0 4|XYL1
P07557446T0000|8 19|transcripts
P07557717A0184|9 17|division
P07558263T0000|0 7|Closure
P07558583A0562|4 9|study
P07559233A0534|0 25|Citrate synthase activity
P07559347A0000|4 14|expression
P07559355A0066|26 31|genes
P07559356T0000|4 19|hypBFCDE operon
P07559402A0622|22 24|VT
P07559430A0909|0 2|R.
P07559478A0389|15 22|O'Neill
P07559488A0440|0 19|Control experiments
P07559510A0000|9 43|Micrococcus luteus UV endonuclease
P07559524A0000|18 27|oncogenes
P07559524A0741|0 27|Cyclin D1 promoter activity
P07559555A0557|8 11|ERM
P07559563A0282|10 18|residues
P07559639A0996|3 11|addition
P07559640A1230|8 13|bases
P07559650A0558|6 13|results
P07560137T0000|13 24|sensitivity
P07560662A0496|6 14|recovery
P07562775A0596|4 9|range
P07563072A0773|0 11|Comparisons
P07563076A0766|6 21|intron chimeras
P07563090A0124|49 62|DNA synthesis
P07563090A0624|0 16|Characterization
P07563994A0488|4 12|patients
P07564004A0292|7 14|minutes
P07564210A0557|38 45|regimen
P07565031A0454|7 20|food products
P07565049A1032|45 52|outline
P07565104A0084|4 14|expression
P07565113A0000|31 48|transposon Tn4451
P07565669T0000|0 10|Ras p21Val
P07565672A0798|3 8|cells
P07565685A0420|4 21|peptide sequences
P07565688A0797|0 29|Immunofluorescence microscopy
P07565688T0000|0 10|Expression
P07565709A0000|0 17|T-cell hybridomas
P07565712A0286|0 9|Deletions
P07565713A0634|0 14|Overexpression
P07565720A0256|4 22|DNA binding domain
P07565723A0200|4 10|kinase
P07565731A1629|10 15|model
P07565736A2134|29 40|C/EBP alpha
P07565740T0000|0 11|Endocytosis
P07565775A1265|11 20|mutations
P07565775T0000|11 19|analysis
P07565776A0612|0 10|Disruption
P07565797A0116|0 8|Deletion
P07567079A0014|7 13|method
P07567300T0000|15 26|enterotoxin
P07567830A0072|0 7|METHODS
P07567979A1266|4 12|findings
P07567980T0000|5 8|p53
P07568026A0622|4 15|Stat5b mRNA
P07568116A0902|4 19|hydropathy plot
P07568118A1267|6 13|results
P07568576A0074|5 11|report
P07568865A0305|4 13|carcasses
P07569075A0585|10 15|stage
P07569532T0001|0 9|Pediatric
P07569640A0539|0 23|Protein electrophoresis
P07569770A0298|0 7|METHODS
P07571766A0122|19 29|percentage
P07571953T0000|30 42|mycobacteria
P07572582A0000|0 10|Mibefradil
P07574064A1416|28 52|concentration anesthesia
P07574682T0000|0 4|cDNA
P07575416A0000|0 16|Protein kinase C
P07575416A1970|5 9|work
P07575438A1409|5 11|action
P07575947T0000|4 10|debate
P07576178A0000|0 26|Polypeptide growth factors
P07576179A0781|30 39|frequency
P07576307A0144|23 27|role
P07576307A1654|31 37|motifs
P07577904A0141|16 21|years
P07579023A0214|11 23|dose-finding
P07579164A0409|3 13|comparison
P07579328A0653|0 5|MZF-1
P07579328A1345|25 43|DNA binding domain
P07579683A0660|0 8|Analyses
P07579695A0336|33 43|phenotypes
P07579695A0693|22 26|data
P07579704A0085|20 32|actin cables
P07580058A0000|4 11|effects
P07580330A0331|16 23|intakes
P07580782T0000|0 16|Imaging features
P07581364A0500|15 20|cases
P07582316A0696|23 28|pairs
P07582592A0545|0 4|HRES
P07583190A0306|23 32|processes
P07583562A1826|3 6|men
P07585246T0000|0 18|SL1 trans-splicing
P07585559A0000|21 29|compound
P07586403A0765|7 12|basis
P07588240A0000|4 52|Caenorhabditis elegans death susceptibility gene
P07588245T0000|0 10|Repression
P07588603A1054|4 11|results
P07588608A1687|0 11|Obstruction
P07588628A0318|0 14|Overexpression
P07588633A0362|13 18|c-Fos
P07588750T0061|0 7|Cloning
P07588777A1524|6 18|observations
P07589069A1245|43 48|forms
P07590264A0373|36 47|differences
P07590268A0350|44 46|Dm
P07590268A0740|9 26|MAPKAPK-2 message
P07590283A0820|4 11|finding
P07590525A0811|12 18|values
P07590657A0624|0 15|Cholangiography
P07590744A0829|4 13|integrity
P07592072A0217|3 8|Trial
P07592220A0846|10 13|PO2
P07592337A0891|6 13|results
P07592439A0000|0 4|A511
P07592467A0000|4 13|mechanism
P07592485A0734|17 32|gene expression
P07592647A0797|20 53|DNA Pur alpha recognition element
P07592647T0000|0 11|Association
P07592658A0309|32 39|complex
P07592676A0466|14 24|conditions
P07592706A1465|0 8|Exchange
P07592710T0000|25 43|protein kinase PKR
P07592711T0000|10 15|forms
P07592721A0827|15 23|mutation
P07592723A0814|0 14|Phorbol esters
P07592730A0204|0 6|Levels
P07592771A0258|4 14|mouse beta
P07592790A1457|15 19|data
P07592946A0261|19 26|cloning
P07592946A0997|27 37|TATA boxes
P07593266A1174|54 60|region
P07593896A1053|26 47|measurement technique
P07594047T0000|0 7|Effects
P07594592A0755|0 8|Deletion
P07595221A0733|6 11|cells
P07595374A1215|4 11|domains
P07595857A0521|4 19|peak velocities
P07596283A0396|18 24|enzyme
P07596287A0183|4 23|nucleotide sequence
P07596287A1724|4 14|ORF3 probe
P07596558A0824|6 13|results
P07596697A0971|28 39|polypeptide
P07597030A0260|19 26|cloning
P07597488T0000|10 18|jaundice
P07597804A1007|4 15|transcripts
P07598106A0709|0 19|Mean growth changes
P07598303A1728|17 24|studies
P07599449A0445|4 19|fracture groups
P07599653A0898|3 11|addition
P07600111A0000|4 14|prevalence
P07600986A0605|12 32|immunoprecipitations
P07601078A1003|0 8|Subjects
P07601121A0153|0 8|Analysis
P07601445A0207|21 45|BAT1 translation product
P07601827A0778|9 21|lacZ fusions
P07601828A0095|8 14|report
P07603726T0000|11 31|adaptation exercises
P07603956A0115|17 23|design
P07604047A0704|2 12|cDNA clone
P07604783A0952|26 33|changes
P07604794A0958|6 17|cholesterol
P07605990A1110|17 24|studies
P07606548T0000|0 8|Benefits
P07606587A0266|0 23|Piperacillin-tazobactam
P07607197A1048|6 27|plasma renin activity
P07607213A0140|26 57|structure/activity relationship
P07607233A0186|15 19|gene
P07607342A0703|5 10|paper
P07607537A0954|4 12|spectrum
P07607607T0000|0 8|Increase
P07607669A1112|15 21|region
P07608268A0194|25 34|disorders
P07608649A1429|10 24|blood pressure
P07608968A0836|0 8|Analysis
P07609037A0775|3 11|addition
P07609079A0387|0 15|Transactivation
P07609372A0261|0 6|M.M.C.
P07610052A1064|22 31|complexes
P07610324A0319|40 47|aspects
P07610716A0117|4 12|analysis
P07610735A1471|0 9|Diltiazem
P07612174A1064|9 17|primates
P07612557A0635|15 23|children
P07614762A0224|17 29|antigen test
P07615541T0000|11 19|analysis
P07615634A0535|6 17|transcripts
P07616056A0278|5 7|mu
P07616563A0532|9 13|CarP
P07616569A0168|13 18|genes
P07616802A0315|5 8|day
P07618280A0550|26 36|structures
P07618548T0000|4 27|Babcock Surgical Clinic
P07620491T0000|0 9|Resources
P07622058A0411|4 24|PEBP2 alpha proteins
P07622060A0967|23 28|cells
P07622521A0418|18 25|mapping
P07622932T0000|18 26|features
P07623807A0162|17 27|mechanisms
P07623814A1040|3 13|CV-1 cells
P07623821A0649|13 20|factors
P07623821T0000|0 10|Regulation
P07623825T0000|22 44|transactivation domain
P07623838A1112|0 2|D.
P07623840A0352|44 53|sequences
P07623844A0639|16 21|Bcl-2
P07624119A0528|15 19|PAX3
P07624581A0312|4 12|subjects
P07624615A0267|6 14|decrease
P07626378T0000|0 19|Hepatitis B vaccine
P07626469A1341|6 23|promoter activity
P07626806A1098|4 13|RAT3 gene
P07627317A1502|4 6|Al
P07628389A0145|0 27|Tumor necrosis factor-alpha
P07628438T0000|15 39|insulin receptor homolog
P07628451A0114|18 20|RA
P07628456A0000|20 38|RNA binding domain
P07629103T0000|23 44|protein isoforms beta
P07629113A0726|0 3|SCA
P07629122A0323|11 19|analysis
P07629123A0885|19 27|mutation
P07629150A0155|0 10|Expression
P07629163A0770|0 3|NH2
P07629196A0274|23 33|expression
P07630687A0010|4 13|objective
P07630934A0343|0 5|Harel
P07631267T0001|0 12|Radiotherapy
P07633444T0000|11 23|organization
P07633756A0690|4 25|ARX2 procedure models
P07635140A0172|4 14|expression
P07635312A0692|6 17|mutagenesis
P07635572A1153|0 10|CIITA mRNA
P07636179A0000|11 21|cell cycle
P07636187A0585|20 43|protein expression data
P07636337A0687|6 13|results
P07636408T0000|0 10|Comparison
P07636648A1229|4 9|month
P07636962A1288|35 46|determinant
P07636962A1883b|21 28|fusions
P07636984A1349|29 33|role
P07637718A0218|18 32|messenger RNAs
P07638517A0000|5 8|May
P07639106A0678|2 7|model
P07639703A1703|12 16|acid
P07640309A0000|15 32|peptide sequences
P07640422A0649|0 14|Thromboxane B2
P07642490A0318|6 12|vector
P07642538A0138|15 24|mechanism
P07642538A0744|3 11|contrast
P07642544A0868|12 21|treatment
P07642633T0000|12 20|promoter
P07644127A0000|17 28|stimulation
P07644466A0578|29 34|assay
P07644503A0729|3 11|contrast
P07646439A0535|17 25|proteins
P07647303T0000|4 22|homeobox gene ATK1
P07647570A0713|16 27|explanation
P07648338A0815|6 13|results
P07649098A0676|4 12|evidence
P07650958A0123|4 11|changes
P07651131A1407|11 17|assays
P07651141A0265|7 15|terminus
P07651340A0286|0 16|Retransformation
P07651386A0925|18 25|element
P07651398A0257|3 8|flies
P07651398A0803|12 24|binding site
P07651398T0000|17 29|gene product
P07651400A0335|5 15|inhibition
P07651424A0487|12 20|analysis
P07651424A0743|13 18|cells
P07651734A0961|0 22|Northern blot analysis
P07651835A0652|22 38|binding affinity
P07652066A0677|7 12|basis
P07652575A0435|13 27|microinjection
P07652582A0000|0 17|INF-alpha therapy
P07653094A0169|2 8|series
P07653812T0000|12 44|acetyl cholinesterase inhibitors
P07653892A0306|18 32|isoflurane MAC
P07654239A0698|0 3|Max
P07654712A0774|4 16|yeast enzyme
P07654740A0563|0 9|Key areas
P07655184A0852|4 13|transport
P07655505A0527|8 14|shoots
P07655509T0000|24 37|motif signals
P07656588A0101|12 33|DNA sequence analysis
P07657162A1412|17 41|transcription activation
P07657668A0642|0 14|TH-SH3 binding
P07657705A1181|6 13|results
P07658262A0944|0 16|Protein S levels
P07658471A0000|4 23|plant hormone auxin
P07658777A0400|4 8|test
P07659085A1520|15 57|transcription factor Oct-1 forms complexes
P07659515T0000|14 29|retrotransposon
P07659529A0135|8 25|deletion analysis
P07659746A1464|4 34|CVA16.4 proteolipid transcript
P07659757A0191|0 10|Incubation
P07660712A0118|4 13|character
P07663138A0835|6 13|nadolol
P07663160A0287|14 26|DNA sequence
P07663963A1588|11 28|system activation
P07663998T0000|15 21|repair
P07664278A0135|0 2|A.
P07665172A0000|0 21|Transcription factors
P07665187A0208|0 16|Primer extension
P07665187A0824|0 16|Primer extension
P07665477A0901|0 4|EsaR
P07665567A0495|0 17|Sequence analysis
P07665605A1127|20 21|D
P07665633A0284|13 21|isolates
P07665948A0591|0 10|IgE levels
P07666414A0614|16 26|expression
P07666415A0000|4 23|nucleotide sequence
P07666523T0000|0 13|Investigation
P07666538A0000|0 10|Initiation
P07666966A0207|0 4|Mean
P07667097A0267|4 15|association
P07667195A0146|0 5|L-735
P07667621T0001|0 26|Doppler ultrasound studies
P07668009A0172|14 24|cumlations
P07669351A1278|4 14|properties
P07670504A0834|47 62|banding pattern
P07670943A0308|15 19|male
P07672821A0763|13 20|linkage
P07672822T0000|8 17|structure
P07673128A0989|10 16|domain
P07673154A0688|28 33|state
P07673178A0982|4 11|results
P07674649A0508|27 31|ABAB
P07675445A0463|6 12|clones
P07675449A0848|7 29|glioblastoma cell line
P07676492A1000|21 31|comparison
P07676587T0000|11 24|certification
P07676655A0214|4 23|serum concentration
P07677573A0000|14 25|correlation
P07677715A1076|4 14|TAF factor
P07677836A1356|14 27|matter injury
P07678006A0472|0 25|RNase protection analyses
P07678006A0901|13 23|protection
P07678051A1303|4 17|PDGFR mutants
P07678242A0473|18 29|correlation
P07678593A0708|16 21|clone
P07678602A0153|25 49|B lymphoblast cell lines
P07678695A0604|12 22|expression
P07679390A0721|0 16|RNase protection
P07679836A0387|6 13|results
P07680035A0221|4 9|roles
P07680120A1008|0 6|RT-PCR
P07680629T0000|10 17|cloning
P07681147A1420|31 39|analyses
P07681513A0000|0 10|Piroximone
P07681539A0000|12 19|studies
P07682842A0294|13 19|origin
P07682842A0771|10 14|exon
P07683131A0885|12 21|structure
P07683375A0000|23 30|effects
P07685263A0503|10 35|polymerase chain reaction
P07685823A1234|0 14|RNA polymerase
P07685874A0258|9 15|sodium
P07686619A0704|0 4|Chem
P07687320A0526|12 26|plasmid pFV100
P07687541A0200|49 62|fission yeast
P07687541A0992|6 11|RCC1p
P07687745T0000|22 27|FK506
P07688112A0274|0 8|Prostate
P07689154A0168|0 23|Protein phosphorylation
P07689501A0420|9 17|carriers
P07691837A1359|9 11|bp
P07691885T0000|0 14|Identification
P07692366A0000|0 10|BACKGROUND
P07692668A0326|47 50|RNA
P07692754T0000|0 12|Risk factors
P07693132A0100|9 16|cloning
P07693372A0115|5 10|agent
P07693672A0259|0 5|DNase
P07693699A0831|13 22|stability
P07693708A0000|13 19|growth
P07693967A0905|4 12|presence
P07693975A1418|3 11|contrast
P07693975T0000|8 21|transcriptase
P07695629A0489|3 11|addition
P07696183A0567|25 35|properties
P07696450A0271|0 8|PATIENTS
P07696878A0222|4 19|leader sequence
P07697294A0329|8 14|amount
P07698219A0551|0 13|Cell adhesion
P07698727A0386|9 20|destruction
P07699632A0522|16 28|race persons
P07699632A0715|4 19|data complement
P07699845A0537|9 23|studies SY5555
P07700361A0125|23 35|interactions
P07701266A0808|0 7|RESULTS
P07702327T0000|13 33|adhesion prophylaxis
P07702378A0668|18 23|sleep
P07702752A0545|19 28|sequences
P07702808A0427|15 29|BP differences
P07704040A0000|33 48|mouse NMO1 cDNA
P07704273A0000|17 23|JRG582
P07704456A1014|7 16|mechanism
P07704689T0000|9 23|thyroid nodule
P07704730T0000|5 18|contraception
P07705476A0292|12 23|food intake
P07705627A1107|16 19|Mad
P07706273T0000|16 26|regulation
P07706287A0698|13 22|inability
P07706291T0000|3 16|E box element
P07706299A0563|0 17|Inhibition assays
P07706307A0914|4 23|amino acid sequence
P07706396T0000|0 9|Mutations
P07707523A0704|7 12|cells
P07707531A0550|18 24|design
P07707544T0000|16 29|transcription
P07708058A0178|4 7|GRE
P07708488A0151|3 11|contrast
P07708497A0000|16 26|activation
P07711667A0766|15 23|analysis
P07711730A0000|0 30|Carnitine palmitoyltransferase
P07713421A1435a|25 49|gain-of-function mutants
P07713421A1435b|25 49|gain-of-function mutants
P07713936A0393|0 7|Binding
P07714608A1252|15 26|differences
P07714758A1193|0 14|Blood pressure
P07715200A0000|0 17|Anesthesiologists
P07715602A1088|21 39|gene cluster codes
P07715922A0188|8 13|paper
P07717823A0328|0 26|Standard reference sources
P07719527T0000|5 18|allergenicity
P07720572A0701|3 11|contrast
P07720572A1584|17 27|difference
P07720709A0755|25 34|3T3 cells
P07720710A0861|4 7|Oct
P07721074A0766|7 17|dermatitis
P07721422A0241|0 28|Primer extension experiments
P07721878A1163|4 16|beta subunit
P07723247A0187|13 23|mechanisms
P07723247A1161|9 24|hour incubation
P07724452A0344|13 22|treatment
P07728201A0660|3 11|contrast
P07729427A0942|0 17|Deletion analysis
P07730273A1309|4 8|NarX
P07730328A0000|21 26|cells
P07730336A0606|8 13|ATF-1
P07730337A1439|4 10|Ng/RC3
P07730337T0000|0 9|Structure
P07730795A0104|4 24|amino acid sequences
P07731686A0000|4 14|TTG-2 gene
P07731898A0823|9 16|studies
P07733075A1200|6 13|therapy
P07735590A0990|4 17|concentration
P07735833A1078|0 11|CONCLUSIONS
P07737024A1003|6 22|bowel irrigation
P07737118A0317|4 8|MPS1
P07737508A0649|6 8|Tb
P07737944A0000|14 28|growth factors
P07738026A0216|13 18|mouse
P07738839A0173|7 17|IC breaths
P07739382A0457|13 21|analyses
P07739520A1250|3 11|homologs
P07739542A1419|24 32|cyclin E
P07739544A0364|14 33|amino acid sequence
P07739566A1076|12 38|Pax-6-BSAP fusion proteins
P07740487A0167|24 35|association
P07740490T0000|11 20|estrogens
P07741255A0194|10 19|districts
P07742024A0121|13 21|symptoms
P07742363A0135|14 21|enzymes
P07742363A0941|9 12|Ser
P07742550A0407|4 9|cases
P07742917T0001|0 7|Icterus
P07743472A0181|7 15|patients
P07743515A0223|5 13|analysis
P07743697A0703|0 4|Data
P07744763A0514|0 16|Binding activity
P07744776A0617|0 19|Transcript analysis
P07744846A1006|0 8|Analysis
P07744954A0418|4 11|protein
P07745008A0892|0 19|Radioligand binding
P07745311A0264|0 9|Diagnosis
P07745684T0000|6 25|papillomavirus type
P07745685A1442|15 22|virions
P07745693A0914|0 7|Studies
P07745696A0932|0 28|Restriction mapping analysis
P07745726A0960|4 35|replication reporter constructs
P07745726A1496|50 60|palindrome
P07746397A0233|0 7|METHODS
P07746794A0000|42 53|formulation
P07746937A0100|0 19|Lung function tests
P07747462A0332|0 20|Sequence comparisons
P07748451A0343|4 8|mean
P07748493A1045|18 33|Aplysia Afurin2
P07748502A0794|0 4|Rats
P07748848A0263|4 8|term
P07748952A0462|3 11|addition
P07748952A1329|6 13|results
P07749088A0119|9 11|T1
P07749461A0632|6 8|kb
P07749461A1022|11 19|analysis
P07750217T0000|0 26|Indium-111 OncoScint CR/OV
P07751848A0222|4 34|carnitine palmitoyltransferase
P07752223A0960|4 10|Myc LZ
P07752454A0341|26 29|CNS
P07752644A1031|6 8|VF
P07752886A0595|20 35|FecR derivative
P07753027A0240|4 24|gene pairs psbB-psbT
P07753030A0173|0 21|Hybridization signals
P07753796A0625|14 33|amino acid sequence
P07753796A0743|0 10|Expression
P07753837A0724|5 8|RNA
P07754713A0227|13 17|NUC1
P07755884A0000|14 20|grafts
P07755914A0000|0 9|OBJECTIVE
P07757315A1227|16 27|aggregation
P07758167A1488|0 13|Growth curves
P07758246A0469|4 11|protein
P07758459A1277|4 7|UAS
P07758837A1118|13 23|complexity
P07759094A0634|14 26|dinucleotide
P07759525A0417|4 12|proteins
P07759529A0288|12 22|approaches
P07760790A0327|0 15|Serum induction
P07760819A0731|12 22|activation
P07760841A0221|0 4|UAS1
P07760841A0647|7 14|context
P07760844A0413|0 9|Induction
P07761091A0294|0 12|Inactivation
P07761216T0000|13 35|amphotericin B therapy
P07761420A0909|26 32|assays
P07761434A1084|6 10|AP-1
P07761467A0666|11 18|complex
P07762431A0356|4 11|protein
P07762504A0648|4 9|study
P07763727A1035|0 15|Plasmids pAMS12
P07765118A0967|4 21|maximum induction
P07766885A0405|13 30|polypeptide chain
P07767011A0689|0 6|Repair
P07768824A0167|4 10|timing
P07768836A1126|0 28|Primer extension experiments
P07768848A1880|0 12|Polypeptides
P07768898A0492|23 29|values
P07768953T0039|0 4|EEA1
P07770033A0978|0 20|Nucleotide sequences
P07771671T0000|50 67|carbon electrodes
P07771745A0442|0 9|Elevation
P07772036A1000|5 11|region
P07774137A0000|14 20|impact
P07774807A0405|9 17|proteins
P07774925A0084|0 3|YAC
P07775428A0172|14 20|clones
P07776685A0000|5 10|study
P07776711A0295|0 8|MATERIAL
P07776882A0000|12 17|study
P07776979A0702|3 11|contrast
P07777518A0483|0 14|DNA sequencing
P07779558T0000|0 22|Muscle GSH-Px activity
P07779811A0901|0 8|Mutation
P07779812A0000|4 14|c-myc gene
P07780148A1153|14 17|PML
P07780525A0495|0 9|Schooling
P07780719A0477|29 36|driving
P07780738A0091|11 15|Cdks
P07782087A0559|24 54|transcription initiation sites
P07782113A0726|4 23|roxithromycin doses
P07782302A0479|30 45|DEDDDL sequence
P07782775A0889|13 17|ORFs
P07783064A0452|16 29|strength data
P07783641A0591|0 4|CodY
P07783822A0000|0 9|OBJECTIVE
P07784061A0894|24 34|G proteins
P07784078A1064|3 14|explanation
P07784079A1018|0 12|Transfection
P07784197A0827|10 18|extracts
P07784199A0000|14 21|protein
P07784870A0119|16 23|reports
P07784942T0001|12 26|thrombomodulin
P07786820A0284|0 6|CPT-11
P07786821A2292|0 10|CONCLUSION
P07787179A0312|5 16|bp fragment
P07789275A0325|14 22|function
P07789342A1352|27 33|domain
P07789396A0504|0 8|Lipiodol
P07789809A1246|10 23|Western blots
P07789971A0758|4 11|absence
P07790271A1185|13 22|lens dose
P07790377A0561|0 10|Antibodies
P07790719A0098|20 26|effort
P07791760A0424|0 14|GnRH treatment
P07791763T0000|10 17|cloning
P07791764A0357|32 46|Jurkat T cells
P07791768A0930|4 10|effect
P07791769A0826|0 4|ICP4
P07791771A0183|0 4|Otte
P07791776T0000|0 16|Characterization
P07791783A0000|12 16|cDNA
P07793783A0189|0 11|Scalp flaps
P07794556A0000|7 13|Center
P07795104T0000|0 5|Risks
P07795576A0126|0 11|Examination
P07796935A0284|27 33|effect
P07797077A0842|31 37|domain
P07797346T0000|3 11|outbreak
P07797476A1001|4 17|RAP74 subunit
P07797583A0222|26 44|base substitutions
P07798134T0000|4 21|hsp70 gene family
P07798207A0759|12 32|amino acid sequences
P07798217T0000|12 27|phosphorylation
P07798217T0095|2 6|role
P07798271A0330|10 16|region
P07799437A0656|6 12|assays
P07799925A0526|0 14|Reconstitution
P07799931A0287|60 67|control
P07799931A1232|3 11|contrast
P07799939A0628|12 19|element
P07799948A0777|3 11|contrast
P07799950A0282|3 10|studies
P07800479A0201|10 14|gene
P07800505T0000|0 16|Characterization
P07801180A0197|5 10|paper
P07802355T0000|12 17|study
P07802655T0000|0 16|Characterization
P07803809A1852|8 15|studies
P07806492A1162|5 14|structure
P07806507A0121|10 20|dissection
P07806532A0659|0 13|Protein cHMGI
P07806651A0097|5 10|study
P07806820A0091|42 49|pedicle
P07807002A0500|12 20|segments
P07808210A1510|24 29|value
P07809128T0000|10 18|capacity
P07809410A0606|15 20|cases
P07811639A0222|0 18|Endo16 transcripts
P07811964A1252|25 39|repeat element
P07812450A0849|13 16|ORF
P07813466A0074|4 13|U14 genes
P07813786A0641|12 17|cDNAs
P07814321A0850|0 8|Deletion
P07814323A0313|0 9|Inclusion
P07814388A0662|10 26|L-cell membranes
P07814403A0433|0 4|Chem
P07814405A1170|14 18|time
P07814717A0669|0 8|Increase
P07815546A0411|0 5|Virol
P07815811A1487b|9 25|vasoconstriction
P07816025A0196|0 10|Comparison
P07816049A0686|0 6|Atcys1
P07816049A1157|0 39|Southern blot hybridization experiments
P07816617A0763|6 13|results
P07816619A0000|23 55|Arabidopsis thaliana cDNA clones
P07816619A0872|17 31|identification
P07816630A1333|28 30|bp
P07816808A1102|6 10|data
P07818416A0895|27 53|haemoglobin concentrations
P07819225A1094|4 16|introduction
P07820057A0000|0 27|Tumor necrosis factor alpha
P07821790A1084|14 19|UCRBP
P07822161A1172|4 12|sequence
P07822329A0773|4 11|complex
P07822333A0376|0 4|Chem
P07823919A1422|12 22|activation
P07823951A1100|6 13|results
P07823953A0777|8 15|battery
P07823964A0922|24 32|activity
P07824325A0714|13 18|times
P07824464A0169|20 26|images
P07824657A1456|13 31|cysteine formation
P07824726A0454|5 9|type
P07825888A0715|12 21|subgroups
P07826412T0112|6 16|hypothesis
P07826625X0000|6 16|components
P07828584A0681|0 11|Mutagenesis
P07828600A0095|0 7|Binding
P07828811A0556|5 12|failure
P07828824A0307|0 9|Mutations
P07828852A0153|24 33|telomeres
P07829057A1097|4 17|marker orders
P07829057T0000|0 27|Integrated mapping analysis
P07829097A0000|4 10|region
P07829102T0000|0 17|Haplotype mapping
P07829519A1251|5 16|utilization
P07829554A0257|15 24|knowledge
P07830112A0532|3 11|contrast
P07831310A0000|10 32|complementation system
P07831799T0000|0 19|Nucleotide sequence
P07831829A1324|0 10|Comparison
P07832086A1023|4 20|drug sensitivity
P07832779A0719|0 15|Deglycosylation
P07834582A0115|8 18|supplement
P07835088A0238|4 10|HSD3B1
P07835214A0603|14 25|prevalences
P07835273A0000|19 36|glucose transport
P07835273A0411|6 15|selection
P07835710T0000|12 21|structure
P07835826A0195|0 8|Fraction
P07835886A0894|4 20|kallistatin gene
P07835888A0402|4 9|locus
P07836218A0128|5 12|studies
P07836228A1052|15 28|communication
P07836364A0000|0 4|Self
P07836390A1152|4 19|characteristics
P07836406A0884|32 40|peptides
P07836471A0375|12 28|protein sequence
P07838156A0789|9 31|cotransfection studies
P07840643A1006|2 12|comparison
P07841230T0000|0 12|Dissociation
P07841663A0685|0 20|Superoxide dismutase
P07841663A0845|6 13|studies
P07844142A0640|10 17|cloning
P07844155A0327|18 26|function
P07844201T0000|0 13|Sex selection
P07844425A0289|4 12|students
P07844555A0406|24 34|E mu pim-1
P07845672A0368|0 10|Comparison
P07846153A0403|0 10|Chrispeels
P07846163A0422|4 9|mRNAs
P07846199A0000|4 10|effect
P07846942A0717|0 20|Digitalis glycosides
P07846942T0001|7 19|fibrillation
P07847036A0353|8 13|doses
P07848358A0254|2 11|reduction
P07851643A1365|12 19|studies
P07851758A0330|9 27|analysis maps SAL6
P07852037A0548|18 35|DCT method yields
P07852361A0868|0 7|Removal
P07852400A0519|0 30|Rho GDP/GTP exchange inhibitor
P07853448A0601|8 12|task
P07853476A0159|0 7|Schnell
P07853488T0000|0 13|Encapsidation
P07853524A1944|0 7|Removal
P07854130A1387|4 15|requirement
P07854130T0000|4 21|pilE gene product
P07854324A0281|26 38|conservation
P07854324A0742|4 14|expression
P07856102A1616|6 10|data
P07857086A0949|18 19|%
P07857163A0551|4 12|activity
P07857344A0591|7 16|half-life
P07857762A0611|4 22|MAP kinase cascade
P07858986A0310|14 19|study
P07859238A1150|11 23|side effects
P07859301A0325|5 11|region
P07859371A1246|9 16|binding
P07859665A0498|4 15|mean jitter
P07859739T0000|0 4|Lack
P07859777A0000|18 31|serum albumin
P07860208A0000|21 28|release
P07860646A1363|8 20|intervention
P07862092A0302|21 26|clone
P07862108A0987|0 28|UV cross-linking experiments
P07862129A1391|15 21|livers
P07862141A0317|32 39|alleles
P07862141A1412|4 10|member
P07862150A0429|5 11|mutant
P07862154A0340|0 7|Cloning
P07862162A0408|7 15|presence
P07862165A0184|12 28|monkey COS cells
P07862168A0000|4 15|interleukin
P07862533A0000|4 9|Wilms
P07863047A0229|0 10|OBJECTIVES
P07863619A0098|3 8|order
P07863992A0908|8 13|group
P07864652A0753|0 10|Constructs
P07864652A1901|30 47|domain constructs
P07864709A0324|0 7|METHODS
P07865129A0293|19 26|ATF/CRE
P07865786A0457|0 15|Gene expression
P07865787A1086|4 11|results
P07865876A1292|20 30|expression
P07865888A1309|24 35|cells PBP74
P07865895A0896|12 22|experiment
P07865917A0191|0 9|Treatment
P07867604A1777|4 11|results
P07867622X0000|0 15|Promoter region
P07867944A0365|0 8|Upstream
P07869721A0000|8 13|paper
P07869913A1076|7 22|ISO+AT infusion
P07869937A1142|19 39|kilogram body weight
P07870305A1015|3 20|nucleus ventralis
P07871718A1132|9 18|inclusion
P07871721A0000|15 28|reading frame
P07871721A0392|5 24|sequence alignments
P07871754A0857|5 12|finding
P07871755A0521|11 17|method
P07871757A0846|0 8|Analysis
P07871891A0227|0 5|SUP46
P07872673A0332|26 38|relationship
P07872788A1717|9 15|degree
P07873631A0114|4 11|regions
P07873831T0000|21 32|involvement
P07873876A1035|4 14|NR2 hybrid
P07874060A0810|0 5|TDEYA
P07875595A0910|5 11|humans
P07876134A0348|20 36|characterization
P07876191A0808|0 10|Expression
P07876192A0443|3 12|ICE gamma
P07876194T0000|0 11|Endocytosis
P07876210A0275|69 74|genes
P07876210A0751|0 8|Mutation
P07876300A0994|17 23|nuclei
P07876562A1646|12 19|outcome
P07877308A1175|9 17|protocol
P07877619A1284|3 11|addition
P07878029A0721|13 18|CBF-A
P07878040A0505|25 34|sequences
P07879204T0000|0 16|OKT3 prophylaxis
P07880442A0236|10 48|PKC beta transcription initiation site
P07880449A0091|7 13|course
P07880650A0493|15 23|analysis
P07881077A0195|0 33|Supplementary Phase Contraste RSE
P07883167A0157|3 8|yeast
P07883168A0090|0 9|Mutations
P07883193A0000|2 14|DNA fragment
P07883754A0993|6 28|gel retardation assays
P07885999A0000|16 23|factors
P07886610A0000|7 17|population
P07887226A0858|19 33|serum ferritin
P07887859A0315|23 31|patients
P07887859A0998|0 17|TcPO2 measurement
P07888156A0169|15 34|University Hospital
P07888156T0000|8 14|status
P07888306A1659|0 10|Expression
P07888623A0721|0 14|PMEK1 displays
P07888629A0344|0 11|Translation
P07888788A1010|4 12|presence
P07888828A0765|5 12|concept
P07890485A0827|12 24|illumination
P07890599A0132|21 39|mouse cDNA library
P07890674A0916|4 12|catenins
P07890680A1193|9 17|addition
P07890740A0997|4 13|PSD2 gene
P07891638T0000|13 22|detection
P07891685A1051|6 13|results
P07891708A0690|5 8|Epo
P07891708A1192|30 40|expression
P07891709A1542|6 18|observations
P07891713T0000|6 18|Maf proteins
P07891720A0818|22 29|binding
P07892076A0578|0 8|Survival
P07892353A0667|5 12|factors
P07894021A1130|6 10|data
P07894359T0000|11 23|hemodynamics
P07894761A0000|4 7|aim
P07896088A0720|4 12|function
P07896291A0693|60 63|map
P07896615A0554|4 16|contribution
P07896817A0204|0 8|Proteins
P07896846T0000|24 32|isoforms
P07896852T0000|0 11|Involvement
P07897359A0354|26 31|forms
P07897696A0000|0 11|Erythrocyte
P07898178A0849|13 17|risk
P07898275A0254|6 13|classes
P07898589T0000|5 18|tobacco issue
P07898840X0000|0 19|Pregnancy screening
P07899581A0000|4 10|effect
P07899634A0000|0 7|PURPOSE
P07900915A0000|21 25|food
P07901121T0000|0 24|Cooperative dimerization
P07901125A0416|8 17|advantage
P07902532A0312|8 13|study
P07902532A1655|0 17|Deletion analyses
P07902583A0545|0 8|Analysis
P07903099A0918|4 12|presence
P07903670A1202|11 17|allele
P07905413A0585|15 24|treatment
P07905453A0281|0 7|Results
P07906265A0897|12 23|experiments
P07906616A0191|25 33|response
P07907846A0623|0 5|Group
P07908012A0678|15 26|possibility
P07908187T0000|0 4|ISIS
P07908827A1200|4 7|use
P07909936A0672|12 30|treatment strategy
P07910716A0359|4 17|study cohorts
P07910946A0323|0 8|Analysis
P07911736A1715|7 10|MTD
P07912123A0711|16 40|lymphocyte proliferation
P07913080A0564|2 34|decanucleotide promoter sequence
P07913891A0174|14 21|targets
P07913926A0878|0 17|Northern analysis
P07914192A0211|0 25|HER2 overexpressing cells
P07914192A0844|0 16|Gel-shift assays
P07914507A1029|0 10|Comparison
P07914700A0000|4 8|gene
P07915144A0000|0 14|High-frequency
P07916003A0688|15 25|mouse gene
P07916326A0000|19 31|organization
P07916327A0250|19 26|cloning
P07916577A0190|3 8|order
P07916588A0471|5 10|virus
P07916685A0455|4 9|ratio
P07916689A0312|13 24|POT1 clones
P07916689A1407|4 17|Y. lipolytica
P07916729T0000|2 23|leucine zipper domain
P07916983A0623|21 23|CT
P07917016A0581|14 25|DNA-binding
P07917540A0000|3 11|patients
P07918097T0000|10 37|Notch homologue mouse Notch
P07918128A0000|0 10|BACKGROUND
P07918494A1163|7 15|presence
P07919540A0240|14 25|alterations
P07919540A1119|3 11|addition
P07922709T0000|11 21|activities
P07925022A0285|0 10|Expression
P07925097A1205|15 25|AR content
P07925282A0705|0 10|Disruption
P07926729A0000|8 19|alterations
P07926739A0766|4 22|expression pattern
P07926748A0383|0 4|NOT4
P07926749A0471|8 22|site selection
P07926774A0652|4 28|p73pct1/p85cdc10 complex
P07926775A0895|20 27|stripes
P07926789A0960|4 16|DNA sequence
P07927130A0625|0 33|CMV hyperimmunoglobulin treatment
P07927267T0000|17 25|drainage
P07927711A0698|0 3|ORF
P07927838A0000|9 15|groups
P07928954A0545|0 21|DNA sequence analysis
P07929165T0000|0 12|DNA sequence
P07929238A0734|7 15|Genomics
P07929411A0087|2 12|comparison
P07929431A0949|0 8|Plasmids
P07929559A0000|12 18|dynein
P07929560T0000|0 14|Identification
P07931490A0237|0 8|PATIENTS
P07932095A0000|9 20|naphthalene
P07932943A0113|19 24|study
P07933066T0000|19 30|interaction
P07933076A0211|21 26|EBNA2
P07933095A0000|26 31|v-Rel
P07933101A0131|9 16|studies
P07933107A0991|2 12|comparison
P07933116A0412|4 12|p55 mRNA
P07934331T0037|9 21|registration
P07934666A0158|15 28|magnetization
P07935094A0516|0 7|RESULTS
P07935370A0000|16 26|expression
P07935375A1197|0 10|Expression
P07935379A0347|26 31|cells
P07935383A0108|9 14|RNase
P07935395A0094|4 11|protein
P07935415T0000|16 26|expression
P07935418A0447|8 20|v-erbA probe
P07935426A0714|16 24|isoforms
P07935447A0972|5 10|study
P07935451T0000|6 32|T-cell leukemia virus type
P07935468T0000|0 10|Activation
P07935471A0613|19 22|HSF
P07935472A0276|0 9|Enhancers
P07935472A0790|16 32|binding activity
P07935491A0495|6 18|RZR subtypes
P07935491A1182|21 38|response elements
P07935577A0305|0 9|Treatment
P07935626A1249|15 23|presence
P07935997A0000|4 14|parameters
P07936635A1134|0 8|Mutation
P07936640A0900|15 22|binding
P07936650A0656|17 26|subdomain
P07936650A1752|5 9|work
P07937106A0100|4 18|v-ets oncogene
P07937108A0325|24 29|mRNAs
P07937112A0220|15 23|subunits
P07937127A0645|11 17|method
P07937132A0819|12 15|U21
P07937147A0205|10 16|system
P07937656A0182|0 10|Univariate
P07937841A0790|6 13|results
P07937954A0612|0 3|HBx
P07937965T0000|0 4|Role
P07938137A0384|4 10|groups
P07941174T0001|0 13|Laser therapy
P07941739A0000|7 18|kb fragment
P07941750A0344|29 33|half
P07942076A0497|18 42|estradiol concentrations
P07942448A1227|13 21|patients
P07942722T0000|0 12|Constipation
P07943556A0694|7 14|persons
P07944461A0321|0 6|TG-day
P07944542T0000|0 20|Vibrio cholerae O139
P07945134A0079|4 14|volunteers
P07945330A0103|5 20|differentiation
P07945937A0358|0 17|Sequence analysis
P07947930A0499|4 14|fibrinogen
P07948129A0297|9 16|vectors
P07948921A0051|0 6|Optima
P07949137A0000|2 7|total
P07949137A0532|18 25|regimen
P07949164A0799|18 26|mutation
P07949205A0286|11 25|testololactone
P07949551A0000|0 3|Use
P07949770T0000|24 34|blood flow
P07951235A0277|4 8|gene
P07951410A0647|4 8|HeLa
P07951410A1332|0 18|E1A autoactivation
P07951874A0320|0 16|Cestode invasion
P07953785A0648|7 20|heat exposure
P07954475A0714|0 8|Analyses
P07954891T0000|0 4|ERV1
P07956578A0851|0 16|Lesion diameters
P07956869A0000|42 62|breast cancer tissue
P07957085A0207|0 4|Cbf3
P07957106A0471|8 19|interaction
P07957106A0875|6 15|mutations
P07957158A1532|16 31|filtration rate
P07957243A1316|15 23|residues
P07957559A1557|9 18|rapamycin
P07957632A0000|17 26|injection
P07958446A0000|4 14|hepatocyte
P07958865A1152|16 23|embryos
P07958898A1050|15 25|dTFIIA-L/S
P07958911A0500|9 31|trithorax binding site
P07958915A1507|15 22|changes
P07958920A1157|0 10|Antibodies
P07959011A0379a|0 11|C/EBP alpha
P07959011A0379b|0 11|C/EBP alpha
P07959015A0478|4 11|results
P07959734A0194|9 14|brain
P07959760A0763|16 26|YAC contig
P07959952A1446|2 6|cDNA
P07959953A0423|0 5|IFI16
P07960608A0228|0 7|Courses
P07960796A0154|0 11|Peter Elfer
P07961545A1314|14 20|events
P07961755A0474|0 8|Homology
P07961957A1565|17 21|data
P07961958T0000|0 27|Rat kidney carboxylesterase
P07963540A0795|12 27|I-kappa B alpha
P07963782A0000|26 35|stability
P07964162A0941|11 21|mechanisms
P07964458A0179|2 16|candidate gene
P07964459A0845|5 10|motif
P07964624A0491|4 12|P131 ORF
P07964770A0172|18 26|patients
P07964814T0000|18 32|hallucinations
P07964918A0000|4 13|influence
P07965152A0764|0 8|Segments
P07966565A0901|12 18|length
P07966583A1268|10 23|transfections
P07966602A0130|0 7|Roizman
P07966873A0693|0 8|Articles
P07967360A1048|12 16|data
P07967725A0262|12 21|receptors
P07968409A0123|4 10|sample
P07969115A0000|9 37|organello footprint analysis
P07969116A0196|4 17|Nur77 protein
P07969132A0268|4 9|class
P07969135A0913|10 18|presence
P07969136A0273|16 37|mobility shift assays
P07969152A0721|29 32|HSF
P07969181A0313|31 37|levels
P07969954T0000|13 34|motor neuron syndrome
P07971282A0000|0 10|Regulators
P07971709A0907|18 26|response
P07972012A0956|14 24|cDNA clone
P07972237A0665|18 33|restriction map
P07972831A0563|0 12|PAI-1 levels
P07973364A0325|15 22|article
P07973397T0001|0 13|Determination
P07973825A0445|4 18|recovery value
P07975763A0000|4 14|importance
P07975882T0000|6 21|adenovirus type
P07977239A1283|0 19|Outflow obstruction
P07977648A0880|0 10|Sequencing
P07978229T0000|11 23|complication
P07978406A0998|7 16|ISO group
P07979810A0340|20 30|parameters
P07979827A0722|0 7|KRN2391
P07980440A0138|3 27|H4IIE rat hepatoma cells
P07980468A0298|0 4|Acta
P07980669A0373|6 23|plasma AVP levels
P07981143A0633|2 9|stretch
P07981246A0112|13 18|study
P07982964A1017|0 3|ATX
P07982995A0000|4 10|effect
P07983011A0617|0 17|Sequence analysis
P07983704A0330|0 4|Type
P07983712A0914|14 20|domain
P07983715A0996|0 15|Point mutations
P07983716A1082|14 22|Northern
P07983744A0920|22 27|forms
P07984088A0592|0 13|Transcription
P07984105A1509|13 28|complementation
P07984261A0536|4 8|ICBF
P07985305T0001|4 13|treatment
P07987924A0670|4 17|inflation hub
P07988559A0836|10 17|element
P07988730A0220|10 27|promoter strength
P07988731A0002|15 21|number
P07988731A1301|12 19|protein
P07988945T0000|0 3|New
P07990136A1124|14 21|ability
P07991437A1032|0 11|Propafenone
P07991582A1023b|11 19|analysis
P07992027A0485|2 10|patients
P07993559A0233|9 14|index
P07994021A1223|12 20|splicing
P07995173A0585|0 8|Transfer
P07995910A0119|5 14|technique
P07997174A0936|4 8|data
P07999066A0238|4 8|role
P07999363A0000|7 17|variations
P07999604A0139|25 33|patients
P07999982A0086|10 28|maximum lod scores
P07999995A0000|16 30|protein kinase
P08000074A0162|2 10|sequence
P08000112T0000|0 11|Goodpasture
P08000427A0000|2 17|cDNA clone pCZ1
P08000497A0179|0 7|METHODS
P08001136T0000|0 12|Relationship
P08001792A0284|4 8|git1
P08001966A0563|11 18|regions
P08002564A0249|0 21|DNA sequence analysis
P08002857A1070|0 11|CONCLUSIONS
P08003700T0000|13 22|screening
P08004442A0265|4 11|effects
P08005230A0222|11 31|reporter gene system
P08005412A0608|25 40|gene expression
P08005438A1185|0 5|SPP41
P08006101A1142|0 39|Standard curve correlation coefficients
P08006772A0000|12 26|pulse oximeter
P08006773A0836|13 23|difference
P08007835A0538|9 17|analysis
P08007954A0374|0 16|Deletion studies
P08007975A0000|4 13|IPL1 gene
P08011017A0169|3 7|drop
P08011166A0207|13 30|gene organization
P08012448T0000|0 4|INO2
P08012566A0254|4 32|pentafluorobenzyl derivative
P08013348A0143|10 14|ABPs
P08013457A0342|0 12|Src homology
P08014228A0278|0 16|Sample treatment
P08014377A1277|14 24|conditions
P08014919A0530|41 46|units
P08015672A1282|3 19|control patients
P08015850A1076|16 24|analysis
P08016102A1238|4 12|presence
P08016189A0741|0 11|Granisetron
P08017290A1347|28 44|sinus difference
P08018361A0636|35 50|neutron fluency
P08020702A0000|0 11|Endotoxemia
P08020702A0137|4 9|study
P08020806A0187|25 30|trial
P08020962A1226|15 21|region
P08020965A0465|22 28|region
P08021175A0486|4 8|pexB
P08021177A0000|4 13|fepA-entD
P08021225A0000|0 17|Sequence analysis
P08022212A0071|29 42|two-frequency
P08023662T0000|15 26|measurement
P08024139A0393|3 11|addition
P08025074A0000|15 20|study
P08025669A0724|4 12|proteins
P08028671A0687|20 34|microinjection
P08029001A1020|6 13|results
P08029334T0000|0 7|Cloning
P08030239A0833|34 38|form
P08030243A1011|29 46|RNA capture assay
P08030704A1503|0 10|CONCLUSION
P08031424T0000|0 8|Ketamine
P08033490A0875|3 13|conclusion
P08034318A0724|4 16|availability
P08034486A0579|4 13|incidence
P08034680A0180|4 13|mechanism
P08034682T0000|7 17|expression
P08034708A0000|14 19|basis
P08034741A0000|14 28|identification
P08034742A0307|0 2|M.
P08035498A0833|3 11|addition
P08035499A0941|21 31|difference
P08035505A0586|0 10|Processing
P08035517A0753|14 22|promoter
P08035796A0890|0 13|32Pi labeling
P08035833A1556|6 10|YMIP
P08036004A0292|4 13|R2 region
P08037338A0000|0 7|PURPOSE
P08039422A0000|4 33|nerve growth factor beta gene
P08040336A0435|25 32|element
P08040391T0000|0 6|Number
P08040468A0303|18 41|mast cell degranulation
P08041362T0000|10 17|cloning
P08041793A0242|11 18|studies
P08043523A0000|18 30|serum levels
P08044794A0000|4 20|tumor suppressor
P08044800A0550|5 37|DNA containing promoter activity
P08044802A0462|9 22|Southern blot
P08045431A0894|0 4|HupI
P08045834A0783|4 24|PCr resynthesis rate
P08046923A0000|3 14|examination
P08048582A0821|18 22|MVO2
P08048916A0000|0 5|IGF I
P08049401A0428|0 16|Immunodepression
P08049444A0351|8 16|cleavage
P08049521T0000|9 32|protein phosphorylation
P08049885T0000|6 18|pancreatitis
P08051019A0365|9 21|biosynthesis
P08051059A1000|4 12|sequence
P08051074A0000|29 41|footprinting
P08051102A0532|0 7|Heparin
P08051151A0347|13 22|abundance
P08053697A0000|0 10|BACKGROUND
P08054281A0731|4 19|retention index
P08055939A0159|21 27|domain
P08055939A0707|4 12|location
P08055941A1264|4 12|topology
P08056474A0438|9 13|NMSC
P08057356A0531|22 26|form
P08057356A1824|0 11|Comparisons
P08057421A1583|7 14|binding
P08057762A0878|29 44|reproducibility
P08057833A0573|8 21|ParA proteins
P08058326A0463|15 23|insights
P08058948A0810|0 10|CONCLUSION
P08062824A0626|15 21|domain
P08062833A0000|13 15|nt
P08063108A0109|4 13|acfD gene
P08063766A0595|13 17|beta
P08063775T0000|0 10|Regulation
P08063791A1370|6 13|results
P08063836A0904|17 22|c-Abl
P08064351A1020|0 12|Long-latency
P08065310A1144|27 33|heptad
P08065324A0458|22 32|expression
P08065327A0000|10 27|DNA rearrangement
P08065331A0279|20 44|site selection procedure
P08065338T0000|4 9|Oct-2
P08065365A0000|0 7|Binding
P08065366A0918|20 24|data
P08065368A0839|0 5|Ariga
P08065901A0997|4 11|results
P08066094T0000|0 11|Marine oils
P08067013T0001|15 27|significance
P08067123A0248|17 24|results
P08067546A0000|16 26|hypothesis
P08067607A0568|12 23|alterations
P08069298A0492|18 33|splice variants
P08069427T0000|0 27|Roux-en-Y gastroenterostomy
P08069481A0736|13 24|experiments
P08070004A0782|19 28|variation
P08070393A0631|12 18|effect
P08070654A0000|0 4|KAR1
P08070654A0574|0 5|CDC31
P08071356A0232|7 28|transcript elongation
P08071982T0000|36 44|syndrome
P08072352A0567|8 16|patients
P08072547A0690|0 3|Ras
P08072547A1009|8 16|sequence
P08072547T0000|0 5|c-Fos
P08073505T0000|6 16|generation
P08075070A1632|10 18|features
P08075421A0621a|12 15|ORF
P08075421A0621b|12 15|ORF
P08076631A0000|4 11|binding
P08076937A0851|6 15|detection
P08077236A0243|0 9|Wild type
P08078167A0000|0 9|OBJECTIVE
P08078416A0581|17 23|effect
P08078473A1107|0 10|Expression
P08079268T0028|0 3|Use
P08082215A0230|11 19|response
P08082286A0748|0 18|Acupuncture effect
P08082292T0000|8 19|NK activity
P08082360A0411|0 15|Smoking history
P08082440A0339a|1 5|LH P
P08083011A0584|13 14|R
P08083220A0988|5 9|mode
P08083963A0795|16 26|activities
P08083998A1723a|6 13|results
P08083998A1723b|6 13|results
P08083999A0501|0 8|Vaccinia
P08084339A0907|27 37|transcript
P08084592A0145|3 7|HeLa
P08085228A0000|12 27|characteristics
P08085609A0384|0 7|Results
P08085782A0164|15 20|cases
P08086450A0467|0 10|Comparison
P08086453T0000|0 9|Structure
P08087887A1067|4 22|polyubiquitin gene
P08088022A1417|35 42|disease
P08088513A0419|25 33|evidence
P08088777A0754|4 24|consensus gene order
P08088818A1053|9 14|level
P08089184A0825|3 11|addition
P08089834A0561|6 13|mutants
P08089887A0742|10 25|OUTCOME MEASURE
P08090571T0001|0 11|Elimination
P08090746A1288|8 16|sequence
P08090767A0000|11 19|evidence
P08091655A0000|23 28|Marek
P08091665T0000|0 12|Cowpox virus
P08091669A0828|21 24|P35
P08093450A0688|0 11|Mutagenesis
P08093616A1214|0 5|DNase
P08093616T0000|6 26|8-base pair sequence
P08093642A0600|3 11|addition
P08094464A0869|9 13|tyrA
P08094464A2014|11 15|span
P08094498A0614|30 36|spouse
P08094927A0311|9 16|studies
P08095698T0000|0 10|Metabolism
P08095872A1672|18 23|study
P08095875T0000|0 7|Effects
P08096066A0623|4 17|RFLP patterns
P08096944A0951|26 37|stimulation
P08097666A1135|0 6|A23187
P08097732A0000|0 10|Activation
P08098228A0625|2 12|transcript
P08098842A0660|0 9|Mutations
P08098882T0001|13 28|desensitization
P08098914A0400|7 15|exercise
P08099443A0359|13 16|HRI
P08100057A0577|51 62|populations
P08100765A0361|29 58|transgene expression patterns
P08100843A0134|0 17|Southern analysis
P08101134A0376|4 18|concentrations
P08101171A0924|13 20|results
P08101839A0000|19 29|regulation
P08101843A0151|4 29|tyrosine hydroxylase gene
P08102364A0000|0 7|Tobacco
P08103379A0577|10 17|stretch
P08103935T0000|0 9|Isolation
P08104189A1168|6 10|data
P08105727A0099|0 10|Fenoldopam
P08105994T0000|9 16|aspects
P08106087A0139|19 25|region
P08106245A0325|11 30|radon concentration
P08106313A1492|4 11|results
P08106325A0000|0 4|DtxR
P08106369A0000|0 11|Vasopressin
P08106398A1003|6 13|results
P08106512A0522|9 24|promoter region
P08107167A0222|0 6|Anti-B
P08107208A0673|4 12|approach
P08108099T0000|0 10|Evaluation
P08108343A0000|12 20|analysis
P08108413A0964|58 68|cell lines
P08111035A0098|26 36|properties
P08111974A1034|24 33|mechanism
P08112341A1128|0 2|L.
P08112526A0443|29 50|calcium concentration
P08112601T0000|11 23|organization
P08112611A0404|4 12|sequence
P08112870A0484|0 16|Western blotting
P08113736A0309|4 21|gene organization
P08114702A0000|0 7|Members
P08114710A0137|30 35|LBP-1
P08114745A0953|6 13|results
P08115744A0462|4 9|films
P08115744A0846|15 21|method
P08116245A0174|14 17|RNA
P08118044A0318|0 11|GATA-1 mRNA
P08119149A0000|0 27|Tumor necrosis factor-alpha
P08119907A0000|25 29|role
P08119958A0273|4 8|lack
P08119995A0814|31 39|function
P08120019A1500|15 26|Hm1 mutants
P08120029A0864|22 45|decay reaction mixtures
P08122364A0954|0 17|Deletion analyses
P08122370A0331|19 31|counterparts
P08123787A0554|13 32|amino acid sequence
P08124785A0445|0 7|METHODS
P08124912A0456|11 22|correlation
P08124956T0000|46 58|pancreatitis
P08125258A0142|21 26|cells
P08125319A1085|4 14|ipiO genes
P08125337A0940|0 15|Sterol analysis
P08125949A1162|34 45|translation
P08126096A0478|9 20|experiments
P08126096A1071|4 21|alpha 7A form RNA
P08127950A0000|3 8|order
P08128629A1164|0 12|CRS function
P08129955A0572|7 13|levels
P08130942A0051|0 15|Regionalization
P08131545A0158|27 32|group
P08131746A0140|0 3|MEK
P08132541A0000|8 18|DNA clones
P08132574A0831|0 7|Members
P08132667T0000|0 10|Expression
P08133502T0105|0 29|European Community Huntington
P08134108A0277|4 9|c-myc
P08134115A1161|0 6|MSSP-1
P08136383A0359|10 15|hours
P08138180A0593|8 13|spt10
P08138364T0000|0 9|Varieties
P08139001A1235|4 11|results
P08139004A0278|7 10|UTR
P08139017A1465|20 24|site
P08139031A1168|56 67|mutagenesis
P08139539A0446|3 15|Rat 1a cells
P08139542A1229|4 13|mutations
P08139542T0000|2 9|segment
P08139543A0427|14 19|genes
P08139543A1520|23 31|analysis
P08139562A0404|8 14|report
P08139577T0000|10 20|components
P08139914A0554|36 53|dnHLH protein Id1
P08139928T0000|0 4|RNP1
P08140847X0001|0 5|Crohn
P08142875A0877|20 30|dissection
P08143198T0001|0 11|Restoration
P08143236A1055|8 23|ethanol regimen
P08143667A0222|4 8|mean
P08144035A0387|25 32|regions
P08144037A0000|0 11|Thioredoxin
P08144470A0711|4 12|mutation
P08144497T0000|18 24|region
P08144504T0064|8 16|coupling
P08144572A0786|0 3|ATP
P08144615A0533|0 9|Digestion
P08144631A0000|0 9|Signaling
P08144668A0802|29 35|exon V
P08144852A0000|4 13|responses
P08145646T0000|0 9|Structure
P08145770A1078|9 21|observations
P08148463A0000|23 30|factors
P08148756A0358|4 10|degree
P08149484A0151|0 19|Expression plasmids
P08149484A1551|6 13|results
P08150970A0434|7 19|cutoff level
P08151787A0355|0 9|Insertion
P08151787T0000|0 7|Mapping
P08151790A0354|4 24|revertant TATA boxes
P08151980T0001|11 20|emphysema
P08152800A0357|10 20|ETS domain
P08152800A0709|0 18|Gel shift analysis
P08153130T0000|0 7|Effects
P08153146A0327|0 10|Dotarizine
P08154171A0649|6 12|issues
P08154182A0955|4 14|usefulness
P08156332T0000|25 38|sympathectomy
P08157009A0264|0 20|Sequence comparisons
P08157009T0000|29 38|APS1 gene
P08157663A0882|6 13|results
P08157674T0000|12 28|characterization
P08159174A0581|4 12|presence
P08160054A0224|4 12|patients
P08160387T0000|21 32|development
P08160905A0217|7 15|patients
P08163183T0000|4 10|xylose
P08163498A0789|4 19|phosphopeptides
P08163528T0000|14 43|Mas70p signal anchor sequence
P08163546A1230|18 22|data
P08164302A0547|17 30|TPN solutions
P08164661A0414|14 26|TFIIIC alpha
P08164679A0809|0 22|Transactivation domain
P08164680A1086|21 38|protease activity
P08164684A1266|4 10|ligand
P08166402A0631|0 19|Cerebral125 albumin
P08167396A0154|22 29|neurons
P08167555A0972|0 8|Response
P08169201A0291|30 38|sequence
P08169709T0000|11 20|bone cyst
P08170400T0000|0 8|Location
P08172416A0860|0 10|Moxidectin
P08172598A0237|14 22|analysis
P08172653A1589|13 20|regions
P08172905A0000|4 9|class
P08173532A0000|7 20|reaction time
P08173693A0390|9 20|study group
P08173814A0132|6 13|viruses
P08175031A0566|0 9|Treatment
P08175188A0685|2 15|concentration
P08176742A0190|28 44|assay conditions
P08177143T0000|6 20|cell carcinoma
P08178446A1160|4 8|data
P08178490A0879|28 43|signal function
P08178572A1118|5 36|concensus poly A addition sites
P08179827T0000|0 7|Factors
P08180129A1256|0 8|Exposure
P08181755A0989|0 17|Northern analysis
P08182041A1067|4 11|results
P08182056A0695|9 15|degree
P08182171A0000|4 12|efficacy
P08183552T0000|10 20|eps15 gene
P08183915A0000|4 8|gene
P08183915T0000|12 20|splicing
P08184923A0829|8 13|L-NNA
P08185288A0106|4 14|experiment
P08187085A0086|6 20|rearrangements
P08187088A0530|9 13|loss
P08187177A0405|9 26|amino acid change
P08188258A0000|14 24|synthetase
P08188290A0544|10 23|sequence data
P08188603A0230|5 13|analysis
P08188606A1034|0 20|Restriction analysis
P08188978A0822|15 22|latency
P08189174A0148|0 6|DESIGN
P08189498T0000|0 14|Identification
P08189503A0000|27 37|cDNA clone
P08189533A0203|39 43|gene
P08189533A0919|0 19|Gel electrophoresis
P08190633A0000|4 29|transcription factor AP-2
P08190633A0273|11 20|AP-2 mRNA
P08191910A0228|0 10|San Martin
P08192140A0209|4 16|participants
P08192451A0885|10 19|treatment
P08192795T0000|28 35|purpura
P08193147A0831|0 10|Comparison
P08194139A0498|0 11|CONCLUSIONS
P08194549A0000|26 34|kayakers
P08194753A0157|25 33|sequence
P08194970A0000|0 5|Women
P08195186A0000|10 23|cDNA sequence
P08195216A1022|24 28|case
P08195217A0799|22 29|protein
P08195233A0147|3 11|addition
P08196607A0280|0 17|Deletion analysis
P08196616A1112|19 30|interaction
P08196618A0473|0 5|PRL-1
P08196624A0593|3 13|Mv1Lu lung
P08198524A1134|3 6|kDa
P08199204A0746|0 3|H-7
P08199878T0000|4 11|effects
P08200528A0970|5 13|strategy
P08201352A0239|7 11|case
P08201758A0125|14 21|patient
P08201932A0355|12 23|examination
P08202546A1206|3 11|addition
P08203260A1204|21 25|SIMV
P08204348T0000|0 5|VP-16
P08204403A0000|2 7|total
P08204426T0001|38 49|ventilation
P08204824A0000|10 15|clone
P08205827A0940|0 11|CONCLUSIONS
P08206848A0296|4 8|pyrR
P08206867A0874|0 26|Southern blotting analysis
P08206991A0466|0 9|Acylation
P08207022T0000|0 19|Subunit composition
P08207232A0503|16 39|mobility shift analysis
P08207405A0372|0 3|BYV
P08207795A0409|24 32|location
P08207805A0000|4 37|p53 tumor suppressor gene product
P08208247T0030|11 19|analysis
P08208540A0000|0 14|Rearrangements
P08208540A0417|0 7|Cloning
P08208540A1114|10 32|co-transfection assays
P08208618A1334|6 12|HR21ap
P08209051T0000|23 30|therapy
P08209423T0000|13 19|frames
P08209772A0167|4 12|ns2 gene
P08212571A0597|0 15|Co-transfection
P08212571A0971|0 8|Analysis
P08212897A0404|4 26|hydrophobicity profile
P08213235A1024|0 11|Measurement
P08213747A0000|32 42|prevalence
P08216115A0158|4 12|patients
P08217862A1336|10 21|development
P08218056A0000|4 18|ultrastructure
P08218230A1505|15 21|region
P08218230A1920|27 30|GRE
P08219072A0287|0 4|Acad
P08219081A0000|4 15|PRB-1b gene
P08219227A0830|0 11|Replacement
P08220494A0231|10 18|promoter
P08220621T0000|10 21|manuscripts
P08221251A0239|16 18|CT
P08222384A0455|0 5|SIN-1
P08222556T0000|0 6|Effect
P08222618A0000|10 27|computer programs
P08223425T0000|4 19|yeast SSS1 gene
P08223554A0574|4 11|lengths
P08223576A1261|4 11|absence
P08223592A0424|0 4|TATA
P08223613A0105|0 4|GGS1
P08223613A0519|21 29|sequence
P08223823T0000|0 19|Stroop interference
P08223875A0711|0 11|Stimulation
P08224260A1248|0 10|CONCLUSION
P08224907A0000|8 30|Southern blot analysis
P08225657A0000|4 10|effect
P08226616A0000|4 14|nit-3 gene
P08226776A0990|42 49|process
P08226777A0936|2 28|Dictyostelium transformant
P08226780A0160|5 10|motif
P08226794A0501|1 6|Ala85
P08226798A1124|18 29|CaM binding
P08226956A1397|22 28|effect
P08227129T0000|25 31|domain
P08228805A0540|19 27|molecule
P08228997A0866|4 11|results
P08229102A0768|21 39|QLMI questionnaire
P08229330A0000|5 12|smokers
P08229826A1145|15 23|response
P08230418A0812|4 10|action
P08230445A0000|4 11|product
P08230452A0551|16 24|vaccinia
P08230452A1489|3 11|contrast
P08231398A0802|0 7|RESULTS
P08231577A1027|0 4|Acid
P08231816A1473|23 31|extracts
P08232304A1166|2 8|series
P08232412A1342|4 15|lemdr1 gene
P08234166A0425|4 19|bioavailability
P08234276A0556|20 30|activation
P08234308T0000|0 6|Notice
P08237112A0553|3 11|homology
P08237171A0000|17 21|case
P08237578A0253|11 27|lipid metabolism
P08238626A0248|5 10|PaCO2
P08239164A0551|0 4|CPAP
P08239586T0000|0 7|Effects
P08240170A0000|5 10|forms
P08241139A0378|8 9|%
P08241656A0189|7 16|knowledge
P08242861A0368|5 16|4,8-DiMeIQx
P08243476A1177|6 14|cysteine
P08244034T0000|12 48|Leishmania surface glycoprotein GP63
P08245013A0000|26 31|basis
P08245125A0822|0 8|Addition
P08245456A0501|6 11|cells
P08245461A0700|0 24|Hu-Met-1 mRNA expression
P08245933A0617|8 19|engorgement
P08246984A0512|0 8|Northern
P08246984A0923|6 13|results
P08246987A0260|3 11|addition
P08247005A0584|0 7|Strains
P08247043T0000|0 11|Hepatitis B
P08248246A0838|4 11|complex
P08248253A1785|15 27|observations
P08248688A0726|4 8|rate
P08249319A0578|31 46|mislocalization
P08249390A0111|4 12|duration
P08251506A0503|12 19|complex
P08251622A0000|4 12|promoter
P08252067A0917|17 28|comparisons
P08252976A0467|0 5|Rinit
P08253386A0800|21 30|mechanism
P08253387A0801|0 10|Inspection
P08253387A1291|17 26|sequences
P08253777A0301|2 23|cAMP response element
P08253958A0000|2 8|number
P08254738A0428|8 14|series
P08255022A0827|4 10|degree
P08255341A0554|4 12|patients
P08255758A0000|42 48|region
P08257666A0662|15 20|study
P08257754A0711|11 15|dose
P08258025A1131|0 11|CONCLUSIONS
P08259650A0640|0 28|Nucleotide sequence analysis
P08260635A0926|5 11|intron
P08261398A0392|19 40|cell lines P388/ADR/3
P08261398A0838|17 30|amplification
P08262041A0727|4 18|phi AP3 factor
P08262054A0565|38 44|domain
P08262067A1608|15 23|homology
P08263933T0000|10 17|cloning
P08264579A1209|4 11|cloning
P08264582A0750|37 43|domain
P08264583A0520|27 32|basis
P08264591A1190|6 10|data
P08264617A0000|12 22|expression
P08264628A0418|0 27|Oligonucleotide competitors
P08264631A0746|15 21|region
P08264650A0925|0 8|Analysis
P08264664A0128|0 8|TGF beta
P08265602T0000|0 3|Val
P08265955T0000|10 16|change
P08267658A0391|22 30|solution
P08267667A0748|9 23|administration
P08268718A0676|6 18|bcl3 protein
P08268833T0000|16 22|action
P08268912A0657|9 32|translation experiments
P08269424A0339|17 31|administration
P08269439X0000|12 21|analgesia
P08270257A0551|2 28|sequence homology analysis
P08270580A0155|13 21|response
P08270985A0590|0 18|Response durations
P08273122A0708|0 7|RESULTS
P08274774A0958|3 11|addition
P08275618A0457|0 11|Drug effect
P08276234A0119|11 19|evidence
P08276336A0371|19 27|analysis
P08276732A0799|4 8|rate
P08276762T0000|0 6|Effect
P08276851A0347|14 28|Pay4p sequence
P08276854A1894|4 11|results
P08276865A1188|4 34|kinase inhibitor staurosporine
P08276871A1001|38 46|identity
P08276900A0543|0 2|S.
P08277632A0997|4 17|survival rate
P08278423A0147|0 7|Mothers
P08278480T0002|0 2|G.
P08278548A0597|4 8|psaD
P08278929A0866|12 30|SPF type V embryos
P08279098T0001|31 42|dystrophies
P08280476A0602|7 14|studies
P08280925A0261|45 54|responses
P08281153A0543|29 35|degree
P08281536A0626|0 13|Interleukin-6
P08281634A1801|6 16|parameters
P08281740A0000|0 9|Responses
P08282501A0358|21 27|number
P08282576A0297|0 7|Tumours
P08282749A1474|0 6|Thomas
P08283292A0779|0 6|Plasma
P08283531A0700|4 30|Stryker frame modification
P08284227A0336|21 26|cells
P08284337A0825|21 30|screening
P08285710A0634|16 31|transcript mRNA
P08286035A0587|15 35|sequence information
P08288240A0304|4 23|sequence similarity
P08288240A1343|6 10|data
P08288554A0295|12 31|amino acid sequence
P08288596A0663|14 16|T3
P08288606A0240|8 24|polymerase chain
P08288622A0725|15 23|analysis
P08288633A0144|16 19|DNA
P08289339A0527|11 22|exonuclease
P08289341A1202|0 10|Repression
P08289342A0931|2 8|mutant
P08289357A0724|4 11|results
P08289593A1404|33 37|rats
P08289783A0000|4 9|Oct-3
P08289783A1476|20 31|mutagenesis
P08289784A0381|19 21|M.
P08289793A1226|42 48|effect
P08289831A0290|0 8|Analysis
P08289834A0341|24 34|test cells
P08290278A0374|11 15|Mxi1
P08290421A0165|7 16|knowledge
P08291233A0000|2 12|cDNA clone
P08291620A0372|10 18|patterns
P08291761A0416|0 10|Animal age
P08291886T0024|16 25|expansion
P08293412T0000|26 31|study
P08293992A0432|5 11|repeat
P08293993A0948|0 3|ENV
P08294386A0000|0 10|BACKGROUND
P08294429A0153|0 8|Analysis
P08294459A0446|14 33|amino acid sequence
P08294511A0639|14 22|evidence
P08294865A0236|8 16|features
P08294906A1315|5 17|distribution
P08296434A1141|4 21|Harleco apparatus
P08297376A0236|0 15|Co-transfection
P08298129A0274|33 38|basis
P08298129T0000|0 9|Isolation
P08299181A1148|11 16|fluid
P08299568A1401|6 10|data
P08299725A0724|13 19|region
P08299896A0626|0 11|Concordance
P08299896A0880|0 22|Regression line slopes
P08300463A0581|0 12|Praziquantel
P08300527T0000|0 10|Inhibition
P08300601A0745|5 11|region
P08300605A0432|16 24|analysis
P08300605A0671|13 21|elements
P08300611A0341|14 25|mutagenesis
P08300611T0000|10 16|action
P08300625A1352|21 27|codons
P08301702A1083|13 23|antibodies
P08301841A0000|18 33|enzyme activity
P08302589A1132|16 29|cell motility
P08303233A0313|3 11|addition
P08304301A0331|0 7|METHODS
P08304342A0605|15 21|report
P08305058T0000|0 12|Pneumothorax
P08306356A0000|19 32|malformations
P08306834A0866|0 10|T2 cancers
P08306959A0278|0 9|IFN alpha
P08307338A0227|0 9|Mutations
P08307564A0233|29 34|sites
P08308008A0201|8 13|paper
P08309726A0000|16 23|insight
P08309912A0306|0 10|Amiodarone
P08309953A0776|6 13|results
P08309957A0000|4 15|experiments
P08309975A0662|0 9|Depletion
P08312243A0177|25 34|influence
P08314163T0000|0 8|Recovery
P08314922A0941|10 16|system
P08316100A0586|4 11|neglect
P08316209A0000|27 33|sulfur
P08316240A1068|0 8|Analysis
P08317092A0304|15 21|region
P08317094A0778|7 11|ends
P08319396A0448|3 5|T2
P08319907A0754|10 23|rap1t alleles
P08320120A0361|11 26|microangiopathy
P08321199T0000|11 20|switching
P08321203A0840|0 14|NF-kappa B p65
P08321227A0854|40 54|culture medium
P08321741A0396|10 15|group
P08322117A1019|8 15|methods
P08322823A0839|19 30|correlation
P08323294T0000|0 57|Chicken sterol carrier protein 2/sterol carrier protein x
P08324107A0000|14 35|albumin concentration
P08324280A0098|6 13|lesions
P08324792T0000|21 27|period
P08325504A0226|8 12|RD19
P08325639A0129|9 16|studies
P08325720A0840|7 14|deficit
P08325883A0368|4 12|sequence
P08327488A0839|14 17|RNA
P08331064A0440|0 7|Release
P08331067T0000|9 28|nucleotide sequence
P08331728A0686|0 7|Binding
P08332033T0000|15 29|quantification
P08332492A0145|4 10|member
P08332495A0408|20 25|level
P08333643A0000|0 13|Pneumoscrotum
P08334158A0660|10 20|gene codes
P08334304A0473|17 22|cells
P08334989A0070|24 33|mechanism
P08335710A0338|4 13|influence
P08336012A0632|4 10|number
P08336543A0243|3 7|mice
P08336698T0000|0 4|TFEC
P08336738A1273|4 14|equivalent
P08337828A0895|8 15|results
P08337841A0612|22 27|cells
P08340400T0000|10 17|cloning
P08342703A0966|9 14|power
P08343041A0000|19 29|antibodies
P08343216A0883|13 35|IgG subclass responses
P08343961A0000|0 21|Anterior body pattern
P08344248A0910|0 5|GAP-N
P08345191A1140|4 20|peptide sequence
P08347677A0308|4 30|phosphorylation efficiency
P08348919T0000|0 15|Botulinum toxin
P08349104A0000|29 33|GAL1
P08349104A0450|18 25|results
P08349499A1169|0 3|Sex
P08349632A0679|0 19|Sequence comparison
P08350061A0209|4 14|mechanisms
P08350398A1616|20 22|ER
P08352066A0000|26 40|beta-estradiol
P08352268A0000|18 32|erythropoietin
P08355062A0000|14 22|emission
P08355063A0456|4 14|rCBF ratio
P08355539A0133|0 7|METHODS
P08355680A0824|0 4|2-AP
P08355696A0236|4 16|UV induction
P08355697A0000|0 29|Protein tyrosine phosphatases
P08355857A1293|3 12|elevation
P08356792A1275|15 27|p21X protein
P08356792T0000|0 22|HTLV-1 gene expression
P08356944A0589|32 60|sodium lauryl sulfate method
P08357834A0285|2 12|comparison
P08360112T0036|0 3|XII
P08360180A1041|19 31|barley PSI-K
P08361754A0733|13 17|hand
P08361755A0734|12 22|conditions
P08361761A0174|18 23|v-Rel
P08363332A0365|17 26|recording
P08365944A1537|0 10|CONCLUSION
P08366034A0637|12 21|existence
P08367388T0035|28 36|syndrome
P08367487A1014|22 30|addition
P08369887A0781|0 11|Differences
P08370119A0642|31 35|exon
P08370119A1521|0 8|Deletion
P08370275A0290|4 14|chimpanzee
P08371650T0000|0 11|Dissipation
P08371713T0000|12 22|transcript
P08371936T0000|15 35|Independence Measure
P08373274A0546|0 11|Polymyxin B
P08373972A0335|0 4|SvO2
P08374753A0335|15 30|relaxation time
P08375651T0000|30 40|chain gene
P08376397A0788|4 23|binding specificity
P08376796A0172|15 25|VH regions
P08377199A1432|24 29|patch
P08378082A1031|6 14|findings
P08380736A0895|9 13|mRNA
P08380896A0938|0 8|Kinetics
P08381121A0773|10 31|transmembrane regions
P08382296A0766|0 10|McCann III
P08382300A0341|6 16|cell lines
P08382303A0507|4 6|E1
P08382303T0000|4 26|E1 replication protein
P08382359A0469|3 8|order
P08382769A0924|21 33|conservation
P08382778A0891|2 8|region
P08383129A0776|18 42|mass polypeptide complex
P08383214A0389|10 18|cleavage
P08383217A0357|32 43|amino acids
P08383287A0611|20 27|element
P08383323A0000|8 18|activation
P08383492A1205|64 74|aa stretch
P08383526A0591|16 21|genes
P08383622T0000|0 8|Identity
P08383850A0206|15 20|study
P08384309A0000|24 47|region/helix-loop-helix
P08385131A0000|4 9|alpha
P08385337A0282|2 21|sequence comparison
P08385581A0126|13 18|genes
P08386279A1621|4 28|transactivation function
P08386280T0000|0 8|Mutation
P08386317T0000|8 30|protein phosphatase 2A
P08386318A1102|13 17|IL-6
P08386319A1229|0 8|Mutation
P08386592A0089|0 25|Growth factor stimulation
P08386637A1220|3 11|contrast
P08387155A1248|17 23|effect
P08387507A1015|4 14|regulation
P08387519A0000|38 43|level
P08387662A0302|6 13|surgery
P08387743A0624|0 11|Replacement
P08387994A0980|4 22|orf61 gene product
P08388496A1117|0 10|Expression
P08388510A0891|0 8|Analysis
P08388543A1263|22 30|receptor
P08388600A0000|0 18|Estrogen treatment
P08389074A1227|0 9|Mutations
P08389365A1344|5 16|observation
P08389453A0193|0 22|Uracil DNA glycosylase
P08390120A0785|17 23|trials
P08390665A0000|0 22|Lithium phthalocyanine
P08390747A0586|8 14|report
P08390831A0143|0 10|Recipients
P08391534A0828|0 7|Elledge
P08391748A0452|0 5|Drugs
P08392221A0449|0 6|Losses
P08392623A1374|0 20|IE2-IE2 interactions
P08393143A1281|4 14|Sp1 region
P08394019A0695|0 13|Precipitation
P08394255A0000|2 7|sheep
P08394464A1080|13 25|Rev proteins
P08394862A0565|6 11|group
P08395004A0141|4 11|ability
P08395004A0558|8 20|localization
P08395010T0000|31 37|heptad
P08395014A1364|8 20|interactions
P08395654T0000|14 20|factor
P08395681A0388|24 35|differences
P08396120A0690|4 33|rhaB transcription start site
P08396261A0388|8 13|lines
P08396657A0452|0 3|Liu
P08396667T0000|0 7|BCR-ABL
P08396713A0305|6 17|experiments
P08396749A1112a|0 15|LDL cholesterol
P08396749A1112b|0 15|LDL cholesterol
P08396913A1379|14 21|element
P08397123T0000|10 18|activity
P08399970T0000|6 33|bioencapsulation technology
P08400240A0166|10 31|hypersensitivity site
P08400928A0318|0 13|INTERVENTIONS
P08401570A0828|27 40|binding sites
P08401614A0187|7 11|bean
P08403245A1234|0 28|Plasma thromboxane B2 levels
P08403804A0754|28 47|regression analysis
P08405433A0000|23 36|growth factor
P08406004A0691|23 42|transfection assays
P08406352A0172|0 13|Army veterans
P08406419A0155|39 49|antibodies
P08406497A0000|0 7|Defects
P08407784A0850|21 25|recJ
P08408194T0000|15 20|roles
P08408825A0000|9 28|lupus erythematosus
P08408841A0281|8 21|abnormalities
P08408963A0048|10 12|L.
P08409284A0262|10 20|absorption
P08409593A0357|3 7|CFDN
P08410042T0000|18 25|disease
P08410097A0356|7 21|mean intensity
P08411024T0000|11 17|people
P08411276A0302|2 9|patient
P08412120A0839|0 4|Skin
P08412620A0688|2 8|region
P08412662A0333|19 25|cosmid
P08412665A0000|4 15|scr regulon
P08413186A0077|23 33|mechanisms
P08413186A1199|4 13|Ntl1 gene
P08413205A0733|10 34|transfection experiments
P08413209A0159|19 24|third
P08413215A0327|21 28|ability
P08413223A0847|14 20|copies
P08413239A0490|34 45|sequence CA
P08413260A1437|6 13|results
P08413274A0452|0 4|MDBP
P08413291A1473|11 15|mice
P08414410A0270|0 7|METHODS
P08414502A0244|20 30|hypothesis
P08415637A0000|4 27|ADP-ribosylation factor
P08415643A0555|4 11|E1 gene
P08415712A1153|8 30|Southern blot analysis
P08416952A0956|10 26|labeling studies
P08416977A0892|6 17|CTD kinases
P08417117A0592|9 13|mRNA
P08417330A0149|34 51|promoter fragment
P08417331A0745|4 12|sequence
P08417349A1633|13 17|data
P08418183A0000|12 19|factors
P08419318A1695|0 4|Biol
P08419333A0126|20 30|expression
P08419338A0273|0 2|L.
P08419376A0357|4 23|nucleotide sequence
P08420230A0544|0 5|SAECG
P08420571A1880|17 22|PACE4
P08421295A0365|5 20|fusion proteins
P08421687A0397|4 27|selenocysteine residues
P08421823A1041|0 11|CONCLUSIONS
P08421897A0000|16 22|decade
P08421910A0599|7 17|components
P08422975A1205|23 32|necessity
P08423831A0523|4 7|use
P08425050A0898|22 28|repeat
P08425221A0000|32 47|tyrosine kinase
P08427501A0221|6 17|differences
P08428722A1123|20 28|analysis
P08428750T0000|0 12|Localization
P08428907A0653|13 25|stage larvae
P08428940A1763|9 15|mutant
P08428952A0399|9 18|L-plastin
P08428952A1957|20 28|evidence
P08428953A1718|5 13|promoter
P08428965A1868|4 13|half-life
P08429019A0735|4 9|DNase
P08429019A2022|13 23|competitor
P08429020A0495|4 8|gene
P08429568A0000|0 18|Rhizobium meliloti
P08430087A0467|13 20|ability
P08430095A0161|5 11|report
P08430095A0913|6 10|data
P08431100A0108|5 10|study
P08432137A0000|16 26|parameters
P08432526A0580|6 11|exons
P08432696A1117|0 8|Deletion
P08435755A0938|3 13|Experiment
P08435755A1078|0 3|PNT
P08435794A0658|0 11|CONCLUSIONS
P08435885A0787|21 32|correlation
P08437521A0000|0 9|Mutations
P08437737A0100|0 15|Naval personnel
P08438584A0524|5 22|promoter activity
P08438584T0000|4 12|activity
P08439564A0883|4 33|amino acid sequence alignment
P08439597A0000|11 24|communication
P08439597A0176|4 14|evaluation
P08440238T0000|2 8|region
P08440688A1509|6 13|studies
P08440720A1404|0 10|Constructs
P08441379A0912|20 36|proIL-1 beta cap
P08441394A1297|11 17|PC-PLC
P08441411A1260|22 33|splenocytes
P08441423A0145|39 43|GCD6
P08441869A0334|4 21|plateau MO2 value
P08442384A0430|35 42|protein
P08442384T0000|4 28|SCH9 protein kinase mRNA
P08443122A0657|3 11|contrast
P08443339A1374|14 26|localization
P08443340A0522|3 8|order
P08443341A0384|0 22|Southern blot analysis
P08444184A0245|0 9|Sudomoina
P08444344A0000|0 12|Zinc fingers
P08444345A0403|19 23|EFIA
P08445299T0000|0 6|Effect
P08445655A1009|0 12|Localization
P08445729A0657|0 11|Replacement
P08445792A0469|0 4|Type
P08446579A0784|12 39|transcription factor Gal-ER
P08446579A1210|14 22|fos gene
P08447005T0001|0 11|Elimination
P08449133A0578|0 14|Endosonography
P08449943A0225|15 20|study
P08449978A0000|0 8|Analysis
P08449986A0455|12 18|clones
P08450015A0175|4 10|method
P08451187A0267|28 39|differences
P08451331T0000|0 8|Pathways
P08453101A0128|0 16|Pokeweed mitogen
P08453950A0498|10 27|seizure induction
P08454077A0956|3 11|contrast
P08454591A0692|0 10|Sequencing
P08454591A1322|4 10|region
P08454858A0285|0 8|Ig-alpha
P08455598A0000|8 15|mutants
P08455611A0000|26 37|interaction
P08455611A0154|26 42|expression assay
P08455623A0630|8 15|results
P08455629A0335|0 9|Breitbart
P08456378A0134|5 10|study
P08456879A0000|0 9|OBJECTIVE
P08457205A0240|9 28|amino acid sequence
P08457291A0170|0 9|Estradiol
P08458660A0855|0 8|Air lead
P08458849A0364|17 27|regulation
P08458906A0827|2 14|micrograms/l
P08459012T0000|8 15|dimelia
P08459465A0257|17 22|study
P08460270A0205|24 34|infections
P08460346A0350|71 76|study
P08460918A0252|0 5|Group
P08461946A0386|20 26|change
P08461981A0882|15 19|need
P08463284A1531|8 12|beta
P08463320A1219|8 42|copper-phenanthroline footprinting
P08463485T0000|0 7|Effects
P08464056A0000|0 6|Finger
P08464056A0510|8 16|evidence
P08464924A0243|2 10|rat cDNA
P08466864A0878|11 19|analyses
P08468320A0941|7 9|J.
P08468475A1280|19 41|internalization assays
P08469831T0001|21 29|dynamics
P08470021A0195|16 26|prevalence
P08470895A1617|0 11|Examination
P08471241T0000|15 24|synthesis
P08471629A0816|0 15|Pseudosubstrate
P08471796A1654|15 22|results
P08472750A0999|7 23|oxide inhalation
P08473731A0149|0 1|B
P08473967T0000|0 10|Bipolarity
P08474438A0000|2 9|variety
P08474439A0877|0 9|Mutations
P08474456A1041|10 31|transfection analysis
P08474464A0348|21 33|relationship
P08475104A0341|28 44|promoter element
P08476087A0814|17 27|influences
P08476854A0097|0 5|DNase
P08479742A0985|30 34|part
P08481004A0321|8 13|clone
P08482539A0913|0 22|Northern blot analysis
P08483412A0000|4 8|nifJ
P08483479A1056|6 10|data
P08484514A1536|28 38|isoflurane
P08484689T0000|0 10|Prevalence
P08484891A0000|31 43|conditioning
P08485317A0000|4 22|fission yeast dsk1
P08486035T0000|0 7|Closure
P08486276A0419|0 19|Sequence comparison
P08486705A0181|4 14|yeast gene
P08488700A0283|4 14|strategies
P08490002A0620|0 6|Xylose
P08491124A0517|14 26|construction
P08491383A0154|4 17|alpha-subunit
P08491383A1291|21 34|alpha-subunit
P08491683A0651|6 14|patients
P08492164T0000|12 24|burst firing
P08492290A0306|31 37|method
P08495786A0085|0 23|Cryopreservation straws
P08496157A0000|4 14|bcl-2 gene
P08496184A0772|16 29|reading frame
P08496185A0484|11 18|cloning
P08496475T0000|0 13|Calcification
P08496599A0310|5 11|result
P08496601A1153|2 12|comparison
P08496848A0692|19 39|contrast differences
P08497190T0079|0 17|Sequence analysis
P08497248A0000|4 8|gene
P08497259A0452|4 9|level
P08497269A0999|5 24|sequence similarity
P08497273T0000|0 5|NF-HB
P08497280A0266|10 20|regulation
P08497280A1397|39 46|pathway
P08497280T0000|35 43|elements
P08498570A1118|3 13|conclusion
P08499376A0000|10 13|PRK
P08499903A0883|6 14|patients
P08499916A0000|4 15|COL7A1 gene
P08500524A0424|9 14|study
P08500938A0408|17 22|grade
P08501030A0456|16 25|induction
P08501678A0498|9 18|knowledge
P08503348A0226|4 32|HMG CoA reductase inhibitors
P08504707A0376|4 12|etiology
P08504928T0000|18 31|TFIID subunit
P08504932A0123|14 20|aspect
P08504933A0000|0 5|Pit-1
P08505075A0236|0 14|Maximum number
P08505312A0285|0 4|Biol
P08505340T0000|0 16|Characterization
P08505495A0253|4 13|retention
P08505605A0461|0 23|Patient characteristics
P08506317A0000|0 7|Members
P08506384A0146|13 18|cells
P08507921A1021|3 13|conclusion
P08508774A0242|0 8|Analysis
P08508778A0112|0 13|Yeast mutants
P08508861A0294|4 12|patients
P08509051A0316|16 24|patients
P08509333A0843|9 16|protein
P08509335T0000|0 4|SSG1
P08509419A0785|0 10|Expression
P08509430A0372|19 34|complementation
P08510320A0000|12 19|strains
P08510320A1249|45 50|MRSAs
P08510647A1347|0 4|Beg2
P08510924A0490|40 55|transactivation
P08511994A0000|36 41|carps
P08512728A0991|0 7|RESULTS
P08513025A0000|15 21|effect
P08514757A1100|5 18|immunophilins
P08514766A0732|4 19|GTPase activity
P08515619A0184|0 19|Tl-201 uptake ratio
P08515776A0971|21 27|domain
P08516301A0080|5 9|gene
P08516308A0669|14 17|RAD
P08516324A0000|22 35|translocation
P08517737A0889|6 14|findings
P08518797T0000|9 27|liver glycogenosis
P08519621A0150|5 15|conclusion
P08519862T0001|0 11|Measurement
P08520646A0000|0 23|Embryo coculture system
P08521414A1384|6 16|cell lines
P08521717A0126|20 28|reaction
P08521780A0485|0 10|Umweltchem
P08522175A0306|0 5|Egd1p
P08522511A1250|9 12|PLB
P08522511A1578|16 23|regions
P08522530A1342|5 14|nifA mRNA
P08523031A0737|24 28|data
P08523545T0000|10 29|papillomavirus type
P08523566A1106|13 22|detergent
P08524036A0747|12 24|expectations
P08524229T0000|0 11|Degradation
P08524235A0695|0 7|Cloning
P08524241A0212|19 28|induction
P08524260A0835|4 20|domain structure
P08524267A1022|11 21|expression
P08524272T0000|13 23|regulation
P08524284A0309|18 27|isolation
P08524292A1022|0 7|Results
P08524294A0652|4 8|skp1
P08524314A0216|4 8|TEA1
P08525186A0288|0 8|Refugees
P08526620A1344|5 10|study
P08528479A0000|0 18|Videonystagmoscopy
P08528796A1470|4 7|MCA
P08529098A0549|9 30|sequence similarities
P08529630A0840|30 44|P protein mRNA
P08529654A0589|4 55|B. germanica cyclophilin amino acid sequence shares
P08529662A0507|42 46|form
P08530105A0308|12 18|region
P08530107A1003|42 52|expression
P08530149A0689|0 10|Comparison
P08530342T0000|10 23|gp39 promoter
P08530345A0880|0 21|Transfection analyses
P08530369A0099|4 8|site
P08530384A0559|21 32|interaction
P08530418A1182|14 18|data
P08530432A0093|8 14|series
P08530503A1004|7 10|ARF
P08531373A0470|44 52|erythema
P08531669A0950|0 11|Competition
P08532516A0000|8 13|paper
P08532536A0925|0 15|TIEG expression
P08532967A0364|14 20|origin
P08533472A0777|14 30|protein products
P08533473A0375|36 45|ADH1 gene
P08533757A0204|5 13|families
P08534217A0402|4 12|subjects
P08534367A0984|0 6|PTP-S3
P08534848A0188a|10 21|NR isoforms
P08534848A0188b|10 21|NR isoforms
P08534855A0000|4 25|Arabidopsis FAD7 gene
P08535138A0857|32 42|leaf cells
P08535537A0000|2 8|survey
P08536694A0000|0 15|Protein kinases
P08537388A0825|31 40|deletions
P08537403A0336|4 26|protein kinase domains
P08538052A0000|20 30|cDNA clone
P08538382A1012|0 14|Erythrocyte AA
P08538483A0207|12 32|consideration weight
P08538702A0214|12 23|polypeptide
P08541499A0306|8 27|transcript patterns
P08541793A0796|12 20|recovery
P08542026A0792|0 3|DAF
P08542027A1471|4 12|XS2 gene
P08542746T0000|0 13|Diabetes care
P08543173A0314|12 20|TATA box
P08543275A0130|17 30|investigation
P08543595A1093|3 10|summary
P08543810A0000|24 29|genes
P08544820T0000|0 16|Characterization
P08545502A0914|6 11|SPECT
P08546707T0000|16 26|activation
P08547205A1060|4 11|results
P08548291A1059|19 29|activation
P08549706T0000|15 42|hepatitis B virus infection
P08549859A1604|4 8|gene
P08550425A1401|15 23|subunits
P08550460A0374|27 31|gene
P08550461A0284|0 6|Cheung
P08550462A0815|0 8|Upstream
P08550467A0863|17 27|regulation
P08550470A1021|12 16|CheW
P08550476A0610|4 12|promoter
P08550564T0000|0 14|CXC chemokines
P08551572A0155|0 21|Oligodeoxynucleotides
P08551577A0000|11 22|replication
P08552042A1497|8 12|case
P08552045A0973|10 29|consensus sequences
P08552082A0480|37 43|region
P08552086A0150|39 65|vitamin D response element
P08552092A1678|3 11|addition
P08552093A0657|0 15|Differentiation
P08552095A0686|27 31|role
P08552095A0758|17 27|abundances
P08552095A1115|0 5|Paf1p
P08552096A0151|18 38|suppression strategy
P08552387A0000|10 26|characterization
P08552643A0261|0 6|Clones
P08552670A0665|0 4|Abp1
P08552670T0000|0 14|Identification
P08553580A0102|13 26|reading frame
P08554069A0743|4 11|patient
P08554540A1480|6 13|regions
P08554723A0187|13 17|rats
P08555076A0333|10 24|Amphotericin-B
P08555168A0390|0 3|Mg2
P08555289A0207|9 25|storm indicators
P08555446A0000|11 25|tobacco plants
P08555498A0427|6 11|LAF-4
P08555597A0808|0 9|Hb levels
P08555753A0591|0 3|CBT
P08556707A1390|6 10|data
P08558187A0403|0 6|Cycles
P08561607A1443|8 13|class
P08561893A0100|17 21|deal
P08561897A0604|0 8|Mobility
P08562688A0968|0 8|Upstream
P08563483A0094|9 14|cases
P08564488A1359|5 22|fibrinogen levels
P08564588A1318|0 21|Strontium chloride Sr
P08565330A1783|27 35|features
P08565548A0196|5 10|study
P08566747A0756|0 3|SBF
P08566751A0455|28 36|question
P08566751A0788|5 13|approach
P08566754A0783|8 28|splice site sequence
P08566756A0752|5 13|analysis
P08566773A1023|16 20|CTS1
P08567556A0000|13 24|consumption
P08567683A0401|10 19|purH cDNA
P08567717T0000|29 68|spindle pole body duplication gene MPS1
P08567847A1005|7 14|opinion
P08569443A0123|4 11|purpose
P08569680A0636|9 21|areA product
P08569684A0000|0 16|Oligonucleotides
P08570615T0000|0 10|Disruption
P08572616A0000|9 13|loss
P08573083A0645|5 11|region
P08573637A0434|4 10|method
P08574414A1037|6 13|primers
P08574583A0658|4 15|Clb5 kinase
P08575609A0526|4 13|C/D ratio
P08575614A0264|0 12|Rad6 mutants
P08575618A1138|0 23|RNase protection assays
P08575754T0000|10 17|cloning
P08576042A0765|0 14|Overproduction
P08576131A0151|24 31|cloning
P08576131A0685|17 35|heterodimerization
P08576179A0126|10 13|PKR
P08576245A0000|0 5|GRP78
P08576262A0160|4 17|IL-8 receptor
P08576546A0975|12 18|series
P08580083A0259|28 40|significance
P08580671A0137|50 55|trial
P08581174A0472|24 32|analysis
P08582143A0614|6 13|studies
P08582633T0000|0 11|Suppressors
P08583783A0870|9 12|ANP
P08583846A0121|7 17|literature
P08583846A0807|13 43|methodology beta-2 transferrin
P08584026A0115|4 15|hIGF-I gene
P08584035A0740|0 25|Gel mobility shift assays
P08584074A0000|11 19|patients
P08584530A0545|12 24|correlations
P08585324A0467|34 43|SSC1 gene
P08585324A0823|5 11|region
P08585639T0000|13 21|exposure
P08585883A0381|0 6|Hybrid
P08585957A0101|5 9|gene
P08585994A0567|6 22|reference probes
P08586643A0951|25 31|enzyme
P08586874T0000|0 7|Studies
P08587075T0000|11 25|microaneurysms
P08588852A0236|21 30|pregnancy
P08589315A1029|19 32|survival rate
P08589358A0235|12 20|units/kg
P08589358A0841|9 16|regimen
P08589735A0577|9 19|constructs
P08590465A0773|4 16|organization
P08591700A0972|4 24|mean body mass index
P08592590A0822|6 14|findings
P08592713T0001|10 21|enantiomers
P08593813A0967|9 17|analysis
P08595012A0817|3 15|nondiabetics
P08595184A0407|5 10|study
P08595414A0000|4 12|assembly
P08595627A1513|5 12|opening
P08595658A0961|4 17|DNA sequences
P08595836T0000|7 16|shrinkage
P08595878A0201|24 32|evidence
P08597108A0642|0 5|QBMDs
P08597177T0000|0 7|Effects
P08597596A0135|4 8|gene
P08597636A0000|10 15|motif
P08598051T0000|10 18|analysis
P08598359X0000|11 25|treatment time
P08598449A0784|3 11|contrast
P08599945T0000|0 9|Mutations
P08599946A0999|4 12|evidence
P08600028A1129|4 8|data
P08600048T0000|17 31|conjunctivitis
P08601283A0875|3 7|view
P08601284A0000|28 34|spacer
P08601490A0659|6 13|animals
P08601616A0726|5 19|spindle defect
P08601806A0875|6 10|data
P08602169A0484|7 19|point mutant
P08602608A1056|27 32|cases
P08603921A1346|17 36|Spc110p truncations
P08604338A0198|5 14|EWS-FLI-1
P08604338A0885|3 31|electromobility shift assays
P08604708A1086|11 18|studies
P08605302A1770|0 15|DNA methylation
P08605324A0434|10 13|LTR
P08605326A0772|12 23|cDNA clones
P08605705A0676|3 13|conclusion
P08605931A0777|0 15|Epitope mapping
P08606267A0740|0 9|Variables
P08608126A0811|7 13|length
P08608222T0000|32 38|region
P08608447A0806|33 50|codon recognition
P08608448A0353|14 22|residues
P08610272A0265|19 33|investigations
P08610328A0228|0 7|SUMMARY
P08610582A0150|11 19|patients
P08611280A0820|12 19|volumes
P08612852A0553|0 7|RESULTS
P08614403A0557|21 27|levels
P08614403A0989|29 57|GAL4-REV-erbA alpha chimeras
P08614410A0000|4 24|alpha T3-1 cell line
P08615012A0627|0 14|Cotransfection
P08615025A1214|13 26|glycosylation
P08615183T0000|0 7|Effects
P08616743T0000|7 12|trail
P08617216A0584|23 27|DnaJ
P08617237A0489|18 30|phosphoforms
P08617238A0334|0 13|TNF Treatment
P08617243A0336|25 32|protein
P08617311A0979|19 38|sequence similarity
P08617800A0150|0 7|Control
P08617800A0675|0 5|DNase
P08617802A0993|6 13|results
P08618433A0000|24 49|growth factor FLT3 ligand
P08618433A1720|3 11|contrast
P08618864A0754|8 16|analysis
P08618882A0343|0 8|Analysis
P08619866A0000|12 42|serum hepatocyte growth factor
P08619910A0000|11 20|mechanism
P08620003T0000|0 16|Protein splicing
P08620856A1172|3 12|agreement
P08620889A0771|22 25|G+C
P08621017A1186|0 8|LY290181
P08621384A0935|0 9|Treatment
P08621420A1166|18 23|bands
P08621448A0862|28 31|DNA
P08621451A0552|0 4|Biol
P08621453A0815|3 11|addition
P08621542A0535|10 25|protein kinases
P08621628A1233|6 13|hGRbeta
P08621659A0189|0 4|Gas6
P08621661A1035|5 22|P5CDh cDNA clones
P08621664A1430|0 14|Polymerization
P08621714A0361|4 11|protein
P08621719A0000|7 13|others
P08621719A0568|14 22|fraction
P08621730T0000|3 24|AP-1 binding sequence
P08622030A0667|15 26|differences
P08622070A0889|9 17|patients
P08622596A0189|4 7|men
P08622645A1026|17 20|VDR
P08622668A1155|6 13|results
P08622675A0587|0 9|Inclusion
P08622698T0000|20 26|Notch1
P08622887A1026|16 37|mobility shift assays
P08622893A0000|10 19|subfamily
P08623554A1058|11 18|protein
P08624445A0257|35 54|sequencing analysis
P08625806A0263|0 7|Krox-20
P08625900T0000|10 19|adenylate
P08625924A0411|0 10|Clones 33F
P08625987A1086|10 38|bone marrow cells expression
P08626065A0000|39 56|Bacillus subtilis
P08626290T0000|0 21|Aeromonas salmonicida
P08626313A1037|0 10|Expression
P08626325A0543|3 12|agreement
P08626437A0332|0 10|Lyn kinase
P08626493A1468|0 9|Mutations
P08626529A0000|6 20|autoantibodies
P08626529A0799|28 35|regions
P08626539T0000|0 19|Binding specificity
P08626540A1007|42 56|concentrations
P08626596A0000|17 25|evidence
P08626610A0931|16 27|suppression
P08626612A1040|0 2|Am
P08626667A1372|0 28|EMSA competition experiments
P08626667A1517|0 13|Transcription
P08626698A0989|21 29|increase
P08626777A0537|0 17|Sequence analysis
P08626785A0674|19 29|activation
P08626809A0729|15 19|pPKR
P08627354A0000|11 20|synapsins
P08627649A0734|16 37|mobility shift assays
P08627667A0132|0 5|ZEBRA
P08627688A1520|5 11|result
P08627719A0784|0 28|UV cross-linking experiments
P08628251A1455|0 7|CM-ACO3
P08628254A0665|24 40|Jun/eb1 chimeras
P08628255A0932|16 26|HeLa cells
P08628260A0895|20 40|transfection studies
P08628284A0181|17 38|yeast reporter strain
P08628302A0683|3 10|hnRNP K
P08628681A0364|32 39|kb mRNA
P08628681A0821|0 21|Sequence conservation
P08629348A0237|31 38|history
P08630542A1421|6 14|findings
P08630548A0000|8 17|cytokines
P08630583A1056|3 5|pH
P08630599A0534|3 13|difference
P08631667A0851|0 14|Identification
P08631685A0000|15 19|gene
P08631760A0609|5 16|interaction
P08631797A0982|16 22|ErbB-2
P08631817T0000|0 14|Identification
P08631820A0755|4 8|cDNA
P08631822A0677|13 30|plasmin fragments
P08631908A0224|0 7|VDR/RXR
P08631934A0000|4 11|members
P08631944A0663|3 11|contrast
P08631958T0000|6 21|cytomegalovirus
P08632009A1067|4 15|specificity
P08632015A0879|4 14|antibodies
P08632015A1226|19 27|analysis
P08632018A0587|2 14|DNA fragment
P08632463A1508|5 11|result
P08632779A0351|4 15|XPG regions
P08633855A1064|4 13|lacS gene
P08634290A0000|4 10|genome
P08634357A0527|4 23|extraction recovery
P08634420A1784|0 10|HuEpo-R Ab
P08634423A0498|4 13|frequency
P08634697A1155|4 12|sequence
P08635771A0000|2 7|study
P08636031A1413|0 11|Interaction
P08636124A0410|5 12|protein
P08636149A0220|12 21|receptors
P08636211A0983|0 7|EMBO J.
P08636428A1363|20 27|results
P08637006A0000|0 13|Transcription
P08637711A1121|32 36|IL-6
P08637717A0817|9 16|peptide
P08637717A1231|2 13|p21 peptide
P08638435A0522|0 7|Results
P08639310A0548|0 3|OND
P08639521A1032|12 22|properties
P08639561T0000|0 9|Adduction
P08639742T0000|0 9|Isolation
P08639837A0268|5 13|fragment
P08640866A0473|0 8|Exposure
P08641705A0986|16 28|observations
P08642282A1009|18 29|description
P08642285A1548|0 18|DNA-STAT complexes
P08642313A0770|37 46|cell line
P08642313T0000|0 6|T cell
P08642693T0000|0 22|Polyprotein processing
P08643111A0855|14 17|LL2
P08643382A0752|23 38|transit peptide
P08643513A0361|0 17|Deletion analysis
P08643557A0259|17 25|question
P08643578A0000|0 9|RAS2val19
P08643578A0532|14 38|Rho family protein Cdc42
P08643633A1187|5 22|immunoprecipitate
P08643646A0479|5 11|region
P08643682A0268|12 25|localizations
P08643759A0338|16 21|phase
P08644734A0404|14 23|isolation
P08645214A1052|17 21|BL21
P08645219A1377|0 3|Ca2
P08647086A0622|0 4|Cdk2
P08647086A0720|4 26|Cdk2-cyclin-D1 complex
P08647086T0000|17 25|kinase-2
P08647091A0592|16 22|clones
P08647264T0000|0 8|Ligation
P08647434A1124|6 15|T antigen
P08647451A0663|0 27|Northern blot hybridization
P08647802A0000|20 37|signaling protein
P08647822T0000|9 13|role
P08647884A0547|34 43|reticulum
P08648408A0792|9 12|PHT
P08648665A0956|10 23|LE6 deletions
P08648665A1320|0 15|ORF E8 colinear
P08648726A0713|0 7|Cloning
P08649372A0501|0 17|Clb2/Cdc28 kinase
P08649372A0755|4 20|carboxy terminus
P08649373T0000|25 37|cis elements
P08649386A1032|6 29|UASH consensus sequence
P08649389A0000|36 52|CTCF cDNA clones
P08649389A0692|11 19|analysis
P08649393A0000|2 34|chromosome transmission fidelity
P08649403A0963|4 17|growth defect
P08649405T0000|0 3|Sp1
P08649424A0000|0 10|Expression
P08649425A0373|18 20|bp
P08649425T0000|28 47|chromatin structure
P08649427A0689|19 33|identification
P08649428A1227|8 13|study
P08649440T0000|4 17|heterogeneity
P08649773A1374|4 11|ability
P08649841A0956|17 21|uORF
P08650818A0000|12 18|spread
P08651853A0607|16 25|sclerosis
P08651853T0000|16 25|sclerosis
P08652081A1953|22 28|events
P08654200A0274|20 37|resonance imaging
P08654375A0544|13 21|analysis
P08654390A0000|0 14|Heme oxygenase
P08654435A0540|12 18|analog
P08654946A0475|4 6|aa
P08654946A0986|4 29|transcription start point
P08654972A0000|0 7|Defects
P08654983A0000|17 44|signal recognition particle
P08655497A0000|8 12|gene
P08655555A0772|3 11|addition
P08655555A1368|4 16|DNA sequence
P08656672A0678|12 35|ufo mRNA overexpression
P08657135A1444|23 30|studies
P08657150A1049|4 8|role
P08657157A0000|16 26|regulators
P08657183A0145|9 15|strand
P08657918A0360|0 9|MATERIALS
P08659545A0000|6 12|effort
P08660733X0000|12 23|populations
P08660748X0000|4 9|model
P08660866A0504|13 22|positions
P08660892A1044|16 24|blockade
P08660998A0851|4 19|mMIWC1 promoter
P08661007T0000|6 17|MN/CA9 gene
P08661100A0285|16 28|distribution
P08661101A0396|0 21|DNA sequence analysis
P08661104A0687|4 8|gene
P08661114A0564|14 21|domains
P08661116A0963|0 17|Promoter activity
P08661119A0085|27 53|EP4 receptor gene sequence
P08661613A0691|5 10|users
P08662193A0404|15 36|activation subdomains
P08662499A0484|4 9|front
P08662617A2051|20 24|data
P08662789A0673|18 22|gene
P08662852A1297|4 12|location
P08662928A1153|5 15|regulation
P08662928T0000|0 9|Receptors
P08662936A0428|26 51|FR-19 amino acid sequence
P08662980A0762|5 15|phenomenon
P08663000A0000|4 12|receptor
P08663120T0000|10 15|Raf-1
P08663127A0697|11 19|analysis
P08663141T0000|13 24|DNA element
P08663172A0311|5 12|protein
P08663219A0246|4 12|promoter
P08663310A0157|9 12|SRF
P08663326A0000|28 42|DmpR activator
P08663392A0215|8 13|study
P08664229T0000|9 19|evaluation
P08664347A0923|0 4|None
P08664462A1404|6 13|changes
P08664667A0093|9 14|Delhi
P08665853A0228|33 38|cells
P08666102A0820|0 4|ZIOS
P08666238T0000|10 32|translation initiation
P08666241A0930|40 46|region
P08666383A1252|6 14|findings
P08666398T0000|0 3|YAC
P08666404A0311|0 9|Isolation
P08666913A0000|0 5|Ly-49
P08668124A0744|4 14|Dox-A2 ORF
P08668142A1048|4 16|introduction
P08668158A0765|4 8|data
P08668158A1252|13 20|strains
P08668190A1364|9 26|membrane vesicles
P08668201A1059|9 20|mutagenesis
P08668203A1230|0 3|FTF
P08668209A0406|0 6|Merlie
P08668210A0000|12 20|evidence
P08669274T0000|11 29|chain ossification
P08669676A1644|4 13|incidence
P08670556A0425|5 15|micromol/1
P08670853A0000|0 17|Cluster formation
P08670910A0156|0 16|DNA polymerase E
P08672242A0517|9 33|reporter gene constructs
P08673026T0000|4 20|factor structure
P08675026A0420|62 75|sequence tags
P08675395A0751|0 7|RESULTS
P08675608T0000|0 7|Outcome
P08675763A0788|0 13|Mean increase
P08675769A0158|10 15|rates
P08675821A0657|12 16|EMPD
P08676266A0838|4 15|mean values
P08676383A0518|5 18|half molecule
P08676454A0731|21 24|Pra
P08676456A0879|11 29|VP16-Tat construct
P08676495A0129|16 27|splice site
P08676858A0309|10 17|cloning
P08676858A1084|15 19|tree
P08677443A0238|5 27|Hoosier Oncology Group
P08677678A0258|18 32|administration
P08678959A0640|0 22|Sestamibi scintigraphy
P08679131T0000|7 14|allergy
P08680702A0548|20 29|lethality
P08680706A0889|8 9|h
P08682155A0902|4 30|euglobulin clot lysis time
P08682317A0900|0 15|HS inducibility
P08682868A0738|13 28|DSK2-1 mutation
P08683106A0374|9 13|IL-2
P08683108A0965|21 35|interpretation
P08683108A1501|20 27|results
P08683983A0785|4 11|complex
P08683983A1163|4 11|results
P08684522A0415|0 29|Immunofluorescence microscopy
P08684742A0000|0 9|OBJECTIVE
P08686381A0527|6 10|ORFs
P08688190A0000|8 26|flavone glucosides
P08688556A0242|14 24|laboratory
P08689520T0000|0 19|Reproductive period
P08690118A0845|13 32|regression analysis
P08690198A0346|0 7|METHODS
P08691106A0733|9 19|D8 binding
P08691962T0000|8 12|role
P08692885A0663|4 11|ability
P08692892A0330|4 11|Pro-258
P08692924A0328|11 23|DNA sequence
P08697728A1199|15 20|value
P08698756A1240|0 11|CONCLUSIONS
P08700531A1420|8 20|chromosome X
P08702517A0000|5 11|screen
P08702543A0000|0 4|Gap1
P08702556A0000|28 40|purification
P08702633A0164|4 13|mechanism
P08702644A0499|2 6|cDNA
P08702728A1325|40 43|Shc
P08702756A0000|10 20|GTPase Rho
P08702807A0964|12 22|activation
P08702826A0870|22 31|insertion
P08702845A0000|3 8|order
P08702936A0168|3 21|expression library
P08702936A0984|25 29|TARC
P08703005A0645|15 23|elements
P08703010A0905|43 50|element
P08703908A1814|18 26|findings
P08703959A0659|34 51|proton resonances
P08704124A0420|21 30|fragments
P08704240A1111|12 22|TF-1 cells
P08705056T0000|0 18|Workplace violence
P08706368A1024|0 7|RESULTS
P08706662A1125|4 11|results
P08706731A1303|41 53|similarities
P08707424A0709|4 14|expression
P08707516A0194|8 17|estimates
P08707825A0063|37 49|muscle cells
P08707840A0753|17 36|electron microscopy
P08707846A2308|33 39|uptake
P08707922A0334|0 30|Transcription initiation sites
P08708984T0000|12 19|process
P08709224T0000|13 18|virus
P08709245A1521|4 11|studies
P08709251A0000|11 24|recombination
P08709637A1471|4 8|data
P08709831A0599|17 24|potency
P08710151A0782|31 36|value
P08710371A0000|26 37|interaction
P08710371A0499|0 9|Site S-II
P08710377A0577|0 3|Cbl
P08710504A0995|0 10|Activation
P08711631A0989|0 9|Treatment
P08712799A0123|8 16|attempts
P08713933A0606|0 21|Laboratory evaluation
P08716757T0001|0 24|Microcomputer management
P08717391A0466|6 12|fusion
P08717559A0223|13 19|dosage
P08719155A0105|29 36|cloning
P08719156A0953|13 20|introns
P08719697A0221|0 7|METHODS
P08719832A0397|4 14|experience
P08720407A1386|0 10|CONCLUSION
P08721526A0000|28 37|allergens
P08721989A1012|4 11|results
P08721999A0432|3 11|addition
P08721999A0727|0 3|U24
P08722011A0103|5 12|complex
P08722568A1001|0 20|Chromatin repression
P08723352A0084|5 15|transition
P08723365T0000|9 21|relationship
P08723883A0823|0 21|Blood GSH-Px activity
P08723883A1684|4 18|concentrations
P08726024A0244|6 10|cats
P08726024A0532|26 29|PCR
P08726247A0175|23 44|concentration changes
P08727192A0000|0 12|STUDY DESIGN
P08727992A0570|14 23|injection
P08728040T0000|13 23|activation
P08730470A0000|17 26|agreement
P08731155A0499|4 9|weeks
P08731222A0000|4 16|distribution
P08731511A0625|4 10|levels
P08732665A0000|0 13|Amplification
P08733123A0000|29 38|dystrophy
P08733123A0951|11 21|chromosome
P08733874A0000|0 8|Patients
P08733881A0343|5 29|thyroid function testing
P08734538A0613|11 21|experiment
P08738510A0254|13 29|tumor FDG-uptake
P08739209A0700|0 11|Zatebradine
P08739260T0000|0 5|Catha
P08740416A0239|14 21|protein
P08740416A0919|4 18|SEB1 homologue
P08741206A1551|30 39|afferents
P08741280A0374|6 10|ones
P08742135A0000|0 9|Fragments
P08742385A0211|18 24|causes
P08745669A0000|10 18|patients
P08746605A0377|20 23|use
P08746981A0154|5 15|treatments
P08747078T0000|9 16|aspirin
P08747343A0790|0 13|Protein films
P08748033A0874|13 17|cpxA
P08749393A0783|4 17|PI3K_68D cDNA
P08749394A0874|9 28|interaction studies
P08750173A0000|0 12|AIMS/METHODS
P08750190A0000|4 14|laboratory
P08750702A0183|0 12|Study groups
P08751635A0135|28 34|damage
P08752714A0000|4 14|occurrence
P08754777A1214|4 9|upTRE
P08754802T0000|16 23|control
P08754827A0231|0 6|Hoeben
P08754834A1097|15 24|fragments
P08754840A0793|10 34|glucan synthase activity
P08754852A0960|3 25|gel retardation assays
P08755898A0339|4 11|classes
P08756332A0000|0 7|Members
P08756433A0282|10 26|characterization
P08756556A0406|4 8|cDNA
P08756597A0854|0 7|Mutants
P08756609A0498|12 31|amino acid sequence
P08756617A1204|0 4|Biol
P08756636T0000|13 22|mutations
P08756642A0230|0 11|Alterations
P08756712A0227|9 16|studies
P08757265A0466|0 7|Neurons
P08757943A0876|5 9|site
P08759870A1128|4 10|extent
P08760286A0696|15 25|similarity
P08760776A1559|0 10|CONCLUSION
P08760872A0696|4 11|results
P08760889A0170|4 14|cDNA clone
P08760889A0531|0 10|Comparison
P08761169T0000|17 28|dysfunction
P08761480A0331|0 11|Interaction
P08762021A0156|29 37|measures
P08762172A0178|6 24|strain differences
P08762472A0000|4 10|effect
P08763207A0402|10 24|oxidation peak
P08763311A0189|0 13|Phenylephrine
P08763925A0588|4 14|expression
P08763953A0805|4 8|unit
P08764015A0284|0 2|A.
P08764136A0000|6 12|effort
P08766049A0000|0 11|CASE REPORT
P08766781A0322|12 18|period
P08768374A0765|4 8|P-wr
P08768377A1387|12 24|hcf109 locus
P08769132A0000|10 28|MSH-2 gene product
P08769409A0114|48 58|expression
P08769566A0000|30 34|cDNA
P08769568A0949|4 13|structure
P08770021T0000|10 26|PTHRP production
P08770896A1121|20 29|secretion
P08770920A1220|15 27|coexpression
P08770981A0328|4 12|patients
P08771781A0103|6 13|attempt
P08771781A1103|4 22|ORFII gene product
P08771787T0000|0 16|Characterization
P08774732A0271|16 19|Sp1
P08775674A0000|0 10|OBJECTIVES
P08776735A0000|25 31|kidney
P08776748T0000|8 23|P300 amplitudes
P08776792A0626|0 5|Sleep
P08776793A0811|4 12|patients
P08776901A0000|0 19|Chloroplast mutator
P08777374A1471|7 21|concentrations
P08778265A0422|21 33|test battery
P08778700A0476|16 20|case
P08780339A0142|16 28|single-blind
P08781119A0723|16 22|region
P08781144A1520|5 8|18F
P08783180A0000|9 16|methods
P08783666A0957|3 11|addition
P08784787A0383|14 31|thrombin receptor
P08787110A0981|17 21|CPET
P08789441A0339|6 18|fluorescence
P08790288A0068|27 36|isolation
P08790291A1022|4 8|data
P08790387A0299|7 21|rat rnu allele
P08792217A1407|8 16|increase
P08793029A0246|0 7|Control
P08793693A0237|0 6|DESIGN
P08794254A2957|7 10|SPK
P08794326A0405|43 50|element
P08794339A1162|13 20|binding
P08794348A1067|13 34|complementation assay
P08794363A0259|7 12|basis
P08794547A0648|4 8|rCBF
P08794547A1403|15 22|vessels
P08794601A0000|11 22|combination
P08794869A0274|8 13|lines
P08795304T0000|0 21|Plasma thrombomodulin
P08797362T0037|0 6|Update
P08798420A0207|4 20|characterization
P08798443A0660|0 6|Serine
P08798443A1218|4 15|DNA binding
P08798512A1197|4 10|amount
P08798610A0843|0 4|PIP2
P08798635A0870|9 19|spleen GAP
P08798641A0400|0 4|Biol
P08798643T0000|32 38|domain
P08798648A1816|0 7|Cys-757
P08798700A0134|4 17|transcription
P08798762A1279|16 23|results
P08798782A0976|0 3|Lck
P08798893A0611|13 21|freezing
P08801403T0001|20 28|effusion
P08803710A0701|10 19|survivals
P08803845A0665|4 12|presence
P08804012A0662|12 22|categories
P08804389A0893|0 22|Northern blot analysis
P08805338A1061|9 19|disruption
P08805824A1155|17 20|use
P08806491A0542|0 11|Transcripts
P08806693A0584|3 8|order
P08806817A0244|0 17|Sequence analysis
P08806817A0716|8 25|DNA hybridization
P08807245A0843|7 27|retrospective review
P08807288T0000|0 9|Isolation
P08807408A0524|0 7|METHODS
P08808120A0774|0 8|Patients
P08808275A1193|13 30|RAD23 equivalents
P08808707A0631|0 9|Ha-RasV12
P08808756A0587|0 17|Sequence analysis
P08808924A0326|4 22|hydropathy profile
P08808927A0417|9 16|HindIII
P08808939A0000|0 28|Carbon catabolite repression
P08809680T0000|0 9|Melatonin
P08810040A0955|13 19|screen
P08810278A0682|42 49|protein
P08810323A0735|15 35|polyglutamine motifs
P08812012T0000|4 11|effects
P08812020A0597|11 21|experiment
P08812106T0000|0 9|PCNA mRNA
P08812490A0000|9 19|cDNA clone
P08812490A0542|0 26|PCR/Southern blot analysis
P08812490A1509|9 26|sequence homology
P08813766A0605|10 13|ORF
P08813900A1088|7 14|phytase
P08814651A0000|4 14|importance
P08816052A0238|0 4|Data
P08816438A0316|13 21|analysis
P08816443A1674|24 33|ROK alpha
P08816452A0936|6 14|findings
P08816453A0000|4 13|elevation
P08816459A0090|3 21|interaction screen
P08816460A1769|6 13|results
P08816461A0892|4 12|analysis
P08816472T0000|0 14|Identification
P08816482A0234|20 28|variants
P08816483A0869|0 9|Mutations
P08816498A0000|4 33|serine/threonine kinase Raf-1
P08816504T0000|17 23|growth
P08816507A1125|13 32|cotransfections E1A
P08816759A0000|4 28|retinoid Z receptor beta
P08816792A0000|14 28|protein kinase
P08817323A0714|16 33|sequence identity
P08817324A1070|0 10|Sequencing
P08818436A0557|27 35|analysis
P08818718A1229|41 50|injection
P08820324A1699|4 10|limits
P08820642A0173|20 29|hrpZ gene
P08820648A0123|12 20|presence
P08822208A1364|16 23|results
P08822399A0518|13 20|factors
P08823163T0000|16 25|structure
P08823187A1020|0 9|Titration
P08823260A1161|0 4|FEV1
P08823646A1012|0 14|Administration
P08823709A0220|0 7|Therapy
P08824201A0270|0 8|Chernoff
P08824585A0260|23 37|protein kinase
P08824798A0761|6 23|ESP1/CRP2 protein
P08824800A0808|4 13|fragments
P08824805A0832|15 30|exon boundaries
P08824881A0133|0 15|Linkage studies
P08824884A0000|16 26|expression
P08825087A0213|0 21|DNA sequence analysis
P08825178A0071|12 32|inpatient experience
P08825554A0000|0 15|Tristetraprolin
P08825556A0522|5 12|element
P08825633A0304|0 8|Analysis
P08825636T0000|25 34|structure
P08825639A0827|12 30|Alu repeat element
P08827783A0499|4 8|ewes
P08828142A0000|7 23|leukemia viruses
P08828152A1238|0 10|Comparison
P08828152A1825|4 8|RPO1
P08828857A2423|4 7|use
P08829393A0083|13 30|dipole estimation
P08831364A1252|5 14|verapamil
P08832146A0959|9 12|CBD
P08833153A0628|3 11|addition
P08833653A0304|22 55|LIM domain homeobox protein isl-1
P08833653A0783|9 14|isl-1
P08835393A2829|24 32|pathways
P08835895A1292|4 13|CD4 count
P08835969A0000|20 31|laparoscopy
P08836032T0000|0 15|Bifunctionality
P08836172A1382|0 3|RVR
P08836740A1025|8 12|CES1
P08837503A0392|10 23|repeat motifs
P08837746A0951|6 9|use
P08838144A0107|26 38|significance
P08838148A1218|22 31|cell line
P08838314A0129|26 36|expression
P08838585A0968|20 29|structure
P08838805T0000|8 20|organization
P08839498A0507|35 47|distribution
P08839832A0729|20 33|CD30v protein
P08839832A1220|13 28|phosphorylation
P08839911A0716|4 5|%
P08840501A0345|19 28|discovery
P08840506A0544|11 15|ORFs
P08840997A0765|0 10|MVR typing
P08842143A0000|0 14|Plasmid pAL618
P08843411A0801|4 11|classes
P08843412A0543|32 52|40-amino acid region
P08843419A1290|0 3|OKA
P08844448A0000|55 70|crossover study
P08844577A0000|0 10|Tilmicosin
P08844712A0000|0 6|Effect
P08845378A0368|0 26|Restriction enzyme mapping
P08846775A0110|7 14|absence
P08847138A0609|4 19|detection ratio
P08847403T0000|9 16|embryos
P08847723A2351|0 12|IMPLICATIONS
P08848013A1469|17 25|TATA box
P08848052A0733|6 16|properties
P08849208A1022|0 8|Demispan
P08849569A0615|4 14|techniques
P08849778A0226|18 38|toeprinting analyses
P08849778A0598|9 13|work
P08849834A0000|2 8|system
P08850585A0602|4 21|enzyme activities
P08851337A1092|0 13|Tonsillectomy
P08851434A0383|8 12|mice
P08853303A0431|16 26|parameters
P08853893A0158|8 13|study
P08854459A0000|5 10|paper
P08854844A0637|16 23|finding
P08855804A1528|6 13|results
P08856077T0000|12 22|processing
P08856132T0000|0 8|Evidence
P08858211A0694|5 17|GAP activity
P08858268A1307|0 10|CONCLUSION
P08858463A0853|21 34|AIDS patients
P08861955A0927|31 36|motif
P08861963A0375b|18 33|RNA polymerases
P08861963T0000|0 40|Transcription factor recognition surface
P08862522A0690|21 31|similarity
P08862743A0603|2 10|decrease
P08863824A0509|0 7|Cloning
P08864061A0000|0 10|Expression
P08864219A0178|23 37|concentrations
P08866485A0125|6 14|bacteria
P08867519A0557|4 14|elevations
P08868473A1287|15 18|p28
P08868660A0087|9 12|aim
P08868954A0648|32 39|effects
P08869358A0121|11 18|viruses
P08869763A0378|43 52|phenomena
P08869825A0000|9 16|studies
P08870266A0651|22 34|observations
P08871542A1352|18 27|potential
P08871567A0000|0 13|MSSP proteins
P08871567A0629|0 4|Gene
P08871635A0000|0 23|B cell antigen receptor
P08872162A0884|5 12|alleles
P08872671A0573|4 9|model
P08873063A0493|12 31|amino acid sequence
P08873063A0875|0 14|ECM disruption
P08873159A0791|20 28|patients
P08874399A0277|6 10|days
P08874631A1133|0 14|Discrimination
P08876167A0322|34 41|subunit
P08876167A0717|4 10|HiNF-D
P08876701A0177|30 42|UmuC-homolog
P08877103A0081|13 23|regulation
P08877818A0184|4 17|amplification
P08878019A0357|27 32|cells
P08878037A0000|4 13|gene ccpA
P08878044A1390|3 23|InlC deletion mutant
P08878045A0606|10 23|N-Nus complex
P08878573A1370|0 14|Administration
P08879080A0265|11 16|ACOAs
P08879237A0744|13 29|initiation sites
P08880405A1170|0 9|Selection
P08881036A0351|15 18|PCR
P08881542T0000|0 38|Sodium polystyrene sulfonate treatment
P08882492A0000|14 34|homeodomain proteins
P08882710A0000|0 10|Interferon
P08884273A1413|4 20|TYAC/P1 resource
P08884757A0653|13 23|statistics
P08885270A0428|6 13|mutants
P08886845A1274|33 50|myogenin promoter
P08887643A1167|33 40|signals
P08887647T0000|0 18|Fission yeast mal2
P08887652A0341|0 9|Selection
P08887659A0753|0 9|Mutations
P08887661A0138|0 5|IRF-1
P08887661A1061|3 11|contrast
P08887667A0992|4 15|requirement
P08887674A0630|2 8|subset
P08887674A0920|8 16|settings
P08887678A0000|0 10|Expression
P08890537A0355|5 14|technique
P08891131A0000|0 28|Enterococcus faecium strains
P08891337A0614|19 25|region
P08891341A0724|10 29|transfection assays
P08891345A0684|19 37|UTR characteristic
P08891346A1217|26 32|effect
P08891474A0667|6 14|findings
P08892755A0186|3 11|addition
P08892755A0981|10 22|DNA fragment
P08892757T0000|10 17|cloning
P08892859A0563|13 20|example
P08893779A0229|23 59|digitorum longus muscle tendon units
P08893822A0560|0 17|Northern analysis
P08894144A0330|47 51|rats
P08894144A1173|0 3|CsA
P08894826A0228|0 11|Individuals
P08895522T0000|10 20|activation
P08895579A0583|0 17|Northern blotting
P08895997A0336|0 7|Physiol
P08896272A0000|4 23|nucleotide sequence
P08896280A0860|41 47|levels
P08896402A0587|8 18|FL protein
P08896473A0282|4 13|objective
P08896590T0000|8 13|exons
P08896795A0166|6 11|Spurr
P08896804A0000|12 17|study
P08897663T0000|11 16|Tower
P08897721A0000|0 9|Infection
P08898336A0268|0 25|RNase protection analysis
P08898365A0274|0 5|Rss1p
P08898866A0458|23 50|serine phosphorylation site
P08898893A0202|4 14|PAI-2 gene
P08899719A0318|10 17|contigs
P08900164A0188|0 2|T.
P08900190A0430|0 14|Growth factors
P08900296A0000|4 17|up-regulation
P08901135A1132|4 16|NIT2 protein
P08901635A0000|3 8|spite
P08901658A0498|9 18|responses
P08902214A1486|12 18|period
P08902548A0144|16 30|administration
P08902641A0930|7 18|VA-SMV mode
P08902847A1946|4 12|evidence
P08902988A0258|0 15|Factor V Leiden
P08903339A0264|18 31|determination
P08905819A0531|4 12|majority
P08906056A1290|6 14|patients
P08906139A2935|5 16|observation
P08909546A0810|19 23|PEA2
P08910292T0000|0 9|Signaling
P08910373A0315|0 18|Percent identities
P08910550A0501|30 41|observation
P08910567A2269|10 23|gene fragment
P08912232A0260|12 16|role
P08912807A0411|23 36|deer receptor
P08913186A0431|5 11|report
P08913387A1010|0 9|Rifabutin
P08913974A0533|12 19|percent
P08914388A1645|4 14|assessment
P08914522A0118|4 14|STE20 gene
P08914532A0598|5 11|enzyme
P08915051T0000|9 26|resonance imaging
P08915508A0000|0 7|Moloney
P08915559A0366|0 21|REM sleep deprivation
P08916928A0950|9 16|ligands
P08916960A0350|19 35|biopsy specimens
P08916960A1331|13 18|cases
P08917270A0229|0 10|BACKGROUND
P08917435A0481|13 17|role
P08917449A0000|20 26|factor
P08917696A0485|15 24|mechanism
P08918456A0455|12 20|sequence
P08918464A0225|19 24|Ba/F3
P08918810A0967|9 14|DNase
P08918885A0811|0 4|Kss1
P08918885A1087|3 11|contrast
P08918918T0000|10 20|activation
P08918934A0424|0 10|Comparison
P08919289A0402|18 24|report
P08919907A0763|10 20|expression
P08919986A1262|11 15|mind
P08920499A0164|0 25|Blood sampling procedures
P08921387A1182|0 8|Analysis
P08921667A0294|17 31|input function
P08921865A1293|39 41|ss
P08922344A1539|41 49|subjects
P08922384A0466|0 14|Immunoblotting
P08922385A0622|36 46|inhibition
P08922390A0361|12 17|study
P08922390A0793|6 10|data
P08922390A2076|6 10|data
P08922391A0304|28 37|structure
P08922488A0187|8 14|agents
P08923258A0353|0 7|Jerseys
P08923460A0565|0 11|RUSH-1 beta
P08923469A1391|6 13|results
P08923470A0458|0 22|PPAR gamma mRNA levels
P08924211A0941|0 5|Exons
P08924381T0000|0 13|Growth factor
P08925545T0001|12 26|erythropoietin
P08927169A0178|21 30|infection
P08927612T0000|11 24|p53 mutations
P08927841A0053|16 20|data
P08929089A0231|13 23|ratio M/Pc
P08929563T0000|0 18|Rat liver catalase
P08931388A0806|4 24|mobility shift assay
P08931991A1026|6 10|data
P08932363A0807|9 23|E1A N-terminus
P08932385T0000|6 18|Maf proteins
P08933487A0325|13 27|occasion water
P08933640A0000|4 10|effect
P08934533A0784|19 28|mutations
P08934540A0673|4 11|nm23-H1
P08935931A0787|0 10|CONCLUSION
P08935991A0844|4 33|nucleotide sequence alignment
P08936128A0611|0 11|Discordance
P08936640A0105|0 12|DATA SOURCES
P08937112A0561|0 7|RESULTS
P08937631A1223|13 20|changes
P08937981A0840|13 26|co-expression
P08937989A1365|4 11|results
P08938418A0099|0 4|Merr
P08938420A0862|4 16|accumulation
P08939891A0285|10 15|yeast
P08939966A0816|7 11|rate
P08940132A1120|6 14|findings
P08940134A0705|3 6|3Y1
P08940298A0962|10 18|residues
P08942999T0000|10 29|G-to-A substitution
P08943032A0000|21 34|tet-repressor
P08943354A0295|7 14|studies
P08943928A1137|0 14|Administration
P08943934A0604|8 17|Theriault
P08944755A0211|0 4|Biol
P08945479T0000|11 16|basis
P08945810T0001|10 20|morphology
P08946166A0568|11 18|results
P08946668A0077|0 5|FK506
P08947028A0992|6 13|results
P08948440A0628|4 26|ERH expression profile
P08950144A0172|0 8|Waves N1
P08950352A0525|45 52|samples
P08951815A0465|0 10|Regulation
P08952483A0207|19 27|features
P08952796A0743|17 22|years
P08952965A1182|0 10|Comparison
P08953340A0000|4 11|effects
P08954725A1175|9 20|development
P08955071T0000|0 10|Disruption
P08955111A0989|4 11|results
P08955136A0606|35 46|PIP5KIalpha
P08955159A0000|6 21|acid ceramidase
P08955189A1198|12 31|NheI/BglII promoter
P08955306A0224|0 8|Northern
P08955402A0288|4 11|classes
P08955928A0390|0 6|Damage
P08958137A0534|0 26|Lipid hydroperoxide levels
P08958720A1204|9 15|degree
P08959062A0372|12 16|case
P08959117A0708|41 48|changes
P08959778A0292|26 37|differences
P08960827A1169|6 13|results
P08961873T0000|17 38|coproporphyrin levels
P08962614A0000|4 17|determination
P08964067A0188|0 10|Thrombosis
P08964172A0221|0 6|Filter
P08967870A0000|12 21|protocols
P08967963A1735|4 20|promoter segment
P08969495A0256|4 14|sequencing
P08969777A0771|23 29|scores
P08970352A0880|6 10|data
P08970951A0823|29 35|levels
P08970979A1246|3 11|contrast
P08970984A0765|4 18|SCMV SNE sites
P08970991A0747|5 21|serum withdrawal
P08971009A0860|19 26|problem
P08971721A1314|7 12|basis
P08971835A1057|3 8|Group
P08972182A0000|4 16|Fas receptor
P08972182A0527|0 3|Fas
P08972211A0059|14 24|expression
P08972232A0365|8 14|report
P08973185T0061|4 10|effect
P08973527A0000|14 18|DNAs
P08973630A0923|8 13|cases
P08973917A0632|8 13|cDNAs
P08973917T0000|0 9|Isolation
P08974103A0451|0 8|Patterns
P08974135A0052|19 27|thiamine
P08975532T0001|0 14|Liver injuries
P08975713A0454|15 27|cDNA library
P08976253A0637|30 41|correlation
P08977013A0788|4 16|implications
P08977235A0134|0 5|G-CSF
P08977235A0588|0 7|Mutants
P08977401A0227|4 17|RI alpha gene
P08978690A0262|17 26|Rad3/Mec1
P08978817A0620|3 11|addition
P08978996A0000|4 18|identification
P08979089A1197|7 19|transfection
P08979828A1561|18 30|interactions
P08980413A0500|4 7|P13
P08980522A0280|4 8|cDNA
P08980533A1160|24 30|region
P08980536A1196|4 16|conservation
P08980819A0193|0 9|Mortality
P08981371A2049a|13 25|PIP2 content
P08981371A2049b|13 25|PIP2 content
P08985109A1285|38 44|margin
P08985115A1571|10 24|identification
P08985122A0501|4 19|promoter region
P08985415A1096|4 28|STAT-1 signaling pathway
P08986190A0927|0 11|Reperfusion
P08986214A0000|37 45|response
P08986228A0000|0 8|Children
P08986692A0306|0 12|INTERVENTION
P08986770A0268|20 30|expression
P08986812A1214|17 20|p53
P08987009A0400|4 11|patient
P08987225A0675|16 27|risk factor
P08988257A1256|0 9|Silencing
P08988913A0821|3 11|contrast
P08989025A0359|22 25|Ca2
P08989763A0605|8 17|artifacts
P08990168A0688|9 27|p48 gene induction
P08990194A0000|4 12|syndrome
P08990397A1437|27 34|mutants
P08992115A0199|4 15|progression
P08993393A0498|25 37|implications
P08993393T0000|13 22|signaling
P08993831A0000|16 34|muscle development
P08993836A0699|17 24|results
P08994825A0000|0 10|BACKGROUND
P08994832A0782|8 18|expression
P08994968A0926|14 17|arm
P08995054A0618|0 10|Similarity
P08995054A1368|0 2|D.
P08995410A0000|11 28|initiation factor
P08995410A1109|4 8|data
P08995614T0000|0 14|Identification
P08995652A0812|4 11|results
P08995659A0563|15 38|region splice junctions
P08995681A0518|5 10|ICP27
P08996730A1146|0 4|Lack
P08997490A1127|0 12|C/EBP beta V
P08997532A0116|9 12|IgG
P08998115A0114|0 23|SUMMARY BACKGROUND DATA
P08999414A0819|4 15|differences
P08999857A0801|13 18|E-box
P08999882T0000|0 10|Expression
P09000049A1341|16 19|Mnt
P09000108A0330|4 25|transcription product
P09000146T0000|11 18|changes
P09000589A0000|4 14|resurgence
P09000632A2341|7 18|p51 subunit
P09001213A1111|20 39|level transcription
P09001245A0187|0 6|NUP145
P09001313A0000|0 10|Prevalence
P09001667A0312|7 12|cases
P09001828A0222|2 7|total
P09002648A0202|0 5|BCL-2
P09002672A0439|9 20|translation
P09003001A1593|27 30|E12
P09003001A1909|4 18|E-box sequence
P09003311A0478|9 21|DNA fragment
P09003312A0740|12 19|AT-PHH1
P09003410A0000|10 22|p100 protein
P09003462A0792|18 32|mutation sites
P09003463A0198|5 11|report
P09003617A0000|2 8|cohort
P09004304A0000|4 7|aim
P09004504A0000|12 21|structure
P09004987T0001|0 23|Serotonin concentration
P09005273A0322|0 21|MAIN OUTCOME MEASURES
P09005273A1558|0 10|CONCLUSION
P09005609A0299|0 19|Control examination
P09005836A0977|3 14|correlation
P09005979A0841|4 12|GHR mRNA
P09006007A0997|4 11|results
P09006010A0527|4 28|linker-peptide insertion
P09006022A0252|20 33|gene products
P09006051A1162|0 4|PrpB
P09006555A0738|0 21|MAIN OUTCOME MEASURES
P09006902A0370|19 23|cDNA
P09006910A0000|19 29|mechanisms
P09006914A0812|0 3|JNK
P09006914A1127|4 11|effects
P09006935A0590|0 3|Sp1
P09006936T0000|0 14|Identification
P09008301A0193|7 19|enzyme forms
P09009208A0337|4 10|primer
P09010223A0667|35 39|ELK1
P09010223A1850|5 13|R-domain
P09011591A0309|10 16|number
P09011744A0790|23 32|locations
P09011745T0000|5 12|cloning
P09012405A0785|17 22|TTD-A
P09012636A0723|0 10|Adjustment
P09013499A0198|3 13|Experiment
P09013760A0000|0 11|Cholesterol
P09015543A0210|13 21|solution
P09015757T0000|11 19|analysis
P09015799T0000|0 19|Serotonin receptors
P09016566A0655|22 27|motif
P09017443A0734|17 30|marker screen
P09018122A1389|4 13|detection
P09018133A0244|13 21|analysis
P09019302A0600|8 14|method
P09020138A0833|5 9|HEF1
P09020169A0552|0 4|SIM1
P09020172A0964|0 9|Complexes
P09020856A0560|14 20|effect
P09021684A1418|13 17|data
P09022040A0263|8 28|L-plastin expression
P09022632T0000|42 49|surgery
P09023197T0000|4 15|dnaK operon
P09023378A0959|10 20|expression
P09024039A0247|10 13|ASA
P09024097A0000|0 9|OBJECTIVE
P09024793A1325|7 43|electrophoresis mobility shift assay
P09024805A0905b|15 33|promoter construct
P09025122A0374|11 22|experiments
P09025549A0000|11 16|nurse
P09027346A1957|9 25|antibody binding
P09027506T0000|0 12|cDNA cloning
P09028089A0183|38 50|hypertension
P09028308A0590|12 20|patients
P09028942A0000|48 54|factor
P09028998A0143|3 8|order
P09029091A0881|36 60|tyrosine phosphorylation
P09029104A0226|9 14|IGLL1
P09029159A0000|4 14|interferon
P09029713A1120|14 18|data
P09029956T0000|7 16|relations
P09030581A0990|18 29|COS-7 cells
P09030688A0435|3 15|rlf2 mutants
P09030781A0734|5 12|kinases
P09031639A0474|10 17|kb cDNA
P09032233T0000|0 11|Interaction
P09032248A0239|9 14|Pho85
P09032250A0257|10 15|yeast
P09032254A0724|0 17|Enhancer activity
P09032258A0395|0 7|Studies
P09032259A0150|13 23|activation
P09032259A0972|13 28|Rac1 activation
P09032267A0850|0 14|Overexpression
P09032275A1133|16 22|domain
P09032304T0000|0 14|Identification
P09032328A0650|0 14|DNA sequencing
P09034337A0251|0 7|Studies
P09035307A0000|21 25|case
P09035612T0000|8 26|endothelin release
P09036529A0343|4 10|workup
P09037032T0000|4 17|proliferation
P09037064A0183|7 18|application
P09037163A1652|4 13|relevance
P09038166A0818|0 9|Exons A1a
P09038192A0846|15 24|inhibitor
P09038202A1951|6 10|data
P09039744T0000|21 29|analysis
P09040011A1316|3 10|summary
P09041123A0195|13 19|action
P09042078A0202|21 24|MBF
P09042269A1007|6 14|findings
P09042683A0492|4 21|FBF questionnaire
P09042755T0000|16 35|sigma factor sigmaB
P09042911A0626|8 25|promoter elements
P09043534A1600|22 31|decreases
P09043768A0139|20 31|biokinetics
P09045636A0789|0 17|CD3 cross-linking
P09045805A0945|18 28|expression
P09045842T0000|0 9|Mutations
P09045919A1250|27 35|evidence
P09046013A0000|20 28|efficacy
P09046090T0000|4 9|genes
P09046186A0189|4 13|protector
P09046384A0403|0 23|Marinol/marijuana usage
P09047252A0209|0 7|METHODS
P09047344A0000|19 26|peptide
P09048617A0648|22 26|type
P09049198A0289|8 15|insight
P09049270A0488|0 22|Northern blot analysis
P09049304A1193|3 26|co-transfection studies
P09049306A0830|4 12|HBP gene
P09049313A0116|8 17|instances
P09050689A0685|21 29|ablation
P09050847A0180|7 12|class
P09050849A0000|0 11|Cytohesin-1
P09050849A1459|8 14|regard
P09050861A0903|20 34|identification
P09050867A0542|6 14|elements
P09051656A0390|0 14|Tissue samples
P09053309A1103|24 47|floor plate development
P09053494A0612|0 7|RESULTS
P09053835A0865|10 22|p53 activity
P09053973A1252|0 10|CONCLUSION
P09055221A0288|4 13|intensity
P09056761A0000|14 19|cells
P09057325A0177|4 10|region
P09057648A0422|10 24|cotransfection
P09057703A1389|0 15|Snail mortality
P09057840A0946|16 23|protein
P09057841T0000|0 12|Derepression
P09058002T0000|18 22|task
P09058250A0128|9 22|complications
P09058323A1287|4 11|results
P09058373A0670|0 28|RNase protection experiments
P09058373A1620|11 16|tests
P09058378A1134|22 46|glucocorticoid receptors
P09059039A0850|0 11|99mTc-HMPAO
P09060045A0576|11 26|review analyses
P09060444A0557|5 21|promoter segment
P09060622A1679|18 24|report
P09060623A0961|10 20|coreceptor
P09060676A1634|6 13|changes
P09060971A0982|0 7|RESULTS
P09061697A0629|14 15|%
P09061697T0000|11 23|SPET imaging
P09061698A0177|0 13|99Tcm-DMP-HSA
P09062130A0116|0 6|Relief
P09064659A1055|44 51|homolog
P09064868T0001|2 14|miracle cure
P09065170A0853|4 12|addition
P09065463A1012|0 19|DNA strand exchange
P09065690A0463|0 5|Ume6p
P09065768A0862|11 16|class
P09067577A0307|3 13|cell lines
P09067577A0721|17 22|cells
P09068989T0000|0 6|Effect
P09071308A0376|0 7|RESULTS
P09071407T0000|12 20|oxytocin
P09072361A0357|24 32|fraction
P09073074T0000|10 23|transcription
P09073582A0444|11 17|report
P09074508A0397|10 19|CD38 gene
P09075739A0827|0 4|Type
P09076336A0281|0 13|GH deficiency
P09077076A0219|9 17|CRP test
P09077108A0458|19 25|period
P09077437T0000|0 22|Recognition mechanisms
P09077438A0076|4 11|minimum
P09079625A0935|0 10|Syndecan-4
P09079638A0883|4 16|3ASubE cells
P09079650A0136|0 7|Members
P09079689A0472|0 4|MOP5
P09079817A0928|12 25|NO production
P09079878A0000|9 11|kb
P09079902A0713|9 12|Pra
P09079904A0995|11 26|iron regulation
P09079915T0000|10 26|characterization
P09079928A0525|0 14|M. leprae OxyR
P09079928A1319|4 16|binding site
P09080250A0212|15 20|study
P09080517A0215|12 20|patients
P09081389A1088|0 5|Grade
P09081392A0174|36 52|salvage regimens
P09082335A0730|0 4|None
P09083291A1378|6 15|TGF-beta1
P09083345A0851|13 18|range
P09083563A0971|14 21|lesions
P09084174A0667|5 13|fragment
P09084176A0601|16 24|activity
P09084227A0833|0 11|Hovenitin I
P09084621A0374|0 13|Movement time
P09084621A2567|0 5|Areas
P09085842A0181|7 14|studies
P09085842A1559|29 40|27K protein
P09086268A0611|9 11|P7
P09087430A1046|18 29|U1A peptide
P09088371T0000|0 13|Plasma levels
P09088416A0000|31 37|branch
P09088737T0000|23 45|thickness measurements
P09089093A0373|0 9|Sequences
P09089653A0615|12 20|plasmids
P09089653A1112|0 8|Analysis
P09090050A0419|31 45|sugar carriers
P09090054A0186|25 29|loci
P09090592A0175|9 16|methods
P09091010A1003|6 11|women
P09091125A0161|20 25|cells
P09091403T0001|0 8|Analysis
P09092493A0861|4 15|integration
P09092580A1354|6 13|studies
P09092636A0802|4 11|results
P09092675A0283|2 20|P22 R17 derivative
P09093867T0000|13 30|Ac/Ds transposons
P09094093A0578|5 9|site
P09094315A0541|8 13|study
P09094671A1192|0 32|Candidate tumor suppressor genes
P09096229T0000|0 15|Excision repair
P09096234T0000|21 32|interaction
P09096958A0000|24 29|panel
P09098066A0119|5 10|locus
P09098899A0000|0 9|Coliphage
P09098899A0435|4 26|UV absorption spectrum
P09099683A0000|0 21|Diacylglycerol kinase
P09099702A0000|31 38|cloning
P09099702A0692|13 21|sequence
P09099743A0585|19 31|purification
P09099745A1446|7 16|complexes
P09100202A0000|7 12|Class
P09101085A0686|4 15|derivatives
P09101910A0394|18 27|mortality
P09102113A0739|14 30|failure patients
P09103382T0000|8 23|FIGO definition
P09104816A0610|4 10|effect
P09105042A1497|5 10|study
P09105363A0636|20 26|plasma
P09105530A0000|3 14|egg protein
P09106057A0000|2 8|method
P09108029A0399|27 35|activity
P09108038A1128|10 20|LRR domain
P09108207A0306|13 26|participation
P09108279A0431|4 12|capacity
P09108451A0160|0 7|Results
P09110176A0890|0 8|Northern
P09111004A0732|16 23|effects
P09111048X0000|25 40|mRNA transcript
P09111059A0327|23 29|domain
P09111309A0674|0 14|Cotransfection
P09111314A0970|0 9|Cyclin D1
P09111314A1243|4 14|importance
P09111331A0119|4 16|Rlm1 protein
P09111340A0240|23 31|elements
P09111367A1098|13 24|experiments
P09111863A0743|4 14|likelihood
P09112400A1155|12 20|activity
P09112589A0078|32 39|pattern
P09114972A1366|5 14|induction
P09115242A0934|24 34|supershift
P09115247A2069|0 25|11-Aminoundecanoyl-SK-NH2
P09115265A1160|22 33|CCCC module
P09115279A0345|0 20|Cdc2 co-precipitates
P09115357A0073|26 35|mechanism
P09115365A0000|0 10|Expression
P09115395A0478|9 17|proteins
P09115989A0993|25 33|location
P09117345A0945|0 10|Activation
P09118196A0281|0 11|Performance
P09118664A1734|0 12|L-canavanine
P09118704A0771|0 7|RESULTS
P09119031A1036|14 40|holoenzyme RNA polymerases
P09119112A1350|6 10|data
P09119391A0870|11 19|sequence
P09121424A0296|38 50|Swi3 homolog
P09121430A0132|0 3|Shc
P09121430A1075|3 11|contrast
P09121432A0000|4 15|Ras guanine
P09121433A0463|13 17|Rlm1
P09121435A1183|0 7|Domains
P09121452A0538|0 25|Domain switch experiments
P09121454A1328|12 22|phenotypes
P09121476T0000|0 5|PRH75
P09121774A0611|6 16|activities
P09121774T0000|2 6|role
P09121998A0663|14 20|curves
P09122168A1427|5 10|study
P09122176A0970|4 11|results
P09122198A0478|0 15|Point mutations
P09122215A0335|20 26|method
P09123055T0000|15 21|injury
P09123787A0486|35 44|responses
P09124054A1164|4 13|prognosis
P09126487A1399|7 10|Hum
P09126622A0466|4 21|pigment intensity
P09128730A0000|9 24|decarboxylation
P09129147A0644|4 24|Jem peptide sequence
P09130595A0478|19 26|cloning
P09130700A0676|8 15|support
P09130718A0497|0 9|Sequences
P09130720A0417|10 16|screen
P09131139T0000|0 11|Implication
P09132011A0298|0 10|Comparison
P09132057A0559|2 13|polypeptide
P09132061A0828|4 7|atp
P09133122A0656|11 22|information
P09135066A0653|42 46|Mek1
P09135149A0000|34 42|activity
P09135772T0000|9 17|response
P09135928A0912|14 20|mmol/l
P09136015A0529|4 14|sequencing
P09136080A1469|4 11|results
P09138076A1099|3 28|gel mobility shift assays
P09138492A0806|0 15|Laboratory exam
P09139665A0784|22 36|PhLP complexes
P09139694A0789|0 9|CTF1alpha
P09139721A0183|0 9|Cyclin G2
P09139737A0000|19 27|protease
P09139892A1150|24 28|orfX
P09139910A0350|0 17|Sequence analysis
P09139910A1572|3 11|contrast
P09140079A2528|9 15|effect
P09140474T0000|3 16|leishmaniasis
P09142146A0887|0 7|RESULTS
P09143328A1002|5 12|finding
P09143465A0838|5 7|T1
P09144165A0614|5 10|model
P09144165A1275|26 34|NFAT RIR
P09144195A1051|10 21|association
P09144770A0906|5 14|conformer
P09144958A0047|5 12|protein
P09146027A0809|2 9|patient
P09146071T0001|9 17|movement
P09147420A0623|34 46|HCMV IE1/IE2
P09147420T0000|0 3|TAR
P09147788A0458|12 33|chain enzyme activity
P09147832A0174|0 8|Children
P09148770A0977|9 12|Csk
P09148903A1715|10 17|studies
P09148929A0372|4 6|P1
P09148935A0805|14 32|c-Src PTK activity
P09149825A0151|16 22|cement
P09149929A0750|25 36|predictions
P09150334A0559|5 11|sample
P09150566A0316|19 23|role
P09150595A0225|9 18|elicitors
P09150595T0000|10 26|characterization
P09150728A0596|4 8|mRNA
P09150774A0616|0 10|Anesthesia
P09151152A0174|24 42|protein C activity
P09151376A0000|13 17|case
P09151806A1125|6 10|data
P09151828A0919|12 31|amino acid residues
P09151837A0723|8 27|protein interaction
P09151925A0479|4 9|C-LIP
P09152656A0149|9 17|patients
P09153010A0499|9 19|advantages
P09153319A0844|35 44|triplexes
P09153319A1332|0 24|Transfection experiments
P09153348A0647|9 17|increase
P09153795A0298|11 18|studies
P09154283A0307|0 11|Latanoprost
P09154621A1475|6 13|results
P09154795A0628|14 24|techniques
P09154797A0777|10 30|spermidine transport
P09154819A0501|10 24|overexpression
P09154822T0000|0 10|Inhibition
P09154827A0158|9 16|studies
P09155015A0140|22 42|protein kinase MEKK1
P09155024A0955|0 14|Overexpression
P09156883A0294|9 19|parameters
P09157100A0583|16 23|signing
P09157337A0545|4 11|husband
P09157760A0000|34 42|analysis
P09159111A0437|20 28|proposal
P09159160A0000|11 18|cloning
P09159183A0119|0 5|Genes
P09160361A0858|11 20|mortality
P09160881A0491|23 47|co-precipitation studies
P09162084A0956|5 16|association
P09162092A0675|0 24|MKK3 autophosphorylation
P09162097A0776|25 41|MAdCAM-1 variant
P09162097A1258|3 10|summary
P09163332A0275|29 49|mutagenesis approach
P09164543A0219|0 8|MATERIAL
P09164856A0980|5 11|region
P09165004A1700|0 12|SRE activity
P09165035A0842|0 35|Serum alkaline phosphatase activity
P09165039A0728|4 19|monkey LHR cDNA
P09165039A1372|3 13|conclusion
P09165118A0311|9 16|mutants
P09167421A0234|14 25|irradiation
P09168083A0987|3 10|patient
P09168134A0858|0 19|Sequence comparison
P09168218A0216|0 7|METHODS
P09168511A0640|26 32|number
P09168623A0614|2 6|xylE
P09168879A0219|19 28|Sf9 cells
P09168892A1016|0 8|Mutation
P09169127A0371|10 19|proximity
P09169420A0000|14 40|phosphoinositide 3-kinases
P09169475A0272|7 14|studies
P09169475A0772|0 12|Localization
P09169593T0000|0 18|Insulin regulation
P09169852A0235|0 10|Sequencing
P09169853A0000|0 5|Pax-3
P09170159A0348|34 39|cells
P09170159A0721|6 15|mutations
P09171038A0219|8 12|case
P09171081T0000|0 7|Cloning
P09171235A0851|11 25|overexpression
P09171239A1118|10 21|amino acids
P09171239A2146|31 37|ligand
P09171363A0149|3 11|ciliates
P09171389A0549|13 23|occurrence
P09171468T0000|0 5|Diver
P09171969A1165|0 11|Measurement
P09172312T0000|0 16|Characterization
P09172414A0000|58 62|HPLC
P09172641A0181|11 18|studies
P09172812A0660|21 32|fludarabine
P09173733A0404|16 26|techniques
P09174049A1788|15 49|p34CDC2 histone H1 kinase activity
P09175708A1526|6 11|PRL-R
P09175858A1449|10 20|B-S mutant
P09176340A1194|0 13|Transcription
P09176837A0211|0 17|Computer software
P09177169A0935|10 17|chimera
P09177857A0000|4 14|conditions
P09178269A0107|8 13|genes
P09178491A0262|16 23|regions
P09178494A1123|59 66|regions
P09178752A0574|0 3|EGF
P09180687A0096|19 25|region
P09181130A1067|20 27|Krox-20
P09181130A1587a|38 46|analysis
P09182281A0197|37 50|Cyclosporin A
P09182527A0443|20 24|role
P09182707A0254|0 3|SPP
P09182990A0245|34 40|allele
P09183145T0001|0 10|Evaluation
P09183406A0637|22 38|thrombocytopenia
P09185183A0089|35 40|years
P09185183T0000|0 7|Merosin
P09185586A0000|16 21|mRNAs
P09185645T0000|0 10|Comparison
P09186056A0514|16 30|overexpression
P09186430A0341|44 52|albinism
P09186507A0882|53 61|sequence
P09187136A0000|0 6|SSeCKS
P09187277A0118|0 4|Type
P09187371A0450|20 32|mRNA species
P09187637A1199|0 18|Taurine deficiency
P09188094A0934|19 23|mcs4
P09188699A1388|13 30|rat SP-A isoforms
P09188863A0954|12 20|splicing
P09189783A0000|5 18|investigation
P09189896A0611|4 12|findings
P09190202A0166|5 17|coat protein
P09190821A0707|57 63|change
P09190940A0127|0 9|Induction
P09191052A0850|10 13|PCE
P09192732A1384|30 37|portion
P09192769T0000|10 17|cloning
P09192786T0000|0 12|Organization
P09192842A0988|26 33|hybrids
P09192998A0356|19 26|enzymes
P09193072A0199|12 16|data
P09193077A0000|17 21|unit
P09193080A0904|0 19|Sequence divergence
P09193671A0347|11 16|state
P09194250A0708|31 43|World Summit
P09195923A0125|4 16|immunophilin
P09197241A0770|12 23|macrophages
P09197342T0000|0 9|Secretion
P09197408A0126|0 10|Sequencing
P09199167A0942|0 14|Overexpression
P09199286A0086|11 17|region
P09199292A0536|27 38|association
P09199318A1147|13 17|p150
P09199322T0000|0 12|Denaturation
P09199327A1250|5 11|effect
P09199328T0000|15 23|residues
P09199348A0156|7 11|view
P09199353A1924|15 22|results
P09199413A0518|14 27|inoculum size
P09199626A0613|6 11|cases
P09199932A1357|0 31|Promoter recognition algorithms
P09199970A1101|20 24|pMCP
P09200029A0211|28 33|signs
P09200498T0000|8 13|zones
P09200530A0411|0 6|Liquid
P09200811T0000|11 24|plasmid pDHL1
P09201946A0000|28 47|helicase activities
P09201980A0910|4 18|p20-CGGBP gene
P09202147A0866|4 8|data
P09202669A0614|4 10|pWP-19
P09202669A1530|34 54|gene transfer system
P09202859A0091|4 16|serum levels
P09203585A0660|11 18|feature
P09203586A1197|20 31|recruitment
P09203731A0497|12 36|International Commission
P09204566T0000|26 34|analysis
P09204570A0110|5 10|study
P09205113A0587|5 8|E14
P09205677A0577|0 4|Lung
P09205965A1249|4 11|results
P09206230A0000|0 9|OBJECTIVE
P09206968A0000|0 11|Disturbance
P09208214A0572|0 19|Sternocleidomastoid
P09208930T0000|0 14|Identification
P09209031A0350|22 28|region
P09209312A0968|4 17|RNA construct
P09209372A0345|25 30|AML1a
P09209406A1021|42 49|regions
P09209438A0994|15 22|ATL-16T
P09210012A0000|4 10|impact
P09210478A0000|45 53|factor-1
P09211354A0000|0 13|Stromelysin-1
P09211605A0478|0 6|Tendon
P09211675A0392|0 12|Surveillance
P09211913A0000|0 25|Aryl hydrocarbon receptor
P09211934A0722|0 5|DNase
P09211981A0526|16 24|evidence
P09212059A1356|24 59|metal affinity chromatography assay
P09212059A1856|12 19|results
P09212063A0425|32 39|A-phage
P09214274T0001|11 20|carcinoma
P09215525A0581|23 30|effects
P09215891A0000|4 12|products
P09216017A0621|0 10|Vitrectomy
P09216936T0000|8 17|editorial
P09218436A0443|5 14|promoters
P09218459A0000|0 21|Serum response factor
P09218520A0075|18 25|studies
P09218599A0184|8 13|study
P09218775A0000|23 30|strains
P09218775A1229|0 8|Activity
P09219526A0383|21 32|specificity
P09220158A0537|17 24|protein
P09220177A0564|4 20|CPK-MB isoenzyme
P09222057A0176|0 5|Serum
P09222115A0545|0 7|Results
P09223042A0000|0 5|Liver
P09223122A0774|9 28|matter NAA/mI ratio
P09223229A0565|29 39|mb-1 genes
P09223475A0898|0 40|Chloramphenicol acetyltransferase assays
P09223479A1193|0 6|ORF M1
P09223506T0000|0 34|Transcription factor binding sites
P09223647T0000|0 17|Crystal structure
P09223667A0139|18 30|transfection
P09223880A1147|21 36|injection speed
P09224655T0000|12 20|splicing
P09224811A0000|12 17|study
P09225151T0000|4 12|behavior
P09225506A0462|4 17|control group
P09225682A0579|4 13|frequency
P09225686A0683|13 37|radiofrequency lesioning
P09225998A0000|0 36|NF-kappa B/Rel transcription factors
P09226113A0857|29 48|source water sample
P09226345A0436|14 25|food intake
P09227099A0106|14 23|technique
P09227332A1798|3 10|summary
P09227799A0254|30 34|tool
P09228042A0109|20 49|dermatan sulfate proteoglycan
P09228092A1779|6 14|analyses
P09228202A0581|14 51|5-HT3 receptor antagonists ramosetron
P09229420A0158|0 13|Re-evaluation
P09229595A0618|4 19|corneal buttons
P09230129A0039|22 33|homogeneity
P09230216T0000|18 34|glycosylase maps
P09230307A0329|0 3|FOG
P09230384A0725|9 14|times
P09230384A1056|11 17|BACTEC
P09230894A0422|22 29|KmMig1p
P09230945A0089|18 27|deformity
P09230986A0000|0 22|Autoimmune neutropenia
P09232593A0946|5 11|regard
P09233487A1386|7 15|analysis
P09233772A0136|5 12|protein
P09233801A1180|10 22|L45 sequence
P09233809A0381|8 19|mouse lines
P09233809A0815|24 34|transgenes
P09233811A0072|5 15|regulation
P09234677A0770|24 34|hypothesis
P09234690A0242|0 8|Upstream
P09234696A0238|10 33|protein kinase cascades
P09234703A0192|0 3|JNK
P09234713A0754|8 13|study
P09234717A0000|7 14|studies
P09234720A1015|42 45|MEK
P09234723A0846|5 14|mechanism
P09234725A1892|37 52|transactivation
P09234727A0770|9 23|fusion protein
P09234736A0999|8 30|hybridization analysis
P09234743A0475|17 25|proteins
P09235073A0000|4 9|years
P09235424A1200|11 19|measures
P09235618A0000|5 11|series
P09235995A0339|1 6|1996a
P09235998A0788|12 31|membrane expression
P09236118A1455|4 11|results
P09236224A0939|10 20|activation
P09236441A0639|17 25|patients
P09236656A0124|21 31|cell count
P09237695A0000|28 33|study
P09237862A0782|20 24|eyes
P09238467A0763|6 13|lesions
P09238850A0785|13 17|ICER
P09238850A2042|15 26|oscillation
P09238860A0175|21 28|nucleus
P09238860A1974|6 11|cells
P09239635A0477|14 18|dogs
P09241092A1108|0 11|CONCLUSIONS
P09241232A0653|4 16|Ogg1 protein
P09241232A1154|2 20|consensus sequence
P09242375A1313|15 23|findings
P09242499A0505|0 10|Volunteers
P09242506A1033|0 3|E2F
P09242551A0653|0 10|EBER1 mRNA
P09243267A0401|0 7|METHODS
P09243385A1314|11 14|use
P09243505A1194|3 11|addition
P09243587A0000|0 18|PURPOSE/OBJECTIVES
P09243840A0663|12 19|studies
P09244100A0194|11 15|rats
P09244282A1371|0 11|Mutagenesis
P09244350A0000|0 5|BRCA1
P09244430A0693|16 28|splice sites
P09246343T0000|0 11|Proteinuria
P09246585T0000|7 15|blockade
P09247645A0000|30 37|alleles
P09248639A0152|5 17|cell strains
P09249039A0124|26 33|enzymes
P09249070A0989|0 4|Cell
P09249710A0331|26 30|sera
P09250554A0402|0 8|Patients
P09251843A0189|18 29|hyperplasia
P09252397A0081|27 39|repair rates
P09252406A0511|0 8|Tyrosine
P09252879A0470|19 32|HRCT findings
P09254678A0106|0 8|Gtx mRNA
P09254709T0000|0 8|Contacts
P09255349A0836|24 30|GTPase
P09256973A0455|4 6|E2
P09256973A0673|0 7|RESULTS
P09257651T0000|10 21|U4/U6 snRNP
P09257887A0457|0 5|G-CSF
P09258439A1001|9 26|expression system
P09258606A0822|0 9|Crosstalk
P09259052A0568|0 17|Supershift assays
P09259313A0950|4 12|majority
P09259315A0809|0 8|Mutation
P09259320A0830|22 36|chromatography
P09259328A0440|0 28|Deletion mapping experiments
P09261155A0833|17 19|PH
P09261178T0000|4 9|mouse
P09261184A0170|19 46|gel mobility shift analysis
P09261200T0001|0 10|MR imaging
P09261397A0509|0 27|Gag protein sequence motifs
P09263010T0000|0 9|Induction
P09263094A0799|0 12|MEASUREMENTS
P09263856A0563|28 34|models
P09264466A0947|4 16|Cut9 subunit
P09265534A0455|4 8|dose
P09265642A0668|25 32|pathway
P09265932A0575|8 13|women
P09267306A0381|24 28|case
P09267431A0000|4 23|soybean cDNA clones
P09267439A0000|0 5|Genes
P09267542A0126|0 10|Naltrexone
P09268298T0000|0 20|Ent-kaurene synthase
P09268387A0293|8 14|report
P09268578A0225|14 28|cDNA sequences
P09268631A0316|4 12|position
P09268638A0332|30 56|chromosome walking studies
P09268652A0116|20 39|zinc finger protein
P09268661A1405|4 11|results
P09269879A0266|6 16|absorption
P09269900A1035|16 23|results
P09271393A1333|16 20|data
P09271394A0558|0 5|DNase
P09271397A1596|21 26|model
P09271400A0475|8 14|assays
P09271417A0585|13 18|mouse
P09271417A1011|4 8|MCAD
P09271496T0000|0 16|Mapping features
P09272108A1295a|0 8|Analysis
P09272108A1295b|0 8|Analysis
P09272138A1153|13 21|response
P09275159T0000|22 42|ribonucleoprotein A1
P09275164A0000|4 25|m7GpppN cap structure
P09275990A0938|13 17|part
P09276882A0479|4 12|addition
P09277472A1070|24 29|edema
P09277629A0268|4 15|experiments
P09278441A0163|0 4|Biol
P09278441A1160|4 11|pattern
P09278441A1777|0 14|Overexpression
P09278445T0000|0 21|Substrate specificity
P09278450A1338|16 37|mobility shift assays
P09278454A1261|0 11|Examination
P09278475A0465|7 12|scs32
P09278494A0762|3 11|contrast
P09278758A1636|0 10|CONCLUSION
P09279379A0310|23 29|pBR322
P09279889A1124|0 4|Area
P09280747A0195|4 15|combination
P09282329A0527|11 21|mechanisms
P09282911A0277|4 8|goal
P09282985A0961|11 22|differences
P09283828A0484|16 25|responses
P09285715A1257|18 22|data
P09285789A0712|6 9|Duo
P09286115T0000|0 3|S2F
P09286981A0147|0 4|ArgR
P09287036A0457|0 28|Plasma leptin concentrations
P09287352A0930|16 23|effects
P09287362A0589|5 16|interaction
P09288848A0780|14 16|Gy
P09288916T0000|10 20|expression
P09290207A0731|25 37|derepression
P09290571A0420|9 17|patients
P09290571A0799|4 16|cycle length
P09291077T0000|10 25|hyperammonaemia
P09291098A0452|28 39|kb mRNA V-1
P09291098T0000|18 26|promoter
P09292499A0887|6 21|repressor sites
P09293006A1412|11 21|expression
P09294139A0729|16 36|core homology region
P09294161A0650|3 11|contrast
P09294161A1103|6 14|findings
P09294262A0885|4 19|promoter region
P09294422A1223|8 25|cysteine residues
P09294422A1376|4 12|por gene
P09294452A2107|20 28|operator
P09294453A0949|4 15|ORF3 mutant
P09294471A1198|8 18|Cox models
P09296251A0163|23 30|reports
P09297698A0933|6 17|transcripts
P09299696A1074|4 16|distribution
P09300323A1182|5 11|result
P09300697A0000|0 11|Proteasomes
P09300698A1219|3 10|support
P09301114A0573|0 9|Takahashi
P09301350A0946|4 24|sputum interleukin-8
P09303437A0875|18 26|deletion
P09303635A0000|0 7|Gaucher
P09304123A0079|6 19|discoloration
P09305592A0000|21 49|translocation characteristic
P09305631A0770|0 14|Overexpression
P09305755A0540|16 22|region
P09305870A0894|4 27|recognition specificity
P09305944A0621|17 32|RanGAP activity
P09307065A0553|7 14|absence
P09307312A0172|0 8|Evidence
P09308234A0225|0 3|Mnt
P09308738A1216|7 20|United States
P09309457A0680|0 6|Assays
P09310836A1019|11 18|repeats
P09311164A0245|24 33|density J
P09311568A0595|4 23|cleavage dipeptides
P09311796A0218|16 23|studies
P09311808A0341|38 49|p4 molecule
P09311810A0814|9 21|accumulation
P09311835A0147|38 54|characterization
P09312025A0373|6 13|effects
P09312025T0000|0 22|Protein phosphatase 2A
P09312028A0975|19 32|RXRalphaF318A
P09312032A0165|6 13|introns
P09312087A0000|7 14|studies
P09313755A0816|15 25|clustering
P09314306A0571|0 15|Supplementation
P09314487T0000|0 9|Detection
P09314537A1600|6 14|findings
P09314554A0149|41 52|translation
P09314570A0153|5 11|family
P09315631A1064|0 8|Deletion
P09315632A1137|23 34|observation
P09315633A0333|12 31|amino acid sequence
P09315651T0000|0 11|Involvement
P09315678A0278|9 14|Cbf5p
P09316937A0133|21 29|organism
P09317131A0000|0 2|Ig
P09317131A1332|14 18|data
P09317757T0000|0 8|EXERCISE
P09317830T0000|15 29|SONG FREQUENCY
P09321406T0000|4 30|pheromone response pathway
P09321657A0439|8 13|study
P09321930A0567|23 45|tumor suppressor genes
P09322738A0510|21 25|gene
P09322872A0745|12 20|deletion
P09323366A0000|4 24|malate synthase gene
P09323366A0299|3 20|deletion analysis
P09323612A0374|0 4|Lack
P09324720A0317|9 14|meals
P09324878A0952|33 37|wall
P09324922T0065|0 20|Fermentation process
P09324988X0000|0 10|Substrates
P09325022A0192|0 7|Ovaries
P09325135A0737|11 25|fusion protein
P09325273A1240|6 13|results
P09325278A0458|2 27|data base homology search
P09325284A0469|14 18|cDNA
P09325322A1293|4 14|inhibition
P09326163A0942|0 7|RESULTS
P09326246A0567|0 17|Sequence analysis
P09326263A0410|8 12|RACE
P09326317A0372|18 23|study
P09326727T0000|4 17|regurgitation
P09327881T0000|0 41|Positron emission tomography radioligands
P09328341A1449|0 11|Attenuation
P09328343A0181|0 10|Expression
P09328349A1679|10 19|CCAAT box
P09328476A0068|0 11|U4/U6 snRNP
P09328476A0374|0 6|Hprp3p
P09328824A0000|21 31|properties
P09328833A0588|21 25|cDNA
P09331119A0659|16 21|grade
P09331864A0230|0 20|Serum concentrations
P09331864A0848|0 23|Serum E2 concentrations
P09333018A0000|0 10|Interferon
P09333026A0397|12 21|structure
P09333026A0851|33 43|expression
P09333168A0310|0 22|Anti-hepatitis A virus
P09333231T0018|4 9|skull
P09334264A0540|14 30|calf thymus CstF
P09334330A0252|5 14|mutations
P09334331A0910|4 11|results
P09334475A0327|0 8|PATIENTS
P09335267A0142|15 31|operon structure
P09335298A0529|30 43|parCBA operon
P09335298A1227|17 26|insertion
P09335298A2129|15 20|basis
P09335608T0000|16 24|elements
P09335619A0583|0 28|Nucleotide sequence analysis
P09336455A0000|21 29|kinetics
P09337861T0000|0 7|Cloning
P09338414A0430|0 8|Ea value
P09339900A0939|11 19|analysis
P09340641T0001|0 6|Effect
P09341139A0690|3 11|contrast
P09341158A0167|4 17|medium chains
P09341182A0605|69 83|BTB/POZ domain
P09341192T0000|8 13|shock
P09341193A0362|19 22|Sp1
P09343208A1405|15 22|segment
P09343210A1112|13 21|deletion
P09343222A0415|4 7|AGM
P09343398A1193|0 12|Processivity
P09343426A0456|0 30|Alanine substitution mutations
P09343432A0209|4 7|Scm
P09343433A0000|34 39|genes
P09343433A0360|10 20|rad6-delta
P09343982A0890|4 13|amplitude
P09344650A0967|17 37|transmembrane domain
P09345037A0886|10 15|roles
P09345495A0000|0 22|PET activation studies
P09346238T0000|6 14|proteins
P09346621A1181|7 14|context
P09346925A0660|4 15|SH3 domains
P09346935A0459|15 23|analysis
P09346935A0927|6 27|ZNF74 sublocalization
P09346938A1680|0 33|Ki-ras4BVal-12 transfectant cells
P09346953A0000|13 17|rate
P09348226A0852|15 18|EGF
P09348931T0000|3 6|end
P09349501A0196|41 48|portion
P09349967A0653|4 11|results
P09351242A0719|0 9|Induction
P09351823A0414|21 35|MAPK functions
P09352016A1110|8 22|AF G-CSF level
P09352127A0953|11 22|correlation
P09353247A0922|17 43|over-replication phenotype
P09353255A0159|0 5|Rip1p
P09353296A0510|4 15|CNXA domain
P09353304A0732|0 9|Deletions
P09353328A0736|21 27|kinase
P09353343A0919|0 14|RNA polymerase
P09353343T0000|0 10|Modulation
P09354349A0338|13 19|slides
P09354644A0124|6 18|biosynthesis
P09354676A1714|6 14|findings
P09354684A1158|3 11|addition
P09354757A1444|0 19|Amino acid residues
P09356645A0672|17 24|patient
P09358045A0000|9 29|length cDNA sequence
P09358055A0590|5 13|sequence
P09358069T0000|0 18|Codon optimization
P09358837T0000|12 16|rise
P09359844A0674|2 3|%
P09359887A1168|20 24|data
P09360422A0135|5 10|group
P09360953A1057|6 14|residues
P09360956A0840|31 46|phosphorylation
P09360993T0000|0 24|Mouse mast cell protease
P09361007A0922|2 7|DNase
P09362105X0422|20 30|resistance
P09362473A1540|14 21|results
P09362480A0452|11 27|cysteine triplet
P09362499A0000|4 15|Fis protein
P09363759A0000|0 20|Protein phosphatases
P09364211A0319|4 8|cell
P09364440A2206|4 9|study
P09364750T0000|16 26|regulation
P09365201A2018|6 13|studies
P09365272T0000|0 7|Xenopus
P09365431A0314|20 31|combination
P09366456A0234|0 7|METHODS
P09366517A0835|0 3|PKA
P09366517A1828|4 12|findings
P09366628T0000|0 2|Re
P09367288A0115|9 12|aim
P09367392A0567|4 12|presence
P09367426A1354|26 30|role
P09367676A0275|0 26|Restriction enzyme mapping
P09367676A1115|0 21|Transfection analyses
P09368006A1332|4 11|results
P09368014A0740|4 21|lysozyme FEF site
P09368026A0000|0 11|Osteocalcin
P09368026A0435|8 13|study
P09368057A1083|19 27|proteins
P09368058A0969|32 57|phosphopeptide comigrates
P09368097T0000|4 7|pen
P09368100A1354|4 16|mHIF-1 alpha
P09368190A1053|42 50|sequence
P09368419A0000|3 14|Arabidopsis
P09368419A0628|2 6|cDNA
P09368760A0665|6 10|PDK1
P09369450A1358|22 29|effects
P09369451A0693|11 19|analysis
P09369453A0273|18 25|members
P09369482A0690|0 21|Electromobility shift
P09370276A0781|8 21|reading frame
P09370307A0093|17 27|AACA motif
P09371431A1172|0 13|Strain CFN037
P09371431T0000|0 10|Expression
P09371455A0000|31 37|region
P09371564A0713|17 23|amount
P09371566A1384|5 12|protein
P09371596T0000|13 23|regulation
P09371612A1964|0 4|Acad
P09371622A0779|0 8|Chimeras
P09371626A1345|4 11|results
P09371657A0165|28 53|alanine cluster mutations
P09371698A1254|0 12|Transfection
P09371731A0627|5 12|inserts
P09372287A0296|16 26|electrodes
P09372451T0000|0 8|Epitopes
P09372908A1068|27 36|Sex Combs
P09372924A0758|18 33|rhHR23 proteins
P09372937T0000|4 9|yeast
P09372950A1283|6 13|results
P09372960A0456|0 17|Polysome analyses
P09372968A0532|0 17|Sequence analysis
P09372968A0996|16 20|HeLa
P09373140A0000|4 20|mouse M-lysozyme
P09373155T0000|0 14|Identification
P09373651A0255|7 14|cassava
P09374082A0504|13 22|mechanism
P09374541A0277|12 33|protein binding sites
P09374541T0000|13 23|protection
P09376325A0167|0 10|Comparison
P09376626A0737|0 9|Radiation
P09376782A0328|21 31|experience
P09377355A0362|4 10|author
P09377374A0000|8 13|paper
P09379301A2036|4 11|microns
P09380504A1255|4 14|ZnF20 cDNA
P09380507A0514|0 25|Glutathione S-transferase
P09380697T0000|4 10|sterol
P09380707A0714|23 32|LAZ3/BCL6
P09381261A0970|0 11|CONCLUSIONS
P09381950A0209|0 9|Ischaemia
P09382498A0618|11 15|MCTs
P09382850A0000|0 10|BACKGROUND
P09382886A1061|7 12|proof
P09382924A0131|12 20|evidence
P09383156A0691|10 34|RNase E cleavage product
P09383188A0654|5 15|difference
P09385169T0000|4 8|AONE
P09386074A0694|4 8|pigs
P09387333T0001|4 12|progress
P09387999A1053|4 14|amplitudes
P09388198A1396|4 8|data
P09388199A0948|6 12|effort
P09388200A0639|0 10|Inhibition
P09388201A1027|3 5|PU
P09388246A0903|27 66|electron microscopy immunocytochemistry
P09388271A1243|4 18|mobility shift
P09389137A0763|4 16|prescription
P09389198A0363|11 20|aftermath
P09389492A0520|13 20|fashion
P09389666A0538|6 20|Hex expression
P09389669A1009|6 9|dpp
P09389982A1383|0 11|CONCLUSIONS
P09390125A0379|0 7|RESULTS
P09390183A1027|0 21|Western blot analysis
P09391173A0811|0 25|Transcription start sites
P09392979T0000|26 40|histoplasmosis
P09393706A1171|6 9|Fis
P09393717A1517|6 18|observations
P09393771A1659|0 18|TNF-alpha exposure
P09393875A0873|28 42|papillomavirus
P09393966A0190|20 23|IgH
P09394650A0121|4 7|aim
P09395456A0424|13 17|role
P09395470A0294|0 12|CKbeta4GT-II
P09395525A0395|47 54|protein
P09396402A0264|0 8|PATIENTS
P09396427A1488|10 17|absence
P09396437A0878|7 17|BMI cutoff
P09396722A0185|4 8|gene
P09396796A1173|20 30|conclusion
P09396823T0000|17 23|domain
P09397261A0940|0 20|Interleukin-1 levels
P09397723T0001|0 22|Responsibility matters
P09398267A0440|0 22|Southern blot analysis
P09398332A0732|0 9|Sequences
P09398598A0256|43 56|hamster ovary
P09398855A0438|0 6|SCID V
P09400613A0594|0 12|Coexpression
P09400613A1209|6 35|GST-PKR fusion chromatography
P09400738A1046|29 37|response
P09402029A1632|29 41|strain H37Ra
P09402088A2250|6 13|defects
P09402139A1121|0 12|Similarities
P09403059A0209|12 18|repeat
P09404725A0644|6 10|days
P09405195A0320|14 24|constructs
P09405380A0800|4 13|existence
P09405536A0777|11 33|conditioning procedure
P09405685A0113|23 55|DNA binding transcription factor
P09407026A0426|0 13|TSA treatment
P09407031A0557|5 14|UV damage
P09407031A0974|19 33|overexpression
P09407036T0000|0 11|Tcn1p/Crz1p
P09407090T0000|0 9|Structure
P09407642A0305|18 31|gel technique
P09408516T0000|0 9|Stability
P09408796A0648|9 28|regression analyses
P09409416A0111|16 24|arteries
P09409774A0214|15 20|level
P09409821T0000|29 39|RAD30 gene
P09411459A0729|18 28|experiment
P09412079T0001|0 12|Diet therapy
P09413375A1486|3 15|ICU patients
P09414074A0827|0 19|Resistance training
P09414287A0637|0 16|Gel-shift assays
P09414319A1442|0 6|Y15170
P09415711A1348|0 18|Gel mobility shift
P09416467A0959|6 13|results
P09416898A1798|4 15|mean values
P09417082A0127|13 30|signaling cascade
P09417108A0000|11 24|Htf9-a/RanBP1
P09417493A0823|3 13|accordance
P09417870A0105|33 42|depletion
P09417928A0980|0 11|Replacement
P09417941A1287|4 22|disulphide bridges
P09418040T0000|0 12|Mg-chelatase
P09418057A0684|4 9|R-EST
P09418861A0623|16 25|structure
P09418871A0620|4 15|interaction
P09418882A0760|14 24|antibodies
P09418905A1396|6 13|results
P09419415A0236|8 13|study
P09419421A0385|20 25|cells
P09419680A1112|0 10|CONCLUSION
P09420219A0284|18 31|investigation
P09420220A0070|0 4|Cell
P09420234A0654|0 9|MpB GroEL
P09420239A1937|13 22|mutations
P09420251A1363|0 2|C.
P09420252A0092|28 34|repeat
P09420269A0000|7 10|end
P09420275A0682|19 31|requirements
P09420275A1111|3 11|addition
P09420671A1190|0 11|CONCLUSIONS
P09421507A0000|7 21|protein family
P09421508A0696|19 27|activity
P09421511A0827|16 27|comparisons
P09421516A1516|0 13|Deadenylation
P09421521T0000|0 27|Holliday junction resolvase
P09422351A0000|0 3|Ca2
P09422727A0196|42 50|TGACGTGA
P09423123A0000|0 4|IVOX
P09423310A0251|0 19|Histopathologically
P09423856A1098|0 19|Protease activities
P09423968A0039|4 13|mechanism
P09424012A1774|12 34|field placement errors
P09425036A0649|3 11|addition
P09425038A0752|0 2|A.
P09425676A0000|9 19|mechanisms
P09426068A0826|4 24|c-myc/TGF-alpha HCCs
P09426143A1358|20 24|data
P09426183A0000|15 35|Rel/NF-kappaB family
P09426239A0386|4 14|cglIM gene
P09426595T0000|21 30|reductase
P09426907A0391|4 11|purpose
P09426958A0110|4 15|study goals
P09427544A0000|4 12|pel gene
P09427551A0501|4 8|gene
P09427627A0802|3 18|Xenopus embryos
P09427627A0930|12 19|variant
P09427627T0000|15 22|control
P09427844A0739|25 36|dAK subunit
P09428389A1805|0 11|CONCLUSIONS
P09428787A0138|10 15|clone
P09428799A0897|13 17|gene
P09429913A0528|0 7|RESULTS
P09430461A0742|16 21|study
P09430661A0796|10 24|overexpression
P09430668A0172a|4 12|promoter
P09430730A0374|0 2|S.
P09431812A0576|25 27|Hh
P09431828A1472|23 31|increase
P09432752A0109|0 8|Patients
P09434160A0767|8 15|PTPases
P09434160A2078|0 10|Expression
P09434185A0902|4 16|organization
P09434979A0790|4 11|results
P09435056A0128|22 28|domain
P09435116A0437|0 7|Isomers
P09435789A0961a|9 14|RAD17
P09435806T0001|9 14|value
P09436657A0303|5 11|review
P09436706A0168|4 11|patient
P09436795A0350|0 20|Protein C deficiency
P09436989A1011|11 19|addition
P09437001A0769|3 11|contrast
P09438165A0405|7 15|baseline
P09438427A0727|15 19|role
P09438427T0000|26 33|element
P09440166A0857|0 7|RESULTS
P09440616A0422|14 19|phase
P09441664A0377|47 67|transcription factor
P09441746A0546|2 12|cDNA clone
P09442017A0435|7 14|Science
P09442024A0236|0 2|P.
P09442024A0708|2 17|hybridoma clone
P09442031A0586|5 16|information
P09442072A0716|9 14|DNase
P09442080A0856|13 26|binding assay
P09442172A0908|22 25|FSH
P09443948A0000|14 19|study
P09443972A1145|4 11|results
P09443973A1028|0 4|CES4
P09443978A0262|32 37|cells
P09444316A0388|21 26|signs
P09445056A0215|31 53|chemical cross-linking
P09445488A0230|6 12|effort
P09445488A1169|0 19|PowerBLAST analysis
P09446600A0260|2 16|fusion protein
P09446616A0780|0 14|Reconstitution
P09446815A1021|3 11|addition
P09447917A0000|4 14|hypothesis
P09447962A0452|11 21|transcript
P09447962A1027|21 35|interpretation
P09447963A0223|0 4|Sip1
P09447973A0168|25 32|reports
P09447979A1430|5 14|mutations
P09447994A0000|8 15|studies
P09448268A0186|17 23|kinase
P09448574A0964|4 12|findings
P09449018T0000|0 21|Childhood misbehavior
P09450932A0142|8 16|analysis
P09451003A0894|6 24|Esigma54 promoters
P09451016A1037|0 6|GlcNAc
P09451857T0001|0 13|Demonstration
P09452421A1042|0 10|Antibodies
P09452444A0000|0 13|Interleukin-6
P09452444A0450|5 13|analysis
P09453537A0863|5 11|region
P09453689A0000|4 11|purpose
P09454719A0181|12 23|termination
P09454735A1782|0 6|Levels
P09455695A0762|0 10|ALT levels
P09456312A1064|32 38|domain
P09458021A1373|4 5|%
P09458030A0192|4 9|study
P09459241A0707|0 4|Pao2
P09459685T0001|8 22|configurations
P09459835A0297|5 9|cats
P09460171T0000|0 10|Resistance
P09461594A0000|17 25|evidence
P09463174A0670|27 34|results
P09463380A1050|10 17|xTAK1KN
P09463560A0124|0 8|PATIENTS
P09463964A0243|4 9|assay
P09463991T0000|13 18|audit
P09464248A0289|12 20|TATA box
P09464525T0000|0 10|Expression
P09465035A1032|11 20|inhibitor
P09465783A0449|0 20|Platelet aggregation
P09466267A1192|6 18|himA mutants
P09466931T0000|0 13|Cross-talking
P09467044A0973|16 41|breast tumor relapse rate
P09467707T0000|0 19|Sibling aggregation
P09467900A0701|4 18|CAPLC1 protein
P09467955A0468|5 15|hypothesis
P09468386A0594|0 5|Pet-1
P09468509A0463|4 11|protein
P09468514A1065|0 17|Northern analysis
P09468515A0621|17 25|deletion
P09469415A1337|4 15|observation
P09469820A0151|4 9|mRNAs
P09469833A0533|27 33|nature
P09469933A1060|7 14|tissues
P09471984A0000|0 10|BACKGROUND
P09472038T0000|13 25|polarization
P09472608A0253|26 33|ability
P09472616A1004|18 29|amino acids
P09473040A1303a|11 20|alcR gene
P09473040A1303b|11 20|alcR gene
P09473317X2131|0 9|Copyright
P09473483A0953|41 45|care
P09473755A0318|0 8|PATIENTS
P09474001A0825|4 13|frequency
P09474648A0298|16 23|P-SAECG
P09475378A1449|20 59|transcription-polymerase chain reaction
P09475724T0000|0 4|TOR2
P09475898T0000|14 27|amnioinfusion
P09476399A0141|11 19|division
P09476520A1326|7 13|models
P09477316A0140|3 8|order
P09478921A0126|0 10|Substrates
P09478971A1896|0 19|Reporter constructs
P09478976A0718|0 20|Transfection studies
P09478976T0000|0 12|Oncostatin M
P09479498A0000|29 45|RING-finger gene
P09480831A0272|28 37|mechanism
P09480843A0848|18 24|region
P09480929T0000|8 12|FasR
P09481826T0000|0 7|Control
P09482107A0551|4 14|inhibition
P09482902A0423|0 8|C.D2-Chr
P09482902A0942|28 33|DBA/2
P09483596A0626|26 36|difference
P09484463T0000|0 7|Cloning
P09484781A1233|20 31|association
P09485308A1165|4 14|FMN moiety
P09485790T0000|0 26|Alison Bell Memorial Award
P09486035A0051|0 7|METHODS
P09486531A0638|7 20|organogenesis
P09486890A0234|9 20|laparoscopy
P09487130A0383|3 13|difference
P09487590A0657|4 17|mean duration
P09487841A0132|4 8|ESEM
P09488441A0615|0 3|Sp1
P09488466A0695|7 15|fragment
P09488486A0000|4 8|TATA
P09488486A0906|16 19|TBP
P09488491A0000|0 12|E2F activity
P09488713A0886|28 38|inhibition
P09488725A0904|32 40|identity
P09488725T0000|10 26|characterization
P09489670A1157|3 14|C. albicans
P09490676A0800|13 20|binding
P09490727A1041|5 28|structure interconnects
P09491074A0104|29 38|mechanism
P09492038A0352|15 20|study
P09494078A1362|8 22|5HT5A receptor
P09495283A0000|17 30|reporter gene
P09495771A0379|10 22|fluorescence
P09498553A0702|3 11|TATA box
P09498553T0000|28 35|studies
P09498769A0095|4 22|expression pattern
P09499031A0000|19 33|gene junctions
P09499048A1003|18 31|virus progeny
P09499061A0000|0 8|Cleavage
P09499254A1309|4 15|DSF regimen
P09501093A0071|0 10|Activation
P09501169A0000|0 26|Histone acetylation levels
P09501982A1178|0 11|CONCLUSIONS
P09502627A0705|0 7|RESULTS
P09502720A0214|0 19|CyIIa transcription
P09502720T0000|29 52|cell type specification
P09503017A1021|16 24|evidence
P09503526A0614|3 11|patients
P09504423A0114|13 23|expression
P09504514T0000|11 21|comparison
P09504553T0000|12 15|use
P09504906A0099|0 8|Analysis
P09505135A0182|18 25|stimuli
P09505733A0246|2 8|review
P09506439A2179|0 9|PKC-gamma
P09506959T0000|0 14|Identification
P09506962A1000|33 42|targeting
P09506983A0304|0 7|Primers
P09506990T0000|6 18|ZFM1 protein
P09507032A1144|18 34|CSF1R/IRDelta960
P09508119A0498|0 11|CONCLUSIONS
P09508377A0863|6 13|results
P09508511A0588|3 10|ferrets
P09508775A0293|29 36|pathway
P09509226A1235|0 11|CONCLUSIONS
P09510189A0192|35 47|organization
P09510398A1138|4 16|risk factors
P09510582A0157|23 31|patients
P09510925A0389|7 32|haemoglobin concentration
P09511724A0483|7 12|cells
P09511760A0221|9 36|restriction enzyme analysis
P09512416A0460|0 7|RESULTS
P09512550T0000|0 3|E1A
P09512559T0000|21 31|expression
P09513759A0716|0 18|Calcitriol therapy
P09514156A1147|0 11|Alterations
P09514159A0562|15 44|hormone-coding gene promoters
P09514260A1083|19 26|inteins
P09514272A0482|0 12|Purification
P09514962A0841|0 4|M-66
P09515031A1020|6 13|results
P09515032A1230|0 6|RT-PCR
P09515665T0000|0 11|Ganciclovir
P09515858A0000|0 10|BACKGROUND
P09515921A1662|16 24|mutation
P09515924A0104|9 10|g
P09515924A0553|4 7|PDH
P09516472A0292|34 42|elements
P09517646A0149|0 12|Azithromycin
P09517989A0476|4 9|study
P09518383A0000|0 10|BACKGROUND
P09518808T0000|0 22|National certification
P09519757A0482|15 24|mutations
P09519828A0809|10 27|VP16-E2 molecules
P09519830A0282|3 8|order
P09520398A0124|6 13|changes
P09521907A0190|26 29|otd
P09521909A0081|0 20|APETALA3 transcripts
P09521913A0400|18 27|mutations
P09522297A0744|0 10|Cell lines
P09522979T0000|22 33|fibronectin
P09523478A0572|3 11|addition
P09523551A0367|5 13|variants
P09524122A0336|15 21|allele
P09524222A0769|4 17|COOH-terminus
P09524222A1113|0 12|PCR analysis
P09524229A0000|4 14|gene lac-1
P09524250A0767|14 22|elements
P09524259A0301|4 22|hp55 gamma protein
P09524267A1023|4 17|plant protein
P09524273A0205|5 10|paper
P09524276A0939|0 13|LysR proteins
P09525105A0298|28 38|activities
P09525598A0325|0 10|Regulation
P09525888A1482|12 23|FLAP clones
P09525891T0000|0 7|Members
P09527921A1178|31 40|complexes
P09528758T0000|0 5|Rex-1
P09528766A0915|9 19|inhibition
P09528768A0000|0 5|Cells
P09528770A1379|29 56|protein kinase cAPK pathway
P09528784A0000|4 8|mei4
P09528792A0000|12 20|splicing
P09528858A0205|8 13|cases
P09528950A0716|12 21|fragments
P09528987A1348|0 23|Cotransfection analyses
P09529156A1238|0 8|Deletion
P09529216A0644|0 13|Flap survival
P09529649A0307|0 9|Jean Klig
P09529721A0000|10 20|indicators
P09530251A0766|0 4|SNAC
P09531538A0983|12 23|requirement
P09531549A0658|9 24|binding studies
P09531559A1153|9 26|affinity analyses
P09533030T0000|0 12|Cytochrome b
P09533109A0449|11 19|decrease
P09535082A0537|4 12|addition
P09535579A1105|20 31|assumptions
P09535833A0228|14 33|amino acid sequence
P09535835A0279|0 6|ROCK-I
P09535851A0591|12 20|isoforms
P09535892A0000|4 16|beta subunit
P09535908A0321|29 41|LNX messages
P09536028A0945|3 11|contrast
P09536440A0000|7 14|studies
P09536901A0362|14 22|occasion
P09537295A0951|21 31|start site
P09537295T0000|0 8|Analysis
P09537361A0149|4 19|iron dependence
P09537375A0198|5 25|gntR deletion mutant
P09537378A1227|17 25|deletion
P09537651A0366|9 14|sites
P09538156A0130|0 13|BRCA1 protein
P09538220A0000|29 35|region
P09538258A0200|8 14|report
P09539421A0970|6 18|Sir proteins
P09539721A0599|28 32|DnaA
P09539746A0781|0 10|Expression
P09539779A0621|20 33|hybridization
P09540062A0755|6 13|mutants
P09541280A0404|10 20|plasma IgE
P09541636T0000|0 23|Creatine kinase release
P09541721A0894|20 41|ischemia/angiotension
P09543227A0815|0 7|Group A
P09544987A1583|28 38|RU486-PR-B
P09544991A0483|0 12|PRL receptor
P09544991A0750|22 28|mutant
P09545146A0884|0 11|CONCLUSIONS
P09545293A0590|0 5|Sites
P09545312A1197|4 16|observations
P09545323T0000|14 22|assembly
P09545332A0137|0 8|Mutation
P09545353A1071|33 48|kappaB elements
P09545638A0330a|35 64|yeast hnRNP methyltransferase
P09545638A0330b|35 64|yeast hnRNP methyltransferase
P09545638A0836|12 27|HRMT1L2 protein
P09545638A1181|13 18|roles
P09545638T0000|0 14|Identification
P09546424A1550|29 47|PDGF beta-receptor
P09547311A1394|13 25|interactions
P09547349A0000|4 76|ether phospholipid 1-O-octadecyl-2-O-methyl-rac-glycero-3-phosphocholine
P09548481A0000|3 11|addition
P09549179A0774|0 12|Serum levels
P09549398A1463|8 17|agreement
P09549632A1189|6 9|use
P09549660A0782|22 31|data sets
P09549783T0000|8 16|accuracy
P09550591A0454|11 20|treatment
P09550919A0365|5 9|data
P09551096A0108|0 4|RNAs
P09551182A0212|9 28|retinoid signalling
P09551938A0318|31 38|factors
P09551972A1033|0 12|Fluorescence
P09552469A0225|4 15|interaction
P09553040A0651|0 13|Cell survival
P09553134A0596|25 42|neurite outgrowth
P09553143A0729|11 27|ZAP-70 substrate
P09553686A0000|20 28|patterns
P09555046A1617|4 11|results
P09556557A1238|24 31|regions
P09556561A0671|10 23|H/ACA snoRNAs
P09556566A0174|12 30|vitamin D receptor
P09556573A1062|8 15|studies
P09556861A1018|21 31|literature
P09557678A0140|38 48|expression
P09557682A0490|14 22|isoforms
P09557708A1426|0 23|Specialized actin tails
P09557912A0699|11 14|IOP
P09560221A0282|2 6|cDNA
P09560325A1285|19 32|modifications
P09560390A0771|3 11|addition
P09560430A0000|0 4|Ime1
P09561560A0579|0 15|Rhesus macaques
P09561616A0142|0 12|Deltamethrin
P09562398A0848|0 17|Trichloroethylene
P09562558T0000|0 18|Solution structure
P09564860A2139|3 11|contrast
P09564860A2315|6 10|data
P09564917A0900|10 16|levels
P09565576T0000|12 18|domain
P09565584A0770|2 9|cluster
P09565606A0520|25 34|structure
P09566731A0458|10 15|genes
P09566871A0343|3 15|fus3 mutants
P09566871T0000|18 28|regulation
P09566876A0000|12 36|transcription factor IIA
P09566882A0693|6 14|function
P09566918A1115|0 12|Substitution
P09568445T0000|10 16|angina
P09568549A0188|8 13|study
P09570030T0000|6 24|growth retardation
P09570107A0355|11 28|PCDFs/PCDDs ratio
P09570133A0474|3 11|addition
P09570944T0000|0 12|Localization
P09570952A0000|25 37|organization
P09571563A0000|0 7|PURPOSE
P09572428A0526|0 4|Mean
P09572491A1044|18 23|cells
P09572511A0148|8 17|algorithm
P09572965A1235|8 11|ORF
P09572990A0630|3 14|association
P09573187T0000|16 26|repression
P09573202A0900|35 41|levels
P09573244A0523|10 22|mRNA species
P09573374A0687|6 28|Southern blot analysis
P09573378A0761|0 3|U73
P09573884A0392|20 28|position
P09574799A1072|0 15|Echinostomiasis
P09575143A1189|4 16|localization
P09575187A1558|11 15|role
P09575217A0000|5 23|cytokine receptors
P09575217A0971|16 30|R618K mutation
P09576230T0000|4 10|effect
P09576915A0269|14 27|recombination
P09577365A0747|3 17|angiodysplasia
P09577395A0000|46 49|VOR
P09578042A0363|34 42|patterns
P09578570A0200|8 13|study
P09579602A1720|6 19|modifications
P09579789A0974|12 19|results
P09579808A0000|0 10|UDP-GlcNAc
P09580062A0100|6 14|patients
P09580563A0331|14 33|amino acid sequence
P09580700A0841|4 26|DNA binding activities
P09581552A1323|10 19|modelling
P09581775A0185|15 20|study
P09581834A2578|22 29|results
P09581872A0000|14 20|tissue
P09582267A0326|15 23|function
P09582306T0000|2 16|point mutation
P09582308A1165|41 50|formation
P09582326A0151|0 2|N.
P09582327A0295|30 39|GH3 cells
P09582331A0506|16 22|region
P09582343A0000|34 47|cell line SX9
P09582350A0165|3 11|patients
P09582635A0523|0 7|Results
P09582953A0000|0 10|OBJECTIVES
P09582953A1097|0 7|RESULTS
P09582953A1670|4 8|data
P09583201A0759|0 4|None
P09583208A0171|7 16|elevation
P09583592A0263|0 6|DESIGN
P09583823A0238|0 7|METHODS
P09584165T0000|0 5|RACK1
P09584179A0673|0 17|Peptide sequences
P09584180A0701|24 37|reporter gene
P09584194A0000|0 4|HEF1
P09584194A1305|3 10|support
P09585253A1147|4 8|data
P09585540A0440|25 31|enzyme
P09586285A0551|4 12|patients
P09586832A0229|4 9|lines
P09587549T0001|11 18|seizure
P09588228A0370|23 38|anticytokeratin
P09590294A0453|8 15|studies
P09590540A0513|4 13|bZP2 cDNA
P09591221A0137|0 16|Control subjects
P09592125A0000|0 5|Class
P09592168T0000|11 19|features
P09592208A0470|14 23|qualities
P09592219A0652|4 11|results
P09593302A1165|16 28|implications
P09594299A0468|0 7|RESULTS
P09595496A0000|25 31|levels
P09596536A0219|34 54|knee loading changes
P09596542A0542|17 25|surfaces
P09596638T0000|12 19|mapping
P09596738T0000|0 5|Roles
P09598205A0430|12 20|reaction
P09598894A0732|8 16|subjects
P09599102A1191|0 8|Analysis
P09599664A0881|4 18|DNA sequencing
P09599724A0193|20 26|sample
P09599897A0000|17 36|laboratory features
P09601007A0223|11 20|community
P09601510A0215|3 11|contrast
P09601516A0695|0 12|Substitution
P09601921A0000|0 11|Tributyltin
P09601940A0280|16 22|region
P09602124A0127|0 7|Fregnac
P09603345A1257|0 7|GLRaV-2
P09604052A0166|25 29|data
P09605137A0677|9 19|expression
P09605930A1428|10 17|results
P09605934A0801|5 19|E box sequence
P09606633A0523|0 23|Interferon beta therapy
P09606924T0000|0 6|Liquid
P09609342A0000|23 28|types
P09609705A0895|0 11|Examination
P09609720A0357|23 32|fragments
P09610755A1731|4 27|side-to-side difference
P09611016A0652|0 10|CONCLUSION
P09611229A1664|4 11|ability
P09611234A0098|0 18|Rev-erbAalpha/beta
P09611877A0455|15 23|isolates
P09612351A0386|13 21|evidence
P09612775A0726|4 20|ParaSight-F test
P09613574A0905|25 32|protein
P09613946A0194|2 28|deproteinization procedure
P09614065A0966|0 11|Elimination
P09614106T0000|11 19|mobility
P09617765A0174|4 12|sequence
P09617807A0929|15 23|analysis
P09618150A0127|17 22|doses
P09618150A1464|3 11|addition
P09618164A0709|17 18|O
P09618475A0747|8 16|deletion
P09618481T0000|0 10|Regulation
P09619631A0344|0 7|RESULTS
P09619777A1583|9 26|base ketoconazole
P09620273A0189|3 10|mammals
P09620606A0000|3 11|addition
P09620873A1710|14 25|observation
P09620955A0370|21 30|structure
P09621062A0810|4 14|importance
P09621372A0369|8 25|blood examination
P09621893A0000|9 16|studies
P09622055A0207|4 11|members
P09622121A0525|9 19|antibodies
P09622121T0000|4 7|use
P09623830A0000|16 19|use
P09625762A0426|10 25|oncoprotein E1A
P09625807A0000|20 24|mRNA
P09626662A1076|8 19|experiments
P09627285A0160|0 7|SETTING
P09627285A0554|0 6|RESULT
P09627598A0384|0 7|RESULTS
P09628375A0700|7 22|ePTFE specimens
P09628419A0812|20 24|Wing
P09628821A1194|22 38|KG1a EST dataset
P09628890A0455|13 22|following
P09629449A0540|4 11|results
P09630245A0102|0 14|Yeast U1 snRNP
P09630245A0903|0 14|Yeast U1 snRNP
P09631366A0951|16 21|cycle
P09632217A0477|11 32|antagonist naltrexone
P09632637A0361|8 13|study
P09632709A0464|4 14|cDNA clone
P09632734A0081|23 31|proteins
P09632734A0943|8 22|p82 expression
P09632785A0000|4 33|pre-mRNA splicing factor U2AF
P09633171A0321|4 12|brackets
P09633274A0000|0 17|Exercise training
P09633630A0740|4 10|growth
P09633879A0246|19 29|compliance
P09635149A1148|0 10|Hematocrit
P09635276A1608|0 10|Regulation
P09636119T0000|21 30|generator
P09636358A0000|21 28|VAI RNA
P09636670T0000|0 9|Structure
P09636708A0460|4 16|YccA protein
P09637689A0150|10 14|type
P09638342T0000|12 16|role
P09638485A0111|12 19|benzene
P09638650A0169|27 33|region
P09638793A1446|28 40|hemodilution
P09639074A0707|0 3|Sp1
P09639410A3282|6 11|genes
P09639558A0957|36 46|haemolysis
P09639565A0225|46 63|enhancer activity
P09640162A0242|11 18|patient
P09640802A0467|43 55|consequences
P09641167A1359|0 10|CONCLUSION
P09642042A0646|0 18|Binding affinities
P09642200A0956|47 51|size
P09642214A0244|8 14|report
P09642227A0000|0 12|Osteoadherin
P09642238A0532|0 6|Intron
P09642238A1285|4 10|intron
P09642276A0881|4 12|cleavage
P09642764A0469|14 18|mass
P09643153T0000|1 10|Treatment
P09643546A0436|0 24|Transcription initiation
P09643548A0000|4 9|genes
P09645576A0148|0 3|RNA
P09645942A1164|8 12|pool
P09645961A1158|4 11|results
P09647233A0336|3 14|macrophages
P09647240A0000|4 13|influence
P09649069A0490|39 59|laryngeal parameters
P09649265A1575|0 11|CONCLUSIONS
P09649315A0943|0 11|Examination
P09649426A0636|15 27|PKA activity
P09649437A1140|31 43|interactions
P09649438A0182|18 56|transcription elongation factor P-TEFb
P09649501A0358|29 36|repeats
P09649537A0000|12 23|cDNA clones
P09650180A1130|12 25|recombination
P09650186A1043|8 14|number
P09650275T0000|29 47|weapons convention
P09650299A0000|0 5|VirD2
P09650299A1334|22 26|data
P09650403A0868|4 16|DHEAS levels
P09650789A0185|0 11|Orientation
P09651321A0000|0 10|Cystatin A
P09651367T0000|2 6|role
P09651375T0000|0 6|GTPase
P09651383A0967|9 18|mutations
P09652736A1205|3 11|addition
P09652737A1244|25 33|analysis
P09652742A0455|38 41|p53
P09653182A1298|6 10|data
P09653641A0471|6 14|isoforms
P09653648A0445|0 10|Comparison
P09653745A0180|0 7|Malaria
P09655248A0000|4 21|gp330/Megalin/LRP
P09655916A0415|7 28|DNA recognition helix
P09656414A0220|0 6|Dosage
P09656485A0351|16 22|copies
P09657003T0000|13 26|relationships
P09658104T0000|0 4|Role
P09658122T0000|0 13|Fowlpox virus
P09658403A1207|0 8|Addition
P09658405A0000|4 14|Dax-1 gene
P09658769A0058|32 44|IFN alpha-2b
P09660823A0934|9 32|Ser/Thr phosphorylation
P09660836A0983|13 23|evaluation
P09660838A0920|0 10|Regulation
P09661676T0000|9 20|implication
P09662339A0744|9 14|cells
P09662443A0402|47 59|organization
P09663062A0175|0 22|Tensile bond strengths
P09664033A1204|5 17|distribution
P09665361T0000|12 19|therapy
P09665503A0526|22 32|volunteers
P09665720A0325|7 14|absence
P09665720A1145|21 24|Mg2
P09666103A0496|4 19|missense allele
P09666114A0389|11 19|analysis
P09667482A0978|4 10|report
P09667795A0000|6 18|pancreatitis
P09668063A0274|25 29|role
P09668096A0806|13 17|site
P09668098A0868|22 37|FGF-BP promoter
P09668108A1017|0 12|Manipulation
P09668119A0496|16 37|mobility shift assays
P09669641A0425|15 23|accuracy
P09670034A0340|20 25|Ddc1p
P09670912T0000|18 26|seizures
P09670943T0000|0 23|B cell antigen receptor
P09671313A0334|0 5|Chem.
P09671464A0316|9 13|SNF1
P09671496A0557|24 28|role
P09671576A0900|34 42|endoderm
P09671579A1168|16 24|noi/pax2
P09671791T0000|19 29|activation
P09673037A0358|0 7|METHODS
P09673436A0898|22 26|rats
P09675154A0690|40 48|families
P09675896A0959|0 7|Removal
P09676349A0000|3 10|Level A
P09676419A0158|0 6|METHOD
P09677330A0584|29 46|linker region LR1
P09677405A0856|0 18|Pol32Delta strains
P09677410A1059|12 16|time
P09678579A0768|8 15|insight
P09678837A0736|4 7|aim
P09679066A1352|6 13|results
P09679750A0304|19 28|potential
P09680994A0169|5 10|study
P09681822A0520|10 29|c-erbB3 transcripts
P09682897A0218|18 23|years
P09683576A0542|21 34|cleavage site
P09685021A0127|0 7|METHODS
P09685226A0000|4 8|role
P09685346A0419|4 15|combination
P09686344T0000|30 38|spectrum
P09686603A0124|26 30|role
P09687498A1173|4 11|results
P09687511A1091|0 14|Downregulation
P09687514A0521|8 13|study
P09688264A1029|5 14|repressor
P09689047A0253|2 14|prerequisite
P09689919A1192|17 26|PEDF cDNA
P09691031A1050|13 18|model
P09691037A0355|9 18|sequences
P09692965A0904|5 13|cysteine
P09693035T0000|6 10|ULK1
P09693134A0782|30 37|markers
P09693306T0000|21 31|potentials
P09694034A0713|6 13|results
P09694514A0000|4 41|complement C3a anaphylatoxin receptor
P09694599A1355|0 11|CONCLUSIONS
P09694725A0500|11 17|assays
P09694860A0498|15 21|region
P09694869A0932|3 11|addition
P09694897T0000|26 62|ribonucleoprotein C protein tetramer
P09695194T0000|7 17|comparison
P09696164A0000|18 24|system
P09696819A0450|14 21|mutants
P09698457A0778|18 22|mice
P09698457A0976|11 18|protein
P09698512A0296|0 7|METHODS
P09700644T0000|4 12|spectrum
P09701609A0116|4 14|laboratory
P09701616A0108|8 47|transcriptase-polymerase chain reaction
P09701821A1108|3 11|contrast
P09701895A0119|22 30|children
P09703021A0000|3 10|insects
P09703213A0280|3 14|experiments
P09703276A2346|6 13|results
P09703816A0139|0 5|IA-CT
P09704006A0224|0 10|Arnt3 mRNA
P09704296T0000|34 41|purpura
P09704569T0000|12 21|structure
P09704857T0000|0 11|Correlation
P09704927A0479|6 12|shares
P09705258A0837|4 20|IE13.1 cell line
P09705324A0213|0 5|DNase
P09705324A1602|12 19|studies
P09705352A0879|9 13|Hsk1
P09705497A0227|4 19|yeast MMS2 gene
P09705564T0000|0 10|Expression
P09706565A1072|0 10|Anesthesia
P09706643A0206|30 35|agent
P09707498A0262|0 21|MK-801 administration
P09707577A1047|3 11|contrast
P09708450A0648|0 8|Toxicity
P09708565A0000|4 11|purpose
P09710131A0374|5 12|methods
P09710582A0535|4 10|effect
P09710589A1111|14 25|mutagenesis
P09710591A0981|0 9|Mutations
P09710599A0310|14 19|cells
P09710599T0000|11 21|activation
P09710614T0000|0 14|Identification
P09710615T0000|0 5|Vam7p
P09710621A0598|20 31|possibility
P09710641A0000|41 46|Pax-6
P09712037A0470|0 15|Tctex-1 binding
P09712297T0000|4 37|prothrombin gene G20210A mutation
P09712644T0000|16 26|regulation
P09712859A1110|4 11|binding
P09712898A0911|6 11|TRAF2
P09712898T0000|0 31|Tumor necrosis factor signaling
P09712915A0672|4 12|activity
P09712919A0307|7 14|studies
P09713584A1193|0 11|Respondents
P09713990T0000|0 9|Isolation
P09713996A0262|0 14|Overexpression
P09713996T0000|26 42|characterization
P09714109A0000|0 10|BACKGROUND
P09714109A0785|9 32|blood pressure increase
P09714835A0345|11 17|report
P09715278A1079|0 12|RA-treatment
P09715278A1526|4 18|histopathology
P09715384A0235|12 19|vessels
P09716095T0000|0 15|Pressure ulcers
P09716179A0974|0 20|RXR-gamma expression
P09716183A1036|0 3|TBP
P09716435A1004|11 21|CR/PP diet
P09717246A0526|10 13|ILC
P09717835A0941|6 23|sequence analyses
P09717887A0239|12 17|study
P09718372T0000|0 8|Evidence
P09718671A0000|16 28|Injury Scale
P09719636A1134|5 15|hypothesis
P09721207A0637|16 24|analysis
P09721798A1734|13 20|percent
P09722043A2070|14 24|TPN groups
P09722161A3065|0 10|Regulation
P09722508A0953|34 48|Galpha11 Q209L
P09722766A0706|4 24|micturition pressure
P09723896A0000|0 10|Peroxisome
P09724654A0761|36 43|origins
P09724654A1120|13 21|presence
P09724754A0173|0 8|Tyrosine
P09724763T0000|14 26|substitution
P09724772A0840|0 22|Gel retardation assays
P09725292A1473|0 10|CONCLUSION
P09725651A0077|13 17|RTPS
P09725854A1060|19 29|similarity
P09726201T0000|0 5|JCAHO
P09726979T0000|10 17|cloning
P09726987T0000|8 45|SPT3-TAFII31-GCN5-L acetylase complex
P09726988A0275|0 6|Oleate
P09726991T0000|0 7|Mapping
P09727045A0817|10 19|mechanism
P09727046A0000|43 50|protein
P09727046A0784|4 13|CBF1 site
P09729481A0000|4 47|rat branched-chain-2-oxo-acid dehydrogenase
P09729481A1177|0 15|Co-transfection
P09730413A0642|11 25|investigations
P09731354A0963|17 26|degrees C
P09731513A1090|22 29|results
P09731704A0000|5 10|study
P09731704A1472|0 12|Transfection
P09731705A2126|0 7|Studies
P09733493A0493|4 11|results
P09733647A1960|5 13|sequence
P09733794A1323|23 30|changes
P09733815T0000|0 8|Tyrosine
P09733854A0198|24 34|transcript
P09734808A0000|11 26|test efficiency
P09735286A0599|4 10|defect
P09735366A1180|6 33|homology cloning techniques
P09735368A0636|22 24|m8
P09735371A0227|41 60|homeodomain protein
P09736239A0436|14 34|resuscitation period
P09736697A0783|0 10|Expression
P09736697A1107|0 4|MEKs
P09736715A0729|13 33|phosphatidylinositol
P09736770A0351|0 12|Transfection
P09737453A0557|0 6|Plasma
P09737921T0000|0 17|Genome plasticity
P09738010A0305|4 16|FAS promoter
P09738087A0583|4 10|effect
P09738693T0000|0 7|Effects
P09739401A0000|0 9|OBJECTIVE
P09739913A0194|0 11|CASE REPORT
P09741391A0581|33 41|body box
P09741783A0000|0 11|Anastrozole
P09742129A0491|0 2|W.
P09743128A0969|0 7|Moritta
P09743233A0526|0 8|Mutation
P09743720A0268|0 7|ANIMALS
P09744095A1016|21 28|mutants
P09745797A0943|25 41|underpredictions
P09747651A0000|0 14|Laser ablation
P09747873T0000|19 40|adapter protein GRB10
P09748261A0000|45 65|acyl-CoA synthetases
P09748286A0000|41 49|enhancer
P09748513X1360|0 9|Copyright
P09748669A0414|10 14|time
P09749533A0764|0 5|Clone
P09749988A0000|0 7|Badcock
P09750325A0000|4 11|effects
P09750540A0000|9 29|chemical sensitivity
P09751061A0000|0 19|POU-domain proteins
P09751114A0967|21 25|MyoD
P09751114A1987|6 13|results
P09751166A1460|18 25|results
P09751458A0845|0 20|desmethyltrimebutine
P09753241A0524|11 23|examinations
P09753730A0881|0 16|T7 transcription
P09753769A0362|4 11|primers
P09753774A1642|0 6|Plants
P09753774A2246|13 23|comparison
P09753775A0734|9 13|ICK1
P09754571A0169|9 19|transcript
P09754571A1257|4 14|hBRAG gene
P09755191A0553|21 27|swa5-1
P09755199A0373|33 40|lesions
P09755199A0559|32 45|Scm mutations
P09755478A0366|0 17|Northern analysis
P09756687A0981|12 28|characterization
P09756895A0322|8 13|locus
P09757012A0942|4 12|presence
P09759180A0000|0 10|BACKGROUND
P09759691A1051|3 11|analyses
P09759865A0673|15 23|IL-1beta
P09760243A0970|0 15|Cotransfections
P09760341T0000|0 26|Phosphocreatine hydrolysis
P09761711A0000|0 20|Pseudocontact shifts
P09761723A0226|0 6|GETS-1
P09761791A0489|4 15|interaction
P09763421A1199|10 20|phenotypes
P09763446A0000|6 13|GTPases
P09763446A1234|4 7|GEF
P09763470A0000|0 25|Dopamine beta-hydroxylase
P09763470A1756|19 24|study
P09763522A2545|18 26|antibody
P09763607A0521|23 34|Ngo strains
P09764741A0092|8 13|beams
P09765261A0000|10 16|T cell
P09765271A1108|5 13|sequence
P09765277A0000|24 51|glucose transporter isoform
P09765285A0998|22 31|half-site
P09765285A1763|4 10|levels
P09765372A0669|9 16|density
P09765388T0000|0 12|Inactivation
P09765394A0000|17 41|virus transactivator Zta
P09765394A1590|0 14|Cotransfection
P09765411A0991|0 20|Sequence comparisons
P09765466A0231|0 2|J.
P09765754A1727|12 17|trend
P09767504A1371|16 20|dose
P09767575A0657|5 11|domain
P09767593A0130|9 13|YopH
P09767687T0000|13 21|position
P09769209A0100|17 24|studies
P09769910A1700|4 14|activation
P09770241A0000|2 11|technique
P09770378A0641|0 11|EGFR levels
P09770415A0139|25 32|THOV NP
P09770493A0499|3 7|PP2A
P09770686A0484|18 29|risk factor
P09771555A0499|4 11|results
P09771967A1052|13 21|LB1 gene
P09771985A0238|3 11|subjects
P09773975A1873|10 24|AT1A receptors
P09773981A0415b|14 37|glucocorticoid receptor
P09774403A0107|0 2|T.
P09774444A0351|22 29|portion
P09774450A0000|30 42|mouse enzyme
P09774484T0000|0 18|UGA codon position
P09774641A0824|0 9|Forskolin
P09774662A0958|4 16|ARF promoter
P09776293A0777|0 7|RESULTS
P09776360A0620|0 2|CM
P09776360A1781|0 9|NF-kappaB
P09777477A0000|0 9|Observers
P09777600A0000|20 26|method
P09777999A0796|0 7|RESULTS
P09778006A0718|16 29|baseline Vmca
P09778068A1129|13 34|Cox survival analysis
P09778191A0000|24 30|method
P09778197A0415|0 27|Cost-effectiveness analysis
P09780002A0996|9 15|E2FBP1
P09780228A0122|0 10|Sequencing
P09780228A0613|14 31|domain structures
P09780336A0771|0 8|Analysis
P09781761A0384|5 21|Ho Chi Minh City
P09781871A0404|0 18|Glycogen synthesis
P09781874A1061|4 19|cwg2-1 mutation
P09784063A0621|0 17|Deletion analysis
P09784192A1027|12 19|peptide
P09784245T0000|23 32|protein C
P09785114A1026|12 15|PND
P09786197A0322|0 8|Analysis
P09786404A0541|10 23|aggregates/ml
P09786926A0095|27 33|region
P09786926A1372|24 39|binding studies
P09786932A1042|6 11|IRF-7
P09786949A0114|0 2|J.
P09787323A0000|0 7|PURPOSE
P09788739A1096|26 39|serine kinase
P09789025A0149|0 7|Galphaq
P09789795A0607|22 30|subjects
P09790499A0545|0 22|Northern blot analyses
P09790767A0372|36 55|sequence tag clones
P09790768A0621|0 11|Htra2-beta3
P09790771A0956|0 18|Gng3lg transcripts
P09790771A1032|23 38|backcross panel
P09790986A0689|28 36|antibody
P09792439T0000|0 10|Inhibition
P09792627A0441|0 5|SRC-1
P09792630A1127|12 20|sequence
P09792682A0713|6 13|results
P09792702A0754|0 10|Expression
P09792714A1408|4 15|interaction
P09794414T0000|4 8|role
P09794795A0183|0 14|Ligand binding
P09795130A0742|18 26|increase
P09795170A0774|20 40|polyadenylation site
P09795213A0129|0 13|RBP56 protein
P09795341A0806|19 39|mobility shift assay
P09797189A0559|13 27|shift analysis
P09797456A0000|0 10|BACKGROUND
P09797456A0883|0 5|AMY-1
P09798068A0290|0 7|RESULTS
P09798100A0705|3 6|Day
P09798263T0000|20 30|properties
P09799086A0725|18 34|hotspot mutation
P09799237A0624|14 21|embryos
P09799362A0507|32 40|features
P09799362A1463|0 15|Over-expression
P09799634A0161|20 34|computer model
P09799793T0000|12 22|sequencing
P09800187A0100|8 13|Trp53
P09801156A0220|13 22|fragments
P09801333A0174|16 22|N gene
P09802206A1058|9 26|sequence homology
P09802902A0225|30 34|ARNO
P09803081T0000|6 15|pathology
P09804779A0000|0 21|Transcription factors
P09804779A1163|20 28|pathways
P09804836A0000|36 43|protein
P09805052A0119|0 4|Dose
P09805977A0143|22 26|data
P09806516A1212|5 16|association
P09806516A1689|0 10|CONCLUSION
P09806546A1270|4 15|interaction
P09806826A0244|30 36|defect
P09806826A1773|6 10|data
P09806830X1174|0 9|Copyright
P09806857A0854|8 21|reading frame
P09806858T0000|0 14|Identification
P09806919A0447|8 11|usp
P09807755A0146|24 30|supply
P09808155A0813|0 11|Examination
P09808216A0000|0 10|BACKGROUND
P09808366A0828|6 14|apneusis
P09808441A0320|14 22|analysis
P09810087A0379|0 7|RESULTS
P09811695A1146|6 13|results
P09811718A0979a|6 13|results
P09811730A1396|0 16|Competition EMSA
P09811730T0000|0 9|Mechanism
P09813041A1122|0 2|GH
P09813063T0000|0 10|Expression
P09813093A0624|15 21|effect
P09813098A0521|0 10|Paralemmin
P09813110A0982|12 31|amino acid sequence
P09813203T0000|4 10|effect
P09813207A0434|0 32|Transcription start site mapping
P09813254A0000|17 31|oligoadenylate
P09813259A1097|4 12|findings
P09813635A0678|6 16|striations
P09814637A1214|4 18|PbrO2 readings
P09814905A0598|4 16|consequences
P09815578A1245|5 10|study
P09815948A1065|20 30|parameters
P09817131A0296|15 32|SF-36 survey form
P09817190A0074|13 16|use
P09817373A0000|0 7|PURPOSE
P09817601T0000|0 16|Characterization
P09819038A0448|12 17|FVIIa
P09819110A0703|0 14|CD4 lymphocyte
P09819216A0220|7 19|Biochemistry
P09819288A0578|0 6|Levels
P09819377A1209|2 10|mutation
P09819391A1123|34 38|Arfs
P09819411A0897|3 8|DNase
P09819414A1103|14 20|nexins
P09819421A0000|0 12|Cyclophilins
P09819422A0768|9 38|protein retention experiments
P09819430A0000|16 23|GTPases
P09819440A0000|12 25|transcription
P09819440A0783|11 14|RMP
P09819507A0000|8 13|study
P09820163A0565|4 11|mapping
P09820205A0000|4 18|zona pellucida
P09820611T0000|12 15|use
P09820621A0067|22 38|thyroid function
P09821978A1255|16 24|deficits
P09822602A0237|29 38|mechanism
P09822602A1172|32 38|import
P09822647A0000|4 23|rat aldolase C gene
P09822652A1118|14 20|effect
P09822661T0073|16 22|domain
P09822685A0596|8 16|analyses
P09822690A0000|10 24|sperm motility
P09822825A0141|8 13|paper
P09823014T0000|0 6|Effect
P09823561T0001|18 31|MALT lymphoma
P09823775A1122|6 13|studies
P09824001A1665|3 11|contrast
P09824021A1263|0 10|CONCLUSION
P09824158A1336|13 39|BCL-6 POZ domain mutations
P09826434T0000|8 24|characterization
P09826658A0691|5 18|core sequence
P09826778A0943|0 15|Over-expression
P09827446T0001|20 29|hepatitis
P09827724A1362|3 12|mutations
P09827878A0091|6 28|glutathione peroxidase
P09827993A0000|11 32|nucleocapsid proteins
P09828137A0000|30 34|rad1
P09829836A0000|32 43|progression
P09829836A0815|17 27|selections
P09829843A0119|37 44|factors
P09829843A0819|4 14|injections
P09829916T0000|0 10|Expression
P09832099A0000|40 51|wall motion
P09832436A0738|0 15|RT-PCR analysis
P09832436T0000|10 17|cloning
P09832504A0596|32 43|interaction
P09832505A0903|28 45|activation target
P09832511A0269|13 25|neurogenesis
P09832518A0615|4 21|repression domain
P09833610A0626|4 13|exodomain
P09833740A1112|0 27|Pyrrolidine dithiocarbamate
P09834070A0793|25 35|activation
P09834521A0000|17 29|hydatid cyst
P09835615A0574|12 20|analysis
P09836881A0441|13 22|BCH group
P09837714A1068|4 11|results
P09837715A0581|36 42|amount
P09837824A0419|14 30|telSMN mutations
P09837907A0857|4 12|decrease
P09837913A0000|0 4|Type
P09837913A0419|45 64|sequence tag clones
P09837914A0844|0 4|Biol
P09837920A0222|41 53|requirements
P09837933T0000|0 6|P-CIP1
P09837945A0820|0 18|Immunolocalization
P09837978T0093|10 20|activation
P09838122A0489|31 51|coding cDNA sequence
P09840822A0462|4 10|method
P09840928A0884|31 34|Dlk
P09840932A0365|8 13|study
P09840934A0435|8 14|Ha-Ras
P09840943A0144|31 37|cyclin
P09842517A0497|8 18|experience
P09843378A0187|4 24|dopamine D4 receptor
P09843412A0130|36 40|form
P09843572A0944|5 10|model
P09843577A0000|26 31|cells
P09843944A0976|0 8|A-tracts
P09844106A0835|5 20|phosphorylation
P09844921A0000|0 3|Raf
P09845043A0000|4 25|US National Institute
P09845662A0085|0 8|Collagen
P09845856A0560|0 7|RESULTS
P09846033A0488|0 7|RESULTS
P09846482A0441|3 7|turn
P09846927A0227|4 7|tip
P09847371A0000|0 22|Jembrana disease virus
P09847397A0935|16 17|%
P09848653A0597|0 5|Nhp2p
P09849421A0332|5 11|survey
P09849722A0797|7 19|presentation
P09849961A0387|0 15|Down-regulation
P09849965A0000|5 10|study
P09851614A0109|18 26|features
P09851700A0000|4 8|gene
P09851988A0085|9 17|presence
P09852005A1287|0 11|Competition
P09852068A0150b|10 14|SHBG
P09852109A1475|9 20|translation
P09852136A0174|21 29|mutation
P09852136A0507|0 17|Wild type HA-p190
P09852752A0950|34 44|vasculitis
P09854034A0536|26 34|promoter
P09855111A0905|27 41|overexpression
P09856397A0099|0 17|Dry matter intake
P09856732A0114|12 19|studies
P09857038A1374|0 2|E.
P09857197A0289|0 5|Yap1p
P09857265A0669|0 11|Mean intake
P09858094A0583|10 19|amplitude
P09858531A1017|13 33|RING1 overexpression
P09858571T0000|4 19|yeast RER2 gene
P09858572A0000|4 29|yeast retrotransposon Ty5
P09858577A1186|4 8|loss
P09858581A0183|9 19|expression
P09858588A1046|36 40|form
P09858593A0334|19 39|amino acid sequences
P09858599A0392|5 25|NUP98-HOXA9 chimeras
P09858619A0356|7 14|studies
P09858713A1174|22 26|data
P09858714A1171|8 11|ORF
P09858745A1350|4 12|location
P09858745A2033|9 29|transcription assays
P09858883A1106|0 16|BIAcore analysis
P09860979A0521|0 10|Expression
P09861099A1011|9 21|correlations
P09861365A0000|4 9|Og4C3
P09862343A0225|17 35|gp200-MR6 ligation
P09862481A0000|4 18|Mig1 repressor
P09862496A0187|0 8|Ethylene
P09863624A0629|4 14|divergence
P09863624A2301|16 40|receptor internalization
P09863720T0000|30 37|disease
P09864141A0528|15 20|Stat3
P09864335A1226|20 27|results
P09864689A1408|6 14|findings
P09865775A0162|5 10|study
P09866068A1058|0 11|CONCLUSIONS
P09867159A1444|5 11|regard
P09867253A0229|5 19|c-Jun activity
P09867855T0000|0 19|Dorsal root ganglia
P09868412A1628|0 10|CONCLUSION
P09869297A1807|14 19|roles
P09869356A0926|0 8|CAL gain
P09869400A0203|0 11|Comparisons
P09869528T0000|5 13|fixation
P09871353A0174|32 40|evidence
P09872326A0566|41 49|CBF/cdc2
P09872337A0000|17 27|absorption
P09872832A1262|4 22|BAL concentrations
P09873060A0901|0 24|Phosphorylation analyses
P09873291A0620|8 16|analysis
P09874803A0000|21 52|bacterium group A Streptococcus
P09875541A0210|4 17|orbitofrontal
P09876794T0000|0 9|Improving
P09877417A0704|0 17|Plasma CCK levels
P09878256A0000|4 35|peroxisome biogenesis disorders
P09878437A0967|11 15|site
P09878542A1151|22 30|findings
P09879766A0402|3 8|PAV-3
P09880029A0703|13 32|MDV genome products
P09880103A0387|0 3|MPO
P09880327A0322|19 26|variety
P09880512A1251|4 8|data
P09880513A1013|5 13|proteins
P09880543A0570|0 4|HEED
P09880544A0693|14 36|DT-40 lymphoma B-cells
P09881666A0535|2 7|motif
P09881692A0094|39 47|variants
P09881692A1109|14 19|order
P09882303A1413|0 5|TRAF2
P09882303A1984|6 10|data
P09882303T0000|34 50|membrane protein
P09882321A0948|3 11|contrast
P09882334A0822|16 24|passages
P09882337A0000|0 22|Varicella-zoster virus
P09882348A0611|8 11|end
P09882451A0195|6 11|genes
P09882489A0451|8 13|study
P09882499A0231|30 46|mouse technology
P09882593A0996|14 24|experiment
P09882638A0235|7 13|tissue
P09883639A0000|0 6|Number
P09884232A0286|0 10|Comparison
P09884275T0000|0 26|Interferon-alpha treatment
P09884747A0477|14 21|testing
P09885431A0000|0 9|OBJECTIVE
P09886602A0000|0 10|OBJECTIVES
P09886843A0339|30 34|gene
P09886850A0145|20 28|activity
P09887544A0000|0 10|BACKGROUND
P09888711A0781|0 22|Bioplastique granuloma
P09888994A0858|20 24|gene
P09889202T0000|19 27|analysis
P09889306A0321|3 11|addition
P09890778T0000|0 13|Carbohydrates
P09891009T0000|10 17|cloning
P09891046A0269|10 16|manner
P09891046A0554|24 35|protein L18
P09891049A0761|0 10|Processing
P09891061A0373|30 40|regulators
P09891061A1240|27 31|SpHE
P09891065A1493|27 41|SRE activation
P09891085A0815|15 20|cells
P09891092A1000|28 32|site
P09891707A0000|15 23|subtypes
P09892017A2151|8 19|experiments
P09892021A0712|0 14|Overexpression
P09892422A1096|30 43|tissue sheath
P09892642A0172|0 2|E1
P09892662A0334|19 39|mutant alpha subunit
P09892736A0343|9 15|search
P09893060A0767|0 22|Northern blot analysis
P09893262A1272|16 23|variety
P09893913A0656|0 9|Induction
P09894962T0000|2 12|comparison
P09895323T0000|23 28|roles
P09897032T0000|29 41|self-pulsing
P09900679T0000|0 16|Wave cybernetics
P09903722T0000|0 20|Autoionization rates
P09904139T0000|14 22|approach
P09911328T0000|9 17|approach
P09913308T0000|11 17|lasing
P09914156A1496|18 25|regions
P09914500A0000|8 22|factor kappa B
P09914518A1217|15 26|enhancement
P09914525A0890|12 15|Ffh
P09915118T0000|11 26|naris occlusion
P09915798A1077|5 11|region
P09915860A0000|4 12|promoter
P09915860A0119|0 3|Sp1
P09916786A0811|0 12|Measurements
P09916809A0405|6 9|MGP
P09917064T0000|5 10|roles
P09917387T0000|4 18|RNA polymerase
P09917389A1239|4 11|pattern
P09917391A0380|0 25|Transcription readthrough
P09917555T0001|0 8|Analysis
P09918096A0520|14 18|case
P09918715A0304|0 4|MotA
P09918715A1158|16 20|MotA
P09918720A0998|4 17|S229A variant
P09918842A0184|9 21|conservation
P09920539A0272|4 16|stimulations
P09920775A0075|4 12|sequence
P09920882A0287|0 4|Chem
P09920896A1230|15 26|differences
P09920903A1045|6 13|results
P09920930A0521|0 8|C3 toxin
P09920930A0959|9 17|C3 toxin
P09920982A0253|4 7|aim
P09921179T0001|4 8|role
P09922230A1482|20 27|results
P09922856A0459|0 10|Trinipatch
P09923245A0482|4 8|RMRI
P09924675A0412|13 18|point
P09924987A0000|0 8|Pokeweed
P09925120A0074|0 9|OBJECTIVE
P09925372A0458|16 20|ZFPs
P09925372A1063|20 30|expression
P09925777A1195|14 31|affinity hnRNP A1
P09927193A0107|3 7|date
P09927449A0421|0 14|Overexpression
P09927570A0507|17 31|RNU2 fragility
P09927585A0796|0 33|Competitionsupershift EMSA assays
P09927589T0000|0 10|Similarity
P09929088A0000|0 7|CONTEXT
P09929811A0000|0 11|Experiments
P09931118A1072|12 18|p42/44
P09931191A0434|3 11|protocol
P09931216A0566|0 7|Airflow
P09931252A1055|5 14|mutations
P09931391A0944|9 17|recovery
P09931435A0357|14 25|transcripts
P09932288A0378|0 10|Expression
P09933428A0351|0 9|IFN-gamma
P09933641A0241|15 24|sequences
P09933848A1008|6 20|alloantibodies
P09934611A1054|5 15|dependence
P09935377T0108|0 5|Genoa
P09936001T0000|11 20|structure
P09938097T0000|14 22|transfer
P09940132T0000|8 14|theory
P09943651T0000|9 14|modes
P09944066T0073|0 2|II
P09945838T0000|18 37|matching conditions
P09947191T0000|0 31|Neutron scattering measurements
P09949160A0600|14 28|32D Epo1 cells
P09949178A0264|8 18|expression
P09949312A0524|0 7|Airflow
P09950213A1660|38 50|goblet cells
P09950394A0336|4 11|history
P09952378A0529|4 14|odds ratio
P09952425A0893|8 13|group
P09959737T0000|4 8|case
P09961326T0000|11 23|fluctuations
P09961682T0000|0 5|Model
P09964171T0000|0 3|NMR
P09964770T0000|0 14|Microstructure
P09965234T0000|12 26|heat transport
P09965909T0000|7 15|approach
P09971776A0838|0 9|Mutations
P09971790A0856|8 17|mutations
P09971806A1585|10 15|cycle
P09971815A2094|48 71|candidate latency genes
P09971822A1542|6 10|data
P09973351A1522|23 39|DcuS-DcuR system
P09973607A0254|21 35|identification
P09974642T0000|0 9|Crossover
P09976626T0000|0 7|Erratum
P09980944T0000|0 19|Interplane coupling
P09982923T0000|11 20|structure
P09983871T0000|0 19|Raman investigation
P09984526T0000|0 7|Effects
P09985302T0000|8 25|electron dynamics
P09986796A1761|9 18|deletions
P09987176A0260|6 12|months
P09987634A1265|15 18|PRK
P09987961A0093|10 17|lesions
P09988682T0033|10 17|cloning
P09988767A1496|14 39|mouse back-cross analysis
P09988850A0000|4 10|Scales
P09989334A0964|29 47|processing signals
P09989339A0968|19 22|use
P09990057T0000|0 13|Recombination
P09990060A0803|13 19|motifs
P09990060A0937|3 10|concert
P09990315A0205|0 3|TPO
P09990507A0000|0 10|BACKGROUND
P09990507A0763|0 11|CONCLUSIONS
P09994942T0000|4 15|NMR studies
P09995847T0000|0 26|Optical-absorption spectra
P09995897T0000|0 11|Observation
P09999256T0000|20 26|theory
P09999742T0000|0 3|NH3
P10000253T0000|0 15|Chirality-glass
P10001333T0038|0 15|Echo modulation
P10001541T0000|0 10|Mechanisms
P10002245T0000|21 33|conductivity
P10006319T0000|0 18|Surface spin waves
P10007469T0000|19 26|librons
P10007564T0000|22 30|geometry
P10008261T0000|0 22|Temperature dependence
P10009565T0000|0 22|GW Gamma approximation
P10013227T0000|0 21|Precision measurement
P10019841T0000|8 15|gravity
P10021333A0674|8 19|experiments
P10021350A0093|15 20|model
P10022032A0000|3 10|support
P10022210A0620|0 7|Factors
P10022850A0929|3 11|contrast
P10022858A0985|3 11|addition
P10022867A1069a|0 11|Elimination
P10022867A1069b|0 11|Elimination
P10022875A1265|6 10|data
P10022880A0000|10 39|Ras GTPase-activating protein
P10022905A0446|6 19|mog-1 alleles
P10022921A0608|20 29|SIN3 gene
P10022925A0870|4 25|Nmd3 protein sequence
P10022978A1261|4 16|distribution
P10024383T0000|0 10|Calcitonin
P10024498A0783|31 37|assays
P10024882A0541|3 11|addition
P10025050A1052|4 11|therapy
P10025506A0079|3 9|humans
P10025506A1078|3 7|TATA
P10026146A0680|4 14|inhibition
P10026211A0136|0 8|Proteins
P10026211A0543|5 14|construct
P10026229A0950|3 11|addition
P10026275A0549|18 36|structure elements
P10026784A0331|9 17|evidence
P10026784A0929|28 39|DNA binding
P10026784A2166|7 20|Oct-1 crystal
P10026824A0309|22 30|analysis
P10027498A0536|11 21|end points
P10027904A0768|61 67|region
P10029337A0406|4 20|fatigue exercise
P10029860A0605|19 26|aspects
P10029917A0366|0 7|Results
P10031854T0000|0 22|New Langevin equations
P10032519T0000|10 21|corrections
P10032581T0000|17 46|grazing-incidence diffraction
P10033973T0000|12 20|exchange
P10034615T0000|0 23|Structure determination
P10035841T0000|9 17|trapping
P10036181A0603|0 13|Northern blot
P10036191A0000|4 22|microphthalmia-TFE
P10037004A0000|12 20|patients
P10037378A0176|4 17|dorsal nerves
P10037460A0221|7 12|brain
P10037576T0000|20 28|necrosis
P10037681A0494|11 22|interaction
P10037774A0366|8 13|study
P10041728T0000|0 21|Vacuum Rabi splitting
P10043466T0000|14 21|effects
P10044519T0000|5 14|reduction
P10046849T0000|6 11|scale
P10047970T0013|8 24|world literature
P10049357A0608|6 13|results
P10049359A1073|12 15|unr
P10049742T0000|0 8|Analysis
P10049775T0000|0 7|Mapping
P10049912T0000|0 14|Identification
P10050883A0967|0 10|Inhibition
P10051030A1080|3 13|difference
P10051400A0000|4 12|Lp mouse
P10051488A1293|8 16|analysis
P10051488A1610|0 9|Mutations
P10052371A0171|0 12|STUDY DESIGN
P10052878A0135|16 31|set-up accuracy
P10053852T0000|0 4|Role
P10054976T0000|0 12|Spectroscopy
P10055173T0000|0 22|Band structure effects
P10059496T0000|9 29|transmission spectra
P10063122T0000|0 25|Two-Channel Kondo Lattice
P10063739A0601|26 55|esophageal sphincter pressure
P10064604A0824|0 4|CPDs
P10065176A0657|13 23|difference
P10065684A0916|13 17|hand
P10066790A0497|0 14|Gel filtration
P10066798A0391|0 6|Cyclin
P10066815T0000|4 7|SH2
P10068040A0136|17 29|mouse genome
P10068418A1194|3 11|increase
P10068446A0124|18 25|studies
P10068637A1320|15 23|Csx/Nkx2
P10068674A0644|42 46|form
P10068834A0713|4 9|costs
P10069815A0285|15 23|evidence
P10070158A0573|12 27|splicing events
P10071205A0833|14 19|genes
P10071212A0399|22 38|O. australiensis
P10071761A2374|3 11|addition
P10071806A0377|4 8|rate
P10072205A0167|3 8|order
P10072774A0537|0 6|RT-PCR
P10073899A0740|11 31|culture failure rate
P10073940A0335|8 18|expression
P10073947A1110|18 29|differences
P10074135T0000|33 41|elements
P10074282A0236|13 17|side
P10074425A0729|14 26|inactivation
P10074520T0000|0 14|Identification
P10074903A0915|22 29|results
P10074921A1169|8 15|results
P10075415A1178|8 18|sequencing
P10076007A0656|4 8|MSY2
P10077188A1172|33 38|genes
P10077533A0976|6 10|data
P10078734A0480|13 27|recovery curve
P10078876A0000|4 11|origins
P10079173A0000|25 33|proteins
P10080436T0000|0 10|Comparison
P10080875A0772|4 11|results
P10080901A0271|2 5|set
P10082137A0262|4 11|results
P10082554T0000|11 18|domains
P10082570A0440|30 40|gene UBP43
P10082573A1015|6 13|results
P10082585A0512|31 38|factors
P10084294A0219|23 27|need
P10085088A0918|6 13|results
P10085120A0000|8 13|study
P10085140A1004|6 13|results
P10085383A1367|4 9|WORDS
P10085505A1184|13 17|peak
P10085605A0239|0 9|Specimens
P10085697T0000|0 45|FASEB Federal Funding Consensus Conference FY
P10086544A0504|14 18|data
P10086725A0000|0 9|MDS1/EVI1
P10087213A0878|0 8|Analysis
P10087549A0720|4 13|JTc delta
P10087993A0782|3 11|contrast
P10087993A1352|14 25|mutagenesis
P10090125A0750|18 44|alpha1 antagonist prazosin
P10090146T0000|13 23|expression
P10090535A1194|4 13|algorithm
P10090943A1426|9 14|value
P10090943A1976|10 17|B cells
P10091594A0284|15 22|studies
P10091619A0104|0 6|Schwab
P10092132A0285|11 16|gains
P10092847A0455|5 12|respect
P10092856A0798|4 8|cDNA
P10094314A0935|19 32|RNA sequences
P10094396A0000|0 16|Topoisomerase II
P10094701A0000|7 11|work
P10095059A1003|4 11|numbers
P10095061A0592|0 17|Sequence analysis
P10095062A0558|29 38|structure
P10096469T0000|13 23|modulation
P10096573A0207|9 16|studies
P10097120T0000|3 7|exon
P10097932A0915|17 25|patients
P10098601A1320|11 19|analysis
P10098744A0630|3 11|contrast
P10099247A1051|7 17|reactor pH
P10099576A0666|14 20|valves
P10100605A0392|24 29|burst
P10101159A0742|2 10|mutation
P10101198A0632|2 28|deletion mutation analysis
P10101198A0946|2 17|database search
P10101744A0917|7 13|trials
P10102000A1206|13 21|patients
P10102136A0220|20 23|PSA
P10102136A0646|0 4|Type
P10102627A0217|13 33|DNA binding activity
P10103002A0705|9 29|N-glycosylation site
P10103057A0251|21 33|optimization
P10119827T0000|0 14|Judge OKs docs
P10120952T0000|0 5|HANYS
P10125354T0000|0 13|Groups dicker
P10132730T0000|9 20|CareNetwork
P10134977T0000|0 5|JCAHO
P10146207A0223|0 15|Ultrasonography
P10153759A0360|0 4|UPMC
P10171173A0955|11 19|concerns
P10181397A0641|14 20|trends
P10184191T0045|0 6|Holger
P10187317T0000|0 8|Hospital
P10187798A1098|0 14|Overexpression
P10187842A1155|11 19|contrast
P10187864A1372|6 13|results
P10190324A0000|21 33|elastin gene
P10191090A0000|15 25|expression
P10192134A1088|0 8|25-OH-D3
P10192432A0214|2 6|list
P10192638T0000|0 24|Methanesulfonyl fluoride
P10193950A0478|0 7|METHODS
P10194225A1132|10 15|wheel
P10194230A0817|18 25|surgery
P10194451A0000|31 43|relationship
P10194762A0648|9 22|precipitation
P10194769A0146|9 16|element
P10195425T0000|0 16|Characterization
P10195690A0000|4 14|peroxisome
P10195697A0456|9 23|F-SRC-1 mutant
P10196127A1059|14 18|site
P10196248A0482|22 32|TTV genome
P10196266A0000|10 29|mouse Mus castaneus
P10196316A0715|17 25|function
P10196318T0000|0 26|CCAAT displacement protein
P10196597A0510|12 20|findings
P10197763A0580|30 39|mutations
P10197985A0145|9 33|RNase H protection assay
P10198003A1505|0 8|Analysis
P10198056A0000|16 37|cell surface proteins
P10198061A0339|17 29|import assay
P10199539A1353|24 31|hypoxia
P10200473A0171|24 33|regulator
P10201468A0297|0 14|Plasma glucose
P10202006A0546|17 24|product
P10202006A1266|0 14|Polypyrimidine
P10203611T0000|0 56|Technetium-99m methylene diphosphonate scintimammography
P10205099A0377|0 13|INTERVENTIONS
P10205176A0000|8 17|receptors
P10205176A0704|44 50|domain
P10205588A0000|0 9|OBJECTIVE
P10205933A0699|0 8|Bacteria
P10206152A1024|18 28|expression
P10206698A2041|6 14|findings
P10206959A0368|0 6|Pathol
P10207041A0065|15 25|cell cycle
P10207049A0693|4 13|GAC1 gene
P10207049A1001|4 11|results
P10207087A0956|0 3|MEF
P10207090A0801|21 29|presence
P10207092A0924|5 20|phosphorylation
P10207115A0389|34 39|level
P10208865A1246|28 47|osteoclast cultures
P10208893A0839|13 20|results
P10209021A0212|14 23|mechanism
P10209031A0832|4 20|Fyn NH2 terminus
P10209119A0076|11 16|yeast
P10209119A0594|59 71|similarities
P10209759T0000|0 16|Antithrombin III
P10210952A0261|3 13|retrospect
P10211329A0457|6 18|observations
P10211422T0000|6 18|pancreatitis
P10211919A0846|22 33|improvement
P10212278A0387|17 32|protein kinases
P10212284A0000|13 26|growth factor
P10212332T0000|0 18|Chronotherapeutics
P10212426A1067|0 5|Group
P10212969A0470|0 12|Uroflowmetry
P10214610A0900|14 23|variation
P10215485A0837|12 24|correlations
P10215594A1728|0 8|Glucagon
P10215608A0161|8 13|study
P10215803T0000|39 47|infusion
P10215811A0635|8 15|control
P10215850A0754|35 47|organization
P10216052A0105|4 8|aims
P10216052A1682|17 25|validity
P10216161A1530|0 19|Sequence comparison
P10217683A0509|0 22|Canalith repositioning
P10218109T0000|0 18|Solution structure
P10218200A0534|6 10|eyes
P10218357A0486|0 7|RESULTS
P10219091A0246|32 41|gene CTL1
P10220275A0694|4 11|binding
P10220364A0087|6 16|afterglows
P10221467T0000|13 25|pericarditis
P10221820A0902|13 17|type
P10223338A1601|3 11|addition
P10223338A2186|4 11|results
P10223498A0479|0 8|Efficacy
P10224244T0000|0 8|Evidence
P10224257A0079|3 11|XO males
P10224289T0000|0 9|Induction
P10224293A0000|0 38|Receptor protein tyrosine phosphatases
P10224293A2021|25 38|brain regions
P10224513A0240|14 23|stressors
P10224758A0202|4 17|control group
P10225279A0450|25 29|gene
P10225945A0436|3 11|contrast
P10226029A0905|14 19|cells
P10226074A0637|31 38|regions
P10226838A1011|4 12|motility
P10228009A0600|0 9|Induction
P10228155A1293|0 7|SCFFWD1
P10228157T0000|18 44|spindle checkpoint pathway
P10228561A0539|24 36|organization
P10228795A0842|0 7|RESULTS
P10229084A0000|16 35|gel electrophoresis
P10229668A0190|19 32|cdc33 mutants
P10229668A0560|2 16|cdc33-1 strain
P10229682A1151|11 17|motifs
P10231026A0253|4 18|gene structure
P10231454A0731|6 19|serum calcium
P10231485A0342|0 17|Sequence analysis
P10231513T0000|14 25|differences
P10231581A1125|14 25|mutagenesis
P10231862A1117|19 26|infants
P10232078A0552|0 8|Ischemia
P10232600T0000|18 25|antigen
P10232872A0081|40 42|CD
P10233147A0218|0 5|Ras2p
P10233885A0899|21 31|prediction
P10233946A0000|9 13|work
P10234698A0728|33 40|effects
P10235265A0197|7 16|mechanism
P10236651T0000|0 10|Predictors
P10240361T0000|9 15|survey
P10243927A0000|5 11|series
P10271171A0458|7 12|LATCH
P10281637A0000|0 9|Reporting
P10304090T0000|0 21|Medicare SNF benefits
P10308312A0203|8 13|paper
P10318806A0000|0 7|Members
P10318806A0476|15 20|study
P10318806A0918|0 8|Analyses
P10318859A0535|18 27|calpeptin
P10318900A0637|29 36|studies
P10318918A0824|20 28|analysis
P10319320A1022|22 30|findings
P10319327A1237|0 8|Analysis
P10319955A0941|14 25|differences
P10320177A0487|0 29|Baseline electrocorticography
P10320480A0451|22 28|system
P10320579A1831|16 20|FlgN
P10321158T0000|0 4|Post
P10322022A0263|0 6|Rep63A
P10322629A0198|19 26|cloning
P10323225A0244|0 9|Km values
P10323463T0000a|0 16|Interferon-alpha
P10323463T0000b|0 16|Interferon-alpha
P10323863A0852|3 11|addition
P10325413A1211|13 20|binding
P10326221A0531|11 19|mutation
P10326654A0351|13 30|pilot experiments
P10326856T0000|14 36|pancreaticojejunostomy
P10327051A0688|32 63|Stress-Activated-Protein-Kinase
P10328351A0443|0 13|Blood samples
P10329135A1326|6 13|results
P10329566A0610|7 15|terminus
P10329574A1733|0 2|O.
P10329586A0414|9 13|gene
P10329625A0715|22 38|cell surface CD4
P10329736A0681|28 33|yeast
P10329736A1106|0 19|Insulin stimulation
P10330134A0765|4 19|mRNA expression
P10330146A0730|7 11|case
P10330159A1258|6 9|VDR
P10330168A0135|29 36|kinases
P10330396A0387|4 25|RanQ69L preincubation
P10331276A0298|11 19|elements
P10331646A0595|3 11|contrast
P10331730A0504|0 7|RESULTS
P10331875A0523|5 20|dimer interface
P10332733A0000|4 24|paramyxovirus fusion
P10333481A1102|14 31|deletion analysis
P10333526A0459|4 14|hTERT gene
P10333529A0277|5 17|betaAPP mRNA
P10334888A0960|3 16|reperfusion B
P10336495A0547|5 15|repression
P10339552A0361|15 20|study
P10339566A0602|0 6|Spc42p
P10340447A0424|12 24|coefficients
P10340883A1266|11 13|OS
P10341219A0481|13 36|heparin lyase treatment
P10342511A0909|4 15|coefficient
P10342536A0954|6 19|determination
P10342829A0236|3 8|light
P10342829A1370|12 33|mobility shift assays
P10343189A0911|0 5|Grade
P10344736A0796|0 22|CDK4 kinase activities
P10347144A0516|25 32|protein
P10347197A0502|0 9|Induction
P10347203A0832|0 22|Serine phosphorylation
P10347220A1477|61 66|yeast
P10347839A0434|4 15|IC50 values
P10348859A0292|30 43|binding sites
P10349084T0000|4 13|influence
P10349443A0358|4 11|results
P10350027A0942|0 11|Amisulpride
P10350454A0000|0 4|MutY
P10350484A0346|4 12|kinetics
P10350638A0000|0 7|Latexin
P10353073A0118|0 19|Regression analyses
P10353880A0257|64 71|infants
P10355085A1119|0 7|Subsets
P10355536A0172|11 14|age
P10355910A0369|14 23|follow-up
P10357751A0866|13 18|group
P10358031A0303|3 11|addition
P10358075A0984|0 5|DAF16
P10358079A0391|9 28|neu differentiation
P10358080A1114|9 23|linker regions
P10358080T0000|0 10|Modulation
P10358083A0263|16 24|analyses
P10358138A0672|6 13|results
P10359014A1077|22 49|Fra-2 phosphorylation sites
P10359575A0317|53 62|FcalphaRI
P10359603A0430|0 5|Vac1p
P10359663A0425|34 40|system
P10359663A1280|3 26|co-transfection studies
P10359664A0579|18 23|sites
P10359673A0000|4 19|yeast LPD1 gene
P10359792A0610|20 27|defects
P10360454A0916|13 38|serum TNF-a concentration
P10360839A1338|3 11|addition
P10360947A1113|10 35|fluorescence spectroscopy
P10361038A0281|27 36|locations
P10362652A0350|5 14|carbachol
P10362652A1456|18 21|Sos
P10362897A0545|0 7|RESULTS
P10363517A0401|8 13|paper
P10364076A0429|6 13|regions
P10364159A0813|17 26|questions
P10364163A0092|0 3|Hrs
P10364202A0646|4 16|coexpression
P10364314A0919|6 16|subgenomes
P10364319A0109|0 2|Cp
P10364425A0610|6 17|indications
P10364523A0826|5 18|exon trapping
P10364523T0000|11 46|dysplasia translocation breakpoints
P10365883A1355|16 31|characteristics
P10366446A0893|14 20|domain
P10366503A0812|0 18|Binding affinities
P10366503A1506|13 22|terminase
P10366559A0605|4 18|hybrid viruses
P10366722T0000|0 4|cDNA
P10367240A1354|13 29|cryopreservation
P10367385A0000|25 31|method
P10367460A0191|4 19|FCMS conditions
P10367646A0569|7 16|hemolysis
P10369418A0644|0 4|EMSA
P10369625A0942|8 18|monitoring
P10369757A0000|10 31|transcription factors
P10369775A0178|12 29|protein fragments
P10369926A0251|4 8|exon
P10369965A0000|4 16|Aa-Pri2 gene
P10370675A0649|9 15|causes
P10370778A0000|10 30|aromatase inhibitors
P10371097A0963|0 11|CONCLUSIONS
P10372627A0530|9 17|injuries
P10373029A0204|12 23|artery/vein
P10373507A0680|0 9|SRFDelta5
P10373523A0924|14 19|media
P10374632A0818|4 11|potency
P10374632A0897|0 10|CONCLUSION
P10375107A1138|0 11|Progression
P10375638A0859|0 9|Mutations
P10375640A0153|23 42|nucleotide sequence
P10375694T0000|39 50|input zones
P10375718A0000|6 30|fibroblast growth factor
P10376065A0881|5 12|filters
P10376446A0000|11 16|women
P10376873A0706|6 12|sgRNA2
P10376874A0759|24 31|defects
P10376877A0611|0 7|Removal
P10376991A0977|0 3|Ras
P10377345A0740|0 5|Green
P10377438A0647|15 22|protein
P10378989A0000|4 7|aim
P10379547A0000|0 9|Molecules
P10379899A0446|10 18|findings
P10379942A0956|30 38|residues
P10379942T0000|0 14|Identification
P10380232A0000|0 9|OBJECTIVE
P10380659A0545|0 13|Baseline data
P10380800A0194|2 12|comparison
P10380878A0542|21 32|possibility
P10380890A0619|12 21|sequences
P10381257A0000|21 28|protein
P10381377T0000|10 17|cloning
P10381570A1355|0 4|Slp1
P10383764A1809|4 11|results
P10383966A0000|4 31|penicillin binding proteins
P10384129A0000|0 9|TCR alpha
P10385384A0654|8 15|results
P10385395A0000|9 28|density lipoprotein
P10385915A1341|0 7|D3S1261
P10388670A1976|4 15|percentages
P10390158A1150|0 15|Point mutations
P10390538T0000|23 42|zinc-finger protein
P10391075A0000|20 32|autopsy case
P10391246A0756|13 18|MOM-4
P10391277A0000|0 10|BACKGROUND
P10391903T0000|0 4|Gab2
P10392266A0111|4 12|presence
P10392669A0935|6 13|attempt
P10392710A1000|0 15|Lung mesenchyme
P10392900A1020|4 14|activation
P10392903A0000|11 36|papillomavirus E2 protein
P10392903A0889|0 16|E2 point mutants
P10392914A0000|0 18|BACKGROUND/PURPOSE
P10393192A0792|0 24|Neurospora crassa CYT-18
P10393197A0543|0 4|DDP1
P10393201A0654|25 42|DNA repair system
P10393251A0283|4 13|PAC clone
P10393251T0000|0 8|Sequence
P10393422A0476|9 11|kb
P10393910A0705|14 25|mutagenesis
P10393969A0000|13 29|cell protein no.
P10394116T0000|0 17|Wrist measurement
P10394900A1166|15 25|expression
P10394919A1058|8 15|element
P10395199A0792|5 9|scFv
P10395283A0960|13 24|competition
P10395378A1198|4 8|data
P10395827A1297|22 47|parallel beta helix model
P10395908A0236|42 49|protein
P10395911A0288|0 16|Characterisation
P10395920A1424|6 13|results
P10396343A0754|17 27|proportion
P10396343T0000|15 25|evaluation
P10396793A0815|0 7|Results
P10397257A1142|0 11|Mutagenesis
P10398286A0678|6 13|Scheffe
P10398682A0365|4 21|crystal structure
P10399136A0389|0 7|Ozagrel
P10400032A0304|11 17|method
P10400593A1084|3 11|contrast
P10400712A0000|7 26|parainfluenza virus
P10400712A0577|19 28|functions
P10400757A0000|0 5|CXCR4
P10400757A1498|6 10|data
P10400760A0663|4 11|results
P10400774A0240|0 2|y.
P10400785A0912|0 2|SM
P10400794T0000|0 14|Identification
P10402022A0432|9 15|clicks
P10402467T0000|0 6|Myosin
P10403575A1401|4 14|inhibition
P10403690A0000|28 33|study
P10403839A0140|6 26|sequence information
P10403839A1459|0 10|Comparison
P10405635A0374|20 30|activities
P10406047A1244|35 46|differences
P10406122T0000|23 30|element
P10406459A0000|8 13|study
P10406462A1127|17 25|evidence
P10406464A0687|3 11|contrast
P10406465A0589|5 13|sequence
P10406466A0000|35 44|receptors
P10406843A1265|0 10|Expression
P10406954A0715|0 24|Chemical stability tests
P10407184A0149|3 17|overexpression
P10407184A0520|15 22|studies
P10407269A0000a|7 9|bp
P10407269A0000b|7 9|bp
P10407985A0574|0 5|G-CSF
P10409656A1016|0 14|Overexpression
P10409699A0292|16 35|sequence tag clones
P10409724A1021|0 10|Activation
P10409730A0597|4 17|transcription
P10409741A0382|30 37|alleles
P10409749T0000|0 4|Role
P10409755A1846|3 10|summary
P10411139A0887|0 12|Accumulation
P10411139A1344|4 11|results
P10411140A0499|26 29|RNA
P10411160T0000|4 13|mysteries
P10413604A0063|47 54|kinases
P10413607A0085|33 41|contrast
P10413662A0193|39 64|pMJ101 replication region
P10413676A0000|0 3|FAK
P10413676A0595|0 10|Expression
P10413676A1193|23 29|effect
P10414451A0093|16 24|patients
P10416429A0221|0 6|DESIGN
P10416558A0000|0 7|PURPOSE
P10417331A1008|4 10|enzyme
P10417703A1326|22 29|results
P10419006A0378|14 22|evidence
P10419521A0136|3 11|addition
P10422291A0572|2 11|diagnosis
P10422342A0535|4 20|radiation burden
P10422468A0524|13 17|risk
P10423156A0265|0 13|TaV particles
P10423193A1309|0 10|CONCLUSION
P10423292A0782|13 15|bp
P10425094A1006|13 23|relaxivity
P10425445T0000|0 9|Structure
P10426450A1458|10 18|recovery
P10426878A0367|4 11|results
P10427654A0000|5 10|study
P10428091A0322|5 11|report
P10428294A0227|0 25|Preheparin LPL mass level
P10428759A0743|2 10|decrease
P10428811A0628|0 5|Cat-1
P10428811A1067|0 12|Cat proteins
P10428862A0834|0 31|Immunoprecipitation experiments
P10429184A0000|0 9|Expansins
P10429740A0000|5 11|review
P10429946A0473|15 21|region
P10429946A0988|13 21|addition
P10430421T0000|0 19|APOE-epsilon4 count
P10430580A0000|0 6|Repair
P10430583A0000|6 21|DNA repair gene
P10430883A0000|22 27|cells
P10430886A0838|15 22|mutants
P10430890A1059|6 15|elongin C
P10430944A1298|4 8|data
P10430980A0465|14 17|men
P10433729A1559|0 2|A.
P10433970A0279|0 6|Spfkh1
P10435595A0203|14 23|mechanism
P10436016A0337|0 14|Gel filtration
P10437043A0164|0 7|METHODS
P10438540A1185|36 50|domain mutants
P10438593A0000|10 39|immunodeficiency virus type-1
P10438607A0330|13 18|SEBPs
P10438627A0885|0 17|Identity elements
P10438924A1009|22 27|cells
P10438924T0000|4 27|B cell antigen receptor
P10438941A1197|6 26|recombination events
P10438950A0580|0 4|IL-1
P10439040A0658|18 28|role eIF4E
P10440923A0684|0 8|Analysis
P10441243A0443|0 7|RESULTS
P10441449X1212|0 9|Copyright
P10441483A0454|0 22|Oligonucleotide probes
P10441506A0098|0 7|PKNbeta
P10442493A0815|3 11|baseline
P10443990A0000|0 10|BACKGROUND
P10444597A0586|25 34|induction
P10444813A0448|16 22|relief
P10445161A1565|3 10|summary
P10445506A0073|30 35|sperm
P10445945T0000|0 19|John leonard dawson
P10446131A0132|0 19|PDGF A-chain levels
P10446149A0809|29 34|yeast
P10446206A0000|0 16|Deletion mapping
P10446833T0000|17 28|oxygenation
P10446910A0147|0 8|Analysis
P10446912A0883|7 13|course
P10446998A0375|3 11|contrast
P10446998A0955|0 25|Adipocyte differentiation
P10446998T0000|0 14|Transformation
P10447593A0144|4 15|core enzyme
P10447597A1004|4 17|Cr.psbA-4 ORF
P10448036A0748|4 15|interaction
P10448095A0865|4 29|STAT protein accumulation
P10448285A1035|11 20|durations
P10448440T0020|4 8|role
P10448902A0921|23 30|enzymes
P10449072A0560|11 15|goal
P10449899A0881|14 21|results
P10450815A0180|12 25|investigation
P10451209A0000|0 9|OBJECTIVE
P10452306A0502|0 8|Patients
P10452951A0000|8 25|hormone receptors
P10452991A0331|6 11|cells
P10453006A0000|0 10|Sequencing
P10453006A0478|3 11|addition
P10453248A0094|11 15|Udry
P10453371A0640|0 6|Weight
P10453721A0445|10 27|sampling strategy
P10454533A0859|0 11|Interaction
P10454540A0392|4 28|amino acid changes D206A
P10454550A0960|22 30|evidence
P10454557A0000|15 20|yeast
P10454557A0975|6 13|results
P10454561A0594|15 20|study
P10454568A0815|13 29|Grb10 expression
P10454570A0846|4 12|analysis
P10455087A1400|0 11|CONCLUSIONS
P10455143T0000|0 21|Interdomain signaling
P10455183A0530|3 11|contrast
P10455183A0930|20 27|results
P10455189A0104|3 10|B cells
P10455189A0427|23 47|tyrosine phosphorylation
P10457075A1198|0 40|Independent protrudor muscle stimulation
P10458905A0000|14 26|construction
P10458907A0543|10 16|RAD30B
P10458914A0674|0 8|Analysis
P10459809A1262|10 29|matrix distribution
P10460015A0465|9 15|months
P10460171A0842|0 21|Viscosity experiments
P10460172A0823|0 22|Velocity sedimentation
P10463057A0534|9 26|expression levels
P10463242A0316|3 6|EEG
P10464185T0000|10 26|characterization
P10464250A0275|7 15|FASEB J.
P10464291A0597|0 8|IL-1beta
P10464302A1109b|4 15|recruitment
P10464310A0218|10 34|tyrosine phosphorylation
P10466306A0000|21 51|Technetium-99m sestamibi SPECT
P10466825T0000|0 4|Role
P10467004A0116|4 14|intron RNA
P10467004A0683|4 10|intron
P10467403A0000|4 36|Trk/Nerve Growth Factor receptor
P10467465T0000|4 15|controversy
P10468033T0000|0 15|Chemical uptake
P10468585A0980|5 16|DNA binding
P10469140A0336|19 27|function
P10469174A0678|11 28|sequence analysis
P10469656T0000|16 24|response
P10470220A1011|4 15|arrangement
P10471587A0239|9 16|strains
P10471696A0734|5 12|alleles
P10471721A0141|17 25|analysis
P10471743A0000|2 6|cDNA
P10471746A1102|9 13|MyoD
P10472314A0717|0 7|RESULTS
P10472836A0189|0 11|Feed intake
P10473589A0189|4 14|N terminus
P10473598A0691|0 6|Skn-1a
P10473623A0081|9 24|Xenopus embryos
P10474898A0629|28 37|structure
P10475610A1289|0 5|Natl.
P10475972A0269|7 11|face
P10476970A0542|26 33|isoform
P10477545T0000|4 14|B-oligomer
P10477583A0000a|18 36|B cell Ag receptor
P10477583A0000b|18 36|B cell Ag receptor
P10477597A0126|0 5|TRAF2
P10477599T0000|25 32|element
P10477620A0580|17 48|NF-kappa B DNA binding activity
P10477748A1076|2 9|portion
P10478275A1230|9 15|issues
P10478844A1604|0 14|Cotransfection
P10478848A0331|0 4|SF-1
P10479025A0528|16 25|locations
P10479382A1098|17 24|results
P10479492A0000|0 9|OBJECTIVE
P10480937A0000|8 42|Drosophila A kinase anchor protein
P10482516A1158|9 30|transcription results
P10482516T0000|5 18|RNA stem-loop
P10482565A0469|28 37|mutations
P10482620A1009|33 46|transcription
P10483124T0000|0 8|Regional
P10483945A0641|0 7|RESULTS
P10484695A0791|6 24|NART-R performance
P10484818A0292|10 15|areas
P10485353T0000|8 37|Haemophilus influenzae type b
P10485470A0242|8 13|study
P10485585A0175|0 7|Galoyan
P10486210A0126|13 23|regulation
P10487040A0453|20 28|staining
P10487217A0735|4 11|C2C-Prx
P10487307A0768|19 35|surgery patients
P10487744T0000|17 31|sorting signal
P10487753A0788|4 13|injection
P10487759A0630|17 32|Xenopus embryos
P10487760A0336|3 8|order
P10487762A0252|0 4|NuA4
P10487921A0132|0 18|ATF1 transcription
P10487953A0765|4 12|patients
P10488087A0340|0 8|Mutation
P10488088T0000|13 28|growth factor-I
P10488129T0058|0 9|Synthesis
P10488147A1176|0 14|Identification
P10488148A0111|0 9|NF-kappaB
P10488148A1267|6 13|studies
P10488148T0000|0 37|ERK MAP kinase links cytokine signals
P10488337T0000|26 35|chaperone
P10488875A0000|9 24|differentiation
P10489680A0927|0 11|Sputum IL-8
P10489822T0000|0 11|Montelukast
P10490065T0000|0 9|Treatment
P10490604A0601|26 37|kinase-dead
P10490609A0413|0 13|Substitutions
P10490639A0000|29 34|PHO85
P10490662A0431|0 7|Mutants
P10490662A0819|3 7|fact
P10490816A0000|0 9|Mutations
P10490822A1167|6 13|results
P10490826T0000|0 4|EB-1
P10490835T0000|0 23|Protein kinase A-Ialpha
P10490843A0159|0 4|BCL6
P10490955T0000|0 4|Beta
P10491133A0365|0 10|Optical CD
P10491187T0000|4 29|phosphotransferase system
P10491213A0263|0 20|Serum concentrations
P10492127A0914|11 16|study
P10492169A0939|5 12|cluster
P10493203T0000|11 16|value
P10493575T0000|11 18|changes
P10493580A1126|16 21|Gly84
P10493876A0000|4 22|solution structure
P10495573A0365|6 16|sildenafil
P10496161A0503|0 16|Serum antibodies
P10496284A0115|27 35|episodes
P10496303A1968|0 11|CONCLUSIONS
P10496388A1956a|11 23|nonperfusion
P10496388A1956b|11 23|nonperfusion
P10496553A1004|4 16|healing rate
P10497117A0358|4 10|P mRNA
P10497199A0559|10 16|screen
P10497262A0000|31 35|gene
P10497800A0000|4 10|MMPI-A
P10497874A0925|13 17|hand
P10498616A0157|2 13|G22V mutant
P10498616A1280|10 15|M-Ras
P10498706A1219|20 24|data
P10498717A1048|6 18|observations
P10499121A0542|21 38|hearing aid users
P10499357A0439|0 12|SCOB testing
P10501034A0839|0 30|Ribonuclease protection assays
P10501656A1415|13 23|expression
P10501936T0000|0 12|Inactivation
P10501965A0879|8 13|genes
P10501969A1329|4 11|results
P10502216A0289|5 10|study
P10502402A0129|23 28|TRAIL
P10502402A0533|2 7|panel
P10502434A0367|5 13|February
P10502434A0604|7 15|patients
P10502522A0000|10 26|provirus genomes
P10503540A0602|2 7|total
P10503812A1450|2 12|population
P10504332A0701|0 22|Immunofluoresence data
P10505694A0000|0 14|Interleukin-12
P10505694A0739|0 16|IL-12 production
P10506143A0610|3 13|HeLa cells
P10506160A0297|0 2|J.
P10508522A1598|4 11|results
P10509768A1118|4 13|reduction
P10510295A0606|13 46|ethanol repression autoregulation
P10510379A0105|10 30|transcription factor
P10511216A0654|0 11|CONCLUSIONS
P10511554T0000|41 57|polymorphism map
P10512699A0364|5 14|machinery
P10512699T0000|11 21|expression
P10512857A0000|3 16|Wnt signaling
P10512882A0137|0 8|Assembly
P10513756A0584|4 7|EPV
P10513922A1237|4 9|study
P10514493A0199|25 40|differentiation
P10514808T0000|9 19|dysplasias
P10516011A0471|7 11|work
P10516026A0270|5 16|HERV-K type
P10516072A0146|0 4|Duch
P10516738A0925|7 18|time-points
P10516878T0000|0 12|Modification
P10517666A1069|14 27|binding sites
P10517672A1417|15 23|fragment
P10517675A0809|0 21|Western blot analysis
P10518496A0952|0 11|Aggregation
P10518502T0000|0 5|nos-1
P10518561A0261|18 28|regulators
P10518561A0885|10 25|phosphorylation
P10518822A1037|0 10|CONCLUSION
P10518937A0572|4 23|expression analysis
P10518956A0137|6 29|thyroid hormone changes
P10518956A1212|0 8|ESS type
P10520800A0307|0 7|METHODS
P10521345A0202|18 22|data
P10521443A0486|5 11|effect
P10521447A0606|4 10|factor
P10521447A1190|13 27|overexpression
P10521450A0437|12 26|Akt activation
P10521509A0000|0 10|Regulators
P10521544T0000|0 7|Cloning
P10521796A0872|4 7|ORs
P10523319A0209|20 25|Dbp5p
P10523520A0986|10 24|nematode genes
P10523634A1404|2 8|subset
P10523640A0367|13 32|Src tyrosine kinase
P10523647A0000|4 29|transcription factor CHOP
P10523647A1001|6 10|CHOP
P10523663A0404|5 10|motif
P10523674A0000|0 9|RNase MRP
P10524258A0286|21 31|regulation
P10524258T0000|0 10|Regulation
P10525413A1408|4 21|backbone dynamics
P10526670A0236|0 3|Rac
P10526670A1828|20 31|ICE/caspase
P10527106A0384|0 9|OBJECTIVE
P10527158T0000|4 12|AL-R8 SI
P10527180A0869|0 7|RESULTS
P10527426A0521|4 8|form
P10527475A0643|3 5|PC
P10528035A1102|3 10|percent
P10529198A0068|25 31|domain
P10529354A0375|4 14|proteasome
P10531334A0525|3 9|assays
P10531340A1275|0 2|R.
P10531342A0348|15 21|domain
P10531342A1111|3 11|contrast
P10531360A0958|16 25|infection
P10531446A0203|0 10|Neuregulin
P10532354A1374|4 11|results
P10532805A0792|3 13|PC12 cells
P10532805A1084|5 21|PC12 cell mutant
P10533066A0758|0 14|TSC1 mutations
P10533066A1197|7 15|patients
P10534048A0297|10 19|algorithm
P10534402A0126|15 19|cDNA
P10534402A0659|0 6|RT-PCR
P10534691A0542|0 7|Animals
P10535715A0268|4 7|RMR
P10536125A0093|0 11|Oseltamivir
P10536369A0662|3 28|gel mobility shift assays
P10536369A1280|13 23|importance
P10536788A0931|9 10|d
P10540015A0664|0 13|C-SP duration
P10540292A1179|6 10|data
P10540553A0980|10 19|synthesis
P10540915A0697|9 21|transsection
P10541432A0185|17 30|erbB proteins
P10541550A0487|6 24|immunolocalization
P10541865A1301|22 34|co-deletions
P10542237A0357|26 34|explants
P10542249A0415|0 18|Albumin expression
P10542260A0832|4 15|requirement
P10542269A0000|0 20|Amyloid beta-protein
P10542274A1376|18 28|activation
P10542277A0000|4 18|importin alpha
P10542281A0382|14 19|G1-G2
P10542281A2021|4 11|results
P10543270A1054|8 28|i.v. steroid therapy
P10543727A0282|20 25|sites
P10543728A0358|16 19|E1A
P10543730A0000|4 9|yeast
P10543949A0686|19 21|S1
P10544037A0617|0 4|FZD4
P10544088A0308|4 13|NF-kappaB
P10544089A1208|4 19|RNA transcripts
P10544113A0293|0 29|EIAV LTR sequence variability
P10545192T0000|0 41|Phosphatidylinositol 3-kinase requirement
P10545248A0567|4 8|core
P10545281A0836|4 11|example
P10548434A1549|26 33|ability
P10548622A0906|31 36|block
P10548722A0099|4 8|loci
P10549354A1782|2 12|proportion
P10549354A2371|8 18|mechanisms
P10549912A0136|5 11|report
P10550139A0191|0 8|PATIENTS
P10550571A0000|0 7|PURPOSE
P10550574A1038|5 11|regard
P10551788A0229|0 6|LHbeta
P10551796T0000|0 10|Regulation
P10551816A0162|6 12|LTBP-1
P10551848A0000|14 19|study
P10551867A0350|20 39|amino acid residues
P10551879T0000|21 43|protein kinase binding
P10552357A1936|0 11|CONCLUSIONS
P10553551A0000|0 20|Factor XI deficiency
P10553959A0812|4 19|Ishasha samples
P10554946A0082|21 26|SERMS
P10555079A0254|0 2|Ti
P10555285A1065|5 17|organization
P10555964A0778|0 2|S.
P10556028A0292|4 14|cop region
P10556029A0852|0 13|WA constructs
P10556033A0000|4 22|RFX protein family
P10556044A0913|0 7|Binding
P10556046A0328|62 79|signaling pathway
P10556063A0092|6 13|kinases
P10556089A0901|4 8|data
P10556145A1034|0 10|Gentamicin
P10556263A1035|0 11|CONCLUSIONS
P10556595A0391|3 11|analysis
P10556751A0758|17 21|view
P10557008T0000|0 9|Detection
P10557072A0127|30 35|mouse
P10557072A0418|0 4|ULKs
P10557072A1218|6 13|results
P10557308A0000|0 18|Connector enhancer
P10559207A0207|11 20|organisms
P10559303A0000|13 18|virus
P10559320A0080|19 23|half
P10559324A0716|24 26|Ad
P10559364A0846|3 7|HCMV
P10560014A0000|26 47|heart vascularization
P10560997A1072|0 10|CONCLUSION
P10561095A2141|9 20|reoperation
P10561153A0225|13 17|case
P10561251A0000|0 7|PURPOSE
P10561460A0615|4 21|GPI anchor moiety
P10561546A0000|41 48|protein
P10562418A0238|18 24|events
P10562456T0000|11 18|regions
P10562495A0188|14 23|SFV genes
P10563212A0514|24 43|SF-36 questionnaire
P10563605A0773|12 17|trend
P10563789A1951|3 11|addition
P10563836A1234|3 11|contrast
P10564231A0315|0 11|N. van Hoek
P10564280A0140|52 59|protein
P10564472A0853|6 13|mutants
P10564474T0000|10 20|homologues
P10564479A0384|0 8|Deletion
P10564484A0859|5 15|constructs
P10564495A0444|3 11|addition
P10564593A0428|0 4|FISH
P10564593A1618|4 12|MXR gene
P10564939A0981|4 10|effect
P10566630A0371|0 5|Serum
P10566862A0000|0 10|BACKGROUND
P10567430A0785|11 18|studies
P10567524T0000|4 25|elm1 kinase functions
P10567533A0818|8 21|transcription
P10567538A1028|3 11|addition
P10567581A0119|27 32|HNF-3
P10567582A1334|7 12|mouse
P10567589A1268|13 22|functions
P10568275A0679|4 8|role
P10568455A0000|31 40|injection
P10568728A1445|4 9|level
P10568744A0728|23 28|sites
P10570262A0000|0 10|Activation
P10570996A1213|15 23|analysis
P10571047A1009|8 11|7SL
P10571474A0571|0 7|Results
P10572087A0326|19 34|binding partner
P10572130A1623|6 13|results
P10572131A0000|0 18|Klebsiella oxytoca
P10572866A0481|7 16|hemolysis
P10573781A0631|0 7|Studies
P10574913A1108|38 62|receptor phosphorylation
P10574929A0583|21 34|fractionation
P10574982A1075|0 16|Supershift EMSAs
P10574992A0901|12 23|E1A binding
P10575231A0355|0 8|Analysis
P10575545A0147|18 23|CACCC
P10575642T0000|0 15|Skin pH changes
P10576177A0308|5 16|distinction
P10576545A0926|4 16|availability
P10578528A0730|23 31|location
P10579331A1225|4 11|results
P10579722T0000|0 15|Phosphorylation
P10580071A0436|9 17|patients
P10580438A0508|19 39|mobility shift assay
P10582831T0000|0 9|Syndromes
P10584138T0001|0 14|Cytoprotection
P10584704A0913|20 28|staining
P10585311A0494|0 8|Patients
P10585311A1542|17 30|abnormalities
P10585417A1412|16 27|differences
P10585440A0204|43 56|FAK homologue
P10585453A1029|12 23|Pit-1 sites
P10585463A0859|12 32|prenylcysteine lyase
P10585480A0157|28 38|SH3 domain
P10585480A0265|0 15|Point mutations
P10585491A0945|3 28|gel mobility shift assays
P10585808A0000|0 29|Mycoplasma hominis infections
P10586074A0129|9 16|purpose
P10586107A0160|29 34|types
P10586115A0477|54 63|cytokines
P10586626A0607|14 22|diseases
P10587460A0302|22 41|VDRE binding domain
P10587461A0341|18 27|mechanism
P10587576A0596|6 10|REPs
P10588946A0432|16 23|minimum
P10589562A1208|3 7|part
P10589711A1228|3 11|addition
P10590092A0124|9 19|mechanisms
P10590368X0000|11 24|trachelectomy
P10591633A0138|6 11|event
P10591933A0798|16 20|Type
P10591976A0317|0 12|Measurements
P10591990A0178|2 7|group
P10592791A0370|3 13|conclusion
P10592791T0001|0 10|Comparison
P10592824A1157|17 26|frequency
P10593939A0747|50 73|interaction experiments
P10593950A1113|3 10|summary
P10594130A0652|15 21|hearts
P10594239A0614|0 9|Tih1 maps
P10594239T0000|8 18|pleckstrin
P10594903A0000|4 13|potential
P10595315A0344|28 35|effects
P10596955A1032|23 39|failure patients
P10597222A1371|27 30|p27
P10597223A0339|22 36|Ras-expression
P10597232A0000|4 26|RET/PTC3 rearrangement
P10597317A1156|0 9|Apoptosis
P10598101A0000|3 11|addition
P10598101A0754|4 19|mEmBP-1 protein
P10598316A1534|0 3|GHB
P10599013A0505|14 20|deaths
P10599727A1567|10 12|GH
P10600171A1066|28 42|responsiveness
P10600171A1432|7 14|CYP3A23
P10601280A0674|34 41|element
P10601290A0742|18 23|basis
P10601335A0892|0 14|Redistribution
P10601344A1653|3 11|addition
P10601410A0977|3 13|conclusion
P10601606A0152|4 24|rhabdomyosarcoma R1H
P10601747A0482|21 34|control words
P10602419A1253|18 25|effects
P10602502A0422|9 20|Tob protein
P10602507A0652|15 23|increase
P10602516A0182|3 11|addition
P10602838A0127|8 13|study
P10603349A1667|4 29|signalling molecules Wnt1
P10604246A0523|0 12|STUDY DESIGN
P10604583T0000|0 16|Albumin dialysis
P10604945A0731|16 35|promoter constructs
P10606245A0906|0 14|Overexpression
P10606272A1241|0 9|Injection
P10606515A0389|5 12|domains
P10606664A0000|0 21|Snail family proteins
P10607566A0880|21 28|finding
P10607899A0605|0 17|Sequence analysis
P10607900T0000|0 25|Sak kinase gene structure
P10608053A0923|0 12|Thrombolysis
P10608893A0727|11 16|Hp140
P10610716A1127|19 37|missense mutations
P10611225A1127|6 10|data
P10611228A1388|4 12|DAP5/p86
P10611235A1927|27 31|step
P10611242A0541|21 28|finding
P10611320A0816|73 81|CAK gene
P10611353A0458|0 13|Northern blot
P10612044A1180|30 42|conservation
P10612505A1317|11 15|type
P10612773A1210|0 11|CONCLUSIONS
P10612805A0716|20 30|alteration
P10612918A0318|4 12|problems
P10613816X0000|0 7|Statins
P10613843A0107|16 24|products
P10613863T0000|4 27|VirR response regulator
P10613874A0663|0 7|Cloning
P10614676A0000|0 9|Objective
P10614857A0584|0 18|Leukocyte cultures
P10616948A0998|7 19|BF ECT group
P10617126A1005|13 21|analysis
P10617144A0386|4 11|extents
P10617232A0393|0 13|Serum HBV-DNA
P10617613A1192|0 4|Chem
P10618645A0750|0 17|Maximum induction
P10619062T0000|0 27|Haycocknema perplexum n. g.
P10619169A0411|0 4|Rams
P10619254A1055|0 14|Animal studies
P10619353T0000|0 4|Role
P10620010A1155|0 10|CONCLUSION
P10620335A0749|20 23|AHR
P10620777A1399|0 8|AB004534
P10622574A0000|4 14|prevalence
P10622576A0552|26 37|information
P10623758A0947|7 14|latency
P10623804A0808|18 26|approach
P10624787A0432|36 45|functions
P10625438A1429|7 14|tissues
P10625494A1059|6 13|results
P10625683A0091|5 14|receptors
P10625721T0101|0 11|Hypothermia
P10627518A0544|16 22|effect
P10627532A0739|25 26|R
P10627834A0178|4 6|US
P10628490T0000|0 7|Anatomy
P10628748A0344|9 19|activation
P10628748A0746|0 8|Deletion
P10628750A0298|31 35|APRE
P10628750T0000|0 11|Angiotensin
P10628755A0000|10 17|ligands
P10628971A0824|4 14|collection
P10628971A1165|12 20|spectrum
P10629035A0827|11 23|strandedness
P10629176A0887|3 11|addition
P10629938A1352|22 34|distribution
P10630471T0000|3 12|ASIC-chip
P10630630A0614|9 21|calphostin C
P10633075A1111|10 13|IgG
P10633499A1306|0 24|Arhythmacanthus Yamaguti
P10634007A0202|14 18|case
P10635209A0419|10 22|conditioning
P10637149A0806|18 33|G-A anastomosis
P10637230A0332|8 18|expression
P10637238A0291|0 46|Eastern Cooperative Oncology Group trial E3186
P10637337A0545|18 28|DNA repair
P10638607A0000|6 14|articles
P10639585A0157|0 7|Studies
P10640683A0204|0 12|NDRF/NeuroD2
P10640683A0670|10 29|transfection assays
P10640701T0000|21 26|sites
P10640734A0190|5 29|tyrosine phosphorylation
P10641037A1371|0 8|AF154055
P10641688A0341|0 9|Alignment
P10642524A0156|16 27|interaction
P10642531A2322|0 23|Competition experiments
P10642889A0393|0 17|Sequence analysis
P10643313A0345|6 25|i.v. administration
P10644357A0935|6 13|results
P10644414T0000|13 23|expression
P10644753A0725|10 18|isoforms
P10644760A0000|4 19|differentiation
P10644760A0956|0 8|Analysis
P10645921A0000|0 10|BACKGROUND
P10645921A1320|13 23|predictors
P10646820T0000|4 8|case
P10646863A0838|0 14|Overexpression
P10647177A0599|4 15|RNA aptamer
P10647633A1685|4 9|study
P10647817T0000|0 9|Isolation
P10647859A0000|38 44|effect
P10648020A0151|0 7|METHODS
P10648211A0000|9 29|signaling properties
P10648489A1117|0 9|Treatment
P10648619A0000|25 37|contribution
P10649449A0413|4 13|sequences
P10649456A1061|4 10|clones
P10649738A0953|4 12|episodes
P10650104X0284|0 9|Copyright
P10650938T0000|4 21|estrogen receptor
P10650939A0789|0 9|Induction
P10650939A1542|14 17|SMC
P10650958A1315|0 9|Element B
P10651076T0000|5 15|resolution
P10651805A1600|7 19|transfection
P10651805T0000|0 16|Characterization
P10652093A0139|0 8|Electron
P10652102A0620|25 31|dosage
P10652228A0759|14 24|activation
P10652324A0177|13 26|participation
P10652362A0933|16 20|data
P10652800A0984|4 27|insulin therapy regimen
P10653359A1297|0 10|Scmh1 maps
P10653400A0000|4 17|applicability
P10653550A1120|0 20|Hyaluronan treatment
P10653693A0429|24 30|issues
P10653693A0903|4 15|RING finger
P10653697A0133|0 6|Actins
P10653733A0596|9 16|domains
P10654032A1133|0 4|JPEG
P10655164A0546|40 53|uncertainties
P10655230A0685|11 28|yeast counterpart
P10656154A0722|5 10|women
P10656161A0316|0 3|MBI
P10656802A1724|13 22|insertion
P10657238A0541|0 24|Transfection experiments
P10657658A0165|8 15|studies
P10657899A0685|0 12|Pretreatment
P10658425A1567|4 9|level
P10658445A0208|0 7|METHODS
P10658588A0304|0 28|Desmethylferrochloroquine 1a
P10660069A0819|4 22|rrd1,2delta mutant
P10660304A0522|0 7|Members
P10660604A0748|9 25|CARbeta/RXRalpha
P10660676A0000|0 17|Zebrafish cyclops
P10662550A0679|6 10|SOX8
P10662614A0000|4 23|genome organization
P10662614A0972|15 20|assay
P10663558T0000|19 31|light chains
P10664876A0000|0 10|Patch test
P10665308T0001|0 10|Mechanisms
P10665798A0598|3 11|increase
P10665949A1131|12 23|farm budget
P10666222A0330|35 55|survivin cDNA clones
P10666238A1322|10 19|induction
P10666253A1291|13 26|stabilization
P10666509A0494|26 37|arrhythmias
P10667597A0668|0 3|ZK7
P10668701A1311|0 10|CONCLUSION
P10669319A1722|12 23|conclusions
P10669594A0000|24 32|fimbrins
P10669594A0969|10 18|contrast
P10669596A0430|11 17|growth
P10669633A0391|8 13|study
P10669736A0903|21 31|difference
P10669751T0000|27 60|protein kinase signaling pathways
P10670358A0143|0 11|Dermatology
P10671224A0254|15 20|study
P10671519A0641|0 25|Protein sequence analysis
P10671520T0000|10 17|cloning
P10671554A0492|12 32|amino acid sequences
P10671606A0884|5 27|chemical shift imaging
P10672433A0199|9 14|night
P10672899A0078|0 4|Acad
P10673335X0782|0 9|Copyright
P10673426A0168|13 14|R
P10674395A0262|37 47|expression
P10674484A0633|6 10|data
P10675154T0000|8 15|potency
P10675331A0600|3 11|contrast
P10675610A0279|0 5|MSSPs
P10677214A1045|9 18|type MutT
P10677214A2842|11 18|changes
P10677297A0933|9 19|expression
P10678144A0509|6 10|i.v.
P10678968A1096|0 8|Immunity
P10679015A0216|13 17|view
P10679065A0711|0 17|BCR cross-linking
P10679065A1217|0 10|Activation
P10679190A0693|11 19|evidence
P10679649A0311|0 7|METHODS
P10679781A1183|6 37|bp Glucocorticoid Response Unit
P10679922A1110|11 20|mutations
P10681520A0525|0 8|Ras-GRF1
P10681562A0263|15 36|PPARgamma antagonists
P10681588A0899a|0 4|EMSA
P10681588A0899b|0 4|EMSA
P10681679A0220|8 18|resolution
P10682570A0453|0 3|LPO
P10683072T0000|22 33|tachycardia
P10683244A0939|17 21|NBF1
P10683244A1860|20 31|experiments
P10683244X2359|0 9|Copyright
P10683259A0774|0 20|Sulfhydryl titration
P10683989A0251|13 29|oxide inhalation
P10684069A0508|4 11|results
P10684097A0175|18 20|SD
P10684111A1411|30 37|variety
P10684265T0000|9 21|modification
P10684304A1242|4 15|interaction
P10684534A0634|0 9|Protamine
P10684646A0224|8 13|study
P10684660A1266|0 10|Comparison
P10684941A0722|4 15|requirement
P10684967A0000|0 6|NKX2.1
P10687366A0000|0 22|National abortion laws
P10687855A1197|0 10|Expression
P10687855T0000|0 47|Mouse growth hormone transcription factor Zn-16
P10687862A1980|4 31|CCAAT core sequence mutants
P10687945A0000|0 11|Deglutition
P10688639A1310|5 15|repression
P10688646A0535|23 33|K562 cells
P10688660A0992|15 23|addition
P10688661A0237|12 27|binding protein
P10688663A0207|0 7|Removal
P10688666A1010|13 22|mechanism
P10690702A0065|0 7|OUTCOME
P10690725A1037|10 18|patients
P10690866A0783|4 14|variations
P10691972T0000|0 16|Characterization
P10692167A0364|16 25|mechanism
P10692374A1873|6 13|results
P10692433A0000|4 28|transcription factor E2F
P10693246A0252|19 29|dissection
P10693314A0521|11 19|patients
P10694189A0469|4 10|effect
P10694210A0385|13 21|blockade
P10694511A0570|4 14|expression
P10694605A1327|19 34|infection rates
P10694609A0309|19 29|compliance
P10695685T0000|12 19|therapy
P10696007A1325|12 23|correlation
P10698516T0000|0 3|KFC
P10698937T0000|0 5|TIP30
P10698974A0951|25 35|STAG3 gene
P10699354A0557|0 13|Reaction time
P10699653A0967|3 13|experiment
P10699684A0661|13 18|Zelen
P10699896A0455|0 7|RESULTS
P10700262A0000|17 26|attention
P10701534A0164|4 11|patient
P10702241A0357|13 23|a1 isoform
P10702253A0357|11 18|cloning
P10702285A0855|14 26|relationship
P10702389A1148|11 13|BL
P10702794A1495|16 20|data
P10702926T0089|0 14|Cross-reaction
P10703633A0747|0 17|Strontium nitrate
P10704196A1051|19 36|sulfhydryl groups
P10704283A0649a|0 8|Analysis
P10704285A0536|6 13|AP-2rep
P10704338A0354|3 8|order
P10704410T0000|0 17|Clb/Cdc28 kinases
P10704499A0682|15 28|PC12-E2 cells
P10704853T0000|0 17|Cooperative roles
P10704975A0479|0 18|Thiopentone sodium
P10705380A0629|40 59|Xretpos transcripts
P10705783A0433|13 18|cases
P10706475A0644|33 37|DSPP
P10706513A0843|15 24|prognosis
P10706688A0376|14 27|TCR signaling
P10706736A1091|6 14|patients
P10706887A0281|16 17|%
P10706887A1457|3 11|addition
P10708243A0000|14 25|observation
P10708424A0800|10 14|ions
P10708769A0433|4 8|Mif1
P10709705T0000|6 32|point feature registration
P10710499A0000|0 12|Methysergide
P10710742T0000|0 27|Serum leptin concentrations
P10710985T0000|8 16|families
P10711674A0000|0 7|PURPOSE
P10712512A0506|0 6|Ste18p
P10712599A0349|19 24|IRF-1
P10712618A0181|14 33|sequence comparison
P10713083A0170|15 21|system
P10713083A0560|25 30|assay
P10713155A0151|18 40|IIIa pre-mRNA splicing
P10713161A0985|0 12|Inactivation
P10713175A1399|18 25|results
P10713176A0422|0 19|Cyclin A expression
P10713176A0885|0 21|D-cyclin-cdk activity
P10713239A0988|0 10|CONCLUSION
P10713453A0172|4 11|protein
P10714985A1057|3 27|RNA boundary experiments
P10715322A0000|0 14|Gene silencing
P10715325A0834|4 15|AtERF genes
P10715602A0149|0 7|Animals
P10717612A0000|0 10|BACKGROUND
P10720434A0291|12 21|injection
P10721698A1195|6 10|data
P10721704A1155|24 36|organization
P10721704X0000|0 8|Analysis
P10721714A1087|16 37|mobility shift assays
P10721717A0676|0 4|Fgd3
P10721726T0000|10 17|cloning
P10722063A0328|4 15|HPLC method
P10722509A0392|6 14|patients
P10722661A0146|0 4|CYC2
P10722661A0406|16 20|CYC2
P10722737A1726|6 14|findings
P10722969A0510|15 23|progress
P10723723A0781|18 32|mouse promoter
P10723727A0713|18 24|region
P10724436A0085|22 26|U3O8
P10724483A0540|24 36|cAMP control
P10724519A1185|44 48|RNAs
P10725017A0673|5 10|paper
P10725382A0398|0 17|Sequence analyses
P10725433A0543|2 10|mutation
P10727247A0461|21 28|cloning
P10727413A1244|14 27|binding sites
P10727426A1280|4 19|kinase activity
P10727428A0000|9 12|MAP
P10727433A0560|0 12|Transfection
P10727433T0000|0 10|Regulation
P10727511A0294|0 8|Molecule
P10727515A1202|0 12|Coactivation
P10728945A0233|0 8|Patients
P10728986A0000|4 25|Wnt signaling pathway
P10729151A1160|5 13|mutation
P10729155A0653|20 31|MVMi capsid
P10729220A0000|19 23|IGF2
P10729220A1569|15 26|methylation
P10729221A0798|4 14|comparison
P10730292T0000|6 25|treatment mechanics
P10730763A1491|12 15|use
P10731411A0958|4 13|consensus
P10731926A0775|0 16|Advanced adenoma
P10732669A0510|13 19|assays
P10732669A1336|0 7|Results
P10733569A0364|16 20|HSFs
P10733581A1391|25 35|expression
P10733591A0146|27 34|targets
P10733591A0533|0 10|Expression
P10733880X1783|0 9|Copyright
P10734312A0503|22 38|Shc localization
P10735272A0649|0 17|Southern blotting
P10735848A1440|0 4|RegA
P10736161T0000|0 8|Enzyme I
P10736223A1227|15 19|data
P10737366A0280|55 59|PTFL
P10738139A0681|10 17|mimicry
P10739408A0896|0 18|Family environment
P10739671A0136|3 40|electrophoresis mobility shift assays
P10740602A0141|0 12|STUDY DESIGN
P10741850A0452|0 30|Electrophile Response Elements
P10741947T0000|6 15|technique
P10742114A0486|0 4|Dll3
P10742216A0555|0 8|Schlegel
P10743608A1154|0 17|TbRAB31 behaviour
P10743719A0223|10 12|dg
P10744026A0000|0 10|Invertases
P10744749A0315|29 39|mechanisms
P10744749T0000|10 16|T cell
P10744974T0000|0 15|Phosphorylation
P10745563A0409|15 26|hyperplasia
P10747053A1102|4 14|cell cycle
P10747099A0507|24 30|kinase
P10747782A0390|0 11|Proteolysis
P10747879A0607|4 13|evolution
P10747890A1096|6 13|results
P10747987A0658|16 23|enzymes
P10748054T0048|2 9|pathway
P10748113A0187|25 36|RIM protein
P10748125A0000|0 11|Inhibitor-1
P10748164A1284|0 18|Scanning mutations
P10748175A0000|4 14|substrates
P10748194T0000|9 18|targeting
P10748204A0238|7 9|J.
P10748672A0130|0 5|Bites
P10749145T0000|29 42|PCPH proteins
P10749166A0991|6 13|results
P10749849A0000|13 22|mechanism
P10749932A0000|0 8|Paxillin
P10750020A0843|6 30|growth factor activation
P10750021A0728|13 21|analysis
P10750524A0724|0 7|RESULTS
P10751398A1135|3 11|addition
P10752450A0288|2 9|variety
P10752475A1376|6 13|studies
P10752807A1598|0 10|CONCLUSION
P10753553T0000|0 9|Phenazone
P10754312A0798|4 14|solubility
P10756007A0575|20 33|RBE sequences
P10756007A1512|0 11|EM analysis
P10756020A0571|4 11|protein
P10756032A0599|8 37|dimethyl sulfate footprinting
P10756094A0671|2 7|total
P10756100A0457|12 20|mutation
P10756225A1464|0 10|CONCLUSION
P10757975A0509|0 4|Biol
P10757983A0733|7 12|basis
P10758289A0141|0 7|METHODS
P10758489A0206|22 31|isolation
P10758726T0000|9 15|impact
P10759693A0201|0 7|METHODS
P10760109A1050|4 14|prevalence
P10760132A1169|4 8|data
P10760169A1142|22 26|pair
P10760950A1133|11 27|staining pattern
P10761263A1108|5 14|Newcastle
P10762254A0954|4 7|MMA
P10762348A0269|6 21|phosphorylation
P10763823A0824|0 14|Overexpression
P10763827A1158|24 43|senescence pathways
P10764150A0000|8 13|study
P10764574A0718|0 11|Application
P10764729A1846|13 26|cDNA sequence
P10764760T0000|0 15|Transactivation
P10764802A1258|6 10|data
P10764970A1009|4 8|mode
P10765095A0308|5 10|study
P10766246A0000|0 27|Integrin adhesion receptors
P10766493T0000|0 13|Recombination
P10766556T0000|4 24|somatoform conundrum
P10767091A0133|16 26|ultrasound
P10767251A1046|0 11|CONCLUSIONS
P10767338T0000|14 21|disease
P10767553A0100|0 3|Hex
P10767560A0105|6 15|extension
P10769144A0000|4 7|CRE
P10770041A0731|0 13|Kidney length
P10770065A0264|13 18|stage
P10770471T0000|0 11|Benztropine
P10771528T0036|2 7|cause
P10771709A0291|4 14|physicians
P10772856X1492|0 9|Copyright
P10772977A0222|19 27|movement
P10773351A0672|0 9|Induction
P10773455A1268|43 48|sites
P10773458A0000|0 7|SNAP-23
P10773667A0351|4 14|HMG domain
P10773951A0000|0 3|IgM
P10775038A0142|6 13|attempt
P10775267A0363|11 23|transduction
P10775585A0754|0 14|Ab-MLV strains
P10775623A0120|4 15|codon usage
P10777217A0536|4 23|p53-homolog p73beta
P10777499A0883|0 7|Results
P10777586A1022|0 22|Co-immunoprecipitation
P10777669A0582|4 15|ZNF274 gene
P10778740A1493|15 31|Cdk2 truncations
P10778757A0000|32 38|nature
P10779313A1842|33 41|myocytes
P10779329T0000|0 4|Slap
P10779352T0000|0 14|Identification
P10779508A0452|3 8|DNase
P10779508A0897|19 30|coactivator
P10779508T0000|0 8|Estrogen
P10780018A0539|19 25|models
P10780518A1270|4 11|effects
P10780764A0722|11 17|levels
P10780883T0000|0 6|Kaposi
P10781109T0000|31 43|interference
P10781423A0993|0 10|Comparison
P10781541A1063|26 35|sequences
P10781552A0000|0 6|Purple
P10781604A0827|3 11|analysis
P10781611A1023|13 17|bone
P10781990A0455|12 15|MRI
P10782640A0444|4 10|method
P10782989A0575|4 15|interaction
P10784367A0133|0 6|METHOD
P10784393A0000|0 16|Marrow dysplasia
P10785294A0720|28 41|inlays/onlays
P10785668A0000|4 10|plants
P10785880A0947|0 10|CONCLUSION
P10786671A0182|18 22|step
P10786742A0670|7 20|control group
P10787437A1616|13 20|element
P10787804T0000|0 4|AMDA
P10788320A1034|6 14|proteins
P10788476A0891|0 10|Antibodies
P10788480T0000|0 10|Regulation
P10790390X0000|22 32|complexity
P10791251A0110|25 30|kinds
P10791819A0771|5 13|tendency
P10791901A0609|0 12|Transduction
P10792583A0000|0 10|Regulation
P10792718T0000|0 14|Identification
P10793143A1533|32 43|DNA binding
P10793991A0569|19 28|longevity
P10794405A0000|15 20|study
P10794936A0241|4 18|recovery rates
P10795098A0253|9 19|vasculitis
P10796465A0373|0 18|SELECTION CRITERIA
P10796486A0817|0 18|SELECTION CRITERIA
P10797125A0000|12 22|hypothesis
P10797586A0402|4 10|models
P10798607A1359|4 8|data
P10799501A1391|6 13|studies
P10799576A0196|0 2|M.
P10799590A0431|0 6|Jkappa
P10799595A1454|11 14|YY1
P10799863T0000|11 19|cleavage
P10799879T0000|0 7|Cloning
P10801244A0578|0 15|Vancomycin data
P10801330A1714|9 12|Cas
P10801482A0968|18 21|p65
P10801809T0000|16 26|regulation
P10801860A0000|4 11|Siglecs
P10802669A1434|4 8|data
P10802909A0478|0 11|PATIENTS OR
P10804379T0001|0 6|Update
P10805286A0233|15 20|study
P10805286A0914|7 12|study
P10805390A0340|18 29|performance
P10805729A0987|4 17|stoichiometry
P10805737T0000|11 19|analysis
P10805738A0799|5 13|evidence
P10805739A0343|5 13|activity
P10805739A0640|4 12|analysis
P10805747A0633|3 11|contrast
P10805823A1920|0 11|CONCLUSIONS
P10807900A0933|6 20|non-cirrhotics
P10807903A0362|0 5|D5/D1
P10809233A0606|0 8|Modeling
P10810083A1283|21 32|kinase gene
P10810294A0730|0 15|Stat activation
P10810745A0677|0 8|HFA 134a
P10811079A0555|0 7|RESULTS
P10811079A1277|7 26|SPP2 screening test
P10811804A0000|18 25|protein
P10811804A0800|35 43|peptides
P10811908A0938|0 27|HPLC phosphopeptide mapping
P10812294X0000|16 20|diet
P10814989T0000|0 27|Hepatitis C virus infection
P10815410A0000|11 17|system
P10815807A1271|27 40|transcription
P10817754T0000|0 3|H19
P10819327T0000|0 17|C. elegans KLP-11
P10820829T0000|0 10|Flavonoids
P10820904A0000|0 10|BACKGROUND
P10821836A0842|24 37|S transcripts
P10822117A1386|12 22|adjustment
P10823630A1124|13 21|presence
P10823837A1213|4 8|data
P10823961A0664|4 14|C terminus
P10824485A0393|4 12|patients
P10824958A1109|18 24|energy
P10825000A1245|4 28|gene amplification model
P10825200T0000|0 9|Hierarchy
P10825293T0000|12 18|dimers
P10825294A0473|13 24|OC promoter
P10826861A0000|15 38|immunoglobulin products
P10826946A1198|0 13|Investigation
P10827885T0059|33 38|trial
P10827952A0158|23 31|TAFII250
P10828022A0877|0 20|Endostatin treatment
P10828319A0342|11 18|analogs
P10828591A0080|4 14|transcript
P10828751A2258|9 18|challenge
P10829973T0000|0 27|Iodine deficiency disorders
P10830395A0408|4 21|network evolution
P10831972A0744|0 7|RESULTS
P10831972A1091|0 10|CONCLUSION
P10833461A0603|16 20|gene
P10833486A0598|0 3|Age
P10834707A1533|25 32|amounts
P10834781A0693|21 26|group
P10835355A0225|23 47|zinc finger protein Gis1
P10835485A0941|15 18|SH3
P10835732A0911|3 14|differences
P10836542A0363|8 9|%
P10836786A0516|29 33|role
P10837126A1004|6 11|genes
P10838139A1447|16 28|Ha-ras codon
P10838399A0525|15 22|PET FDG
P10838531A0675|0 12|Tumor stages
P10839470A1148|11 21|comparison
P10839547A0978|20 25|model
P10839593A0000|0 9|OBJECTIVE
P10840001A0188|0 21|Mucin gene expression
P10841537A0669|26 33|regions
P10841593A0780|4 9|model
P10841601T0000|0 11|Paper alert
P10843716A0406|4 18|tryptase locus
P10843810A0802|13 17|part
P10845522A0000|0 9|OBJECTIVE
P10846054A0573|11 19|analyses
P10846069T0000|0 4|Role
P10848605T0000|0 15|Phosphorylation
P10848848A0413|0 7|RESULTS
P10848993A0000|8 22|DNA sequencing
P10850329A0248|0 4|IL-2
P10850453A0713|10 20|expression
P10850453A1292|20 24|data
P10850719A0680|0 14|Vbeta segments
P10850849A0730|9 23|administration
P10850942A0989|3 13|experiment
P10850997A1016|3 11|contrast
P10851089A1248|6 9|SAG
P10851267A0000|0 3|E2F
P10851745A0624|16 23|fatigue
P10852221A0422|23 32|treatment
P10852460A0170|4 17|relationships
P10852485A0477|8 14|Spring
P10852953A0000|0 14|Investigations
P10853059X0751|0 9|Karger AG
P10853778A0316|7 25|surgery bone cysts
P10853850A1103|8 12|LTE4
P10854004A0788|6 9|FVR
P10854699A0424|6 18|FGF-AS cDNAs
P10855690A0870|22 29|results
P10855793A1418|0 16|Characterization
P10855796A1160|17 42|RNA hybridization studies
P10856298A0798|0 12|Transfection
P10856491A0178|0 7|SETTING
P10856805T0000|0 33|Improving fissure sealant quality
P10857215A0000|4 26|Menopause-Rating-Scale
P10857215A0806|4 10|MRS II
P10857262A0186|4 11|protein
P10857751A0304|3 11|addition
P10858355A0920|0 12|Sparfloxacin
P10858988A0786|0 3|ECP
P10860131A0847|0 17|Tolterodine users
P10860196A0876|20 27|program
P10860752A1601|4 12|presence
P10860827A0399|0 8|Deletion
P10860846A0480|11 18|studies
P10861080A0433|17 25|transfer
P10861086A0259|3 29|reconstitution experiments
P10861086A0904|3 11|contrast
P10861906A0999|4 24|delta srb10 mutation
P10861906A1479|33 43|conditions
P10861909A0502|4 15|pJR vectors
P10862289A0289|1 4|GUT
P10863048A0000|4 10|effect
P10863352T0001|0 14|Franz Schubert
P10864271A0504|4 11|results
P10864496A0401|4 36|equilibrium dissociation binding
P10864641A1400|6 13|results
P10864989A0484|0 7|RESULTS
P10865422A0138|20 34|serum ferritin
P10865838A0000|21 34|growth factor
P10865940A0000|16 49|agent pyrrolidine dithiocarbamate
P10866323A0666|23 30|effects
P10866677A1839|0 3|Phd
P10866689A0295|7 10|pRb
P10866886A1277|5 11|effect
P10867199A0230|3 11|contrast
P10867496T0001|0 17|Neurofibromatosis
P10868488A0921|17 23|period
P10869076A1384|6 13|results
P10869465A1054|8 21|hybridization
P10870043A0621|4 18|administration
P10870391T0034|0 10|Prevention
P10871045A1221|5 10|study
P10871347A0477|0 17|Mutation analysis
P10871379A0261|8 12|VP16
P10871412A0369|21 27|rounds
P10871615A0368|0 2|G.
P10871842A0988|4 11|results
P10872473A2286|4 18|ATR-X syndrome
P10872535A0000|0 4|AIMS
P10872756A1325|3 13|NASCIS III
P10872827A0000|0 18|Penicillin acylase
P10872831A0000|19 31|sequence tag
P10872851A0714|9 12|LCx
P10873158A0000|0 10|Activation
P10873286X0000|0 13|GAP JUNCTIONS
P10873386A0000|52 62|mouse gene
P10873387A0816|29 33|gene
P10873388A0623|15 28|Rhotekin cDNA
P10874044A0647|11 24|co-expression
P10874151A0000|0 10|BACKGROUND
P10878398A0542|16 24|patients
P10878606A0876|35 45|structures
P10878675A1278|0 10|CONCLUSION
P10878944A0000|9 42|diphtheria toxin polymer particle
P10880486A0790|35 44|mutations
P10880702A0966|15 22|results
P10881275T0000|12 29|serum IgM binding
P10882163A1077|0 19|Objective responses
P10882213A0163|0 6|Topics
P10882462T0000|4 11|science
P10882850A0000|0 12|Endonuclease
P10884978A0633|4 12|duration
P10885708T0000|9 27|bile duct blockage
P10885731A0915|18 23|study
P10885750A0236|48 56|function
P10886067A0520|10 18|diameter
P10887912A0740|9 13|MVBF
P10887921A0718|0 11|CONCLUSIONS
P10888570A0678|10 19|alkaloids
P10889399A0243|4 26|detection success rate
P10890911A0470|21 26|Smad3
P10891093A0000|4 26|transmembrane topology
P10891266A0421|0 5|ACE-2
P10891286A0000|0 7|Members
P10891399A1185|18 28|activation
P10891441A0871|15 41|pTyr317 Shc phosphopeptide
P10891489A0152|19 29|expression
P10891632A0435|4 37|naltrexone/lofexidine combination
P10892300A0268|10 18|symptoms
P10892823A1040|0 9|Screening
P10893243T0000|16 26|regulation
P10893258T0000|13 29|protein response
P10894149T0000|0 4|PNRC
P10894816A0836|0 7|Studies
P10894886A0375|26 32|subset
P10895417A0000|33 36|EPI
P10895417A0669|10 19|EPI-C0401
P10895851A0696|0 18|Bailey Instruments
P10896008A0531|0 12|PARTICIPANTS
P10896859A0000|4 10|effect
P10896859A0838|22 27|cause
P10897233A1057|0 10|CONCLUSION
P10897973T0001|0 27|Antithrombin III deficiency
P10898795A0527|9 14|class
P10899128A0661|18 25|example
P10899142A0000|20 28|Berkeley
P10900129A0138|0 18|Degenerate primers
P10900269A0396|5 10|cells
P10901133A0381|0 16|Methyllevamisole
P10902348A0566|0 17|Resistance ratios
P10903440A0515|5 16|transcripts
P10903495A0533|5 26|gel retardation assay
P10903583T0000|0 11|Reliability
P10903733A0540|0 33|Coimmunoprecipitation experiments
P10903837A1208|10 19|RINX gene
P10903843A0447|16 28|localization
P10903877A0879|0 10|Activation
P10904191A0000|12 17|study
P10905349A0329|0 6|Mus81p
P10905349A0609|14 22|analysis
P10905352A0000|11 24|plasmid pCLU1
P10906176A0000|15 18|ETn
P10906317A0351|26 35|variables
P10906999T0000|4 15|measurement
P10907348A0508|12 24|examinations
P10907971A0806|0 12|Atorvastatin
P10907971T0000|17 27|assessment
P10908317A1459|24 33|E domains
P10908364A0000|0 5|G-DNA
P10908462A3159|4 17|effectiveness
P10908478A0717|0 18|SELECTION CRITERIA
P10908822A0519|1 2|%
P10909973A1508|3 11|contrast
P10910073A0876|12 29|PDGFbetaR fusions
P10910439A1196|0 11|CONCLUSIONS
P10910908A0767|5 12|finding
P10913094A0424|5 18|DNA fragments
P10913172A0442|37 42|motif
P10913276A0510|35 41|domain
P10913276A0684|15 33|expression studies
P10913304A0894|13 22|Ets mRNAs
P10913304A1180|4 17|kb transcript
P10915728A0216|16 24|patients
P10915780A1063|0 20|Wnt-1 overexpression
P10917402T0000|24 38|administration
P10918059A0569|0 8|Deletion
P10918164A0878|9 28|regression analysis
P10918440T0000|0 31|Erythema exsudativum multiforme
P10918572A0794|0 3|VaI
P10918572A1547|6 18|interactions
P10918596A0000|33 47|p53 C-terminus
P10918599A0071|3 11|contrast
P10918612A0000|4 28|transcription factor Jun
P10918943T0000|14 22|toxicity
P10918948A0110|5 13|compound
P10919971A0606|3 11|addition
P10920186A0528|17 26|formation
P10920906A0759|0 10|CONCLUSION
P10921197A0179|0 12|Measurements
P10924061A0588|0 10|Activation
P10925159A1353|8 14|MARTA1
P10925207A0634|15 20|exons
P10926776A0731|12 25|PDP1 isoforms
P10928179A0101|12 21|technique
P10928337A0590|8 18|correction
P10928477A0764|5 10|study
P10930526A0174|35 42|cloning
P10931524A0313|26 34|activity
P10931927A0655|9 24|oligomer duplex
P10931950A0869|0 4|Cdk2
P10931960A0630|4 8|loss
P10932196A0359|0 9|Mutations
P10932329A0597|4 9|limit
P10932527A0947|14 16|HD
P10932527T0000|4 17|effectiveness
P10932679A0049|25 33|evidence
P10933154A1118|6 14|findings
P10933728A1398|6 13|results
P10933732A0000|4 10|genome
P10934073A1433|14 25|limitations
P10934310A0698|0 14|DATA SYNTHESIS
P10934640A1114|0 12|TB bone area
P10934751T0001|0 14|CREST syndrome
P10935488A1033|0 12|Troglitazone
P10935880A1049|0 7|Viruses
P10936051T0000|4 9|RS447
P10936920A0105|9 19|experience
P10938102A0265|21 27|effect
P10938102A1359|45 49|data
P10938102T0000|11 44|translation initiation factor 4GI
P10938105A0000|0 8|Splicing
P10938109A1361|15 20|cells
P10938113A0388|57 70|isoforms Vav2
P10938120A1093|16 26|regulation
P10938130A0338|0 5|X-ray
P10938135A0259|4 11|ability
P10938556A0248|3 11|addition
P10939030A0986|4 15|differences
P10939785A0540|0 8|Patients
P10940413A1153|4 11|results
P10940553A0912|6 13|regions
P10940557A1687|23 30|CF1/USP
P10940562A0379|0 17|Sequence analysis
P10940562T0000|23 39|characterization
P10940892A0573|23 42|susceptibility loci
P10942587A0981|7 16|treatment
P10942599A1298|8 24|characterization
P10943891A1062|4 11|ability
P10944466A0451|23 32|structure
P10945010T0001|4 8|role
P10945781A0412|12 29|Aeromonas strains
P10946303A0000|0 9|TNF-alpha
P10947274A0839|4 16|therapy time
P10947840A0762|0 4|Mis3
P10950398T0100|0 21|Losartan Intervention
P10950415A0866|0 10|CONCLUSION
P10950924A0393|0 3|RNA
P10950935A0111|14 26|manipulation
P10951579A1238|6 23|gamma-irradiation
P10951848A0230|0 12|Mobilization
P10952828A2638|43 52|resonance
P10954093A0000|13 27|DNA transposon
P10954525A1161|13 21|presence
P10954564A1262|37 43|domain
P10954913A0152|21 31|cDNA clone
P10955313A0000|0 6|PLUS-3
P10955913A0827|5 11|HIT II
P10955998A1124|12 22|efficiency
P10958271A0365|0 7|METHODS
P10958456A0529|6 11|cDNAs
P10958673A0142|19 28|signaling
P10958688A0265|2 28|Y. lipolytica Kar2p mutant
P10958698A0280|51 62|mutagenesis
P10958698A0485|4 11|spacing
P10959676A0200|4 9|bases
P10959838A0153|3 16|invertebrates
P10961046A0342|0 15|Platelet counts
P10961585A0273|4 18|manifestations
P10962564A0883|2 31|beta2 RARE reporter construct
P10962593A0580|18 26|AFP rate
P10962738A0000|0 13|Consciousness
P10962881A0900|0 11|Multiparity
P10963577T0016|0 7|Picture
P10963735A0193|4 7|aim
P10963735A0651|9 26|plasma parameters
P10964833A1696|15 27|participants
P10964995A2152|41 48|concern
P10965135A0735|0 17|Promoter activity
P10965135A1207|4 11|results
P10965830A0305|0 13|INTERVENTIONS
P10965905A1618|19 33|Akt activation
P10965905T0000|0 16|Insulin receptor
P10967361A0000|20 37|resonance imaging
P10967531A1025|24 29|aorta
P10967890A1120|4 11|results
P10970048A0352|18 26|increase
P10972688A1272|13 22|follow-up
P10972894A0488|8 17|libraries
P10972980A0295|11 21|cell lines
P10972990A0196|21 32|protein p53
P10972990A0526|0 10|Abrogation
P10972990A0966|12 20|analysis
P10972990A1518|6 13|results
P10973151A0883|4 14|importance
P10973385A1423|3 11|patients
P10973400A0664|0 7|RESULTS
P10974541A0389|14 31|K562 cDNA library
P10975465A0134|10 26|cDNA clone NFBD1
P10976413A0514|0 7|RESULTS
P10980416T0000|12 30|hormone regulation
P10981094A0779|7 22|target BP goals
P10982076A0000|35 54|morbidity recording
P10982143A0346|4 10|muskox
P10982391A0425|14 25|NPF repeats
P10982825A0363|23 33|difference
P10983344A0000|4 11|article
P10983857A0923|8 19|application
P10983979T0000|11 22|recognition
P10984122A0911|3 10|control
P10987280A0604|4 23|amino acid sequence
P10987301A0332|8 14|regard
P10989777A1286|12 20|subgroup
P10991383A0289|7 14|lattice
P10991648T0000|45 59|half syndromes
P10992299A0745|22 29|members
P10992983T0000|15 23|relation
P10993773A0717|5 10|slope
P10993787A0369|13 16|MAP
P10995121A0569|0 8|Analysis
P10995751A0093|57 69|protein-beta
P10997330A0361|0 22|Northern blot analysis
P10997863A0753|7 19|TLE patients
P10997904A1258|4 18|Spo0F residues
P10998679A0500|16 23|factors
P10999205A0607|24 34|resolution
P10999301A0000|13 23|evaluation
P10999369A0192|18 27|amplitude
P11000203A0752|6 15|mutations
P11000250A0200|0 5|LMP-1
P11000266T0000|0 14|Identification
P11000521A0588|23 41|signaling pathways
P11002236A0328|0 7|METHODS
P11003471A1149|13 21|analysis
P11003641A0811|27 38|motif KEFGK
P11003652A0961|6 13|results
P11003653A0198|0 8|Deletion
P11003669A0000|4 11|product
P11003805A0443|0 7|Studies
P11003807A0303|0 8|Symptoms
P11004369A0000|0 9|OBJECTIVE
P11005808A1082|6 13|results
P11005831A0242|6 11|cDNAs
P11006283A1180|12 20|AROM-p64
P11006284T0000|21 31|kinase fer
P11006331A0319|13 22|phenotype
P11007509A1271|7 22|PMR target area
P11007777A0813|0 8|Analysis
P11007949A1395|25 45|inactivation mutants
P11007949A1607|30 38|activity
P11007954A0170|4 17|growth factor
P11007961A0930|0 9|Mutations
P11007968A0255|9 16|purpose
P11008139T0000|11 19|learning
P11008420A0580|4 12|detector
P11011139A0000|36 53|SIN4 gene product
P11012568A0192|16 32|hypersensitivity
P11012671A0576|3 11|addition
P11012680A0676|0 14|Src activation
P11012680A1020|4 7|use
P11013079A0927|9 34|transcription start sites
P11014197A0339|9 28|inhibitor scaffolds
P11014213A1019|21 32|interaction
P11014215A1092|18 34|deletion studies
P11014465A0479|9 12|day
P11014821T0000|4 25|LAMMER protein kinase
P11015197A0310|19 27|cysteine
P11015200A0156|7 9|J.
P11016014A0181|0 10|HYPOTHESIS
P11016724A0536|3 10|group B
P11016737A0275|26 33|outcome
P11016850A0423|12 24|DNA fragment
P11016954A0438|0 4|AGO1
P11017876A0787|14 34|localization studies
P11018028A0263|25 36|involvement
P11018264A0397|0 33|Reporter gene expression analyses
P11019257A0159|13 20|3T1-3T2
P11020375A0134|2 7|total
P11023074A1105|4 8|cost
P11023832A1038|17 24|results
P11023853A0188|27 45|weather conditions
P11023934A0855|0 3|L/H
P11024026A0133|9 20|selectivity
P11024036A0984|22 33|fibroblasts
P11024047A0626|0 10|Expression
P11024182A0781|7 13|alpha1
P11024300A1579|0 6|Nature
P11025367A1009|0 13|Abnormalities
P11027027A0061|3 20|Sunset Yellow FCF
P11027267A0752|0 8|Polysome
P11027274A1682|34 45|PI 3-kinase
P11027280A0536|0 10|Cam kinase
P11027289A0000|28 38|suppressor
P11027289A0321|5 11|result
P11027294A0483|5 16|interaction
P11027724A0335|12 19|BRI1-KD
P11027833A0362|0 13|Flow cytomery
P11028131A1374|8 16|research
P11028131T0000|0 18|Cost-effectiveness
P11028944A1020|9 13|Cmax
P11029045A0000|0 15|Hyperactivation
P11029262T0000|0 5|Diary
P11029458A0000|0 5|Cells
P11029459A0000|13 32|growth factor-beta1
P11029467T0000|22 29|peptide
P11029656A0640|0 3|Mn2
P11029700A0295|6 8|Pt
P11029700A0746|32 37|assay
P11029704A0378|13 21|analysis
P11030066A0142|23 37|manifestations
P11030476A0685|0 6|Spores
P11030744A0763|0 14|Overexpression
P11031252A0646|4 13|LMW FGF-2
P11031366T0001|0 19|Helicobacter pylori
P11031773A0174|9 16|purpose
P11032599T0000|15 30|recommendations
P11032677A0230|10 18|findings
P11034392A1072|20 24|data
P11034547A0674|10 14|Arix
P11034547A1355|22 27|study
P11034933A0389|0 7|METHODS
P11035037A0183|21 28|segment
P11035867A0000|0 9|OBJECTIVE
P11036786A0628|14 21|results
P11036938A1162|3 11|increase
P11036939A2149|0 3|Dsh
P11037759T0000|0 15|Catch-up growth
P11037823A1134|0 11|CONCLUSIONS
P11038042A0948|0 10|Escalation
P11038118A0000|0 14|Methyl formate
P11038317A0000|32 40|proteins
P11038366A1322|13 17|loss
P11038366A1417|6 17|methylation
P11039341A0180|4 11|purpose
P11039780A0770|4 11|authors
P11040101A1180|16 23|results
P11040219A0548|0 7|Binding
P11041308A0156|4 12|subjects
P11042197A0386|0 3|Lys
P11042199A0572|0 9|Elevation
P11042204A0186|12 17|study
P11042703A0875|5 9|BFDS
P11043469A0440|15 31|border sequences
P11044097A0422|27 30|HMG
P11044097T0000|20 27|protein
P11044105A0616|19 26|element
P11045180A1892|0 11|Leptinaemia
P11045607A0239|3 16|RACE analysis
P11046146A1202|6 23|diamide treatment
P11046148A0716|0 5|LMP2A
P11046153A1052|22 31|apoptosis
P11046517A0619|4 11|results
P11048832A0271|0 6|Fisher
P11049241A0659|0 7|RESULTS
P11049889A1271|0 19|Thromboelastography
P11050084A0000|5 15|expression
P11050084A0888|17 24|element
P11050168A1185|6 13|results
P11051364A0890|0 7|RESULTS
P11051370A1906|0 8|Response
P11053009A0000|0 7|Aspirin
P11053263A0200|2 7|total
P11053370A0708|0 10|Expression
P11054011A1685|0 11|CONCLUSIONS
P11054341A0599|0 7|RESULTS
P11054539A0114|4 8|gene
P11054565A0654|9 20|p190-B exon
P11054571A0230|17 27|teneurin-1
P11054970A0282|4 26|plexiform neurofibroma
P11055513A0564|11 19|lookback
P11055786A0306|13 22|algorithm
P11056007A0224|25 36|amino acids
P11056019A0926|0 4|MED1
P11058008A0159|14 23|instances
P11058119A0957|6 13|results
P11058120A0256|13 20|factors
P11058132A0264|16 20|CDSs
P11058406A0447|18 21|SLN
P11059492A0376|0 9|Bacteriol
P11059777A0813|9 25|deoxynucleotidyl
P11059786A0682|0 22|VEGF promoter activity
P11059786T0000|10 32|growth factor receptor
P11062047A1208|6 11|IHHNV
P11062067A0000|17 31|protein kinase
P11062068T0000|10 20|activation
P11062257A0977|10 29|class C-Vps complex
P11062274T0000|52 80|tissue plasminogen activator
P11062705A0658|28 32|role
P11063127A0000|0 19|Signal transduction
P11063169T0000|0 17|Botulinum toxin A
P11063252A0437|0 6|Exon A
P11063742A0000|0 9|NF-kappaB
P11064829T0058|0 27|Cardiovascular risk factors
P11066245T0000|26 43|compliance review
P11067797A1306|0 11|CONCLUSIONS
P11067928A0532|10 14|mAbs
P11069011A0224|0 15|SSF experiments
P11069075T0000|0 16|Characterization
P11069223A0593|0 8|Patients
P11069307A0546|0 10|Inhibition
P11069756A2618|0 13|Abbreviations
P11069788A0531|28 30|SB
P11069791A0226|16 24|subjects
P11069825A0530|15 20|cases
P11069897A1112|6 13|results
P11069999A1602|4 11|U17/U16
P11070007A0136|0 13|Transcription
P11070056A0704|4 20|Cili-2 sequences
P11070078A1153|13 21|response
P11071651A1308|38 45|pathway
P11071789T0000|22 33|dose levels
P11071852A0297|23 29|SOCS-3
P11071924A0588|2 9|protein
P11071974A0155|16 23|effects
P11072155A0764|29 40|correlation
P11072388T0000|6 17|feasibility
P11073163A0131|28 39|degradation
P11073218A0800|10 20|nucleotide
P11073539A0866|11 19|analysis
P11073870A0375|0 8|Patients
P11073919A0631|3 11|addition
P11073954A0337|4 13|Psc2 cDNA
P11074003A0741|4 11|results
P11074210A0623|4 15|QT interval
P11075678A0298|4 15|wavenumbers
P11075929A1657|4 8|data
P11075944A0691|3 11|addition
P11076860A0872|0 11|Experiments
P11078726X0000|15 30|phosphorylation
P11080796A0883|27 36|cell line
P11080796A1277|4 28|Tax/IKKgamma interaction
P11081962T0000|12 16|AFLP
P11082185A0415|3 11|addition
P11082587X0000|0 7|Effects
P11082715X0001|13 26|determination
P11083154A0881|4 9|males
P11083358A1071|0 10|CONCLUSION
P11083432A0332|8 14|groups
P11083868A0386|0 11|DNA binding
P11084022A1178|14 28|ALK7 signaling
P11084334A0590|4 17|swa2-1 allele
P11084556T0000|0 11|Association
P11084649A0497|18 25|embryos
P11085267A0562|0 14|Transformation
P11085600A0123|4 11|authors
P11086872A0000|0 9|Influence
P11087141A0977|9 17|analysis
P11088635A0200|10 41|Kubo-Martin-Schwinger condition
P11089911A1267|19 28|sequences
P11090172A0612|4 15|time course
P11090272A1240|4 17|transcription
P11090762A0527|0 7|RESULTS
P11092770A0238|4 14|extraction
P11092809A0823|3 11|addition
P11092850A1023|9 40|16S rRNA gene sequence analysis
P11092886A0341|14 42|protein kinase A stimulation
P11093745A0563|17 26|HNF3 site
P11094066A0505|21 31|regulation
P11094066A1194|22 34|observations
P11094072A0842|0 5|DNase
P11094072A1234|17 22|c-Myb
P11094073A0000|24 30|member
P11094075A0257|31 43|reexpression
P11094087T0000|8 18|expression
P11094091A0000|4 12|activity
P11094109A0600|0 7|RESULTS
P11094590A0617|8 14|fields
P11095248A0423|21 29|proteins
P11095248A1523|25 32|Xenopus
P11095981A0254|26 38|cis-elements
P11096662T0000|0 9|Tranilast
P11097040A0000|4 14|objectives
P11097079A0525|5 10|study
P11098217A0674|4 14|Aie1 locus
P11098420A0175|12 21|disorders
P11099377T0000|10 17|cloning
P11100515A0282|0 14|Thyrotoxicosis
P11101008A0649|0 15|Chaperones/HSPs
P11101847A0159|10 20|signalling
P11102367A1170|5 10|study
P11102458A0000|16 30|identification
P11103472A0802|0 8|Children
P11103601T0025|6 11|UMDNJ
P11103792A0755|0 14|Overexpression
P11105129T0000|14 28|Susceptibility
P11105716A0782|0 10|CONCLUSION
P11105717A0123|0 7|METHODS
P11106216A0918|7 20|COPD patients
P11106428A0635|12 15|end
P11106667A1061|6 13|Pet111p
P11106668A0875|13 25|transfection
P11107637X0001|4 17|determination
P11108151A0560|0 3|Ang
P11108374A1466|0 6|Acoust
P11108523A0326|0 12|Video images
P11108548A0710|0 18|MS characteristics
P11108616A0000|0 10|Young fish
P11108720A0124|0 4|S6K2
P11108720A1130|0 12|Pretreatment
P11108839A0401|0 7|T cells
P11110040A0000|0 10|Ketanserin
P11110528A0414|22 24|2D
P11111051A0051|31 36|Tip60
P11112417A1126|4 8|data
P11112438X0847|0 9|Copyright
P11112700A1936|0 7|Plectin
P11112700T0000|0 16|Characterization
P11112790A0989|6 13|results
P11113179A0541|16 24|contrast
P11113179A1020|14 23|construct
P11113199A0800|6 9|MEK
P11113201A1114|0 4|Pmt2
P11113546A0728|6 13|samples
P11113692A0169|4 7|aim
P11113822A0999|10 19|quadrants
P11113823A0197|5 10|cases
P11114294A0075|9 16|studies
P11114521A0282|0 10|Regulation
P11114718A0349|16 33|mouse fibroblasts
P11114924A0808|0 4|ORFA
P11116084A0000|0 12|Mouse Impact
P11116131A0863|6 11|cells
P11116148A0741|0 20|Coexpression studies
P11117263A0570|25 32|species
P11117523A0650|3 11|contrast
P11117826A0788|8 11|PET
P11118062A1691|27 32|model
P11118438A0411|22 31|isolation
P11118440T0000|13 24|association
P11118619A0835|16 20|data
P11118712A1296|5 25|sensitivity analysis
P11119611A0428|0 6|ORFK10
P11120441A1193|17 26|believers
P11121043A0074|3 10|Xenopus
P11121118A0075|22 30|variants
P11121118T0000|8 20|organization
P11121397A0587|12 20|findings
P11121434A0915|0 10|Inhibition
P11121490A0000|4 42|transcription factor CHOP/GADD153 gene
P11122381A0908|0 8|Addition
P11122588A0549|0 21|MAIN OUTCOME MEASURES
P11123054T0000|25 34|syndromes
P11123089A0362|5 12|article
P11123316T0000|0 20|Tec kinase signaling
P11123701A0442|8 16|evidence
P11123912A0306|4 13|structure
P11124024A1098|33 38|sites
P11124902X1337|0 9|Copyright
P11125151T0000|0 19|Nucleotide sequence
P11125363A0525|0 8|Patients
P11125411A0857|16 24|patients
P11125872A0133|5 15|philosophy
P11126275A1068|10 16|levels
P11126353A0582|0 7|RESULTS
P11126806A0206|11 19|sequelae
P11127161T0000|0 9|Bupropion
P11127200A1024|38 42|AP-1
P11127250A1111|0 2|PM
P11127955X0001|9 16|therapy
P11128312A1238|23 34|differences
P11128925A0000|0 10|BACKGROUND
P11129515A0000|30 35|trial
P11129724A0904|0 7|Studies
P11131321T0000|0 7|Effects
P11131634A0955|0 10|NF kappa B
P11132063A0250|13 32|treatment exposures
P11132148A0162|4 12|presence
P11132195A0000|12 18|number
P11132790A0609|13 19|method
P11133741A0617|0 4|NiCl
P11133830A0174|0 10|Engagement
P11133927T0000|0 8|Validity
P11133986A0350|9 16|studies
P11134033A0000|11 22|int-6 locus
P11134033A0639|3 16|int6 deletion
P11134351A1405|14 20|MIP-2A
P11134508A0317|23 29|plants
P11134822A0629|12 13|P
P11137296A0923|5 35|transcription initiation sites
P11137296A1216|0 10|PFK-A mRNA
P11137367A0297|12 31|Toshiba IIDR system
P11137551A0437|9 16|sardine
P11138009A1032|3 11|addition
P11138231T0000|0 7|Closeup
P11138694A0000|1 4|18F
P11139148A0421|24 31|protein
P11139336A0257|14 26|associations
P11139469A0402|0 6|Ang II
P11139473A0696|0 17|Promoter analysis
P11139567A1440|0 25|LH/CG receptor activation
P11139605A0811|0 17|Deletion analysis
P11139974A0762|0 11|Termination
P11140472A0497|15 22|results
P11141003T0000|0 7|Changes
P11142380A0389|0 8|Nuclease
P11143384A0267|0 9|Tele-Talk
P11145562A0000|9 17|decrease
P11145562A0468|4 17|P69 cell line
P11145563A0202|32 45|StAR promoter
P11145563A0303|0 10|Expression
P11145566A0000|25 45|lipoprotein receptor
P11145571A0788|15 28|gene factor-3
P11145590A0217|40 50|mechanisms
P11145717A0936|22 28|lysine
P11145743A0170|28 38|regulation
P11145813A0668|0 19|Regional blood blow
P11145887A1393|0 10|Activation
P11145955A0189|4 13|mechanism
P11146961T0000|0 19|Perfusion technique
P11148042A1258|9 17|mixtures
P11148589A1124|0 11|CONCLUSIONS
P11149472A1257|12 34|NP/NMP4/CIZ expression
P11150114T0000|0 9|Chlamydia
P11150315A0226|8 16|approach
P11150315A0844|0 3|NGF
P11150315A1126|0 3|NGF
P11150439A0701|0 18|Energy expenditure
P11151826T0000|0 8|Workload
P11152070A0573|4 13|actA gene
P11152081A0413|10 20|mmol SDS/l
P11152283A0223|25 29|role
P11152344A0416|5 12|animals
P11152451A0529|4 33|Schistosoma mansoni homologue
P11152451A1580|6 10|data
P11152521A0181|19 35|protein products
P11152963A0000|0 10|Expression
P11153302A0000|0 24|Naltrexone hydrochloride
P11154491A0322|0 7|METHODS
P11155096A0222|0 7|METHODS
P11156303A1098|34 42|shunting
P11156413T0000|0 10|Derivation
P11156484A0223|0 12|TBARS levels
P11156618T0000|11 21|comparison
P11156789A1669|20 31|observation
P11157035A1405|4 13|utilities
P11157334A1107|0 9|Serum PTH
P11157763T0000|0 9|Structure
P11157774A0789|12 25|dSLBP alleles
P11157784A0141|14 24|DGCR6 gene
P11157879A0192|0 7|METHODS
P11158236A0000|0 19|Nerve growth factor
P11158288T0000|0 11|Recruitment
P11158290A0728|4 10|region
P11158295A0158|5 13|function
P11158310A0993|28 32|ERSF
P11158324A1073|13 23|phenotypes
P11158326A1032|6 13|effects
P11158337A0000|39 49|expression
P11158456A0223|0 7|METHODS
P11159081A1155|9 14|cases
P11159363A1251|0 11|Methylation
P11160096A1067|6 15|mutations
P11160280A1275|27 37|expression
P11160307A0394|5 13|molecule
P11160656A0000|0 10|Inactivity
P11160683A1220|5 16|interaction
P11160688A1726|14 20|events
P11160721A0932|10 23|transfections
P11160732A0464|0 13|Vector stocks
P11160732A1199|13 24|PCR studies
P11160738A1414|26 35|functions
P11160742A0696|5 6|Z
P11160860A0662|19 27|activity
P11160896A0713|0 26|Immunofluorescence studies
P11160902A0962|16 20|TFOs
P11160929T0000|6 15|evolution
P11161455A1286|0 22|Southern blot analysis
P11161720X1294|0 9|Copyright
P11161793A1033|4 12|presence
P11161816A0851|19 31|similarities
P11162278A0629|7 15|rotation
P11162576A0213|21 35|identification
P11162666A0442|4 31|glucose/insulin stimulation
P11162936A2727|15 26|development
P11163932A0000|12 17|tests
P11163968A0152|15 19|work
P11164078A0833|5 17|animal model
P11166478T0000|33 48|antinociception
P11166863A0167|14 15|%
P11167019A1249|4 8|TATA
P11167111A0957|21 45|lung function parameters
P11167778T0000|9 32|antithrombin deficiency
P11168366A0569|3 11|addition
P11168422A0248|7 13|Nature
P11168446T0000|10 34|erythropoietin synthesis
P11168588T0000|0 10|Expression
P11169080T0000|13 22|education
P11169113A0555|21 25|role
P11169149A0097|19 28|knowledge
P11170476A1546|18 27|stability
P11171118A0836|14 21|binding
P11171320A0894|0 12|Coexpression
P11172610A0508|13 16|p73
P11172944A0548|0 7|RESULTS
P11172944A0826|3 11|contrast
P11175333A0336|21 45|co-precipitation methods
P11176098A0342|0 7|METHODS
P11176290T0000|0 14|Identification
P11177538A0655|0 16|Tumor cell lines
P11177686A0243|0 9|Treatment
P11178248A1042|38 58|screening techniques
P11178696A0301|7 16|US images
P11178765A0642|19 26|effects
P11179272T0000|0 15|Cytomegalovirus
P11179400T0000|0 9|Responses
P11179664T0000|0 12|Architecture
P11179668A0869|34 42|proteins
P11179687A0280|8 13|paper
P11179687A1118|24 32|metazoan
P11179689A0000|4 19|Sox gene family
P11179956A1818|12 19|results
P11180027A1306|12 22|parameters
P11180255A0776|23 32|arguments
P11180688A0000|14 35|maximum oxygen uptake
P11181516A0119|16 61|deletion insulin promoter-reporter constructs
P11181525T0000|4 21|androgen receptor
P11181531A0464|8 17|mechanism
P11181548A0214|45 52|element
P11181564A0733|7 12|mouse
P11181995A1093|0 8|Analysis
P11182520A0889|18 26|genotype
P11182746A0872|16 24|patients
P11185475T0034|3 10|Caveman
P11187016T0000|11 17|models
P11188971A0000|22 29|surgery
P11188993A0298|0 7|Corneal
P11189314A1000|6 13|results
P11191208A0000|10 20|resistance
P11191365A0682|0 14|Susceptibility
P11193045A1193|2 9|picture
P11193666A1269|30 39|outbreaks
P11193704A0000|18 33|pleuropneumonia
P11194101A0532|0 19|Baseline BMD values
P11194147A1496|4 16|distribution
P11194183A0866|4 12|increase
P11195338A0494|8 18|expression
P11195401A1030|5 22|plasma AVP levels
P11196191A1789|9 36|T47D breast carcinoma cells
P11196199T0000|6 15|homologue
P11196340A1046|18 25|methods
P11197288A0855|5 13|patients
P11197328T0000|0 7|Binding
P11197549A0748|0 7|RESULTS
P11197926A0000|0 10|BACKGROUND
P11198053T0000|6 13|effects
P11198289T0000|10 29|serum ceruloplasmin
P11198385A0000|25 38|algerae Vavra
P11198424T0000|10 17|cloning
P11200568A0830|0 5|Blood
P11201250A0849|0 24|Plasma DHE concentration
P11202434T0000|7 31|amino acid substitutions
P11202705A1112|0 12|Implications
P11203702A1307|6 12|Xlim-1
P11204897A0797|15 19|time
P11207216A0296|11 22|PGHS-2 cDNA
P11207216A0719|4 14|regulation
P11207261A1421|11 19|analysis
P11207269A0745|15 18|mAb
P11207282A0729|20 30|expression
P11207288A0897|0 13|Substitutions
P11207308A0999|11 19|curcumin
P11207609A0994|3 11|contrast
P11208017A0070|2 12|cDNA clone
P11208814A0673|20 31|specificity
P11209100A0069|25 35|properties
P11209814A0243|4 11|purpose
P11210401A0000|0 23|Sevelamer hydrochloride
P11210401A0544|20 28|profiles
P11210839A0282|7 25|PO3 administration
P11210988T0000|4 12|survival
P11211759A0165|0 8|Patients
P11211936A1490|12 16|data
P11212249A0993|4 11|effects
P11212327A1564|7 14|studies
P11213342A0492|0 7|RESULTS
P11214177A1125|13 18|sense
P11214354A1104|7 14|animals
P11215622A0949|0 8|Grippers
P11216247T0000|4 9|child
P11218739A0811|0 10|Transition
P11220166A0616|16 23|effects
P11220306A0911|0 6|HexA71
P11220306A1753|9 15|copies
P11220486A0686|1 2|%
P11220487T0000|11 17|review
P11220857T0000|0 4|CHAP
P11221836A0981|23 29|fusion
P11221845A0295|27 45|methylation status
P11221845A0800|4 20|Genescan program
P11221845A1370|0 22|Northern blot analysis
P11221845A1713|0 9|Treatment
P11222387A1497|21 29|compound
P11222639A1273|6 13|results
P11222720A1699|17 21|RPMS
P11223131A0000|0 17|Folate metabolism
P11223153A0533|4 14|BFA System
P11223164A0000|0 9|Retinoids
P11223186A1095|0 15|Transactivation
P11223199A0751|6 13|results
P11223240A0655|11 34|Menin1 gene transcripts
P11223246A0359|0 17|Sequence analysis
P11223255A1034|3 11|addition
P11223256A1212|51 57|region
P11223257A0404|0 6|OsBBPI
P11223938X1218|0 9|Copyright
P11224226A0000|4 11|effects
P11226228A0899|9 17|plasmids
P11226752A0750|13 33|tissue culture cells
P11227039A0953|12 17|women
P11227182A1475|4 11|authors
P11227484T0000|13 26|determination
P11228700T0000|4 12|position
P11230145A0732|4 11|results
P11230169A0480|14 20|method
P11230534A0688|14 19|total
P11230889A1151|4 9|cases
P11231287A0158|4 15|sensitivity
P11232947A1451|13 34|lymph node dissection
P11233643A0000|24 27|use
P11234223A1451|16 27|antibiotics
P11235335T0000|9 12|HIV
P11235777A0878|3 14|Klinefelter
P11235817A0000|4 37|histamine H1 receptor antagonists
P11236056A0374|0 10|Conclusion
P11237038A0889|2 8|subset
P11237491A0000|0 4|AIMS
P11237598A0962|27 36|framework
P11238105A0959|0 5|Cells
P11238375A0617|14 18|RhoA
P11238402A0191|37 47|mechanisms
P11238405A0817|3 10|strains
P11238447A0524|9 24|binding studies
P11238586A0000|11 18|studies
P11238882A0157|29 33|eIF6
P11238884A0892|0 4|Mice
P11238916A0838|12 19|complex
P11238947A0636|9 20|base change
P11239184A1340|0 18|Baseline variables
P11239529A0981|0 8|IL-1beta
P11240600A0523|11 23|drug history
P11241166A0677|7 15|analysis
P11241215A0566|11 20|receptors
P11241243A0693|4 11|authors
P11241332A0393|9 16|purpose
P11241356T0000|13 28|phosphorylation
P11241672T0000|0 7|Cloning
P11243306A0961|0 11|CONCLUSIONS
P11243336A0000|12 19|MD-55-2
P11243494A0833|0 7|RESULTS
P11243777A0000|11 25|CCAAT elements
P11243980A0510|12 20|patients
P11244568A0506|4 10|Gap69C
P11244733A0782|0 5|Cases
P11245986T0000|31 38|protein
P11246679A0000|0 9|OBJECTIVE
P11246887A0000|5 10|study
P11247663A1447|4 12|families
P11248463A0187|4 16|blood levels
P11248626T0000|0 8|Efficacy
P11250196A0455|16 27|domain fold
P11250942A0626|11 19|analyses
P11251083T0000|0 9|Mechanism
P11251104A0526|4 14|expression
P11251252A0494|0 19|3D image-processing
P11251276A0793|10 18|patients
P11251697T0000|7 37|superoxide scavenging activity
P11251951A0000|0 10|BACKGROUND
P11254134A0648|10 14|PTax
P11254504A0766|13 28|promoter region
P11254713A1029|10 21|interaction
P11254864T0000|25 34|treatment
P11255035A0331|13 29|progenitor cells
P11255252A0961|10 22|ER3 sequence
P11255423A0211|0 9|OBJECTIVE
P11256845A0340|12 20|analysis
P11256944A1144|25 30|forms
P11256962A0233|0 17|Sequence analysis
P11257870A0000|12 17|study
P11258906A0743|3 32|DNA strand exchange reactions
P11259347A0000|10 22|observations
P11259503A0212|0 19|Forskolin treatment
P11259593A1094|0 8|Analysis
P11260468A1179|4 11|results
P11260662X0000|0 2|A.
P11263622A0683|0 7|RESULTS
P11263664A1085|4 8|data
P11263664T0000|0 4|SIP1
P11264176A0181|0 5|B-myb
P11264177T0000|0 19|Nucleotide sequence
P11264182A0000|6 32|T-cell leukemia virus type
P11264372T0000|0 12|Requirements
P11264375A0000|10 25|cytomegalovirus
P11264561A0167|0 9|OBJECTIVE
P11265853A0000|4 11|Novacor
P11266184A0000|0 8|Atheroma
P11266194A0743|0 4|Body
P11266227A0295|4 14|flux rates
P11266540A0328|39 61|Groucho family members
P11266558A1470|31 52|transcription extract
P11266615A0258|4 11|protein
P11267679A0102|8 25|bp EcoRI fragment
P11268459A0167|25 30|study
P11268887A1174|9 27|misinterpretations
P11271297T0000|0 14|Nephrotoxicity
P11273995A1148|29 37|subjects
P11274109A0129|0 7|Acetoin
P11274149A0625|11 19|analysis
P11274179A0610|10 17|studies
P11274184A0000|0 4|Nrf2
P11274184A1068|6 13|results
P11274357A0724|13 17|hand
P11274368A0469|5 11|effect
P11274368A0818|0 8|Deletion
P11274563T0000|6 17|lung volume
P11275986A0091|7 20|gene products
P11276426A0501|3 8|mouse
P11277913T0000|3 10|element
P11278286A0456|18 23|cells
P11278286A1083|40 50|inhibition
P11278290A1220|8 13|Smad2
P11278310A1516|35 41|mutant
P11278390A0632|8 54|transcriptase-polymerase chain reaction assays
P11278400A0668|31 41|cell lines
P11278440A0095|0 3|SV1
P11278461A0637|11 21|antibodies
P11278488T0000|4 20|v-Src SH3 domain
P11278521A0849|10 30|pair oligonucleotide
P11278563A0917|0 17|Deletion analyses
P11278583A0873|0 11|Mutagenesis
P11278594A0618|21 31|propeptide
P11278604A0300|25 34|N-glycans
P11278610A0902|18 26|SOCS box
P11278671T0000|16 30|Bcl-2 homology
P11278713A1054|24 30|region
P11278819A0565|0 19|Sequence comparison
P11278848A1316|13 21|SB203580
P11278855A0205|17 28|interaction
P11278870A0123|0 8|Analysis
P11278928A1634|20 24|data
P11279038A0194|0 12|WRN helicase
P11279086A1350|6 10|data
P11279108T0000|0 7|Binding
P11279207A0904|16 23|results
P11279217A0273|0 4|Biol
P11279324A0710|4 8|size
P11279385A3917|24 33|technique
P11279720A0844|0 18|SELECTION CRITERIA
P11280495A1330|0 11|CONCLUSIONS
P11280799A1025|3 11|contrast
P11281201T0000|14 21|effects
P11281268A0000|19 35|arginine kinases
P11282029A0075|4 9|mouse
P11282088A0837|0 12|Baseline MBF
P11282394A0841|16 28|VH/VL-chains
P11282395A0530|37 52|RAG1/2 proteins
P11282395A1073|3 11|addition
P11282433T0000|0 5|Phase
P11282761A0531|5 20|supplementation
P11283010A0701|5 15|activation
P11283014A0921|4 11|results
P11283168A0738|27 32|lines
P11283256A0258|32 36|MRCK
P11283354A0548|6 10|data
P11285054A0781|0 19|Regression analyses
P11285235A0466|9 14|TRPS1
P11285329A0682|7 11|% CI
P11286833A0959|6 14|patients
P11287555A1057|4 19|Delta6CCI virus
P11287578A1311|0 9|Secretion
P11287579A1084|8 14|mutant
P11287611A0802|7 16|PPARgamma
P11287623A0286|82 88|kinase
P11287654A0150|0 4|PABP
P11288208A0712|0 8|Children
P11288930A0000|17 24|effects
P11289135A0975|0 10|Coexposure
P11289149A0658|10 21|EWS protein
P11290415A0288|15 20|study
P11290906T0000|11 23|accumulation
P11291552A0156|0 7|METHODS
P11292335A0852|22 29|dnaE173
P11292839A0531|4 17|transcription
P11292844A0081|0 3|HSF
P11294895A0292|29 34|spo20
P11295470A0954|13 21|evidence
P11295523A0218|6 13|numbers
P11295760A1374|0 23|Specimen mass reduction
P11296288A1107|3 11|addition
P11296442A0565|3 13|conclusion
P11297419A0894|3 8|F222W
P11297514A0218|14 27|hos1 mutation
P11297545A0948|7 19|transfection
P11297866A0484|3 11|contrast
P11298326A0677|2 12|comparison
P11301189A1396|3 11|contrast
P11302072A0508|4 11|results
P11302566A1318|19 29|flattening
P11302704T0000|0 20|Homo-oligomerisation
P11303027A0954|6 10|data
P11303638A0559|5 23|NEU overexpression
P11303890A0996|7 11|time
P11305129T0000|0 7|Effects
P11306101A0000|6 21|RACE techniques
P11306463A0383|2 10|mutation
P11306511A1476|3 14|association
P11306845A0168|13 24|examination
P11308851A0333|17 34|response function
P11308877A0213|35 40|input
P11309077A0953|5 12|strains
P11309373A0783|0 8|Analysis
P11309389A0273|31 42|proteolysis
P11309400T0000|0 7|Effects
P11309677A0000|35 42|battery
P11309678A0489|8 34|transcription-PCR analysis
P11310937A0548|0 7|RESULTS
P11311153T0000|4 16|relationship
P11311464A0362|6 15|disorders
P11311480A0079|6 18|nerve biopsy
P11311550A0253|27 37|regulation
P11311563A0423|10 19|CCAAT box
P11311687A0231|4 10|JHRLSS
P11311909A0938|17 21|case
P11311980A1049|0 4|GABA
P11312108A2853|0 4|Raes
P11312120A1311|0 28|NF-kappaB pathway activation
P11312326A0169|10 13|rev
P11312584X1846|0 9|Copyright
P11313249T0000|27 36|zebrafish
P11313342A0224|29 50|alanine substitutions
P11313386A0704|0 21|SH2D1A protein levels
P11313398A0687|0 22|Cross-linking FcalphaR
P11313946A0449|0 8|RPM/RGL3
P11313946T0000|18 26|effector
P11313961A1323|4 8|mice
P11314030A1264|4 11|results
P11314046A0000|0 7|Cyclins
P11314373T0000|15 19|care
P11314428A0651|29 36|ability
P11315633A0920|4 17|cleavage site
P11316127A0485|4 10|%SVend
P11317256A0361|11 19|isolates
P11318363A0085|0 6|DESIGN
P11318608A0669|6 34|brain cDNA library screening
P11318608A1155|0 12|Transfection
P11319098A0164|6 11|genes
P11319880A1108|0 9|Rapamycin
P11321187A0355|31 42|MS patients
P11323411A0505|0 25|Far Western blot analysis
P11323419T0000|10 17|cloning
P11323716A0413|4 15|UBA domains
P11324516A0159|30 44|administration
P11325195A0661|4 6|R2
P11325391A0498|10 15|doses
P11325685A1624|12 33|L-carnitine treatment
P11325944A0511|9 19|expression
P11327292A0190|12 20|location
P11327698A0191|18 21|PKC
P11327858A0087|18 28|mechanisms
P11328699A0000|30 39|test mice
P11328853A0644|0 11|Examination
P11331589A0113|4 15|MSL complex
P11331596A0710|0 4|Prrp
P11331604A0267|0 5|Srb10
P11331613A0827|11 18|effects
P11333263A0240|6 12|intron
P11333268A1521|14 22|analysis
P11334124A0903|13 26|dose-response
P11335116A1099|0 21|Bandshift experiments
P11335710A0320|44 49|phase
P11336211A0132|14 20|method
P11336698A0075|18 22|Rsc3
P11337859A0651|4 7|COD
P11340048A0432|26 37|correlation
P11340080A0096|13 21|proteins
P11340085A0211|13 23|hypothesis
P11340516A0509|0 9|Tolerance
P11340525A0737|7 15|patients
P11341349T0000|6 16|indicators
P11341405A0146|7 17|POPULATION
P11341405A1154|0 11|CONCLUSIONS
P11341828A0744|30 40|D-peptides
P11342479A0430|0 7|METHODS
P11344530A0320|0 11|Percentages
P11345435A0199|21 35|RNA subdomains
P11345445A0533|13 22|OECD soil
P11347201X0001|0 18|Nutritional status
P11348318A0940|19 26|adjunct
P11349796A0950|0 12|Measurements
P11350038A0459|16 24|evidence
P11350165A1606|0 7|Changes
P11350175A0173|27 34|members
P11350812A0829|0 10|Inhibition
P11350957A0457|0 10|PACAP mRNA
P11350982A0560|26 34|evidence
P11352423A0084|11 23|forearm flap
P11352663A0138|3 13|comparison
P11352671A0492|6 17|application
P11353392A1127|4 14|frameshift
P11353770A0085|25 33|activity
P11353774A0255|19 28|isolation
P11354406A1373|13 36|CSF outflow conductance
P11354975A0850|6 13|species
P11355576A1125|4 11|cyclins
P11355615A0766|11 20|education
P11355668T0000|14 26|vasculopathy
P11356214A0794|4 14|difference
P11356716A0372|17 22|clone
P11356835A0000|48 55|network
P11356853A0429|3 13|Ka13 cells
P11356853A0554|0 17|Mutation analyses
P11356853A0873|0 7|Members
P11357063A0138|0 12|Descriptions
P11357063A1053|9 18|consensus
P11358801A1046|19 29|situations
P11358958A0878|0 10|Expression
P11358962A0344|0 5|Foxp1
P11359568T0000|10 18|analysis
P11359827T0000|30 46|characterization
P11359907A0099|8 27|dozen HIF-1 targets
P11360190A0178|28 31|Tax
P11361338A0093|5 10|yeast
P11361338A0447|10 26|PEX5-TPR domains
P11361493T0000|0 5|HIV-1
P11367523A1684|0 26|Immunofixation experiments
P11367523A2624|9 21|C4B proteins
P11368363A0129|7 13|course
P11368363A1103|10 26|protein sequence
P11368787A0180|0 8|Promoter
P11368901A0327|3 11|contrast
P11368911T0000|10 24|identification
P11368914T0071|22 27|exons
P11369066A1210|0 11|CONCLUSIONS
P11369106A0428|7 15|advances
P11369410A0949|10 20|hypothesis
P11369453A1083|13 21|increase
P11369700A0074|0 3|CSR
P11369700A0616|8 18|manuscript
P11369759A0605|0 4|Cell
P11370174A0447|9 31|serum creatinine level
P11371115A0962|4 14|proportion
P11371160A0193|19 30|nucleotides
P11371160A0854|5 11|domain
P11371343A0125|19 29|cell cycle
P11371417A0744|11 22|ventilation
P11372882A1143|9 10|p
P11372959A1447|9 28|regression analysis
P11373277A0812|3 10|summary
P11374051A0437|11 18|factors
P11374559A0103|0 12|SERS spectra
P11374866X0914|0 9|Copyright
P11375392T0000|4 17|core promoter
P11376007A0584|42 46|loss
P11376119A0346|10 14|exon
P11376134A1506|6 17|corrections
P11376165T0000|0 3|FLP
P11376279A0000|2 8|method
P11376687A0344|9 32|nucleotide polymorphism
P11376946A0000|13 20|studies
P11377975A0898|30 40|COS1 cells
P11378898A0164|0 4|ORF1
P11379106A0372|7 15|meantime
P11380028A0000|4 11|purpose
P11380370A0000|2 9|patient
P11380837A1505|0 13|Interventions
P11381094A0797|3 11|addition
P11382701A0688|13 24|transection
P11382948A0793|3 13|conclusion
P11383860A0661|4 10|images
P11384225A0634|8 11|end
P11384229A1669|13 26|N63S mutation
P11384576A1132|3 11|addition
P11384880A0719|4 13|mechanism
P11385840A1684|14 27|RTC algorithm
P11387208T0000|0 37|SKP1-SnRK protein kinase interactions
P11387351A0092|0 8|PATIENTS
P11387940A0647|4 12|severity
P11387950X0001|13 18|study
P11389077A0000|2 9|variety
P11389085A0290|0 8|TT cells
P11389085A1032|0 10|Inhibition
P11390395A1018|14 31|HMGI-C expression
P11390581A1203|10 17|finding
P11390650A0562|11 29|deletion mutations
P11390663A1400|9 18|profiling
P11390684A1170|0 8|Evidence
P11391303A0807|6 9|LHR
P11391303A1023|0 11|CONCLUSIONS
P11391531A1157|0 8|Mutation
P11391793A0856|25 35|complexity
P11392306T0000|7 15|teaching
P11392772A0182|4 15|application
P11393463A0274|0 4|Data
P11393791A1153|0 22|Northern blot analysis
P11395469A1373|8 16|mutation
P11396685A0477|14 21|results
P11397652A0381|0 10|Guidelines
P11398134A1565|3 13|conclusion
P11398899A1183|0 4|Fans
P11399064T0000|0 14|Autoregulation
P11399834T0000|10 14|case
P11400644A0435|5 15|reflection
P11401105T0000|0 10|Gabapentin
P11401611A1703|0 11|CONCLUSIONS
P11402674T0000|0 32|Newcastle disease antibody titre
P11403173A0192|2 7|total
P11403663A0359|4 8|lift
P11403719A1257|4 11|results
P11404010A0235|13 22|triplexes
P11404016A1922|4 16|co-existence
P11404019A0532|11 24|understanding
P11404312A0660|13 22|pmol/24 h
P11406007A0292|0 18|SELECTION CRITERIA
P11406025A0204|0 10|OBJECTIVES
P11406277A0598|12 22|hypothesis
P11406642A0792|16 21|cases
P11407289A1507|0 11|CONCLUSIONS
P11407448A0815|4 11|results
P11407650A0661|0 13|Hypercalcemia
P11408099A0518|25 37|correlations
P11408338A1686|5 10|study
P11408575A0000|29 34|entry
P11408591A0000|20 30|production
P11408604A1440|4 11|results
P11408774X0893|0 9|Karger AG
P11409425A0000|15 29|plasma samples
P11410110A0190|0 4|NIRS
P11410563A0363|21 27|factor
P11410664A0963|8 14|report
P11410679A0000|14 24|alteration
P11411198A0711|11 17|cancer
P11411623T0000|0 9|Influence
P11411961A0735|0 26|Keratoconjunctivitis sicca
P11413148A0573|0 16|STAT5A mutations
P11413277A1121|3 13|conclusion
P11413310A0148|0 6|RANTES
P11413319A0000|0 14|Reovirus mRNAs
P11413641A0373|0 8|Analyses
P11413760A0000|0 10|Myasthenia
P11414754X1099|0 9|Copyright
P11415633A1253|23 33|force data
P11415952A0369|0 6|Angina
P11415958A0000|12 18|decade
P11416012A1982|38 47|mediation
P11416012A2511|30 34|role
P11416012T0000|26 36|activation
P11416132A1351|6 13|studies
P11416144A1324|4 12|findings
P11416260A0000|15 21|method
P11416393A0000|5 15|modalities
P11416650T0000|18 30|Hypertension
P11416737T0000|0 5|Ga-67
P11416879A1589|9 27|blood gas tensions
P11418130A0499|24 38|loxP sequences
P11418662A0917|15 22|portion
P11419938T0000|15 22|changes
P11420612A0303|5 15|complement
P11422200A0000|0 11|Granulocyte
P11422757A0737|6 17|individuals
P11423991A1393|10 16|screen
P11424992A0712|33 42|diagnoses
P11425076A0364|49 54|flows
P11425877A1026|0 5|Cells
P11427329A1077|4 12|validity
P11427611A0000|4 18|susceptibility
P11428276A0352|4 7|Van
P11428283A0228|14 20|infant
P11428435A0446|0 6|DESIGN
P11428487T0000|10 20|vein varix
P11428897A0318|12 23|experiments
P11429702A0917|42 52|conditions
P11430042A0000|1 7|figure
P11430976X0000|8 14|issues
P11431348A0000|0 12|Interactions
P11431472A0540|4 20|affinity binding
P11431857A0186|4 12|students
P11432112A0000|0 7|PURPOSE
P11432748T0000|0 10|Regulation
P11432776A0421|0 8|Northern
P11433014A0683|44 50|fusion
P11433018A0756|6 10|data
P11433024A0260|0 10|Telomerase
P11433379A0000|0 3|SIT
P11434084A0508|15 26|patients DD
P11435428A0000|10 31|acetyl-CoA synthetase
P11435517A0396|6 21|digestibilities
P11435560A1322|15 19|data
P11435578A0760|6 10|TxRE
P11435578A2231|23 37|reconstitution
P11435605A0587|14 25|mutagenesis
P11435688A0262|5 14|subfamily
P11435983T0000|0 9|Tolerance
P11437439A0201|4 21|promoter activity
P11437660A1219|0 12|Substitution
P11438651A1365|6 31|replication fork movement
P11438654A1237|6 14|findings
P11438666A0555|23 36|mouse protein
P11438838A0788|10 19|inhibitor
P11439343A0785|3 11|contrast
P11441163T0000|0 10|Foreigners
P11441311X0001|10 17|results
P11441952A0414|6 10|days
P11441974A0320|7 10|end
P11443509A0293|0 6|DESIGN
P11443999A0573|0 22|Mean Hg concentrations
P11444762A0373|25 34|proposals
P11445008A0816|4 9|assay
P11447490A0598|4 10|amount
P11448051A0093|4 10|system
P11449014A0000|0 15|STUDY OBJECTIVE
P11450490A0565|46 52|acuity
P11450776T0000|7 11|case
P11451447A0205|0 5|Gimpl
P11451682A0190|12 24|chemotherapy
P11451995T0000|27 35|analysis
P11454004T0000|9 19|regulation
P11454190A0000|0 15|BACKGROUND/AIMS
P11454239A0478|12 20|Analysis
P11454703A0000|4 14|telomerase
P11456259A0142|4 9|titer
P11457139A0604|4 11|results
P11459048A0485|33 46|uncertainties
P11459304T0078|0 21|Enantiomer separation
P11459794A1172|0 12|TE-671 cells
P11459960A1109|39 49|components
P11459962A0785|32 37|genes
P11460035A0548|12 16|case
P11461595A0000|19 36|reaction kinetics
P11462004A0886|4 8|role
P11462004A1500|33 37|Vp1s
P11462024A0306|0 3|Zhu
P11462952A1040|8 22|gastrin levels
P11463359A0167|23 40|phorbol ester PMA
P11463834A0606|8 28|deletion mutagenesis
P11464997A0566|5 14|knowledge
P11465518A0000|0 10|BACKGROUND
P11465655A0439|12 16|week
P11465844T0000|0 4|Lack
P11466227A1665|4 12|presence
P11467349A0452|22 26|task
P11468958A0122|14 21|results
P11469701A0377|10 18|approach
P11469737A1791|3 8|visit
P11469853A0702|15 21|system
P11469853A1053|19 23|data
P11469926T0000|0 29|Breast cancer risk assessment
P11469970A0873|0 8|Patients
P11470914A0305|4 12|activity
P11471077A0382|0 7|RESULTS
P11471231A0964|3 11|addition
P11472523A0535|0 10|CONCLUSION
P11472696A0387|4 15|differences
P11473254A0000|0 4|NaeI
P11473261A0587|0 4|Mss4
P11474642A1451|4 14|decrements
P11478627A0573|4 25|desirability function
P11479104A0446|52 60|antibody
P11479501A0744|0 7|RESULTS
P11480490A0443|33 38|signs
P11480497T0000|0 7|Effects
P11480555A0928|4 14|production
P11481625A0202|27 35|subjects
P11484028T0000|3 17|cross purposes
P11484578A1132|0 10|CONCLUSION
P11486032A1261|10 31|transcription factors
P11486141A0424|5 12|factors
P11486399A0000|4 15|combination
P11486476A0147|14 19|trial
P11486476A1512|8 26|markers troponin T
P11489597A0379|3 14|termination
P11489597A0561|13 18|death
P11490862A0141|15 26|development
P11494391A0579|4 11|results
P11495833T0000|15 21|impact
P11495920A0504|9 22|pair mismatch
P11496495A0000|4 11|authors
P11496617A0301|0 7|METHODS
P11498795A0716|10 21|progression
P11500377A0518|3 10|mammals
P11500512A0000|10 20|ABCG1 gene
P11500571A0976|17 27|expression
P11500913A1238|0 13|C/EBPbeta LIP
P11502738A1457|10 17|effects
P11502758A0869|6 14|findings
P11502778A0941|18 21|men
P11504545A0393|0 11|Competition
P11504709A0981|5 10|study
P11505407A0461|0 7|RESULTS
P11509266A0955|3 6|Cox
P11509615T0000|0 29|Phosphatidylinositol 3-kinase
P11509673A0574|14 27|transfectants
P11511544T0000|4 15|loop domain
P11512925A0000|0 18|EXAFS measurements
P11513121T0000|12 17|study
P11513180A1257|11 16|cases
P11513579A0372|21 27|system
P11516890A0236|28 44|cytochrome P-450
P11517190A0352|0 8|Analysis
P11517190T0000|15 23|promoter
P11517269A0472|0 5|Pitx2
P11517399A0858|4 12|patterns
P11517445A0221|10 15|cases
P11518505A0107|73 80|tissues
P11518868A0559|30 37|history
P11519466A0196|13 17|diet
P11520436A0705|6 17|BALB/c mice
P11521191A0000|45 60|12S E1A protein
P11522431A0673|4 14|prevalence
P11522584A0882|8 16|myalgias
P11522626A1374|22 32|regulation
P11522658A0086|29 50|ErbB1/ErbB2 signaling
P11522658A0870|22 37|phosphorylation
P11523446A0523|0 3|ICA
P11524015A0937|7 17|expression
P11524815A0753|6 19|control rates
P11524823X0001|0 7|Utility
P11525102A0970|8 14|sample
P11525486A0350|16 25|CaCO3-CO2
P11525640A0560|0 10|Inhibition
P11528127A1402|7 17|GC content
P11528253X1211|0 9|Copyright
P11528500A0571|3 11|mutation
P11529914T0000|0 9|NF-kappaB
P11530684A0667|6 18|nerve injury
P11530829A0000|5 12|article
P11532556A0000|22 41|angioencephalopathy
P11532856A1175|0 5|Third
P11533238A1137|0 8|Mutation
P11533340A1285|25 35|difference
P11533863A0125|14 18|case
P11534132A0219|14 28|search engines
P11534900A0000|24 36|combinations
P11535014A1157|15 22|results
P11535140T0000|13 21|findings
P11535532A0189|21 33|enzyme DUB-2
P11535832A0586|4 11|isoform
P11536063A0178|10 21|embolectomy
P11538437A0568|8 18|conditions
P11539522A0612|4 19|NAUSICAA system
P11540991A0127|3 8|order
P11542677A0411|5 12|article
P11542780A0086|28 37|detectors
P11543154T0000|0 9|Responses
P11543317A0203|13 17|dose
P11543662A0562|11 15|gstC
P11545594A1556|29 40|Myb domains
P11547819A0532|0 7|METHODS
P11548027A0163|2 10|proposal
P11550795A2583|0 14|Overexpression
P11552058A0235|5 8|ICP
P11552058A0833|6 15|therapies
P11552724A0527|0 11|CONCLUSIONS
P11552922A0361|0 16|CYP2C19 genotype
P11553091A1472|4 11|results
P11553704A0674|8 12|data
P11554469A1386|6 14|analyses
P11554566A0668|4 22|hatcher incubators
P11554566A0833|8 23|companies sites
P11554727A0890|4 24|mutation experiments
P11555516A0639|8 14|output
P11555669A0464|0 10|Experience
P11555669A0983|13 16|mix
P11556809A2085|36 51|enzyme activity
P11557127A0991|3 13|conclusion
P11559366T0000|30 40|inhibition
P11559547T0000|16 26|regulation
P11559564A0459|0 6|NB-506
P11559789A0314|20 24|work
P11559821A1315|0 18|DNA binding assays
P11560292A0557|32 41|structure
P11560509T0000|0 15|DNA recognition
P11560990A0272|0 18|E47 protein levels
P11560992A0000|9 28|specificity kinases
P11560992A0651|0 19|SAPK/JNK activation
P11560992A1184|6 10|MKK7
P11561623A0897|10 45|copepod Pseudonychocamptus proximus
P11561626A0197|24 33|solutions
P11562278A0169|22 27|genes
P11562870A0892|4 15|probability
P11564871A1184|6 13|results
P11564893A1068|16 22|change
P11565747A1020|0 4|Data
P11566874T0000|8 20|motor domain
P11566948A1217|16 31|nephrosclerosis
P11566961A0472|0 21|Body weight reduction
P11566996A1391|21 25|uvrA
P11568988A0960|9 25|regression model
P11569800T0000|0 23|Temperature measurement
P11569900A0660|0 14|APC-resistance
P11569949A2087|0 5|Zarix
P11570735A1097|0 7|RESULTS
P11570820T0000|5 18|casein kinase
P11572377T0000|0 3|Use
P11572388A0000|5 10|paper
P11572467A0658|9 19|blood clot
P11572467T0000|0 10|Management
P11573771T0000|0 6|Effect
P11573891A0525|0 7|RESULTS
P11574088A1687|4 8|mean
P11574105A0727|0 8|Patients
P11575109A0214|10 18|baseline
P11575977A1133|9 17|patients
P11576158A1371|7 19|TVD-patients
P11576776T0081|15 21|moduli
P11577094A1226|6 14|findings
P11578685A0077|0 6|ICAM-1
P11579100T0000|0 23|Phosphotyrosyl peptides
P11580173A0181|0 19|Plane wave geometry
P11580301A1161|4 13|diagnosis
P11580757A0304|0 7|METHODS
P11580941A0815|0 7|RESULTS
P11583428A0191|3 6|Exp
P11583621A0301|27 34|stimuli
P11583880T0000|13 28|aneurysm repair
P11584107T0000|20 28|diseases
P11584328A0532|0 17|Drug interactions
P11585856A0285|0 7|METHODS
P11586096A0699|11 22|differences
P11587514A0758|13 32|abi1-1 gene product
P11587980A1039|3 11|children
P11589568A0744|11 16|yeast
P11589779T0000|0 6|HTLV-1
P11590364A1056|13 34|beta5L splice variant
P11592315A0325|0 9|PROCEDURE
P11592532A0188|0 7|METHODS
P11593394A0000|13 31|growth factor-beta
P11595170A0582|0 9|Alignment
P11595176T0000|12 21|structure
P11595478A1014|0 2|Hp
P11595813A0633|11 21|metabolism
P11595840A0000|4 10|uptake
P11596104A0614|0 22|Northern blot analysis
P11596838A1357|5 13|analysis
P11597185A0477|35 49|metapopulation
P11597936A0570|6 18|CAD patients
P11599079A1040|18 34|orifice voltages
P11599797A0732|0 7|RESULTS
P11599840A0813|4 10|moduli
P11600252A0795|4 6|LA
P11600314A0000|15 27|polarography
P11600365A0471|22 31|organisms
P11600467A1436|35 45|alteration
P11602353A0770|15 25|HNF-3 beta
P11603271T0001|9 16|vertigo
P11604152A0526|4 8|MABP
P11605207T0001|0 9|Treatment
P11605598A0785|0 11|Hepatitis B
P11606538A1002|10 19|insertion
P11614398T0000|11 17|people
P11639485A0478|12 16|work
P11642687T0000|0 10|Comparison
P11653491T0000|13 19|action
P11669281A0653|11 23|cytotoxicity
P11669476A0346|17 25|cytokine
P11675912A0131|10 17|alcohol
P11676899A0704|19 31|risk factors
P11677363A0775|19 26|finding
P11677839A0876|4 14|difference
P11678437A0000|4 10|effect
P11679441A0429|0 14|NO metabolites
P11680835A0756|17 25|analysis
P11683558A0446|4 8|diet
P11684665A0000|0 24|C. elegans embryogenesis
P11685047A0301|23 29|method
P11685284X0000|1 13|Diabetologia
P11686239A0464|16 24|sequence
P11686378A0326|21 28|reactor
P11687083A0218|0 10|OBJECTIVES
P11687180A3209|12 16|term
P11687352A0215|0 7|METHODS
P11687517A1619|3 8|ISREs
P11687737A0000|0 10|BACKGROUND
P11687869A0000|14 19|woman
P11689217T0000|0 34|Cholesteryl ester transfer protein
P11691585A1174|16 37|mobility shift assays
P11691585T0000|4 22|hcKrox gene family
P11692004A1200|2 8|review
P11693461A1649|6 22|utilisation data
P11695481A0310|10 20|conditions
P11697760A0000|5 10|study
P11703464A0560|24 37|subjects rCBF
P11703558A0000|0 11|Doxorubicin
P11704380A1608|4 14|event rate
P11704829A0312|0 25|Subtraction hybridization
P11705093A2016|11 31|vitamin D3 analogues
P11706668A0000|0 10|Hydrocoele
P11706949T0000|0 14|Growth hormone
P11707977A0750|13 17|hand
P11708032A0183|3 11|addition
P11708362A0889|4 18|astronaut crew
P11708431A0904|10 18|patients
P11708761A1388|29 35|number
P11709561T0000|0 5|Phase
P11709890T0000|0 11|Hepatitis A
P11710233T0000|0 9|Hydrogels
P11710685A0994a|16 22|subset
P11710685A0994b|16 22|subset
P11711701A0602|12 31|medicine physicians
P11714429X0000|3 14|clopidogrel
P11715079A1016|20 34|proprioception
P11716043A0380|27 35|patients
P11716441A0585|0 3|ISS
P11718197A1282|4 13|procedure
P11722993A0276|0 12|Paul Monagle
P11723500X0000|30 45|characteristics
P11723511A0780|22 26|risk
P11723675A1022|4 12|severity
P11723928A0294|4 11|process
P11724510T0000|9 19|principles
P11726022A0909|6 13|results
P11726068A0539|0 4|Rind
P11726164A0215|9 16|concern
P11726262A0692|0 25|Lactate accumulation peak
P11726413A1756|14 23|clearance
P11726574A1304|6 13|results
P11727073A0842|0 10|CONCLUSION
P11727209A0502|4 12|patients
P11728771A0187|44 52|reaction
P11730182A0984|38 49|correlation
P11730262A0874|22 27|study
P11730712A0416|0 18|Treadmill training
P11732088A0471|3 8|order
P11732417A0571|12 39|percentage positivity value
P11736254A0000|3 11|analysis
P11736792A0204|10 23|semen samples
P11737056A0680|8 17|timepoint
P11737158A1517|18 23|areas
P11737900A0700|12 23|correlation
P11738404A0120|6 25|chemical structures
P11740571A0114|5 11|toxins
P11740806X0810|0 16|Saunders Company
P11741259A1233|4 15|performance
P11741554T0000|0 10|Comparison
P11742432A0798|8 15|results
P11743360A2491|6 12|stress
P11743612A1179|0 8|Patients
P11744290T0045|1 10|Cactaceae
P11744953A0878|0 12|Skin cancers
P11752821A1365|0 10|CONCLUSION
P11755894A0466|7 16|treatment
P11760398A0553|0 7|METHODS
P11760796A0698|0 8|Evidence
P11761601A0133|2 18|computer program
P11763176A0918|19 27|decrease
P11764062A0000|4 34|Penn State Worry Questionnaire
P11764226A0798|0 14|Classification
P11765448A0588|10 26|X-ray projection
P11766747A0000|39 45|review
P11768467A0000|0 23|Pyrethroid insecticides
P11769229A0357|4 23|sorption mechanisms
P11771979A1141|34 45|variability
P11773168A0915|19 27|survival
P11773921A0397|0 7|METHODS
P11775180A0379|21 32|exploration
P11775301A0797|3 9|effect
P11776922A0830|13 22|sclerosis
P11777575A0363|4 12|quantity
P11777632A1678|0 2|AF
P11778044A0000|16 49|probability density distributions
P11778804A0179|0 9|Frequency
P11781615A0000|26 33|disease
P11782218A0349|12 26|white-on-white
P11783457A0000|0 13|Preservatives
P11785085X0001|12 20|analysis
P11785827A0986|4 11|results
P11786248A1162|0 11|Consumption
P11786945A0958|10 17|freedom
P11787041A0167|7 18|development
P11787322X0001|0 9|Influence
P11787720A1313|14 18|milk
P11787746A0374|0 10|Vitrectomy
P11789206A1182|0 11|CONCLUSIONS
P11789216T0001|0 7|Effects
P11790897T0000|10 18|patterns
P11791292A0193|17 27|laboratory
P11791571T0000|2 53|high-efficiency cross-flow micronebulizer interface
P11791585A0287|4 14|electrodes
P11791853A0532|17 24|results
P11792586A0290|7 14|loading
P11793172A0545|19 26|surface
P11793614A0000|0 9|OBJECTIVE
P11796977T0000|0 8|Postdocs
P11800119A0814|4 20|design principle
P11800586A1090|12 21|DPPD gene
P11800878T0000|0 15|Dynamic imaging
P11801459T0000|0 8|Efficacy
P11802580A0000|4 38|General Practice Research Database
P11802601A0107|5 10|paper
P11803325A0868|9 25|DC cardioversion
P11804081A0552|6 12|August
P11804100A0365a|22 35|disappearance
P11804100A0365b|22 35|disappearance
P11804510A0730|0 6|Losses
P11806132A0253|4 16|TB incidence
P11810685A0147|21 46|displacement distribution
P11811743A0800|4 13|procedure
P11811825A0972|4 11|results
P11815644A0081|13 28|characteristics
P11816458A0319|13 21|Examples
P11816779A0343|4 16|drug packets
P11818675X0897|0 9|Karger AG
P11819326A0000|0 3|AIM
P11821098A0269|0 20|MAIN OUTCOME MEASURE
P11822790A0907|4 12|instance
P11822811A0319|0 5|Group
P11824701A0894|0 8|Patients
P11824801A0661|15 27|continuation
P11825801A1212|27 36|mortality
P11826141T0000|12 19|effects
P11828186A0239|4 14|population
P11830544A0335|0 9|Herceptin
P11831512A0468|12 16|pigs
P11832019A0668|0 11|CONCLUSIONS
P11833863A0987|13 23|difference
P11834476A1187|22 34|animal model
P11835109A0000|48 57|awareness
P11836046A0549|51 53|mg
P11836303A0518|0 8|TNFalpha
P11836303A1191|16 21|study
P11837409A0584|24 51|National Longitudinal Study
P11838058A0084|0 7|METHODS
P11838102T0001|0 7|Wegener
P11840365A0949|24 30|effect
P11842037A0327|18 28|precisions
P11842728X0001|20 35|schistosomiasis
P11843252A0907|9 22|response rate
P11844591A0329|22 31|parameter
P11844812A0915|17 28|ng/mL model
P11845547A0449|10 20|treatments
P11846167A0000|0 8|Selenium
P11846187A0894|4 23|GT-foreign-pictures
P11847580T0000|14 27|cholecystitis
P11849417A0900|0 3|Age
P11849796A0452|0 7|RESULTS
P11851941A0372|37 56|serumalbumin method
P11852907A0871|4 34|equilibrium phosphorus content
P11853943A0122|14 24|prediction
P11858256A0102|21 29|research
P11858548A0241|4 13|structure
P11858635A0896|34 42|property
P11859400A0229|16 24|efficacy
P11859943A0150|4 10|adults
P11860097A1695|0 4|Data
P11860723A0182|2 13|mail survey
P11860876A0409|0 15|HIV-1 C subtype
P11861092A0730|7 14|plateau
P11862350T0000|14 19|study
P11863811A0259|26 40|Nusselt number
P11864173T0000|19 28|pathogens
P11865218A0069|0 9|Treatment
P11866130A0419|3 11|addition
P11867388A0502|4 6|EC
P11870646A0668|4 11|utility
P11872359A0000|26 44|insulin resistance
P11872570T0000|0 8|Dementia
P11873003X0000|0 15|HIV-1 infection
P11874637A0212|4 7|use
P11875695A0718|0 4|Time
P11876937A0261|0 7|Heparin
P11879108A0719|0 20|MAIN OUTCOME MEASURE
P11881268A0000|4 11|purpose
P11881923A1256|0 10|Neutrophil
P11882054A0568|18 25|lesions
P11882054A1250|16 27|correlation
P11882747A0354|0 2|CD
P11883682A0162|22 32|monitoring
P11883763A1062|10 16|fluxes
P11884014A0665|9 28|treatment protocols
P11885053A1897|37 43|Volkan
P11885737A1713|4 9|range
P11886473A0796|0 15|Gastritis score
P11887803A1455|4 18|mean thickness
P11888183A0541|10 18|analysis
P11888867A0000|0 10|BACKGROUND
P11890354A0000|0 18|Genetics Institute
P11890438A0838|0 8|Patients
P11893403A0252|0 8|Elements
P11893767A0356|26 44|minute ventilation
P11894605A1429|0 14|INTERPRETATION
P11895024A1054|5 10|cases
P11895184A0000|4 11|ability
P11897449A0566|4 9|shift
P11897888A0590|0 13|Urine samples
P11897950A0617|0 11|CONCLUSIONS
P11898018T0000|0 15|Data management
P11898797A0124|36 42|levels
P11899479A0122|13 19|smears
P11899489A0119|4 11|effects
P11900770T0000|21 31|incentives
P11902068T0000|4 15|CKD patient
P11902738A0185|0 8|PATIENTS
P11902781A0550|0 14|Concentrations
P11904017A0000|30 37|process
P11907691A0214|4 16|orientations
P11908529A0553|4 11|results
P11909404A0000|6 13|domains
P11910310A0279|0 6|DESIGN
P11910344A1119|0 11|CONCLUSIONS
P11911552A0776|3 11|patients
P11912261A0284|13 19|agents
P11912677A0281|10 18|analysis
P11913427A0290|4 12|subjects
P11915436A0491|13 28|incidence rates
P11917061A0922|9 18|predictor
P11917882A0326|25 30|study
P11920455X1195|0 9|Copyright
P11920896A0298|8 13|study
P11921126A1196|19 25|PDQ-39
